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Abstract 
DNA is constantly under the threat of damage by various endogenous and 
exogenous agents, leading to the structural modification of nucleobases (DNA adducts). 
These DNA adducts can range from smaller nucleoside monoadducts and exocyclic 
adducts, to the helix distorting and super-bulky DNA-DNA cross-links and DNA-protein 
cross-links. If not repaired, DNA adducts can inhibit crucial biological processes such as 
DNA replication, leading to adverse consequences such as mutagenesis and 
carcinogenesis. Therefore, understanding the atomic connectivity, extent of formation, and 
repair of DNA adducts is crucial to fully elucidating the biological consequences of the 
adduct. 
DNA-protein cross-links (DPCs) are ubiquitous, super-bulky DNA lesions that 
form when proteins become irreversibly trapped on chromosomal DNA. The structural 
complexity of cross-linking and the diversity of proteins susceptible to DPC formation 
represents significant challenges to studying the biological consequence of these adducts. 
In the first part of the thesis, we identified the protein constituents, structural characterized 
and quantified, and investigated the repair mechanism of bis-electrophile (Chapter 2) and 
reactive oxygen species (ROS, Chapters 3 and 4)-induced DPCs.  
In Chapter 2, we investigated DPC formation after exposure to N,N-bis-(2-
chloroethyl)-phosphorodiamidic acid (phosphoramide mustard, PM) and N,N-bis-(2-
chloroethyl)-ethylamine (nornitrogen mustard, NOR), the two biologically active 
metabolites of the antitumor agent cyclophosphamide. A mass spectrometry-based 
proteomics approach was employed to characterize the protein constituents of PM- and 
NOR-mediated DNA-protein cross-linking in human fibrosarcoma (HT1080) cells. HPLC-
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ESI+-MS/MS analysis of proteolytic digests of DPC-containing DNA from NOR-treated 
cells revealed a concentration-dependent formation of N-[2-[cysteinyl]ethyl]-N-[2-(guan-
7-yl)ethyl]amine (Cys-NOR-N7G) conjugates, confirming that it cross-links cysteine 
thiols of proteins to the N-7 position of guanines in DNA. A sensitive and accurate Cys-
NOR-N7G isotope dilution tandem mass spectrometry assay was developed to quantify 
PM-induced DPC formation and repair in mammalian cells proficient or deficient in a DNA 
repair pathway. 
In Chapters 3, we employed the model of left anterior descending artery 
ligation/reperfusion surgery in rat to show that ischemia/reperfusion injury is associated 
with the formation of hydroxyl radical-induced DNA-protein cross-links (DPCs) in 
cardiomyocytes. Mass spectrometry based experiments revealed that these conjugates were 
formed by a free radical mechanism and involved thymidine residues of DNA and tyrosine 
side chains of proteins (dT-Tyr). Quantitative proteomics experiments utilizing Tandem 
mass tags (TMT) revealed that radical-induced DPC formation increase after LAD-
ligation/reperfusion compared to the control sham surgery. Using the developed dT-Tyr 
nanoLC-ESI+-MS/MS assay, we investigated the role of the metalloprotease Spartan 
(SPRTN) in the repair of radical-induced DPCs (Chapter 4). Analysis of the brain, liver, 
heart, and kidneys of wild type (SPRTN+/+) and hypomorphic (SPRTN f/-) mice revealed a 
1.5 – 2-fold increase in dT-Tyr in the hypomorphic mice, providing direct evidence that 
Spartan plays a role in the repair of radical-induced DPCs.   
Finally, we investigated the formation of formamidopyrimidine (FAPy) adducts 
after exposure to 3,4-epoxybutene, an epoxide metabolite of the known carcinogen 1,3-
butadiene (Chapter 5). We successfully synthesized and structurally characterized a novel 
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BD-induced DNA adduct EB-FAPy-dG, and developed a sensitive isotope dilution tandem 
mass spectrometry assay for its detection in vitro and in cells. To our knowledge, this is 
the first report of a BD-induced FAPy adduct, and future studies will examine whether BD-
induced FAPy adducts 
In summary, during the course of this Thesis, we utilized mass spectrometry-based 
proteomics techniques to identify the proteins susceptible to PM- and ROS-induced DPC 
formation. After structurally characterizing the atomic connectivity of these adduces, we 
developed sensitive and accurate isotope dilution tandem mass spectrometry assays to 
perform absolute quantitation of PM- and ROS-induced DPC formation in cells and tissues. 
These assays were further utilized to begin investigating the repair mechanism of DPCs in 
cells and tissues, including providing direct evidence that the metalloprotease Spartan is 
involved in the repair of radical-induced DPCs. Finally, we detected EB-FAPy-dG 
formation in vitro and in vivo, the first evidence of 1,3-butadiene induced 
formamidopyrimidine formation. 
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1. Introduction 
1.1. DNA damage and its biological consequences 
1.1.1. Structural modifications of DNA 
Structural integrity of DNA is essential for the accurate expression and transmission 
of genetic information.1, 2 However, DNA is constantly under threat of structural 
modification by endogenous and exogenous agents.3 In addition to chemical reactions with 
oxidants and electrophiles, DNA is subject to spontaneous hydrolysis,4 deamination of 
nucleobases,4 and replication-induced errors. Modified nucleobases (DNA adducts) can be 
recognized and removed by cellular DNA repair enzymes that work to restore damaged 
DNA to its original state.5-8 If not repaired, DNA adducts can induce errors during DNA 
replication or block DNA replication, resulting in mutations, senescence and apoptosis.6 
Therefore, the successful recognition and repair of DNA damage is crucial for cellular 
survival. 
 
1.1.2. Sources of DNA lesions 
DNA can be damaged by many physical and chemical agents including UV light,9 
ionizing radiation,10 reactive oxygen species,11 reactive metabolites of environmental 
carcinogens,12, 13 common anti-cancer drugs,3 and endogenously-produced reactive 
metabolites.14 Exposure to these agents can lead to the formation of multiple types of DNA 
damage, including chemical modification to a single nucleoside (nucleobase 
monoadducts), DNA intra-strand and inter-strand cross-links (ICLs), DNA-protein cross-
links (DPCs), single strand breaks (SSBs), and double strand breaks (DBSs, Figure 1-1). 
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Figure 1-1: DNA damage and repair pathways. Types of common DNA damage formed after exposure to endogenous and exogenous 
agents, and the known repair pathways involved in the removal of the damage. 
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Spontaneous deamination and hydrolysis of DNA are common events within 
human cells (100 – 400 events per genome per day).4 Hydrolytic deamination of cytosine 
yields uracil.15-18 This occurs via either attack of the neutral N3-exocyclic amine by a 
hydroxide anion or attack of the protonated N3-exocyclic amine by water.15, 16, 19 Similarly, 
the N6-exocyclic amine of adenine and the N2-exocyclic amine of guanine can undergo 
deamination to yield hypoxanthine and xanthine respectively, although only at 2 – 3% of 
the rate of cytosine deamination.20  
The glycosidic bonds of purine nucleosides of DNA can undergo acid-catalyzed 
hydrolysis, a process referred to as depurination.21 Protonation of the N7-positions of 
purines stimulates the cleavage of the glycosidic bond, yielding the corresponding free 
bases and an oxycarbenium ion (1), which can undergo subsequent hydrolysis to yield an 
abasic site (AP site 2, Scheme 1-1A).21-23 It has been calculated that spontaneous 
depurination generates 10,000 AP sites per cell per day.21 Conversely, the phosphodiester 
backbone of DNA is extremely stable under physiological conditions, with phosphodiester 
hydrolysis half-life estimated at 30,000,000 years.24-26   
AP sites resulting from depurination are susceptible to further chemical reactions, 
yielding additional DNA lesions (Scheme 1-1A). Abstraction of an α-proton adjacent to 
the aldehyde group (3) leads to β-elimination of the 3’-phosphate group to generate DNA 
single strand breaks (4).23, 27 The aldehyde group is also susceptible to further reaction with 
nucleophilic amino groups of other biomolecules (Scheme 1-1B). For example, the 
exocyclic N2-amine of guanine residues on the opposite DNA strand can react with the 
aldehyde group of the lesion to form inter-strand cross-links (5’-dCAP, 5) via Schiff base 
formation.28 Similarly, reactive lysine residues in the catalytic sites of DNA polymerases 
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can react with AP sites of DNA to form covalent Schiff base DNA-protein cross-links.29, 
30     
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Scheme 1-1: Acid catalyzed depurination of guanine and subsequent chemical reactions leading to DNA strand breaks and DNA-DNA 
cross-linking. (A) Mechanism of acid-catalyzed depurination and subsequent strand scission.21-23 (B) Reaction of apurinic site 3 with a 
2’-exocyclic amine of a neighboring guanine to form an interstrand DNA-DNA cross-link (5).23, 27 
A.  
 
 
 
 
 
 
 
B. 
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DNA can also be damaged as a result of exposure to reactive oxygen and nitrogen 
species (ROS and RNS).3, 31, 32 ROS are produced via partial reduction of molecular 
oxygen. Examples of ROS includes superoxide anion (•O2-), hydrogen peroxide, (H2O2), 
and hydroxyl radical (•OH). RNS include nitric oxide (•NO), peroxynitrite (ONOO-), 
nitrogen dioxide (•NO2), and dinitrogen trioxide (N2O3). Exposure to ROS and RNS 
generates numerous DNA adducts including oxidized DNA bases, intra-strand and inter-
strand cross-links, single and double strand breaks, and DNA-protein cross-links.3, 31-33  
Over 100 different oxidatively damaged bases have been characterized in vitro 
(Figure 1-2).31, 34 For example, hydroxyl radical can abstract hydrogens from the 2’-
deoxyribose sugar backbone and DNA nucleobases, as well as add to the double bonds of 
DNA bases.35 All five carbon positions of the 2’-deoxyribose sugar (dR) are susceptible to 
proton abstraction by •OH to yield direct strand scission and electrophilic moieties.36-38 
Examples of dR-proton abstraction products include 3’-ene-lactone (C’1), DNA erythrose 
adducts (C’2), 3’-lactone (C’3), 4’-keto-1’-aldehyde (C’4), and DNA 5’-aldehyde (Figure 
1-3).38 Due to steric factors, the C’-5 and C’-4 positions are the most accessible to hydrogen 
abstraction.39 The resulting electrophilic lesions can form covalent cross-links with 
nucleophilic sites on DNA and proteins, generating covalent DNA-DNA and DNA-protein 
cross-links. 
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Figure 1-2: ROS and RNS-induced DNA monoadducts, DNA tandem lesions, and DNA 
cross-links. 
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Figure 1-3: Potentially electrophilic DNA adducts formed after hydrogen abstraction from 2’-deoxyribose sugar of DNA. 
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Some of the most prevalent oxidative base lesions are formed following hydroxyl 
radical addition across the π-bonds of bases.40-42 Specifically, hydroxyl radicals can add 
across the 5,6-double bond of thymidine to yield a C6-thymidine radical (6, Scheme 1-
2).43 Radical 6 can be reduced to 5-hydroxy-6-hydro-thymidine (7) or react with molecular 
oxygen to yield a hydroperoxide (8), which will undergo subsequent reactions to yield the 
diastereomers of 5,6-dihydroxy-5,6-dihydrothymidine (9, Gly-Thy).36, 40-42, 44, 45 Similarly, 
the C8-position of guanine can react with a hydroxyl radical to yield a nucleobase radical 
(10, Scheme 1-3) capable of undergoing one electron reduction or oxidation.40, 46-48 
Reduction of 10 results in imidazole ring cleavage to yield ring-opened 
formamidopyrimidine (11, FAPy) lesions. Oxidation yields the ubiquitous 8-oxo-7,8-
dihydroguanosine (12, 8-oxo-dG),49, 50 which is susceptible to further two electron 
oxidation and decomposition to spiroaminohydantioins (13), ureidoimidazolines (14),  and 
guanidinohydantoins (15).51-55  
ROS-induced DNA radicals can engage in secondary reactions with nearby bases 
in the DNA duplex, resulting in multiple damage sites and tandem lesions (Figure 1-2).3, 
31, 56 For example, a 5-(2’-deoxycytidinyl)methyl radical can react with the C8-position of 
an adjacent dG to yield G-T intrastrand cross-links (Figure 1-2).49, 50 Other tandem lesions 
include 5,6-dihydrothymidine radicals generating an adjacent 2’-deoxyribonolactone,57 8-
oxodGuo-dF,58 and 8,5-cyclo-2’-deoxypurine cycloadducts.59, 60    
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Scheme 1-2: Mechanism of ROS-induced thymidine oxidation. Hydroxyl radical adds across the 5,6-double bond of thymidine to yield 
the reactive 5-hydroxy-6-hydro-thymidine radical (6), which be reduced to 5-hydroxy-6-hydro-thymidine (7) or further oxidized to 5,6-
dihydroxy-5,6-dihydrothymidine (9, Gly-Thy).  
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Scheme 1-3. Mechanism of ROS-induced purine imidazole ring opening. Attack of a hydroxyl radical at the 8-position of guanine 
generates an 8-hydroxy-guanine radical, which can undergo one-electron reduction to an unsubstituted formamidopyrimidine (FAPy) 
adduct, or one-electron oxidation to 8-oxo-dG (12) followed by further two electron oxidation and decomposition to 
spiroaminohydantioins (13), ureidoimidazolines (14), and guanidinohydantoins (15). 
 
12 
 
Chromosomal DNA can also become damaged after exposure to physical agents 
such as including ultraviolet light (UV) and ionizing radiation.9, 61 UV irradiation can 
induce cyclobutane pyrimidine dimers (CPDs) and 6-4 pyrimidone photoproducts ([6-
4]PPs) between adjacent pyrimidines.62, 63 Together, these adducts account for nearly 75% 
and 25% of DNA damage after exposure to UV respectively. 6-4PPs can undergo further 
photoisomerization to Dewar valence isomers after exposure to wavelengths longer than 
290 nm.64 Ionizing radiation, such as X-rays and ɣ-rays can directly and indirectly damage 
DNA via ROS generation, forming the same oxidized DNA damage products described 
above (Figure 1-2).31, 65  
Alkylating agents are a ubiquitous group of chemical agents capable of damaging 
DNA. These include industrial or household chemicals, environmental pollutants, known 
carcinogens, dietary chemicals, and chemotherapeutics. Endogenous alkylating agents 
such as methylglyoxal and malondialdehyde can be formed as byproducts of lipid 
peroxidation or other cellular processes (Figure 1-4).14 Alkylating agents can react with 
ring nitrogens, exocyclic amines, and exocyclic oxygens of DNA bases to yield covalent 
DNA adducts (Figure 1-4).5, 66 The specific type of DNA damage produced depends on 
many properties of the alkylation agent, including the number of reactive sites 
(monofuctional or bifunctional), the chemical reactivity of the agent (SN1 vs SN2 
nucleophilic substitution), and the chemical structure of the group added.6 The reactive 
moieties of alkylating agents can include alkyl halides, epoxides, aziridinium ions, 
aldehydes, and quinones. 
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Figure 1-4: Chemical structures of known endogenous DNA alkylating agents and the chemical structures of DNA alkylation products 
formed by these endogenous electrophiles. 
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The most nucleophilic position on DNA is the N7-position of guanine (Figure 1-
5).67 Many small, monofunctional, and freely diffusible alkylating agents such as dimethyl 
sulfate predominately alkylate this position. Preferential alkylation of other sites has been 
justified by the hard-soft reactivity principle.67-70 Hard alkylating agents, which are small, 
positively charged, and non-readily polarizable molecules such as diazonium ions, favor 
reaction with hard oxygen nucleophiles such as the C6-carbonyl position of purines 
(Figure 1-5). Softer alkylation agents, which are large, uncharged, and polarizable 
molecular such as chloroethylureas, preferentially alkylate ring nitrogens such as the N1 or 
N7 positions of purines (Figure 1-5).  
DNA alkylation produces both hydrolytically stable and labile lesions, the latter are 
spontaneously released from DNA giving rise to abasic sites. Alkylation of the exocyclic 
amines of guanine (N2-G), adenine (N2-A), and cytosine (N4-C) and the carbonyl oxygens 
of guanine (O6-G) and thymidine (O4-T) yields hydrolytically stable adducts.71-74 
Conversely, alkylation of the ring nitrogens of guanine (N7-G and N3-G), adenine (N7-A, 
N3-A, N1-A), and cytosine (N3-C) generates positively charged adducts that undergo 
depurination.75-78 Alternatively, positively charged nucleobase adducts can undergo 
hydrolytic ring opening reactions to yield stable adducts. For example, N7-alkylated 
guanine and adenine are susceptible to hydroxyl anion attack at the C8-position of the 
purine heterocycle which initiates the cleavage of the imidazole ring to yield N5-(alkyl)-
formamidopyrimidine adducts.78-80 N1-alkylated adenines can undergo transient 
pyrimidine ring opening via Dimroth rearrangement, where the alkyl group is transferred 
from the N1-position to the N6-position of the heterocycle.81, 82 Furthermore, bis-
electrophiles can cross-link two nucleophilic sites of biomolecules, yielding DNA-DNA 
15 
 
and DNA-protein cross-links. Considering the vast number of DNA adducts generated in 
cells daily, dedicated repair mechanisms are required to prevent the accumulation and 
persistence of nucleobase damage. 
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Figure 1-5: Chemical structures of alkylating agents that react with 2’-deoxyguanosine to form monoadducts or cyclic adducts. 
 
 
17 
 
1.1.3. Repair of DNA damage 
To ensure faithful replication and expression of genetic material, living cells have 
evolved multiple DNA damage response (DDR) pathways to recognize DNA damage and 
return DNA to its unaltered state. These pathways include direct repair, base excision repair 
(BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous 
recombination (HR), and non-homologous end-joining (NEHJ) (Scheme 1-4 and 1-5). The 
molecular size and shape, the degree of helix distortion, and the thermodynamic stability 
of each adduct influence their repair mechanisms. 
Direct repair  
This type of repair involves direct reversal of damaged nucleobases to their native 
state by a single enzyme without the cleavage of the DNA phosphodiester backbone.83 
Three distinct direct repair enzyme classes have been identified: photolyases, O6-
alkylguanine-DNA alkyltransferase (AGT), and AlkB family dioxygenases.  Bacterial 
photolyases reverse UV-induced photolesions such as CPPs and [6-4]PPs through a 
FADH—mediated electron transfer mechanism.84, 85 AGT is a suicide DNA repair protein 
that repairs promutagenic O6-alkylguanine and O4-alkylthymine lesions.86 Following 
protein binding to damaged DNA, the alkylated nucleotide is flipped out of the base stack 
into the AGT’s active site, allowing for the alkyl group to be transferred to an activated 
side chain thiolate anion of Cys145, restoring native base.87 AlkB family dioxygenases 
repair alkylated DNA damage through a Fe(II) and O2-mediated oxidation and subsequent 
C-N bond cleavage.5, 83, 88-92 N1-methyladenine, N3-methyl cytosine, N1-methyl guanine, 
N3-methyl thymine, 1,N6-etheno adenine, 1,N6-ethano adenine, and 3,N4-ethenocytosine 
have been shown to be substrates for AlkB dioxygenases.88, 93-98 
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Scheme 1-4: Detailed mechanism(s) of DNA damage response pathways including; direct 
repair by bacterial photolyase, human AlkB, and human AGT; short patch and long patch 
base excision repair; global genomic and transcription coupled nucleotide excision repair.  
 
 
AGT: O6-alkylguanine-DNA alkyltransferase; APE1: apurinic/apyrimidinic endonuclease; 
PNKP: polynucleotide kinase 3’-phosphatase; FEN1: flap endonuclease 1: PCNA: 
proliferating cell nuclear antigen; RNAPII: RNA polymerase II holoenzyme 
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Scheme 1-5: Detailed mechanism(s) of DNA damage response pathways including: 
homologous recombination (HR) of a double strand break, non-homologous end-joining 
(NEHJ) of a double strand break, and mismatch repair of an insertion/deletion lesion. 
 
Nbs1: nibrin; Ku70/80: x-ray repair cross-complementing proteins; DNA-PKc: DNA-dependent 
protein kinase, catalytic subunit; MutSα/β: DNA mismatch repair protein; EXO1: exonuclease 1. 
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Base excision repair 
BER is the primary cellular DNA repair pathway responsible for removing 
deaminated bases, non-bulky alkylated nucleobases and oxidative lesions, single-strand 
breaks, and AP sites.99-101 The nucleobase adducts are first recognized as BER substrates 
via a “base flipping” mechanism and excised from the duplex by DNA glycosylases.99, 102-
104 These enzymes are classified as either Type 1 (monofunctional) or Type 2 (bifunctional) 
glycosylases based on their catalytic mechanism and ability to execute AP lyase strand 
cleavage.100, 105 Uracil DNA N-glycosylase (UDG), thymine DNA glycosylase (TDG), and 
methyl-CpG-binding domain4 (MBD4) are examples of Type 1 glycosylases, while MutY 
(MYH), 8-oxo-guanine glycosylase 1 (OGG1), and Endonuclease VII-like 1 (NEIL1) are 
examples of Type 2 glycosylases (Table 1-1). 
Type 1 DNA glycosylases catalyze the cleavage of the glycosidic bond between the 
damaged base and the 2’-deoxyribose sugar, releasing the free base and generating an AP 
site.17, 99 The phosphodiester bond at the 5’-position to the AP site can then be cleaved by 
AP endonuclease 1 (APE1) to generate a DNA strand break with a priming 3’-OH group 
and the non-conventional 5’-deoxyribose sugar. Type 2 glycosylases possess 3’-
endonuclease activity and can catalyze both the cleavage of the glycosidic bond and 
incision of the phosphodiester bond 3’ to the AP site.99, 106 Type 2 glycosylases utilize an 
active site amine moiety to generate a covalent Schiff base between the enzyme and the 
AP site formed during the base excision step, keeping the substrate in position to allow for 
lyase activity.  
The resulting abasic sites can be repaired by one of two mechanisms, referred to as 
short-patch BER (SP-BER) and long-patch BER (LP-BER). In SP-BER, DNA polymerase 
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β inserts a single nucleotide to fill the gap and cleaves the remaining 5’-deoxyribose 
phosphate from the DNA.107-111 The DNA strand is then sealed by DNA ligase 3 (LIG3), 
completing the repair.112 In LP-BER, DNA polymerase δ (Polδ), DNA polymerase ε (Polε), 
and proliferating cell nuclear antigen (PCNA) perform “strand displacement synthesis”, 
adding 2 – 12 nucleotides and displacing the existing 5’-DNA end.113 The displaced DNA 
is then cleaved by flap endonuclease 1 (FEN1), followed by LIG3-mediated ligation as 
above.114, 115 The choice between SP-BER or LP-BER appears to be influenced by the 
concentration of available ATP after removal of 5’-deoxyribose, with higher ATP 
concentrations favoring SP-BER iniatiation.116 
Recent studies have indicated that BER enzymes play a role in recognizing and 
removing ICLs formed by certain agents. HeLa cells deficient in NEIL1 enzyme were 
found to be hypersensitive to psoralen treatment.117 Although psoralen mono-adducts have 
been identified as substrates for NEIL1 in-vitro,117 McNeill et al showed NEIL1 is 
specifically recruited to ICL sites.118 They treated HeLa cells with the psoralen derivative 
trioxsalen, which upon low laser micro-irradiation will stimulate ICL formation but will 
not induce ROS generation.118 Furthermore, they treated HeLa cells with the psoralen-
derivative angelicin, which can only form monoadducts upon the same laser micro-
irradiation.118 NEIL1 was recruited immediately to ICL sites, while angelicin treatment 
yielded no effect, showing NEIL1 recognized a specific feature of the psoralen-induced 
ICL.118 Paradoxically, NEIL1 recruitment to ICL was also found to inhibit the excision of 
ICLs by XPC (NER pathway), suggesting the NEIL1’s role in ICL repair is not fully 
elucidated. 
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Table 1-1: Mammalian BER enzymes and their substrates. 
 
 
Enzyme Subcellular 
localization 
Type Substrates 
Uracil-DNA glycosylase 2 
(UNG2) Nucleus I 
Uracil: adenine mismatch 
Uracil: guanine mismatch 
5-fluorouracil 
Uracil-DNA glycosylase 1 
(UNG1) Mitochondria I 
Uracil: adenine mismatch 
Uracil: guanine mismatch 
5-fluorouracil 
Single-strand selective 
monofunctional uracil 
DNA glycosylase 
(SMUG1) 
Nucleus I 
5-hydroxymethyl Uracil 
Uracil: guanine mismatch 
Uracil: adenine mismatch 
5-fluorouracil 
3,N4-ethenocytosine 
Thymine-DNA 
glycosylase 
(TDG) 
Nucleus I 
Uracil: guanine mismatch 
Thymine: guanine mismatch 
5-hydroxymethyl uracil 
5-fluorouracil 
Methyl-CpG-binding 
domain 4 
(MBD4) 
Nucleus I 
Uracil: guanine mismatch 
Thymine: guanine mismatch 
5-hydroxymethyl uracil in CpG islands 
5-fluorouracil, 3,N4-ethenocytosine 
3-methyl adenine-DNA 
glycosylase 
(MPG) 
Nucleus I 
3-methyladenine, 7-methylguanine, 3-
methylguanine, Hypoxanthine, 
1,N6-ethenoadenine 
8-Oxoguanine 
glycosylase 
(OGG1) 
Nucleus II 8-oxoguanine opposite cytosine FAPy-G opposite C 
mutY DNA glycosylase 
(MUTY) Nucleus I 
Adenine opposite 8-oxoguanine 
Adenine opposite cytosine 
Adenine opposite guanine 
Endonuclease III-like 
protein 1 
(NTHL1) 
Nucleus II Thymine glycol, FAPy-G, 5-hydroxycytosine, 5-hydroxyuracil 
Endonuclease 8-like 
protein 1 
(NEIL1) 
Nucleus II 
Thymine glycol, FAPy-G, FAPy-A, 8-
oxoguanine, 5-hydroxyuracil, 
Dihydroxyuracil, 
Spiroaminohydantioins, 
Guanidinohydantoins 
Endonuclease 8-like 
protein 2 
(NEIL2) 
Nucleus II Same as NEIL1 
Endonuclease 8-like 
protein 3 
(NEIL3) 
Nucleus II 
FAPy-A, FAPy-G, 
Spiroaminohydantioins 
Guanidinohydantoins 
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Nucleotide Excision Repair 
NER is the primary repair pathway used to remove bulky, helix distorting lesions 
including UV-induced cyclobutene pyrimidine dimers (CPDs) and (6,4)-pyrimidone 
photoproducts ([6,4]PPs), adducts of the environmental carcinogens such as 
benzo[a]pyrene and polyaromatic amines, and adducts of anti-tumor drugs such as cisplatin 
and phosphoramide mustard.119-124 NER can be initiated by two subpathways, 
transcription-coupled NER (TC-NER) and global genome NER (GG-NER). TC-NER is 
responsible for rapid removal of distorting lesions from the transcribed strand of an active 
gene, and is initiated by the stalling of a RNA polymerase II.125 Cockyane syndrome A 
(CSA), Cockyane syndrome B (CSB), and XPA binding protein 2 (XAB2) then facilitate 
the removal of the stalled polymerase to allow TC-NER to continue. GG-NER can occur 
anywhere in the genome, and is initiated by the GG-NER-specific XPC-RAD23B complex 
recognizing and binding a balky/distorting lesion. Specifically, the XPC protein binds the 
undamaged DNA strand and recognizes the two nucleotides opposite the lesion because 
they have increased ssDNA characteristics caused by thermodynamic destabilization of the 
adduct.126 After damage recognition, both TC-NER and GG-NER share similar 
mechanisms and enzymes for completing the repair (Table 1-2). 
The transcription factor IIH (TFIIH) complex, which consists of 10 subunits 
including XPB, cyclin-activated complex, and XPD, is recruited to the XPC-RAD23B 
complex.127-129 The XPB protein will initially “open” the DNA strand, allowing the rest of 
the TFIIH complex to bind.130 The XPD protein is believed to translocate across the 
damaged DNA strand, both unwinding the DNA and verifying the damage via helicase 
inhibition.130-132 The loading of XPD allows the recruitment of RPA, XPA, and XPG to 
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complete the preincision complex.129, 133 RPA binds to the undamaged strand, stabilizing 
the open “bubble” intermediate.134, 135 XPA binds to the 5’-side of the bubble and interacts 
with TFIIH complex, RPA, XPC-RAD23B complex, DDP2, ERCC1-XPF complex, and 
PCNA, ensuring that these NER proteins are correctly positioned for the upcoming steps. 
136, 137 
Once the endonucleases XPG and ERCC1-XPF are in position, they catalyze dual 
incision of the damaged strand, releasing a 24 – 32 nucleotide patch containing the 
nuclebase adduct and the TFIIH complex.123, 138, 139 ERCC1-XPF performs the 5’-incision 
to generate a free 3’-hydroxyl group while XPG performs the 3’-incision.138 The resulting 
gap is filled by either Pol δ/ε with a PCNA clamp or the TLS polymerase Pol ƙ, followed 
by DNA ligase 1 fixing the resulting nick.140-142 
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Table 1-2: Dynamic role(s) of nucleotide excision repair enzymes.  
Enzyme NER pathway Step(s) Activity Protein binding 
XPC GG-NER Damage recognition 
TFIIH loading 
 
ssDNA binding RAD23B, RAD23A, TFIIH, 
XPA, UV-DDB 
RAD23A/B GG-NER Damage recognition 
TFIIH loading 
Stabilize XPC 
Deliver XPC to UV-damage 
XPC 
CSA TC-NER Stalled fork recognition 
RNAPII removal 
Ubiquitin ligase activity 
Recruit UVsS-A-USP7 
Protein binding 
CSB, TFIIH (p44 subunit), 
XAB2, DDB2, UVsS-A 
CSB TC-NER Stalled fork recognition 
RNAPII removal 
DNA binding/unwinding 
Protein binding 
CSA, XPB, XPD, XPG, 
XAB2, TFIIH (p34 subunit), 
RNAPII 
XAB2 TC-NER Stalled fork recognition 
RNAPII removal 
TBD XPA, CSA, CSB, RNAPII 
XPB Both TFIIH loading 
Pre-incision complex 
ATPase 
DNA opening 
TFIIH (p52) 
XPD Both TFIIH loading 
Pre-incision complex 
ATPase 
DNA helicase 
Damage verification 
TFIIH (p44) 
XPA Both Pre-incision complex 
Lesion excision 
Protein binding 
Coordinate excision 
TFIIH, XPC-RAD23B, 
DDB2, ERCC1-XPF, RPA, 
PCNA 
XPG Both Lesion excision Endonuclease TFIIH, RPA 
XPF Both Lesion excision Endonuclease TFIIH, ERCCI, XPA 
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Homologous Recombination 
HR is a high fidelity, sequence-dependent repair process that preserves the genome 
by repairing complex DNA damage such as DNA gaps, double-strand breaks, and inter-
strand DNA-DNA cross-links. HR also plays a prominent role in the faithful replication of 
the genome by supporting DNA replication and telomere maintenance. For all HR repair 
reactions, the key step is the homology search and 3’-DNA strand invasion by the Rad51-
ssDNA presynaptic filament. This step ensures the new template DNA is in place to initiate 
the repair synthesis. A detailed explanation of DSB repair by HR is described below. 
HR is initiated by the Mre11-Rad50-Nbsl (MRN) complex binding to DNA, 
followed by Mre11 enzymatically digesting DNA to creates 3’-DNA overhang regions at 
the site of the break. The resulting ssDNA region is quickly bound by RPA to prevent the 
formation of disruptive secondary hairpin structures. Rad51, with the aid of mediator 
proteins Rad54, breast cancer associated 2 protein (BRCA2), and Rad51 paralogs, will then 
bind to the ssDNA to form a nucleofilament (Scheme 1-5).  Homology search and Rad51 
recombinase-mediated strand invasion inserts the unaltered homologous strand from the 
sister chromatid across the damaged strand, an intermediate known as a D-loop. The 
homologous strand is then used as an error-free template for DNA synthesis by the TLS 
polymerase η. Ligation of the new oligo by DNA ligase 1 yields a four-stranded structure 
referred to as a Holiday junction. This junction is disassembled into either crossover or 
non-crossover products by Resolvase A or BLM DNA helicase with the type 1 
topoisomerase TOPIII complex.  
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Non-homologous end joining 
A competing repair pathway of DSBs is NHEJ, which directly ligates the two ends 
of a DSB.143, 144 However, NHEJ does not consider sequence homology, and can lead to 
nucleotide additions and deletions. NHEJ is initiated by the Ku70/Ku80 heterodimer 
recognizing and binding the ends of the DSB, which both protects the ends from non-
specific processing and ensures the recruitment of additional NHEJ proteins.145, 146 Binding 
of DNA-PKCs to the Ku heterodimer forms a stable synaptic complex that holds the two 
broken ends together (add figure). This stabilized structure allows DNA end processing 
enzymes to remove end groups, fill gaps, and resect DNA ends to ensure the ends can be 
ligated together.147, 148  
The removal of inhibiting end groups to yield ligatable ends is performed by 
polynucleotide kinase phosphate (PNKP), apraxtin and PNK-like factor (APLF), and the 
Ku heterodimer. PNKP is able to remove a phosphate from a 3’-hydroxyl group and to add 
phosphates from a 5’-hydroxyl group.149 APLF catalyzes the removal of adenylate groups 
attached to a terminal 5’-phosphate.150 The Ku heterodimer is believed to have 5’-dRP/AP 
lyase activity, particularly for AP sites within a 5’-overhang region of a DSB.151 Resection 
of the DNA ends is performed by Artemis, APLF, and Werner (WRN), which create blunt 
ends that can be sealed together by DNA ligase 4.152-155    
DNA mismatch repair 
MMR is a highly conserved repair pathway that corrects DNA base-base 
mismatches that escape DNA polymerase proofreading, base-base mismatches generated 
by nucleobases deamination, oxidation, or alkylation, and insertion/deletion loops (IDLs) 
resulting from DNA polymerase slippage events.156-158 The MMR pathway in Esherichia 
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coli has been extensively characterized biochemically and genetically, and has thus 
provided the framework for investigating the pathway in eukaryotes.156, 159 In human cells, 
MMR is initiated by MutSα or MutSβ recognizing and binding to a DNA base-base 
mismatches or IDL in the unmethylated daughter strand.158 MutSα preferentially 
recognizes mismatches and IDLs 1 or 2 nucleotides long, and MutSβ recognizes larger 
IDLs. Once bound to the mismatch, MutSα and MutSβ recruit MutLα and form a stable 
ternary complex that pulls the daughter strand out of the duplex.160, 161 A portion of the 
single stranded DNA is bound by single-stranded binding-factor replication protein A 
(RPA),162, 163 which allows exonuclease 1 (EXO1) to remove the DNA fragment containing 
the mismatch.164 The resulting gap is filled by Pol δ and Pol ε, and the nick sealed by DNA 
ligase 1.165  
 
1.1.4. Biological consequences of DNA damage 
The accumulation and persistence of DNA adducts has been linked to the initiation, 
promotion, and development of diseases such as cancer,166, 167 neurodegeneration,168, 169 
cardiovascular disease,170, 171 and aging.166 Unrepaired DNA adducts can contribute to 
these disease states by causing mutations in oncogenes or tumor suppressor genes, 
inhibiting DNA replication, and increasing chromosomal instability.  
Mutations in genes associated with cell cycle checkpoints and DNA repair enzymes 
can lead to carcinogenesis. For example, mutations in the oncogenes RAS and MYC can 
lead to unregulated cell proliferation and eventually cancer.172 Ataxia talengiectasia (AT) 
is a genetic disorder characterized by an increased risk of developing leukemia and 
lymphoma.173 AT is caused by mutations to the ATM gene, which encodes the ATM 
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serine/threonine kinase that is activated by DSBs and key to the activation of DNA damage 
checkpoints.173 Another genetic disorder caused by gene mutations is Xeroderma 
pigmentosum (XP). XP patients are unable to repair UV-induced DNA damage such as 
cyclobutane pyrimidine dimers (CPD) and pyrimidine-(6-4)-pyrimidone photoproducts 
([6,4]pps) by NER, and are thus susceptible to sun-induced pigmentation abnormalities and 
an increased risk in skin cancers.174  
Deficiencies in DNA repair pathways are also associated with neurodegeneration, 
premature aging, and carcinogenesis. For example, Cockyane’s syndrome is caused by 
mutations to the CSA and CSB genes, and trichothiodystrophy is caused by mutations to 
the XPB and XPD genes.175 Patients with both conditions are unable to execute TC-NER, 
leading to premature ageing and neurodegeneration.175 Recently, germline mutations to the 
metalloprotease Spartan have been determined to be causative of Ruijs-Aalfs Syndrome, 
which is characterized by genome stability, premature aging, and early-onset 
hepatocellular carcinoma.176 Spartan is currently being investigated as a crucial protease 
involved in DPC repair, making RJALS the first disease directly linked to the inability to 
repair DPCs. Considering the serious biological consequences of unrepaired DNA damage, 
is crucial to fully characterize DNA adducts and elucidate their repair mechanism(s). 
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1.2. 1,3-Butadiene-induced DNA damage 
1.2.1. 1,3-Butadiene 
1,3-butadiene (BD) is a colorless, volatile gas that is present in automobile 
emissions, urban and industrial air, and cigarette smoke.172, 177-179 BD exposure in urban 
centers has been calculated between 1 – 10 ppb, while concentrations near petrochemical 
fueling centers have been calculated at over 100 ppb.178-180 Comparatively, individual BD 
exposure from mainstream and side stream cigarette smoke has been estimated at 205 and 
360 µg/cigarette respectively.181, 182 BD is also an important raw material used in the 
production of synthetic rubber and plastics, especially tires used in the automobile 
industry.178, 179  
Exposure to BD has been linked to many adverse health effects. Epidemiological 
studies have found that inhalation of BD is linked to an increased risk of leukemia, 
lymphatic and hematopoietic cancers, cardiovascular disease, and respiratory disorders.183-
190 Given these risks, the International Agency for Research on Cancer has classified BD 
as a known human carcinogen since 2008.191 Despite the known risks of BD exposure, the 
molecular mechanism of BD-induced mutagenesis and carcinogenesis has not been fully 
elucidated. 
 
1.2.2. Metabolism of 1,3-butadiene 
The pathways of metabolic activation of BD to DNA-reactive species have been 
extensively studied over the years (Scheme 1-6). BD is first metabolized by the 
cytochrome P450 monooxygenases CYP2E1 and CYP2A6, which catalyze the epoxidation 
of the double bond to produce 3,4-epoxy-1-butene (EB).192, 193 EB can either be hydrolyzed 
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by epoxide hydrolase (EH) to yield the unreactive 1-buten-3,4-diol (BED) or further 
oxidized to 1,2,3,4-diepoxybutane (DEB).194, 195 The double bond of BED can be oxidized 
by CYP2E1 to yield 3,4-epoxybutan-1,2-diol (EBD), and one of the epoxide groups of 
DEB can be hydrolyzed by EH to yield EBD.196, 197 All three possible stereoisomers of 
DEB (S,S, R,R and meso) are formed.194 The epoxide metabolites of BD can be detoxified 
by glutathione conjugation/mercapturic acid pathway and excreted from the body in urine 
as a N-acetylcysteine conjugates (Figure 1-6).198 If not detoxified, epoxide metabolites of 
BD can alkylate nucleophilic positions on biomolecules such as proteins and DNA.199-203 
The resulting BD-DNA adducts have varying mutagenic potentials depending on their 
molecular characteristics such as size, shape, hydrogen bonding potential, and 
thermodynamic stability. 
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Scheme 1-6: Metabolism of 1,3-butadiene and the formation of BD-DNA adducts 
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Figure 1-6: Detoxification of 1,3-butadiene metabolite epoxides through the mercapturic 
acid pathway. 
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BD-DNA monoadducts 
  BD epoxides (EB, DEB, and EBD) are reactive electrophiles that can alkylate 
multiple positions of DNA including the N7-position of guanine, the N3-position of 
thymidine, and the N1, N3, and N6-positions of adenine (Figure 1-7). Some examples of 
the resulting adducts include N7-(2-hydroxybut-3-en-1-yl)2’-dG (N7-HB-dG I),200, 204  
N6-(2-hydroxybut-3-en-1-yl)2’-dA (N6-HB-dA I),200 N3-(2-hydroxybut-3-en-1-yl)2’-dU 
(N3-HB-dU),205 N7-(2,3,4-trihydroxybut-1-yl)2’-dGuo (N7-THB-dG I),206, 207 N3-(2,3,4-
trihydroxybut-1-yl)2’-dGuo (N3-THB-dG I), N1-(2,3,4-trihydroxybut-1-yl)2’-dA (N1-
THB-dA),208 and N6-(2,3,4-trihydroxybut-1-yl)2’-dA (N6-THB-dA) (Figure 1-7).208 
As described in section 1.2.2, DEB is a bis-electrophile that has two electrophilic 
epoxide moieties. DEB can react with two nucleophilic positions on the same nucleobase 
to form exocyclic lesions (Figure 1-7). The Tretyakova laboratory has identified exocyclic 
adenine lesions of DEB such as 1,N6-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2’-
Ade (1,N6-α-HMHP-dA), 1,N6-(2-hydroxymethyl-3-hydroxypropan-1,3-diyl)-2’-Ade 
(1,N6-ɣ-HMHP-dA), and N6,N6-(2,3-dihydroxbutan-1.4-diyl)-2’-Ade (N6,N6-DHB-dA), 
with both 1,N6-α-HMHP-dA and 1,N6-ɣ-HMHP-dA observed in the tissues of BD-exposed 
rats (Figure 1-7).209 The Elfarra laboratory reported the formation of exocylic guanine 
lesions 7-hydroxy-3-(2’-deoxy-β,D-erythro-pentofuranosyl)-6-hydroxymethyl-5,6,7,8-
tetrahydropyrimido[1,2a]purin-10(1H)-one (H2) and 7.8-dihydroxy-3-(2’-deoxy-β,D-
erythro-pentofuranosyl)-6-hydroxymethyl-3,5,6,7,8,9-hexahydro-1,3diazepino[1,2a] 
purin-10(11H)-one (H2’), although these lesions have not yet been observed in vivo.210 
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Figure 1-7: Structurally characterized nucleobase monoadducts and fused ring adducts 
induced by epoxide metabolites of 1,3-butadiene. 
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Intrastrand and interstrand DNA-DNA cross-links induced by DEB 
Studies in cell culture have established that DEB is 50 -100-fold more mutagenic 
and genotoxic than other epoxide metabolites of BD (EB and EDB).211, 212 This increased 
mutagenicity and genotoxicity is attributed to the ability of the diepoxide metabolite to 
form intrastrand and interstrand DNA-DNA cross-links. Among the three stereoisomers of 
DEB, (S,S)-DEB being the most mutagenic.213, 214 The variability seen between the isomers 
is attributed to (S,S)-DEB preferentially forming the highly toxic 1,3-interstrand cross-link 
rather than 1,2-intrastrand cross-links.215, 216 The most abundant DNA-DNA cross-link of 
DEB is 1,4-bis(guan-7-yl)butan-2,3-diol (bis-N7G-BD) (Figure 1-8).203, 217 To a lesser 
extent, DEB also forms guanine-adenine cross-links 1-(aden-1-yl)-4-(guan-7-yl)butan-2,3-
diol (N1A-N7G BD) and 1-(aden-3-yl)-4-(guan-7-yl)butan-2,3-diol (N3A-N7G BD) 
(Figure 1-8).218 
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Figure 1-8: Chemical structures of DNA-DNA cross-links induced by the 1,2,3,4-diepoxybutane. 
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1.3. N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-
4-oxo-N5-(alkyl)-formamidopyrimidine (N5-alkyl-FAPy) adducts 
1.3.1. Formation of FAPy adducts 
N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-
formamidopyrimidine (FAPy) adducts can arise in DNA exposed to ROS (discussed in 
section 1.1.2) and after alkylation of the N7-position of purines. Alkylation of the N7-
position of purine yields an unstable, positively charged N7-alkyl-dG cation adduct (16). 
The N7-alkyl-dG adduct can undergo two competing reactions: depurination to yield an 
AP site, or hydroxyl anion attack of the C8-position to yield an 8-hydroxy-N7-alkyl-dG 
intermediate (17), which immediately undergoes opening of the imidazole ring to yield the 
stable N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-N5-
(alkyl)-formamidopyrimidine (N5-alkyl-FAPy) adducts (18, Figure 1-9).  
N5-alkyl-FAPy adducts have been observed after exposure to many electrophilic 
species. These include known carcinogens such as dimethyl sulfate,219, 220 N-
methylnitrosamines, N,N-dimethylnitrosamines,221 environmental toxins such as aflatoxin 
B1(AFB1) epoxide222, 223 and mitomycin C,224 and antitumor and antibacterial compounds 
such as cyclophosphamide225 and azinomycin.226 All N5-alkyl-FAPy adducts are 
characterized by significantly altered molecular structures and impaired hydrogen bonding 
potential as compared to the parent purine, leading to incorporation of incorrect DNA bases 
and/or DNA polymerase arrest during DNA replication.227, 228  
As mentioned above, BD epoxides preferentially alkylate the N7-position of 2′-
deoxyguanosine in DNA to form positively charged N7-guanine DNA adducts such as EB-
Gua I, EB-Gua II and N7-THBG (see section 1.2.2).200, 201, 206 Although no Fapy-dG 
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adducts of BD metabolites are reported in the literature, it is conceivable that EB, EDB, 
and DEB alkylation of purines could lead to the formation of N5-alkyl-FAPy (e.g. EB-
FAPy-dG and DEB-FAPy-dG), which could then contribute to the cytotoxicity and 
mutagenicity of  BD.    
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Figure 1-9: Mechanism of N5-alkyl-FAPy formation after alkylation of the N7-position of guanine. After alkylation of the N7-position 
of guanine, an unstable cation intermediate N7-alkyl-dG (17) is formed. The N7-alkyl-dG intermediate can undergo two competing 
reactions: depurination via oxyanion formation to release the alkylated guanine adduct and form an AP site (purple), or hydroxyl anion 
attack of the C8-position (18), immediately followed by the breaking of the imidazole ring to yield the stable (N5-alkyl-FAPy) adducts 
(19). 
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1.3.2. Biological consequences of FAPy adducts 
The formation of FAPy adducts dramatically changes the molecular shape and the 
hydrogen bonding characteristics of the parent nucleobase.229-232 These structural 
modifications impair Watson-Crick base pairing preferences, leading to disturbances 
during DNA replication such as mutagenicity and genotoxicity.227-230, 232-234 For example,  
N5-alkyl-FAPy adducts have been shown to block DNA polymerases and induce G→T 
transversion mutations during DNA replication in SOS-induced E. Coli.227, 228, 235 
Similarly, N5-alkyl-FAPy-dG adducts have been shown to inhibit DNA polymerases,234, 
236, 237 translesion synthesis (TLS) polymerases,234 and induce G→T transversion in 
mammalian cells.238 These increases in mutations may contribute to the mutagenic and 
toxic effects of known carcinogens, such as the epoxide metabolites of aflatoxin B1 and 
methylating agents. The mutagenicity and genotoxicity of several N5-alkyl-FAPy adducts, 
most notably AFB1-FAPy-dG and Me-FAPy-dG, has been thoroughly investigated in vitro 
and in vivo. 
AFB1-FAPy-dG 
Aflatoxins are mycotoxins generated by certain molds including Aspergillus flavus 
and Aspergillus parasiticus, which grow in decaying vegetation, hay, and grains.239 People 
can become exposed to AFB1 by consuming food stuffs that have been improperly stored, 
especially corn, rice, and wheat. There are four known aflatoxin isomers (aflatoxin B1, B2, 
G1, and G2, Figure 1-10), with aflatoxin B1 being the most hepatotoxic.240 Acute AFB1 
exposures can cause liver necrosis, while chronic exposures to AFB1 are linked to an 
increased risk of developing liver and gallbladder cancer.241 
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A combination of in vitro and in vivo studies have provided convincing evidence 
that AFB1-FAPy-dG is largely responsible for genotoxicity and mutagenicity of AFB1. 
Compared to N7-AFB1-dG, AFB1-FAPy-dG is significantly more stable in rat liver 
DNA.242-244 Furthermore, AFB1-FAPy-dG adducts have been shown to stabilize double 
stranded DNA, presumable due to the intercalating ability of the AFB1 moiety.229, 245 The 
major rotamer of AFB1-FAPy-dG, formed upon rotation around the C5-N5 bond (Figure 
1-10), has been reported to block Salmonella typhimurium DNA polymerase MucAB and 
E. coli polymerase UmuDC.246 In cell culture studies, rat hepatocytes treated with AFB1 
developed frequent G →T transversion mutations in the Ki-Ras oncogene, while human 
hepatocytes treated with AFB1 exhibited G →T transversion mutations in the p53 
oncogene.247, 248 The latter results are consistent with G →T transversion mutations within 
codon 249 of the p53 gene, which are observed in 50% of assayed hepatocellular carcinoma 
samples.249, 250 Taken together, these results indicate that AFB1-FAPy-dG may be the 
major lesion responsible for mutagenicity of AFB1. 
Me-FAPy-dG 
The N7-position of guanine in DNA is the primary alkylation site for small 
methylating agents such as dimethylsulfate and N-methylnitrosamines. The resulting N7-
methyl-dG undergo base-catalyzed transformation to the corresponding Me-FAPy 
adducts.79, 80 Me-FAPy adducts were first observed in vitro by Hanes et al, who methylated 
guanosine with diazomethane and structurally characterized the depurinated 2,4-diamino-
6-hydroxy-N5-methyl 5-formylamidopyrimidine (Me-FAPy) adduct. The first in vivo 
evidence for the formation of Me-FAPy adducts was provided by Beranek et al, who 
identified Me-FAPy in liver DNA of rats treated with N,N-dimethylnitrosamine and 1,2-
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dimethylhydrazine, confirming that Me-FAPy-dG could form under physiological 
conditions.251 Extensive NMR experiments have shown Me-FAPy can exist as a mixture 
of four rotational isomers due to the hindered rotation of the C5-N5 and formyl-N5 bonds.251  
Recent in vitro studies have demonstrated the blocking and mutagenic potential of 
Me-FAPy-dG and Me-FAPy-dA adduct. E. coli DNA polymerase I exo and T4 DNA 
polymerase were completely inhibited one nucleotide before Me-FAPy-dG lesion.236, 252  
Ide et al investigated the bypass of a site specific methyl-FAPy-dG adduct by the Klenow 
fragment of E. Coli DNA polymerase 1 (KF) and observed that the FAPy lesion inhibited 
the extension step of lesion bypass.237 Similarly, high fidelity eukaryotic DNA polymerases 
α, β, and human DNA polymerase δ were blocked at the insertion or extension step.234 The 
TLS DNA polymerases η, κ, and Rev1/Polζ were able to efficiently bypass the lesion, 
although Pol η and Pol κ misinserted dT, dG, and dA opposite Me-FAPy-dG.234  
Mutagenesis studies with M13mp18 phage plasmids in E. coli revealed that Me-
FAPy-dA was 2-fold more mutagenic compared to Me-FAPy-dG following SOS 
induction.227, 253 Specifically, M13mp18 phage DNA containing Me-FAPy-dG did not 
induce an increase in G → C transition mutations following SOS-induction. Conversely, 
the same phage DNA containing Me-FAPy-dA induced a two-fold increase in A → G 
transition mutations.227, 253 These results suggest that methyl-FAPy-dA can mispair with 
2’-deoxycytidine, while methyl-FAPy-dG is primarily a lethal lesion.227  
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Figure 1-10: Observed isomers of AFB-FAPy-dG adducts. Chemical structures of characterized aflatoxin metabolites (Aflatoxin B1, 
AFB1; Aflatoxin B2, AFB2; Aflatoxin G1, AFG1; Aflatoxin G2, AFG2) and the proposed major/minor rotamers of AFB1-FAPy-dG 
adducts.  
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1.3.3. Repair of N5-alkyl-FAPy adducts 
Despite the growing evidence that N5-alkyl-FAPy adducts are mutagenic, there is 
a relatively small amount of information regarding their cellular repair mechanisms. 
Several BER enzymes have been shown to remove N5-alkyl-FAPy adducts. E. coli 
formamidopyrimidine DNA glycosylase (Fpg) efficiently removes unsubstituted FAPy-
dG, unsubstituted FAPy-dA, and Me-Fapy-dG from DNA.254, 255 The size of the N5 
substituent strongly influences this efficiency of Alk-FAPy repair by Fpg, as ethyl-FAPy-
dG is removed nearly seven-fold slower than Me-FAPy-G.256 8-oxo-guanine DNA 
glycosylase (OGG1) also recognizes and repairs Me-FAPy-dG and unsubstituted FAPy-
dG, as well as the carbocyclic analogue of Benzoyl-FAPy-dG.257, 258 The only human BER 
enzyme known to remove unsubstituted FAPy-dA is NEIL 1, which can also remove Me-
FAPy-dG.259, 260 
NER has been identified as the repair pathway utilized to remove bulky AFB1-
FAPy-dG adducts.261 Plasmids containing AFB1-FAPy-dG adducts were transfected into 
wild type and repair deficient strains of E. coli, and host cell reactivation (HCR) assays 
were used to monitor lesion repair.261 E. coli strains deficient in the NER protein uvrA were 
unable to repair the damage, while adduct repair in strains deficient in the BER protein 
mutM was less hindered.261 Considering that the majority of published investigations have 
focused on unsubstituted FAPy-dG and Me-FAPy-dG, repair assays should be performed 
with additional N5-alkyl-FAPy adducts to determine substrate specificity of key BER/NER 
enzymes, to discover how these adducts are ultimately repaired, and to help elucidate how 
these adducts could contribute to the mutagenicity of the parent compound.  
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1.4. DNA-protein cross-links 
DNA-protein cross-links (DPCs) are ubiquitous, super-bulky DNA lesions that 
form when proteins become irreversibly trapped on chromosomal DNA.262, 263 Due to their 
bulky nature, DPCs interfere with key biological processes such as DNA replication,264-267 
gene expression,268 and chromatin packaging. DPC formation has been proposed to play a 
role in ageing,269, 270 cancer,271, 272 heart disease,269, 270 and in neurodegenerative 
disorders.273 Despite significant efforts to elucidate the biological effects of DPCs, their 
contribution to cytotoxicity and mutagenesis of bis-electrophiles is not fully elucidated. 
Furthermore, different cross-linking agents induce DPCs through distinct mechanisms, 
leading to distinct atomic connectivity and different groups of protein constituents involved 
in cross-linking. Finally, the mechanism(s) of active DPC repair remains controversial and 
is still not fully understood. Therefore, comprehensive characterization of the protein 
constituents and understanding the repair of DPCs is crucial to fully understand the 
biological consequences of DPCs. 
 
1.4.1. Formation of DPCs in cells 
DPCs can be induced after exposure to various physical and chemical agents 
including ionizing radiation,274, 275 UV light,276-278 transition metal ions such as Ni and 
Cr,279-282 halogenated hydrocarbons,283, 284 environmental carcinogens,285 and common 
anticancer drugs such as nitrogen mustards and platinum compounds (Figure 1-11).286-289 
Endogenous DPCs can also form as a result of topoisomerases,290, 291 DNA polymerases,29, 
30 and DNA repair enzymes becoming trapped on DNA intermediates, exposure to reactive 
oxygen species (ROS) produced during cellular respiration and inflammation,292-294 and 
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exposure to aldehyde byproducts of lipid peroxidation such as methylglyoxal295 and 
malondialdehyde.296 
One of the most extensively studied DPC inducing agents is formaldehyde (FA). 
FA is a ubiquitous environmental carcinogen present in automobile exhaust, cigarette 
smoke, pharmaceuticals, resins coating particle board and plywood, and vapors from these 
products.297 FA is also produced endogenously as a product of metabolic processes such as 
methanol oxidation, methylamine deamination,298 and histone demethylation.299, 300 
Numerous studies have established FA as mutagenic, carcinogenic, and teratogenic 
compound.301, 302 Although a number of DNA monoadducts and DNA-DNA cross-links 
have been observed in cells exposed to FA.303 DPCs are considered the most abundant FA-
induced lesion.304  
Increased levels of FA-mediated DPCs have been found in the peripheral blood 
lymphocytes from occupationally exposed physicians, laboratory technicians, and 
orderlies.272, 285, 305 Shaham et al observed a linear correlation between the years of 
occupational exposure and the levels of FA-induced DPCs in white blood cells, indicating 
DPCs could serve as a biomarker for chronic FA exposure.285 Furthermore, concentration 
dependent FA-induced DPC formation has been observed in the nasal mucosa and 
respiratory tract of laboratory rats and rhesus monkeys exposed to FA by inhalation.306, 307 
FA-mediated DNA-protein cross-linking takes place between lysine, histidine, 
tryptophan, and cysteine residues of proteins and dG, dA, and dC nucleosides of DNA.308 
Cross-linking initially generates Schiff base intermediates on proteins or DNA, which are 
converted to methylene cross-links upon reaction with another biomolecule (Figure 1-
11A). In vitro cross-linking reactions between formaldehyde, 2’-deoxynucleosides, and 
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amino acids have identified dG-lysine and dG-cysteine cross-links as the most abundant 
adducts, although dG-lysine was unstable at ambient temperature.308 At physiological 
conditions, the half-life of FA-mediated DPCs has been measured as 12.5 hours.309 
However, FA-induced DPCs are reversible upon heating via hydrolysis, a process exploited 
by biochemical assays such as chromatin immunoprecipitation (ChIP).310-312  
Environmental and occupational exposure to the transition metal chromium (Cr) 
can induce DPC formation in cells and tissues.280, 313 Cr-induced DPCs have been observed 
in the lymphocytes of chrome plating operators,281 tannery workers,281, 314 and stainless 
steel welders,281, 313, 315, 316 as well as citizens exposed to Cr-contaminated water.279, 281 
Furthermore, Cr-induced DPCs have been observed in the erythrocytes of fish living in 
contaminated water.317 Cr is present in metal alloys as the stable metallic Cr(0), but upon 
excessive heating or exposure to oxidative chemicals, Cr(0) will become oxidized to the 
water soluble Cr(III) and Cr(VI).318 Due to its tetrahedral arrangement of oxygen groups, 
Cr(VI) structurally resembles sulfate and phosphate anions, allowing for its passive 
transport into cells via non-specific anion carriers.319  
Once Cr(VI) enters the cell, it is quickly reduced to Cr(III) by ascorbic acid, 
glutathione, and cysteine residues.320, 321 Cr(III) has six available coordination sites, easily 
allowing cross linking to the phosphate groups and N7 position of purines on DNA and the 
amino acid residues of proteins (Figure 1-11B).322-325 Thiol containing cysteine and 
glutathione form the most abundant adducts, comprising 24 and 17% of all Cr(III)-DNA 
adducts in Chinese hamster ovary (CHO) cells treated with Cr(VI).322 Additionally, 
histidine, glutamic acid, and ascorbate-Cr(III)-DNA adducts have been identified.281, 322  
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Nitrogen mustards (NM) are a class of anticancer drugs used as first-line 
chemotherapy treatments for lymphoma, leukemia, myeloma, breast and brain cancers, and 
in bone marrow transplantation.326  Examples of clinically useful NMs include 
cyclophosphamide (CP), mechlorethamine, chlorambucil, melphalan, and ifosfamide.327, 
328  The first observation of NM-induced DPCs was made by Ewig et al 329, who detected 
DPCs in mouse leukemia cells (L1210) treated with nornitrogen mustard. Hansson et al 330 
utilized the same methodology to observe nornitrogen mustard and melphalan-induced 
DPC formation in human melanoma (RPMI 8322) cells. Our laboratory employed the 
affinity capture technique mentioned above to identify 15 Chinese hamster ovary and 53 
HeLa nuclear proteins that formed DPCs after exposure to mechlorethamine.286, 287 
The antitumor effects of NMs are attributed to their ability to induce DNA-DNA 
and DNA-protein cross-links, which interfere with DNA replication, ultimately leading to 
cancer cell death. All NMs contain two N-(2-chloroethyl) groups, which can form reactive 
aziridinium ions capable of alkylating nucleophilic positions on DNA and proteins to form 
DPCs (Figure 1-11C). Using mass spectrometry analyses of model protein-DNA 
reactions, our laboratory has shown that the majority of NM-induced DPCs involve the N7 
position of guanine and cysteine residues of proteins.331 
 Platinum agents such as cis-diamminedichloroplatinum(II) (cisplatin), carboplatin, 
and oxaliplatin are another class of commonly used cancer chemotherapeutics. Cisplatin 
was the first FDA-approved platinum anticancer drug, and is still widely used to treat 
bladder, head and neck, lung, ovarian, and testicular cancers.332, 333 Although DNA-DNA 
intrastrand cross-linking is considered to be the major mechanism of activity of platinum 
agents, DPCs are likely to contribute to the observed therapeutic effects.  
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Chválová et al first observed platinum drug-induced DPC formation between 
histone H1 and the Klenow fragment of DNA polymerase with a synthetic DNA 
oligonucleotide.334 For both proteins, Chválová et al observed much greater cross-linking 
with cisplatin compared to transplatin regardless of the length of the DNA oligo, incubation 
time, or concentration of drug.334 Recently, our laboratory investigated cisplatin-induced 
DPC formation in human HT1080 cells and identified 256 distinct cross-linked proteins by 
mass spectrometry-based proteomics. 334, 335 Unlike other bis-electrophiles that are 
selective for cysteine side chains, cisplatin has been shown to form DPCs at various 
residues including arginine and lysine residues of proteins (Figure 1-11D).334, 335  
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Figure 1-11: Mechanisms of DPC formation by formaldehyde (A), chromium IV (B), 
phosphoramide mustard (C), and cisplatin (D). 
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1.4.2. Biological consequences of DPC formation 
The contribution of DPCs to cytotoxicity and mutagenicity of bis-electrophiles was 
first demonstrated by Liu et al.283 This group employed E. Coli cells overexpressing O6-
alkylguanine-DNA alkyltransferase (AGT).  AGT is a DNA repair protein that protects the 
human genome from the damaging effects of promutagenic O6-alkylguanine lesions.86 
Following protein binding to damaged DNA, the O6-alkylguanine nucleotide is flipped out 
of the base stack into the AGT’s active site, allowing for the O6-alkyl group to be 
transferred to an activated side chain thiolate anion of Cys145.87 AGT typically protects 
cells from toxicity associated with exposure to alkylating agents. However, when E. Coli 
overexpressing AGT were exposed to the bifunctional electrophiles 1,2-bromoethane 
(DBE) and diepoxybutane (DEB), toxic AGT-DNA cross-links were formed, leading to 
increased toxicity and mutations in cells overexpressing AGT.283 These results suggested 
that covalent DPCs induced toxicity and genotoxicity in living cells. 
One important limitation of the earlier studies is that cross-linking agents such as 
DBE and DEB form a range of DNA adducts such as DNA-DNA cross-links and 
monoadducts in addition to DPCs, making it difficult to directly attribute the observed 
biological effects to DPC formation. Our group developed a novel methodology to 
selectively induce DPCs into living cells.336 In brief, recombinant human C145A AGT 
protein was treated with DEB to generate a DNA-reactive 2-hydroxy-3,4-epoxybutyl 
moiety on cysteine 150, and the resulting protein containing a DNA reactive epoxide group 
was purified by size exclusion. Electroporation of C145A monoepoxides into mammalian 
cell lines induced cell death and increased the frequency of mutations at the hprt gene (1.8 
per 106 vs 1 per 106, p<0.01, Chi square). When C145A was replaced with a variant unable 
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to accumulate in the nucleus (K125L), lower toxicity and mutations were observed. 
Importantly, toxicity and mutation correlated with the numbers of covalent DPCs as 
detected by LC-MS/MS.336 These results provided the first direct evidence that DPC 
formation leads to cell death.  
Due to their super-bulky nature, DPCs are expected to inhibit crucial biological 
processes such as DNA replication and transcription, interfering with the faithful copying 
and expression of genetic information. The size of the protein constituent of DPC and the 
cross-linking site on DNA largely determine whether they present a complete block or can 
be bypassed by DNA and RNA polymerases.  Nakano et al reported that DPCs over 14.1 
kDa in size located on the translocating strand completely blocked DNA unwinding by 
human helicases (mini chromosome maintenance Mcm467 subcomplex), while DPCs 
between 5 to 14.1 kDa severely blocked helicase progression (Table 1-3).264  
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Table 1-3: In-vitro determination of the size limits for different helicase enzymes to bypass DPCs. 
 
 
 
 
 
 
 Helicase inhibition by DPC 
Protein MW (kDa) DnaB T7gp4 Mcm467 Tag 
Oxanine control 0 None None None None 
Adrenomedullin (22 – 52)* 3.6 None Minor stalling None Minor stalling 
Parathyroid hormone (1 – 22)* 3.7 None Minor stalling None Minor stalling 
Gastric inhibitory peptide 5.0 None Minor stalling Severe stalling Minor stalling 
Midkine (60 – 121)* 6.8 Severe stalling Severe stalling Severe stalling Severe stalling 
Histone H2A 14.1 Blocked Severe stalling Blocked Severe stalling 
T4 endonuclease V 16.0 Blocked Blocked Blocked Blocked 
High mobility group protein 1,2 24.9 Blocked Blocked Blocked Blocked 
NEIL1 DNA glycosylase 43.7 Blocked Blocked Blocked Blocked 
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Our laboratory investigated the effects of DPCs and smaller DNA-peptide 
conjugates on DNA replication in vitro by human DNA polymerases.266, 267 Hydrolytically 
stable model DPCs were site-specifically incorporated into DNA using reductive amination 
reactions between protein’s lysine residue and  7-deaza-7-(2,3-dihydroxypropan-1-yl)-2’-
deoxyguanosine in DNA337 or copper catalyzed [2+3] cycloaddition between azide-
containing proteins and 5-(octa-1,7-diynyl)-uracil in DNA.265 In vitro DNA replication 
experiments have uncovered complete blockage of human TLS polymerases η, κ, β, and ι 
by full size DPC lesions.266, 267 However, when the protein was replaced with a 10-mer 
peptide, the polymerases were able to bypass the adduct.265, 266 Polymerase bypass of 10-
mer peptides attached to C5 position of cytosine in DNA by hPol ƞ and hPol κ was error 
prone, resulting in both base substitutions and deletions.266 In contrast, the same lesions 
conjugated to the N7 position of DNA were not mispairing.267 More recently, we 
investigated the effects of bulky DPC lesions on transcription (Ji et al, unpublished data). 
We found that bacterial RNA polymerases were blocked by protein lesions conjugated to 
the N7 position of guanine. Lesions placed in the non-transcribed strand of DNA had a 
smaller effect on transcription (Ji et al, unpublished data). Taken together, these studies 
show the importance of the protein lesion size and conjugation site on DNA in defining 
their biological consequences.  
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1.5. DPC-inducing agents studied in this thesis 
1.5.1. Reactive oxygen species 
Reactive oxygen species (ROS) are radical and non-radical oxygen species formed 
by a partial reduction of oxygen. Examples of ROS include superoxide anions (O2-), 
hydrogen peroxide (H2O2), and hydroxyl radicals (•OH). ROS can be produced 
endogenously in cells during aerobic cellular respiration,338-340 immune response,341, 342 and 
inflammation,35 and after exposure to exogenous agents such as cigarette smoke and urban 
air,343, 344 alcohol consumption,345, 346 and Cr(VI) exposure.347 ROS production is necessary 
for cellular survival, as it plays a crucial role in protection against pathogens348 and cellular 
signaling pathways such as the phosphoinositide 3-kinase (PI3K) pathway,349-351 mitogen-
activated protein kinase (MAPK) cascades,352-354 and the NF-κB pathway.355 However, 
ROS can also damage cellular biomolecules including DNA and proteins, leading to the 
direct covalent attachment of proteins to DNA to form DPCs. 
 
1.5.2. ROS-induced DPCs 
Some ROS-induced DNA lesions can undergo secondary reactions with 
nucleophilic sites of proteins, leading to the formation of DPCs.263, 356 For example, 5-
amino-3-β-(2-deoxy-D-ribofuranosyl)-3H-imidazo[4,5-d][1,3]oxazin-7-one (2'-
deoxyoxanosine, dOxo) lesions are formed from 2’-deoxyguanosine in DNA upon 
exposure to reactive nitrogen species. The O-acylisourea functionality of dOxo is 
susceptible to nucleophilic attack by protein side chains, forming an amide bond between 
the protein and the DNA.357 Interestingly, histone and HMG proteins, which are highly 
abundant in eukaryotic chromosomes, have relatively low reactivity towards oxanosine as 
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compared to DNA glycosylases involved in base excision repair, probably a result of 
damage-specific protein-DNA interactions.357, 358 Similarly, oxidation of 2’-deoxyribose 
residues of DNA can lead to the formation of inherently reactive abasic sites. For example, 
oxidation at the C’-1 position of the 2’-deoxyribose sugar can lead to the formation of 2-
deoxyribonolactone, which can form amide conjugates to proteins such as Escherichia coli 
endonuclease III (Endo III) and DNA polymerase β (Pol β).359,360  
DNA-protein cross-links can also form directly via one electron oxidation of DNA 
bases. One electron oxidation of guanine can form a radical cation that can react with lysine 
side chain to yield Nε-(guanin-8-yl)-lysine cross-links.361 Similarly, hydrogen abstraction 
from the 5’-methyl group of thymidine yields 5-(uracilyl)methyl radical, which can 
undergo a radical addition reaction to the C-3 position of a neighboring tyrosine molecule 
to form thymidine-tyrosine cross-links.362, 363 
 
1.5.3. ROS-induced DPC formation following myocardial infarction/reperfusion  
One biological event that stimulates a massive and sudden influx of ROS in the 
heart is myocardial infarction/reperfusion. Myocardial infarction (MI, heart attack) occurs 
when the blood flow is decreased or stopped in a cardiac artery, restricting the delivery of 
oxygenated blood to the affected myocardium. In the United States alone, nearly 790,000 
individuals suffered a MI in 2016.364, 365 Current MI therapies are based reperfusion, or the 
re-opening of the blocked artery, returning blood flow to the damaged myocardium. 
However, the sudden influx of oxygenated blood is associated with a rapid influx of ROS 
to the already damaged myocardium.366-368 
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During the myocardial infarction, the lack of oxygen switches the cells to anaerobic 
respiration mode.367, 369 Reperfusion-induced oxygen return triggers reactivation of the 
electron transport chain, producing ROS that can permeate from the mitochondria to other 
cellular components including the nucleus.367, 369 Furthermore, neutrophils accumulating 
in the infarcted myocardium mediate tissue damage release matrix-releasing degrading 
enzymes and ROS for downstream signaling.370-372 Neutrophils have been determined to 
be the primary source of oxygen radicals generated during MI/reperfusion, reaching peak 
concentrations only 10 min after the reperfusion.371 Taken together, rapid influx of ROS 
following MI is expected to oxidatively damage DNA, potentially leading to the formation 
of covalent DPCs. However, ro our knowledge there are no previous reports of DPC 
formation following ischemia-reperfusion injury. 
 
1.5.4. Phosphoramide mustard and nornitrogen mustard 
Cyclophosphamide (CP) is a nitrogen mustard drug used as first-line chemotherapy 
treatment for lymphoma,373, 374 leukemia,375 myeloma,376, 377 breast and brain cancers,378 
and in bone marrow transplantation.379, 380 CP is administered as a prodrug and must be 
first activated by the liver cytochrome P450 enzymes CYP2B5 and CYP3A4 to yield 4-
hydroxy cyclophosphamide (4-OH-CPA).381, 382 The metabolite 4-OH-CPA spontaneously 
equilibrates with the ring-open aldophosphamide form, which can enter and accumulate 
within cells. Aldophosphamide then spontaneously undergoes β-elimination to yield the 
therapeutically active metabolite, phosphoramide mustard (PM), and the byproduct 
acrolein. Under physiological conditions, PM spontaneously dephosphoramidates to form 
another DNA alkylating agent, nornitrogen mustard (NOR).383-385  
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Both PM and NOR can modify the N-7 position of guanine of DNA to yield N-(2-
chloroethyl)-N-[2-(7-guaninyl)ethyl] amine, N-(2-hydroxyethyl)-N-[2-(7-guaninyl)ethyl] 
amine, and N,N-bis-[2-(7-guaninyl)ethyl] amine adducts,383-385 and also produce covalent 
DNA-protein conjugates. Prior to my investigation, the identities of the proteins 
participating in PM-induced DPC formation were not known, and the absolute numbers of 
DPCs induced by nitrogen mustard treatment were not determined.  
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1.6. Characterization of DPCs 
In order to characterize DPC formation, identify protein constituents of DPC, and 
quantify DPC formation, several biophysical and mass-spectrometry-based techniques 
have been developed. Early biophysical techniques such as gel shift assays, comet assays, 
and alkaline elution methods allowed for the confirmation of covalent DPCs and relative 
quantification. Recently, chemical separation techniques have been developed to isolate 
covalent-DPCs from unbound chromosomal DNA and proteins respectively. Furthermore, 
advances in mass spectrometry has allowed for the identification of the protein constituent, 
the attachment site of the proteins, and the absolute quantification of DPC formation. 
 
1.6.1. Biophysical identification techniques 
The simplest technique to confirm DPC formation in vitro is the electrophoretic 
mobility shift assay (EMSA).334, 386, 387 In this approach, radiolabeled DNA duplexes are 
incubated with a protein of interest in the presence of a cross-linking agent. The reaction 
mixture is resolved by denaturing gel electrophoresis and visualized by autoradiography. 
Under these conditions, any non-covalently bound proteins will dissociate from DNA, 
while covalent DPCs will remain intact and can be visualized as reduced mobility bands 
on the gel. Our laboratory has successfully demonstrated DPC formation between specific 
proteins and nitrogen mustards,331 1,2,3,4-diepoxybutane (DEB),388 and cisplatin.289 
Although EMSAs can easily confirm DPC formation in-vitro, they cannot replicate the 
physiological conditions of the nucleus or provide structural information. 
 The first reports of DNA-protein cross-link identification in cells utilized 
biophysical approaches such as alkaline elution methodology.389 In this method, DNA was 
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radiolabeled with 3H-labeled thymidine in cell culture. Treated and control cells were lysed 
onto a polyvinyl filter and washed with the lysis solution to remove intact proteins and 
lipids.389 Free DNA was then eluted from the filter by washing with an alkaline solution, 
leaving the covalent DPCs trapped on the filter.329, 389, 390 Treatment with proteinase K 
digested the protein constituent of DPCs, allowing the cross-linked DNA to be eluted 
through the filter.329, 390 Relative quantitation of DPCs can be achieved by comparing on 
the amounts of radioactive DNA eluting from the filter before and after proteinase K 
digestion.  
DPC formation in cells can also be detected by single-cell gel electrophoresis 
(SCGE), better known as the comet assay.304, 391-395 Following exposure to cross-linking 
agent, cells are irradiated to induce strand breaks. Cells are suspended on agarose covered 
slides, lysed under alkaline conditions, and subjected to electrophoresis. DNA is visualized 
on the slide by staining with a fluorescent dye. The DNA fragments induced by γ-
irradiation will travel through the agarose gel faster than unmodified chromosomal DNA, 
forming a “tail”, while the presence of DPCs will decrease the length of the comet’s tail. 
DPC formation can be confirmed by pretreating the samples with proteinase K and 
observing a recovery of the comet tail. The length of the comet’s tail can therefore be used 
to estimate the amount of DPC formation. Using the comet assay, Oliver Merk and Gunter 
Speit were able to show a dose-dependent increase in FA-induced DPC formation from 0 
to 500 µM FA in V79 chinese hamster cells.304 Although both the EMSA and comet assay 
can identify and relatively quantify DPC formation in cells, these techniques cannot 
separate DPCs from unmodified chromosomal DNA without destroying the protein 
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constituent, eliminating any opportunity to identify the protein constituents or the site of 
cross-linking. 
 
1.6.2. Isolation of DPCs from cells 
The first developed method to isolate DPCs formed in cells from unmodified 
chromosomal DNA was the SDS/K+ precipitation method developed by Zhitkovich and 
Costa (Scheme 1-7).396 In this approach, cells are lysed in the presence of SDS and heated 
to 65 oC, allowing for protein denaturation and dissociation from DNA. SDS uniformly 
binds to the proteins and peptides, yielding a net negative charge on the complex.397 The 
lysate is then treated with potassium chloride, and the solution is passed through a pipette 
tip to uniformly shear DNA. The potassium cations bind to the SDS molecules, creating a 
net-neutral complex that precipitates DPCs out of solution upon cooling. Zhitkovich and 
Costa used this assay to detect DPCs induced by chromium, cisplatin, and formaldehyde 
in CHO cells.396 This method efficiently separates DPCs from free DNA, allowing for more 
accurate quantitation. However, it cannot distinguish between proteins binding to DNA 
non-covalently and those forming covalent DPCs, as both will form SDS/K+ complexes 
during the workup.  
 To ensure that only proteins originating from DPCs are detected, unbound proteins 
and peptides must be separated from covalent DPCs by removing any non-covalently 
bound proteins. One of the most common techniques for DNA isolation from cells and 
tissues is phenol-chloroform or phenol-isoamyl alcohol extraction (Scheme 1-7).398 We 
have adopted this methodology to isolate DNA containing covalent DPCs from cells 
treated with DEB,399 nitrogen mustards,286-288 and cisplatin.289 When nuclear lysates from 
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treated cells are mixed with an equal volume of phenol-chloroform, three distinct layers 
form upon centrifugation. The bottom organic solvent layer contains free proteins, while 
the top aqueous layer contains chromosomal DNA. The middle layer/interface contains 
covalent DPCs. This partitioning allows for proteins covalently attached to DNA to be 
separated from the unbound nuclear proteins. After the top two layers are extracted with 
organic solvent several times, DNA containing covalent DPCs can be precipitated out of 
solution with cold ethanol for further analyses via gel electrophoresis or MS-based 
proteomics. Although DNA and DPCs will be separated from free proteins, there is the 
potential to contaminate the DNA/DPC aqueous/interface layers with protein-containing 
phenol during processing, making sample reproducibility more difficult.  
 Barker et al developed the DNAzol-strip and DNAzol-silica extraction methods for 
DPC isolation from cells (Scheme 1-7). Both methods lyse isolated nuclei using the 
commercially available DNAzol, a guanidine-detergent solution optimized for DNA 
precipitation. Strong chaotropic agents are used to strip unbound proteins from DNA.400 
DNA containing covalent DPCs is then precipitated with cold ethanol. Although the 
DNAzol-strip method successfully removes non-covalently bound proteins from DPCs, 
there is potential for protein degradation due to long processing time in high salt solutions. 
DNAzol-strip methodology was successfully applied by Barker et al to isolate IR-induced 
DPCs in both CHO and human fibroblast cells275 and by Yingsheng Wang’s group  to 
isolate global FA-induced DPCs from HeLa cells.401 
In preparation for the DNAzol-silica extraction method, silica fines are activated 
by heating in nitric acid, and the nuclear lysate is incubated at 37 oC with 4 M NaCl and 4 
M urea to dissociate any unbound proteins. The lysate is then loaded onto the activated 
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silica fines, where DNA (but not proteins) will be adsorbed.  The DNA/DPCs trapped on 
the silica can be subsequently eluted using 8 M NaOH. As with the DNAzol-strip 
methodology, there is the potential to degrade proteins on the activated silica during 
processing. The DNAzol-silica method was successfully used by Prasad et al to isolate 
DPCs formed between PARP-1 protein and abasic sites within DNA.386     
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Scheme 1-7: Schematic representation of methodologies for extracting DNA-protein 
cross-links from cells via phenol/chloroform extraction (1), SDS/K+ precipitation (2), 
DNAzol-strip (3), and DNAzol-silica (4). 
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1.6.3. Mass spectrometry based identification of DPCs 
Recent developments in the field of mass spectrometry have allowed for the 
mapping of the cross-linking sites across specific proteins and the specific atomic 
connectivity of bis-electrophiles to DNA and proteins.402, 403 For example, our laboratory 
mapped the cross-linking of hAGT and C145A AGT to double stranded DNA using 
DEB.388 After hydrolysis of the protein-nucleobase off the DNA backbone and trypsin 
digestion of hAGT, the tryptic peptides were analyzed by HPLC-ESI+-MS/MS. Two 
peptides, G136NPVPILIPCHR147 and V148VCSSGAVGNYSGGLAVK165, revealed a mass 
shift of +237 Da that corresponded to the addition of butanediol cross-linked to guanine.388 
CID fragmentation patterns identified Cys145 and Cys150 as the site of cross-linking.388 
When the same experiment was performed using C145A AGT, the peptide 
V148VCSSGAVGNYSGGLAVK165 displayed the same HPLC retention time and CID 
fragmentation pattern as the wild type AGT, confirming cross-linking at Cys150.388 
To confirm DEB-induced cross-linking occurred exclusively at cysteine residues, 
HPLC-ESI-MS/MS of the total enzymatic digest of the DPC was performed. Following 
incubation with DEB, the AGT protein was completely digested using by carboxypeptidase 
Y and proteinase K to yield a single amino acid. HPLC-ESI-MS/MS analysis was set up to 
monitor the presence of 1-(S-cysteinyl)-4-(guan-7-yl)-2,3-butanediol (Cys-Gua-BD, m/z = 
359.1), 1-(O-tyrosyl)-4-(guan-7-yl)-2,3-butanediol (Tyr-Gua-BD, m/z = 420.1), 1-(N-
lysyl)-4-(guan-7-yl)-2,3-butanediol (Lys-Gua-BD, m/z = 385.4), 1-(N-arginyl)-4-(guan-7-
yl)-2,3-butanediol (Arg-Gua-BD, m/z = 413.4), 1-(N-histidyl)-4-(guan-7-yl)-2,3-
butanediol (His-Gua-BD, m/z = 393.4).388 Analysis revealed the presence of only Cys-Gua-
BD, which co-eluted at the same time as an authentic standard and the same fragmentation 
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pattern: m/z = 359.1 [M + H]+ → m/z = 208.1 [M – Gua + H]+, m/z = 190.0 [M – Gua – 
H2O + H]+. No evidence of Tyr-Gua-BD, Lys-Gua-BD, Arg-Gua-BD, or His-Gua-BD was 
detected, confirming the atomic connectivity of DEB-induced DPC formation to occur 
between the N7-position of guanine and the thiol moiety of cysteine. Analogously, our 
laboratory has performed similar experiments to confirm cross-linking of AGT by nitrogen 
mustards331 and cisplatin (Ming et al, unpublished data). 
 
1.6.4. Mass spectrometry based proteomics 
Recent developments in biological mass spectrometry have allowed great advances 
in mass spectrometry-based proteomics (MS-proteomics). The new Orbitrap and Q-TOF 
mass spectrometers provide improved data acquisition speed, high resolution, and excellent 
mass accuracy (<10 ppm) of peptide fragments, allowing for sensitive and accurate protein 
identification. These improvements now allow for over 5,000 proteins to be identified in a 
single proteomics experiment, a number far exceeding the numbers of proteins expected to 
become cross-linked to DNA. These recent developments have enabled system-wide 
analyses of complex protein mixtures with excellent sensitivity and specificity, and have 
recently been applied to identify the protein constituents of DPCs.  
The most common approach to identify the protein constituent of DPCs utilizes 
bottom-up proteomics methodology. In this method, proteins are digested to peptides with 
specific proteases and identified based on their molecular weights and MS/MS 
fragmentation patterns, which are compared to theoretical spectra present in spectral 
databases.404 To improve digestion efficiency, disulfide linkages of proteins are reduced to 
thiols using dithiolthreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP), which are 
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alkylated with iodoacetamide to prevent their oxidation. Proteolytic digestion of proteins 
generates predictable peptide fragments due to protease-specific peptide bond cleavages. 
The most common protease used in proteomics is trypsin, which cleaves proteins at 
arginine and lysine residues.405 Other commonly used proteases include chymotrypsin 
(cleaves at carboxyl side of lysine and the aromatic residues tyrosine, tryptophan, and 
phenylalanine), Lys-C (cleaves at carboxyl side of lysine and arginine or proline), Glu-C 
(cleaves at the C-terminus of aspartic or glutamic acid and serine), and Arg-C (cleaves at 
the C-terminus of arginine and proline or lysine).404  
Typical bottom-up proteomics analyses utilize nano HPLC separation of peptide 
mixtures coupled to nanospray ionization tandem mass spectrometry analysis, preferably 
using high resolution mass analyzers such as Orbitrap MS (Scheme 1-8).404 Data is 
acquired in an automated data-dependent MS/MS mode, where full scan events are 
followed by MS2 or MS3 analyses of the most abundant ions in the spectra. Details 
regarding mass spectrometers, liquid chromatography separation of peptides, and 
fragmentation patterns of peptides are beyond the scope of this review and have been 
reviewed elsewhere.404, 406   
 Mass spectrometry-based proteomics provides an opportunity to conduct global, 
unbiased analysis of all protein components of DPCs (Scheme 1-8). This approach has 
been successfully used to investigate DPC formation by many cross-linking agents 
including ionizing radiation,274, 275, 407 reactive oxygen species, cisplatin,335 nitrogen 
mustards,331 diepoxybutane,388 and formaldehyde.401 In order to utilize bottom-up 
proteomics to identify DPCs, the protein constituent of a DPC must be released from the 
DNA backbone. Because many bis-electrophiles alkylate DNA at the N7 position of 
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guanine, this creates hydrolytically labile DNA lesions susceptible to depurination and the 
formation of abasic sites. Upon heating to 90° C, such DPCs can be quantitatively released 
from the DNA backbone in the form of protein-guanine conjugates. We have recently 
shown that this methodology can be modified to allow for analyses of hydrolytically stable 
DPCs such as those induced by reactive oxygen species by incorporating a DNA digestion 
step (see Chapter 3 of this Thesis). DNA can be digested to single nucleosides in the 
presence of nuclease enzymes to generate protein-nucleoside conjugates suitable for 
proteomics analyses. 
Following their release from DNA, proteins participating in cross-linking can be 
resolved by SDS-PAGE and visualized by staining with mass spectrometry-compatible 
stains such as Coomasie brilliant blue.408 Individual protein bands or gel regions 
corresponding to specific molecular weight ranges can then be excised from the gel, 
allowing for initial fractionization of the proteins mixtures. The excised gel pieces can then 
be prepared for trypsin digestion followed by extraction of the resulting tryptic peptides 
from the gel matrix. As an alternative to gel-based analyses, filter-aided sample preparation 
(FASP) techniques can be used to simplify sample preparation for MS-based proteomics.409 
This protocol performs protein capture and digestion steps on the same size exclusion 
filters. This method allows for high concentrations of detergents (i.e. 8 M urea) to be used 
to ensure universal solubilization of proteins. Following reduction and alkylation steps 
described above, detergents can be washed off the filter by centrifugation, while the 
proteins remain trapped on the filter. Finally, proteins can be digested to peptides using 
trypsin, and the resulting peptides are eluted and collected for MS analysis. For complex 
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samples, peptides generated by FASP can be pre-fractionated using offline HPLC, and each 
fraction is separately analyzed by HPLC-ESI+-MS/MS.  
To allow for protein identification, experimentally observed peptide mass and 
MS/MS fragmentation data are entered into a software package such as Proteome 
Discoverer (Thermo-Fisher), where the fragmentation patterns are compared to spectra 
present in the database (Scheme 1-8). Identified proteins are matched to their 
corresponding gene ID, creating a gene list. From here, various data mining tools can be 
used to probe the functions of the identified proteins. Singular enrichment analysis tools 
such as DAVID (Database for Annotation, Visualization, and Integrated Discovery) can be 
used to extract the molecular and biological functions of the identified protein.410 While 
large gene lists can provide an overwhelming amount of information due to the linearity of 
the output terms, these terms can then be condensed into relevant categories allowing 
enriched biological and functional themes to be detected. For example, terms such as 
apoptosis, programmed cell death, and regulation of apoptosis, etc. may be condensed 
under a single term, apoptosis, in order to simplify the data output.410 Another method of 
data mining that can be employed is the use of pathway analysis software, such as Ingenuity 
Pathway Analysis (IPA). Here, the gene list is inputted into the software where 
relationships and canonical pathways involved can be elucidated through comparisons with 
an extensive collection of published experimental data.411 These are just two examples of 
the numerous data mining techniques that can be utilized to extract biological meaning 
from the extensive gene lists produced by proteomics experiments. 
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Scheme 1-8: Schematic of protein identification from mass spectrometry-based proteomics 
data analysis 
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Protein identities obtained from LC-MS/MS can be confirmed using 
immunological detection with specific antibodies, also referred to as immunoblotting. 
Incubation with a conjugated secondary antibody allows the visualization of these specific 
proteins using colorimetric or chemiluminescence detection. In preparation for 
immunoblotting, DPCs are digested to protein-guanine or protein-nucleoside conjugates, 
which can then be resolved by one-dimensional or two-dimensional gel electrophoresis. In 
two-dimensional gel electrophoresis, proteins are resolved by two differing properties. For 
instance, proteins can be first separated by isoelectric point using a pH gradient gel and 
then transferred to a PAGE gel to further separate the proteins based on mass. Following 
either gel electrophoresis technique, the gels can be incubated in the presence of specific 
antibodies for identification of individual proteins. Although immunological techniques 
are selective and sensitive, they can only detect several proteins at a time, requiring prior 
knowledge of protein identities.  
 
1.6.5. Quantitative proteomics of DPCs 
Although traditional bottom-up mass spectrometry-based proteomics 
methodologies can help identify protein constituents of DPCs, they are unable of 
quantifying DPC amounts following exposure to cross-linking agents. Background levels 
of DPCs are present in all living cells due to endogenous exposure to reactive oxygen 
species, products of lipid peroxidation, and due to inadvertent trapping of DNA 
topoisomerases, polymerases, and repair proteins on their DNA substrates.29, 30, 412, 413 In 
order to distinguish between background and exposure-mediated cross-linking, the 
amounts of DPCs in control and treated cells must be compared. Recently developed 
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quantitative proteomics techniques use stable isotope labeling of proteins or peptides to 
allow for relative quantitation of proteins across multiple samples/experiments.414, 415 
These quantitative proteomics protocols have been recently applied to studies of DNA-
protein cross-linking, allowing for better understanding of exogenous versus induced DPC 
formation, as well as their persistence and repair over time.  
One of the most powerful techniques of quantitative proteomics is stable isotope 
labeling with amino acids in cell culture (SILAC). In this approach, isotopically labeled 
arginine and lysine are added to the cell culture media, leading to their incorporation into 
all cellular proteins during translation.414, 416 Adding two labeled amino acids ensures that 
every peptide from a proteolytically digested protein will contain at least one isotopic 
label.416 In a typical SILAC experiment, experimental manipulation such as exposure to a 
cross-linking agent is performed with the isotopically labeled “heavy” cells, while the 
control condition is performed with the normal “light” cells. Following treatment, proteins 
from light and heavy cells are combined and subjected to traditional mass spectrometry-
based proteomics workflow. Since the physiochemical properties, such as ionization 
potential, fragmentation, and ESI MS signal response are the same for isotopically labeled 
and unlabeled peptides, their relative HPLC-MS/MS signal intensities allow for relative 
quantitation across samples, enabling the detection of quantitative changes in protein 
levels. To confirm the quantitative results, reverse labeling can be employed with heavy 
cells serving as controls this time.  
To our knowledge, SILAC has not yet been used to quantify DPC formation 
following exposure to environmental and therapeutic bis-electrophiles. However, DNA-
protein cross-linking by formaldehyde in combination with SILAC has been used to 
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measure changes in DNA-protein binding. For example, Byrum et al combined chromatin 
affinity purification with SILAC mass spectrometry to quantify changes in protein binding 
and histone post-translational modifications to the GAL1 loci under “transcriptionally 
silent” or “active” states in S. Cerevisiae.417 These authors introduced a LexA binding site 
upstream of the GAL1 promoter in a strain of S. Cerevisiae constitutively expressing a 
LexA fusion protein.417 The mutant strain of yeast was grown in regular light media, while 
the wild type strain was grown in heavy media. Both strains were then exposed to glucose 
(to repress transcription) or galactose (to activate transcription), followed by FA treatment 
to cross-link bound proteins to DNA. DNA shearing and ChIP purification using a LexA 
antibody allowed for purification of the GAL1 loci along with any trapped proteins. 
SILAC-based proteomics has enabled these authors to identify and quantify the proteins 
interacting with “silent” or “active” chromatin, as well as to eliminate any non-specific 
binders which manifested themselves by having 1:1 ratio of light and heavy peptide signals. 
A similar approach was adopted by Soldi and Bonaldi 310 to observe global changes in 
protein binding at transcriptionally active or silent regions of chromatin. Following 
treatment with FA to induce cross-linking of DNA-binding proteins to DNA, regions of 
chromatin were immunoprecipitated using antibodies against histone H3 with a 
trimethylated lysine 9 (transcriptionally repressed)418 and histone H3 with a trimethylated 
lysine 4 (transcriptionally active) 419, allowing for the relative quantification of proteins 
binding to various regions of chromatin. These examples suggest that SILAC could also 
be used for quantitation of DPCs induced by endogenous and exogenous agents. However, 
SILAC requires in vitro labeling of proteins with unnatural isotopes and thus is limited to 
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cell culture experiments. Furthermore, multiplexing experiments are not practical due to 
limited availability of isotopically labeled cell culture media and cost considerations. 
Another powerful methodology of quantitative proteomics involves chemical 
labeling of reactive residues of tryptic peptides. Two of the most popular chemical labeling 
agents are tandem mass tags (TMT, available from Thermo Fisher Scientific) (Figure 1-
12A) and isobaric tags for absolute and relative quantification (iTRAQ, sold by Sciex) 
(Figure 1-12B). Both TMT and iTRAQ tags contain a mass reporter region, a mass 
normalizer section, an amine-reactive N-hydroxysuccinimide group, and the same number 
of isotopic labels differentially distributed throughout the molecule. These tags react with 
and label lysine and arginine residues and the N-terminal amines of tryptic peptides. 
Experimental samples and controls are labeled with isotope unique tag, and the labeled 
peptides are mixed together prior to analysis. Upon MS/MS or MS3 fragmentation of 
peptides during mass spectrometry analyzes, characteristic product ions are observed in the 
spectra. Since each mass reporter region will have a different number of isotopic labels, 
peptides from differentially labeled samples can be distinguished from each other, thus 
providing a characteristic signal for peptides originating from each sample/experimental 
condition. Furthermore, reporter ion intensities can be used for relative quantitation of each 
protein across samples. Commercially available kits contain four, six, or eight unique 
labels, allowing for ready multiplexing. I utilized TMT labeling to quantify DPC formation 
in cardiomyocytes following myocardial infarction/reperfusion as compared to healthy 
myocardium using 6-plex TMT methodology, which is described in detail in chapter 3. 
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Figure 1-12: Chemical structures of commercially available chemical labels Tandem Mass 
Tags (TMT) (A) and isobaric tags for relative and absolute quantitation (iTRAQ) (B) used 
in quantitative proteomics  
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1.7. Mechanisms of DPC repair 
The mechanisms by which covalent protein-DNA complexes are recognized as 
DNA damage and removed from genomic DNA in cells and tissues are incompletely 
understood. DPCs that are produced by the enzymatic entrapment of topoisomerases 1 and 
2 (TOP1 and TOP2) can be reversed by specific tyrosil-DNA phosphodiesterases TDP1 
and TDP2, respectively.420 These enzymes hydrolyze the covalent bond between the 
topoisomerase’s active site residue and the DNA, releasing the protein.420 For all other 
DPC structures, such as those formed endogenously by ROS exposure or sequential cross-
linking by bis-electrophiles, the repair mechanism remains controversial. 
In the yeast, Stingele et al identified the metalloprotease Wss1 as a DPC-specific 
protease that could relieve replicative stalling by acting directly on the covalently attached 
protein.421Yeast mutants lacking Wss1 exhibited an accumulation of FA-induced DPCs 
and topoisomerase-mediated DPCs, lead to yeast accumulating in the late-S/G2 phase of 
cell cycle.421 Furthermore, yeast lacking Wss1 exhibited an increase in FA-induced 
recombination and gross chromosomal recombination.421 This is consistent with a model 
where DPCs cause replication fork stalling, leading to cleavage by endonucleases and one-
ended DNA double-strand breaks, which in turn lead to recombinational repair.422 
When the roles of canonical DDR pathways in DPC repair were investigated in 
mammalian cells, varied conclusions were achieved. Zhitkovich et al. examined toxicity 
and repair of DPCs induced by Cr(VI) and formaldehyde in human cells.324, 423 These 
researchers found that pharmacological inhibition of nucleotide excision repair increased 
DPC formation, while inhibition of the proteasome activity abolished DPC repair, 
suggesting that proteosomal degradation of DPCs initiates their repair by NER.309 Nakano 
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et al reported that proteins smaller than 14 kDa could be removed by NER in itro, but larger 
proteins were not NER substrates.424, 425 Additionally, DNA-peptide cross-links produced 
from protease-digested DPCs have been identified as substrates for nucleotide excision 
repair in vitro.309, 426, 427 Reardon et al. and Baker et al. demonstrated that DPCs containing 
T4-pdg (16 kDa) and Hhai I DNA methyltransferase proteins (HDnmt, 37 kDa) could not 
be excised by human nucleotide excision repair proteins in vitro, but smaller polypeptide-
DNA cross-links were efficiently removed by NER.426, 427  
Alternatively, Nakano et al has proposed homologous recombination as the major 
DDR pathway that contributes to DPC removal. They were unable to detect 
polyubiquitination of extracted FA-induced DPCs by western blot, which would be 
required for proteasome degradation.424 Furthermore, Chinese hamster cells deficient in 
RAD51 (HR-deficient) were two to three magnitudes more sensitive to formaldehyde and 
5-aza-2’-deoxycytidine (azadC) compared to NEHJ or NER-deficient cells, and recovery 
of RAD51 eliminated this observed sensitivity to the drugs.424 Finally, HR-deficient cells 
treated with FA or azadC were found to accumulate double strand breaks via alkaline comet 
assay (see section 1.5.1).424 Taken together, data of Nakano et al suggest that DPC 
formation leads to replication fork breakage at the site of DPC formation and thus initiates 
HR to alleviate the stalled replication fork.424   
Recent studies have focused on the role of the metalloprotease DVC1/Spartan 
(SPRTN) in digesting the protein constituent of a DPC to allow for their repair. SPRTN is 
considered as a mammalian homolog to the yeast Wss1, as SPRTN shares both similar 
domain organization and a common evolutionary origin.428 SPRTN knockouts are 
embryonic lethal, while hemizygous SPRTN rats experience rapid ageing, genome 
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instability, kyphosis, and early development of cataracts.429 Enzymatic digestion of the 
protein constituent of a DPC was first confirmed by Duxin et al.430 They incubated DPC-
containing plasmid and the corresponding plasmid control with Xenopus egg extract, 
followed by restriction enzyme digestion to yield a 165-nucleotide fragment containing the 
DPC.430 Gel electrophoresis of the plasmid digestions yielded one band for the control and 
multiple bands for the DPC-containing plasmid, indicating the protein constituent was 
enzymatically digested.430 Considering the evolutionary similarities with Wss1, the authors 
proposed that Spartan acts as the DPC-specific protease.430  
Using Xenopus egg extract and DPC-containing plasmids, Duxin et al also 
examined DPC repair mechanism that couples DNA replication and protein digestion to 
adduct bypass. Two-dimensional gel electrophoresis of control and DPC-containing 
plasmids incubated in the extract revealed that a DPC-containing plasmid could not be 
replicated.430 When the control plasmid was incubated in the extract for seven minutes, 
only one linear molecule was observed, indicating the plasmid was completely replicated. 
However, DPC-containing plasmids migrated much slower and in a wider band, which was 
consistent with fork convergence and stalling at the lesion.430 Furthermore, when the DPC-
containing plasmid was incubated in extract with nonfunctional DNA polymerase ζ 
(mutations to subunits Rev1 and Rev7), extension product of the adduct-containing strand 
was greatly diminished.430 In total, the authors concluded that the collision of the 
replisome/CMG helicase with a DPC located on the DNA leading strand triggers 
proteolytic degradation of the protein constituent of DPC, and the resulting peptide-DNA 
adduct is ultimately bypassed DNA polymerase ζ.430  
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The molecular mechanism and regulation of Spartan-induced protein digestion has 
been further elucidated in the past year. Using isolated Spartan, Stingele et al observed 
proteolytic digestion of the DNA-binding proteins histone H1, H2A, H2B, H3, and Hmg1 
in the presence of ssDNA.431 When Spartan was incubated with the same proteins in the 
presence of dsDNA, only autocleavage of Spartan was detected.431  Furthermore, no 
Spartan activity was detected when GFP and BSA, proteins without DNA binding regions, 
were incubated with ssDNA.431 Taken together, Spartan’s protease activity was determined 
to be controlled by a DNA switch, where dsDNA allows for autocleavage, while ssDNA 
also allows for proteolytic digestion of DNA-bound proteins. 
In cells, Spartan exists in two forms: unmodified and monoubiquitinated, with a 
portion of Spartan always bound to chromatin.432 Stingele et al observed only unmodified 
Spartan bound to chromatin by western blot, while both unmodified and mono-
ubiquitinated Spartan were observed in the soluble protein extract.431 When cells were 
treated with FA, a noticeable shift from monoubiquitinated Spartan to chromatin-bound 
unmodified Spartan was observed over time, suggesting that DPC induction by FA 
triggered ubiquitin removal from Spartan.431 Stingele et al concluded that Spartan 
localization is controlled by ubiquitination, with deubiquitinating leading to Spartan 
binding to chromatin.431 Specifically, Spartan will bind to ssDNA regions created by a 
DPC, bringing Spartan into proximity of its substrate and allowing for proteolytic digestion 
of the protein constituent, despite Spartan’s low affinity for proteins in general.431  
 Additional research has coupled Spartan’s protease activity with the inhibition of 
DNA replication in mammalian cells. Morocz et al utilized a DNA fibre assay of FA-
treated cells to show Spartan is required for an immediate bypass of DPCs.433 The speed 
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of replication with or without DPC induction was determined by first pulse-treating cells 
with iododeoxyuridine (IdU, red label), followed by simultaneous incubation with FA and 
bromodeoxyuridine (BrdU, green label) and immunoblotting against the nucleotide 
analogues to visualize newly replicated DNA tracks. In FA-treated Spartan-depleted cells, 
the length of newly formed DNA tracks was significantly decreased compared to FA-
treated wild-type cells, indicating a strong inhibition of bypass across the FA-induced 
damage in the absence of Spartan.433 When the DNA fibre assay was performed with cells 
expressing Spartan with a mutated protease domain (SprT), DNA replication was inhibited 
to the same degree as Spartan depletion.433 These results are consistent with the proposed 
DPC repair model where Spartan degrades the protein constituent to a peptide fragment 
that can be bypassed by translesion synthesis.433  
Although significant progress has been made toward elucidating the mechanism of 
DPC repair, many questions still remain. For example, the shared contributions of NER 
and HR towards removing DPCs of varying size have yet to be fully elucidated. 
Furthermore, no direct evidence of Spartan proteolytically digesting a model DPC in-vitro 
or digesting chromatin-bound DPCs in vivo has been reported. Similarly, the contributing 
effects of cell cycle stage, identity and/or size of the protein, and molecular shape of the 
linker unit needs to be further investigated. 
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1.8. Thesis statement 
DNA-protein cross-links are ubiquitous, super-bulky adducts formed after the 
exposure to many physical and chemical agents. If left unrepaired, DPCs will interfere with 
crucial cellular processes such as DNA replication and transcription. In order to better 
understand the biological consequences of DPCs induced by bis-electrophiles or ROS, the 
identity of the protein constituents, the atomic connectivity, and the extent of DPC 
formation need to be elucidated.  
Towards these goals, mass spectrometry-based proteomics was utilized to 
characterize PM- and NOR-mediated DNA-protein cross-linking human fibrosarcoma 
(HT1080) cells at cytotoxic concentrations (Chapter 2).  PM is the active metabolite of the 
antitumor drug cyclophosphamide, and PM-induced DPCs are expected to contribute to 
the biological effects of cyclophosphamide treatment. Over 130 proteins were found to be 
covalent trapped to DNA only after PM-exposure, including those involved in 
transcriptional regulation, RNA splicing/processing, chromatin organization, and protein 
transport. To structurally characterize PM- and NOR-induced DPCs, a HPLC-ESI+-
MS/MS assay was developed to analyze the proteolytic digests of DPC-containing DNA 
from NOR-treated. A concentration-dependent formation of N-[2-[cysteinyl]ethyl-N-[2-
(guan-7-yl)ethyl]amine (Cys-NOR-N7G conjugate was observed, confirming that it cross-
links cysteine thiols of proteins to the N7 position of guanines in DNA  
Furthermore, we began investigating the DDR pathways that contribute to DPC 
repair. Cell cytotoxicity experiments revealed that NER-deficient (XPA-and XPD-
deficient) and HR-deficient (FANCD2-deficient) fibroblast cell lines were twice as 
sensitive to PM-treatment compared to isogenic controls. To investigate DPC repair over 
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time, the cell lines were treated with an equal concentration of PM for 3 hours, followed 
by incubating an additional 0, 4, 8, or 24 hours to allow the cells to repair PM-induced 
damage. Analysis by the developed LC-MS/MS assay revealed XPA-deficient and XPD-
deficient cells had the highest Cys-NOR-N7G levels at every time point, indicating these 
cells had the least amount of DPC repair over time. Conversely, there was no difference in 
Cys-NOR-N7G levels between HR-deficient cells and their isogenic controls. Taken 
together, we concluded that NER may be involved in the repair of PM- and NOR-induced 
DPCs, and NER contribution to DPC repair needs to be further investigated.  
The second goal of my DPC project was to characterize and quantify endogenous 
DPC formation after exposure to ROS. Specifically, I utilized an animal model of 
myocardial infarction/reperfusion (LAD ligation/reperfusion) to determine whether the 
known influx of ROS following reperfusion (ie. reperfusion injury) would lead to an 
increase in ROS-induced DPC formation. One mechanism of ROS-induced DPC formation 
involves a hydroxide anion abstracting a hydrogen from the methyl group of thymidine, 
which allows a free radical addition to a tyrosine side chains of proteins. I synthesized 
thymine-tyrosine cross-links (dT-Tyr) and developed a sensitive isotope dilution tandem 
mass spectrometry assay for their detection in cells and tissues. Quantitative analysis of 
DPCs extracted from rat cardiomyocytes after LAD ligation/reperfusion revealed an 
increase in DPC formation.  
Quantitative proteomics experiments (TMT labeling) were utilized to both identify 
ROS-induced DPCs and relatively quantify DPC formation after MI/reperfusion compared 
to a sham surgery. A total of 90 proteins participating in ROS-induced DPC formation were 
identified, including ROS scavengers, contractile proteins, and regulators of apoptosis. 
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TMT quantitation revealed that 80 of the DPC proteins were at least 1.2-fold more 
abundant after LAD ligation/reperfusion compared to sham surgeries. Global proteome 
changes were far less pronounced, but did exhibit increased expression of mitochondrial 
proteins required for aerobic respiration and biomarkers of sarcomere breakdown 
following ischemia/reperfusion injury. Overall, these quantitative results are consistent 
with a model where reperfusion injury and the sudden influx of ROS leads to an increase 
in DPC formation, and these lesions may contribute to long-term cardiac injury. 
Another goal of my DPC projects was to investigate the role of the metalloprotease 
Spartan in ROS-induced DPC repair (Chapter 4). Spartan is believed to proteolytically 
digest the protein constituent to a smaller peptide fragment, which could then be excised 
from DNA by NER. Cell cytotoxicity experiments revealed that floxed hemizygous 
SPRTN MEF cells were more sensitive to DPC-inducing agents such as hydrogen 
peroxide, cisplatin, phosphoramide mustard, and 1,2,3,4-diepoxybutane compared to 
isogenic controls. Furthermore, endogenous DPC formation across different organs in 
wild-type mice or hemizygous SPRTN-mice was quantified using the developed dT-Tyr 
nanoLC-MS/MS assay. A small but significant increase in DPC formation was observed 
in the heart, brain, liver, and kidneys of SPRTN-deficient mice as compared to the wild-
type organs. No detectable levels of dT-Tyr were observed in the thymus or spleen of both 
classes of mice. The increase in dT-Tyr in several tissues from SPRTN-deficient mice 
compared to wild-type marks the first evidence that the Spartan protease is involved in 
DPC repair. Furthermore, the lack of detectable dT-Tyr is tissues such as the thymus and 
spleen indicates that additional proteases must be involved in the digestion and repair of 
DPCs. 
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As described in section 1.2, many BD-induced DNA nucleoside adducts have been 
characterized and observed in vitro or in vivo. However, ring open N5-EB-FAPy-dG and 
N5-DEB-FAPy-dG had not been previously investigated. The final goal of my thesis was 
to structurally characterize and quantify EB-FAPy-dG in-vitro and in cells (Chapter 5). I 
first synthesized authentic standards of N5-EB-FAPy-dG and structurally characterized the 
adducts by 1H-NMR, HSQC, and HMBC. These authentic standards were used develop an 
isotope dilution tandem mass spectrometry assay in order to quantify N5-EB-FAPy-dG 
formed in vitro.  
When CTDNA was incubated with an increasing amount of EB (0 – 10 mM) and 
treated with base, a dose dependent increase in EB-FAPy-dG was observed. To determine 
the optimal pH for imidazole-ring opening, CTDNA was incubated with 5 mM EB, 
followed by treatment with tris-buffer at pH 7.5 – 12.0. EB-FAPy-dG was detected in every 
sample, indicating that EB-FAPy-dG formation could occur at physiological pH. However, 
EB-FAPy-dG levels were two-fold higher at pH 12, showing that a significant amount of 
alkylated dG was not subject to ring opening. To investigate EB-FAPy-dG vs EB-Gua II 
formation in-vivo, MEF cells proficient and deficient in the BER enzyme NEIL1 were 
treated with 500 μM EB for 24 hours. Both EB-FAPy-dG and EB-Gua II levels were 
increased ⁓ 2-fold in NEIL1 deficient cells, suggesting that NEIL1 may participate in the 
repair of EB-FAPy-dG. Taken together, we provided the first evidence of FAPy-dG 
formation in cells after exposure to the metabolites of 1,3-butadiene.  
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2. Covalent DNA-Protein Cross-Linking 
by Phosphoramide Mustard and 
Nornitrogen Mustard in Human Cells 
2.1. Introduction 
DNA-protein cross-links (DPCs) are bulky DNA lesions that are formed as a result 
of irreversible trapping of cellular proteins on DNA strands.262 DPCs can form 
endogenously or may be induced by exposure to transition metal ions,281, 434 ionizing 
radiation,275 and anti-cancer drugs such as nitrogen mustards,287, 329, 435 platinum 
compounds,334, 436-438 and haloethylnitrosureas.390 As a result of their size, DPC lesions are 
thought to interfere with chromatin folding, DNA replication, transcription, and repair, 
potentially contributing to toxicity and mutagenicity of cross-linking agents.263 
Phosphoramide mustard (PM, Scheme 2-1) is a biologically active metabolite of 
cyclophosphamide (CP), a chemotherapeutic agent commonly used to treat lymphomas, 
breast cancers, certain brain cancers, and autoimmune diseases.326, 378, 439 Under 
physiological conditions, PM spontaneously dephosphoramidates to form another DNA 
alkylating agent, nornitrogen mustard (NOR) (Section 1.5.4, Scheme 2-1).383-385 Both PM 
and NOR can modify N-7-guanine of DNA to yield N-(2-chloroethyl)-N-[2-(7-
guaninyl)ethyl] amine, N-(2-hydroxyethyl)-N-[2-(7-guaninyl)ethyl] amine, and N,N-bis-
[2-(7-guaninyl)ethyl] amine adducts,383-385 and also produce covalent DNA-protein 
conjugates (Scheme 2-1).  
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Scheme 2-1: Metabolism of cyclophosphamide to phosphoramide mustard and nornitrogen 
mustard and the formation of DNA-protein crosslinks. 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
DNA-protein cross-linking by nitrogen mustards was first observed by Ewig et 
al.329 These authors utilized the alkaline elution approach to detect DPCs in mouse 
leukemia cells (L1210) treated with nitrogen mustard.329 Hansson et al used a similar 
methodology to demonstrate DPC formation in human melanoma cells upon exposure to 
NOR and melphalan.330 When compared to other bifunctional lesions such as DNA 
interstrand and intrastrand cross-links, DPCs accounted for 60 – 70% of total cross-linked 
lesions.330 Our group initially investigated DNA-protein cross-linking by nitrogen 
mustards using a model protein, O6-alkylguanine DNA alkyltransferase (AGT).331 
Covalent AGT-DNA conjugates formed in a concentration-dependent manner following 
treatment with mechlorethamine and chlorambucil331 and involved the N7 position of 
guanine in DNA and AGT active site cysteine residues, C145 and C150.331 More recently, 
a mass spectrometry-based proteomics approach was employed to identify 
mechlorethamine-induced DPCs in human fibrosarcoma (HT1080) cells.287 A total of 38 
proteins were identified, including those participating in DNA damage response/repair, 
RNA processing/mRNA splicing, and transcriptional regulation/translation.287 
Unfortunately, many of the cross-linked proteins remained undetected due to the 
limitations of mass spectrometry methodologies used at the time (ion trap MS).287 
In the present study, highly sensitive and accurate Orbitrap methodology was used 
to characterize DNA-protein cross-linking in HT1080 cells treated with PM and NOR. As 
mentioned above (Scheme 2-1), NOR forms upon spontaneous dephosphoramidation of 
PM, and both mustards produce structurally identical DNA and protein adducts. Proteins 
covalently bound to chromosomal DNA following PM treatment were isolated using a 
modified phenol/chloroform extraction methodology developed by our group.287, 440 
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Neutral thermal hydrolysis was used to release PM-induced DPCs from the DNA backbone 
in the form of guanine-protein cross-links, which were subsequently resolved by SDS-
PAGE and identified by mass spectrometry-based proteomics on an Orbitrap Velos mass 
spectrometer. A total of 134 proteins were found to form DPCs in the presence of PM, 
including gene products that function in DNA repair, transcriptional regulation, apoptosis, 
and cell signaling. Isotope dilution HPLC-ESI+-MS/MS analyses of N-[2-[cysteinyl]ethyl]-
N-[2-(guan-7-yl)ethyl]amine (Cys-NOR-N7G) conjugates with 15N5-labeled internal 
standard were used to quantify DPC formation in NOR-treated cells. Finally, DPC numbers 
were compared between human wild type fibroblasts and the corresponding cells deficient 
in nucleotide excision repair (NER) and Fanconi Anemia (FA) repair pathways to gain 
insight into potential mechanisms of DPC repair in humans.  
 
2.2. Materials and methods 
Chemicals and Reagents 
Ammonium bicarbonate, ammonium acetate, diepoxybutane, bis-(2-
chloroethyl)amine hydrochloride (nornitrogen mustard), mechlorethamine, d,l -1,2,3,4-
diepoxybutane, phenylmethanesulfonyl fluoride (PMSF), Boc-L-cysteine (Boc-Cys-OH), 
triflouroacetic acid (TFA), leupeptin, pepstatin, aprotinin, methoxyamine, UCN-01, 
dithiothreitol (DTT), iodoacetamide, chloroform, ribonuclease A, deoxyribonuclease I, and 
alkaline phosphatase were purchased from Sigma (St. Louis, MO). Phosphodiesterase I 
and phosphodiesterase II were obtained from Worthington Biochemical Corporation 
(Lakewood, NJ).  UltraPure buffer-saturated phenol was obtained from Invitrogen 
(Carlsbad,CA). Mass spectrometry grade trypsin was purchased from Promega (Madison, 
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WI). Proteinase K was obtained from New England Biolabs (Beverly, MA). Cell Lysis 
Solution and Protein Precipitation solution were purchased from Qiagen (Valencia, Ca). 
Phosphoramide mustard was obtained from iTT GmbH/Niomech (Bielefeld, Germany). 
 
N-(2-chloroethyl)-N-[2-(guan-7-yl)ethyl]amine (N7G-NOR-Cl) 
2'-Deoxyguanosine (500 mg, 1.87 mmol) was reacted with nornitrogen mustard 
(3.34 g, 18.7 mmol) in trifluoroethanol (25 mL) at 37 °C for 72 h under anhydrous 
conditions. The reaction mixture containing N7G-NOR-Cl was dried under argon, and the 
resulting solid was washed with 1 mL of anhydrous ether three times to remove unreacted 
NOR. The presence of N7G-NOR-Cl was confirmed by UV spectrophotometry and mass 
spectrometry. UV: λmax = 246 nm, λmin = 275 nm (pH 4.9); ESI+-MS/MS: m/z 257.7 [M + 
H], m/z 178.2 [M + H – NH(CH2)2Cl]+,  m/z 107.1 [M + H – Gua]+. 15N5-N7G-NOR-Cl 
was prepared analogously starting with 15N5-2’-deoxyguanosine, and its structure was 
confirmed by UV and mass spectrometry. UV: λmax 246 nm, λmin 275 nm (pH 4.9); ESI+-
MS/MS: m/z 262.7 [M + H]+, m/z 183.1 [M + H – NH(CH2)2Cl]+, m/z 107.1 [M + H – 
Gua]+. 
 
N-[2-[cysteinyl]ethyl]-N-[2-(guan-7-yl)ethyl]amine (Cys-NOR-N7G) 
Boc-Cys-OH (167 mg, 0.7541 mmol) was combined with N7G-NOR-Cl (335 mg, 
0.9438 mmol) in 7 mL DMSO, and the reaction mixture was stirred at 37 °C for 72 h. The 
insoluble product was isolated by filtration and separated by semi-preparative HPLC on a 
Supelcosil LC-18-DB column (25 cm x 10 mm, 5 μm) eluted with a linear gradient of 
acetonitrile (B) in 20 mM ammonium acetate, pH 4.9 (A). Solvent composition was 
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changed linearly from 0 to 24% B in 24 min and further to 60% in 6 min. Under these 
conditions, Boc-Cys-NOR-N7G eluted as a sharp peak at 20.9 min. ESI+-MS/MS: m/z 
443.5 [M + H]+ → m/z 343.5 [M + H –Boc]+ and m/z 193.3 [M + H – Boc – Gua]+. The 
Boc group was removed by incubating Boc- Cys-NOR-N7G with 50% TFA at room 
temperature for 45 min, and the resulting deprotected product (Cys-NOR-N7G) was 
purified using the same HPLC method (retention time = 10.4 min). Cys-NOR-N7G: ESI+-
MS/MS: m/z 342.1 [M + H]+ → m/z 191.1 [M + H – Gua]+. Cys-NOR-[15N5]-N7G was 
synthesized analogously starting with 15N57G-NOR-Cl. ESI+-MS/MS: m/z 347.1 [M + H]+ 
→ m/z 191.1 [M + H – Gua]+.  
 
Cell Culture 
Human fibrosarcoma (HT1080) cells were obtained from the American Type 
Culture Collection (Camden, NJ). Human Xeroderma Pigmentosum Complementation 
Group A (XPA, XPA deficient), human Xeroderma Pigmentosum Complementation 
Group D (XPD, XPD deficient), and XPD-derivative cells stably expressing XPD (XPD 
corrected) cells were obtained from NIGMS Human Genetic Cell Repository (Camden, 
NJ). Prof. Alexandra Sobeck (University of Minnesota) kindly provided FA-D2 cells 
(PD20, FANCD2 deficient), and FA-D2-derivative cells stably expressing FANCD2 
(PD20 + FANCD2). The cells were maintained as exponentially growing monolayer 
cultures in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), in a humidified incubator at 37 °C with 5% CO2. 
 
Cytotoxicity Experiments 
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HT1080, XPA, PD20, and PD20 corrected cells were plated in Dulbecco’s 
modified Eagle’s medium containing 10% FBS at a density of 3 ×104 cells/dish and 
permitted to adhere for 24 hours. Cells (1.0 x 105, in triplicate) were treated with 0 – 2000 
µM PM, mechlorethamine, or DEB for 3 h at 37 °C. Following treatment, cell media was 
replaced, and the cells were grown for an additional 48 h at 37 °C. Cell viability was 
determined using an Alamar Blue assay441 using a Synergy HI Microplate reader (BioTek, 
Winooski, VT). 
 
Cell Treatment with PM and Isolation of DNA-Protein Crosslinks 
HT1080 cells in culture (~ 1 x 107, in triplicate) were treated with increasing 
concentrations of PM (0, 50, 100, 250, and 500 μM) for 3 h at 37 °C. Following treatment, 
the cells were washed with phosphate-buffered saline (PBS) and re-suspended in 3 mL 
PBS buffer. DPC-containing DNA was isolated by a modified phenol-chloroform 
procedure as described previously.287, 440 In brief, the cells were lysed by adding an equal 
volume of 2X cell lysis buffer (20 mM Tris-HCl/10 mM MgCl2/2% Triton-X100/0.65 M 
Sucrose), incubated on ice for 5 min, and centrifuged at 2000 g for 10 min at 4 °C. The 
nuclear pellets were re-suspended in saline-EDTA solution (75 mM NaCl/24 mM 
EDTA/1% sodium dodecyl sulfate) containing RNase A (10 μg/mL) and a protease 
inhibitor cocktail (1 mM PMSF; 1 μg/mL pepstatin; 0.5 μg/mL leupeptin; 1.5 μg/mL 
aprotinin). The resulting nuclei were incubated for 2 h at 37 °C with gentle shaking. To the 
nuclear lysates, an equal amount of tris-saturated phenol was added, and the solutions were 
mixed for 5 minutes. Following centrifugation at 1500 RPM for 10 minutes, the aqueous 
layer containing DNA and the DPC-containing interface was collected. This material was 
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re-extracted with phenol/chloroform as described above two additional times, and DPC-
containing DNA was precipitated with cold isopropanol. DNA amounts and its purity were 
estimated using UV spectrophotometry (A260) and subsequently determined by quantitation 
of dG in enzymatic hydrolysates as described below. Typical DNA yields from 10 million 
cells were 40-60 μg.  
 
DNA Quantitation by dG Analysis 
To quantify DPC-containing DNA extracted from cells and to detect any potential 
RNA contamination, 5 μg aliquots of DNA were taken and digested to 2’-deoxynucleosides 
in the presence of phosphodiesterase I (120 mU), phosphodiesterase II (105 mU), DNase 
(35 U) and alkaline phosphatase (22 U) in 20 µL 10 mM Tris-HCl/15 mM ZnCl2 (pH 7.0) 
for 18 h at 37 °C. Quantitative analysis of dG in enzymatic digests was conducted by 
HPLC-UV on an Agilent Technologies 1100 HPLC system equipped with a diode array 
UV detector and an autosampler. Samples were loaded onto an Atlantis T3 C18 column 
(2.1 × 150 mm, 5 μm, from Waters Corporation, Milford, MA) and eluted with a gradient 
of 5 mM ammonium formate, pH 4.0 (A) and methanol (B). Solvent composition was 
changed linearly from 3 to 30% B over 15 min, increased further to 80% B over 3 min, 
held at 80% B for 1 min, and returned to 3% B over 2 min, where it was kept for the final 
8 min of the HPLC run. UV absorbance was monitored at 260 nm. With this method, dG 
eluted as a sharp peak at 11.7 min (Figure 2-1). dG amounts were determined by 
comparing HPLC peak areas to a calibration curve constructed by injecting known dG 
amounts. 
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Figure 2-1: Representative trace of DNA dG analysis. 
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Mass Spectrometric Identification of Cross-Linked Proteins 
To identify cellular proteins that become covalently trapped on DNA following 
exposure to PM, HT1080 cells (1 x 107, in triplicate) were treated with 100 µM PM for 3 
h at 37 °C. Chromosomal DNA containing any covalently attached proteins was isolated 
by the modified phenol/chloroform extraction method described above.287, 440 DPC-
containing DNA (30 μg) was subjected to neutral thermal hydrolysis to release protein-
guanine conjugates (Scheme 2-2), dried under vacuum, and reconstituted in 1 × NuPAGE 
Sample Buffer (Invitrogen, Carlsbad, CA). Proteins were resolved by NuPAGE Novex 
12% Bis-Tris Gels (Invitrogen, Carlsbad, CA) and stained with SimplyBlue Safe stain 
(Invitrogen, Carlsbad, CA).  
Gel lanes were divided into five sections encompassing the molecular weight range 
of 5 – 250 kDa. Each section of the gel (260 – 110 kDa, 110 – 80 kDa, 80 – 50 kDa, 50 – 
30 kDa, 30 – 5 kDa) was excised and further diced into 1 mm pieces. The proteins present 
within the gel pieces were subjected to in-gel tryptic digestion by standard methods. In 
brief, gel pieces were washed with 25 mM ammonium bicarbonate, protein disulfide 
linkages were reduced with DTT (300 mM), and the resulting thiols were alkylated with 
saturated iodoacetamide. Gel pieces were dehydrated by incubation with acetonitrile, dried 
under vacuum, and reconstituted in 25 mM ammonium bicarbonate buffer (pH 9.0). Mass 
spectrometry grade trypsin (1 μg) was added, and the samples were digested for 18 hours 
at 37 °C. The resulting tryptic peptides were extracted with 60% acetonitrile containing 
0.1% aqueous formic acid, evaporated to dryness, and desalted using C18 ZipTips 
(Millipore, Temecula, CA). Samples were reconstituted in 0.1% formic acid for 
HPLC−ESI+−MS/MS analysis. 
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HPLC-ESI+-MS/MS analyses of tryptic peptides were conducted using an LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific, Waltham, MA) equipped with an 
Eksigent nanoLC 2D HPLC pump, a nanospray source, and Xcalibur 2.1.0 software for 
instrument control. Peptide mixtures were loaded onto a Symmetry C18 trapping column 
(180 μm ×20 mm, Waters, Milford, MA) using 0.1% formic acid in water (A) and 0.1% 
formic acid in acetonitrile (B) at a solvent composition of 95% A and 5% B at 5 μL/min 
for 3 min. Typical injection volume was 8 μL. Following trapping, the HPLC flow was 
decreased to 0.3 μL/min and reversed to elute the peptides. The peptides were separated on 
a nanoHPLC column (75 μm i.d.,10 cm packed bed, 15 μm orifice) created by hand packing 
a commercially purchased fused-silica emitter (New Objective, Woburn MA) with Zorbax 
SB-C18 5 μm separation media (Agilent, Santa Clara, CA). The gradient program started 
at 5% B, followed by a linear increase to 60% B over 60 min and further to 95% B in 5 
min. Liquid chromatography was carried out at an ambient temperature. The mass 
spectrometer was calibrated prior to each analysis, and the spray voltage was adjusted to 
ensure a stable spray. Typically, the MS tune parameters were as follows: spray voltage of 
1.6 kV, a capillary temperature of 275 °C, and an S-lens RF level of 50%. MS/MS spectra 
were collected using data-dependent scanning, in which one full scan mass spectrum 
acquired in the Orbitrap detector (R = 30,000) was followed by eight MS/MS spectra 
acquired in the Orbitrap detector (R = 7,500) with an isolation width of 2.5 m/z, activation 
time of 30 ms, activation Q of 0.25, 35% normalized CID collision energy, 1 microscan, 
with an AGC setting of 2 x 105 and a maximum injection time of 100 ms. Dynamic 
exclusion was enabled for 60 s, and singly charged species were excluded from MS/MS 
analysis. 
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Spectral data were analyzed using an in-house developed software pipeline “TINT” 
that linked raw data extraction, database searching, and probability scoring. Raw data were 
extracted and converted to the mzXML format using ReadW. Spectra that contained fewer 
than 6 peaks or had measured total ion current (TIC) < 20 were excluded. Data was 
processed using the SEQUEST v.27 algorithm442 on a high speed, multiprocessor Linux 
cluster in the Minnesota Supercomputing Institute at the University of Minnesota. Peptide 
spectra were searched against the UniProt Human Protein Database. Cysteine 
carboxamidomethylation (+57.0215 Da) was set as a fixed modification, and methionine 
oxidation (+15.9949 Da) was selected as a variable modification. Precursor mass tolerance 
was set to 10 ppm within the calculated mass, and fragment ion mass tolerance was set to 
10 mmu of their monoisotopic mass. The identified peptides were filtered using Scaffold 
3 software (Proteome Software, INC., Portland, OR), to a target false discovery rate (FDR) 
of 5%. The FDR was calculated with the following expression: FDR = (2R)/(R + F) × 100, 
where R is the number of passing reversed peptide identifications and F is the number of 
passing forward (normal orientation) peptide identifications. The second round of filtering 
removed proteins supported by less than two unique peptide fragments in the analyses. Any 
proteins also found in control (untreated) samples were excluded from the final list. 
 
Western Blot Analysis  
HT1080 cells (~1 x 107) were treated with NOR (0, 50, 100, 250, or 500 μM) for 3 
h at 37 °C. Chromosomal DNA, along with any covalent DPCs, was extracted and 
quantified as described above. From each sample, 50 μg of DNA was subjected to neutral 
thermal hydrolysis (1 h at 70 °C) to release protein-guanine conjugates from the DNA 
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backbone. The proteins were resolved by NuPAGE Novex 12% Bis-Tris gels (Invitrogen, 
Carlsbad, CA) and transferred to Invitrolon PVDF filter paper membranes (0.45 μm pore 
size, Life Technologies, Carlsbad, CA). The membranes were blocked for 4 h in Tris-
buffered saline-Tween 20 (TBST) containing 5% (w/v) bovine serum albumin. Following 
blocking, the membranes were incubated with the primary antibodies against vimentin, 
nucleophosmin, prohibitin-2, matrin-3, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), poly-(ADP-ribose) polymerase 1 (PARP), and histone-H4 overnight at 4 °C. 
The membranes were rinsed with TBST and incubated with the corresponding alkaline 
phosphatase-conjugated antibody for 1 h at room temperature. The gels were developed 
using SIGMA Fast BCIP/NBT (Sigma, St. Louis, MO) according to manufacturer’s 
protocol.  
 
Quantitation of Cys-NOR-N7G in NOR-Exposed Cells 
HT1080 cells (1 x 107) were treated with increasing concentrations of NOR (0, 50, 
100, 250, and 500 µM) for 3 h at 37 °C. Following treatment, the cells were washed with 
PBS, re-suspended in cell lysis solution (2 mL, Qiagen, Valencia, CA) containing 10 μg 
RNAse A, and incubated for 16 h at room temperature with gentle inversion. Proteinase K 
(10 μg) was added, and the samples were incubated for an additional 16 h at room 
temperature with gentle inversion. The lysates were mixed with 700 μL of protein 
precipitation solution (Qiagen, Valencia, CA), and the samples were vortexed for one 
minute. Following centrifugation at 1500 RPM for 10 minutes, the supernatant was 
collected, and DPC-containing genomic DNA was precipitated with cold isopropanol. 
DNA was quantified by dG analysis as described above.  
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DNA (100 μg) was subjected to neutral thermal hydrolysis (1 h at 70 °C) to release 
protein−guanine conjugates from the DNA backbone. Proteins were cleaved with trypsin 
(10 μg protein in 25 mM ammonium bicarbonate, overnight at 37 °C), and the resulting 
peptides were further digested to amino acids in the presence of proteinase K (10 μg in 100 
μL water, overnight at 37 °C). The digests were spiked with Cys-[15N5]-NOR-N7G 
(internal standard for mass spectrometry, 200 fmol), followed by offline HPLC purification 
as follows. An Agilent Technologies HPLC system (1100 model) was used incorporating 
a diode array detector, an autosampler, and a fraction collector. A Synergi 4μ Hydro RP 
(4.6 × 250 mm, 5 μm) column (Sigma-Aldrich, St. Louis, MO) was eluted at a flow rate of 
1 mL/min using a gradient of 15 mM ammonium formate, pH 4.9 (A) and acetonitrile (B). 
Fractions containing Cys-NOR-Gua and its 15N-labeled internal standard (9.7 – 11.2 min) 
were collected, dried under vacuum, and reconstituted in 0.1% formic acid (20 μL).  
Quantitative analyses of Cys-NOR-N7G were conducted with a Dionex UltiMate 
3000 RSLC nanoHPLC system (Thermo Scientific, Waltham, MA) interfaced to a TSQ 
Vantage mass spectrometer (Thermo Scientific, Waltham, MA). Chromatographic 
separation was accomplished with a Hypercarb HPLC column (100 mm × 0.3 mm, 3 μm) 
eluted with a gradient of 0.1% formic acid (A) and acetonitrile (B) at a flow rate of 12 
μL/min. Solvent composition was linearly changed from 4% to 30% in 13 min and further 
to 90% 1 min, kept at 90% for 1 min, then brought back to 4% in 1 min. Under these 
conditions, Cys-NOR-N7G and its internal standard (Cys-NOR-[15N5] N7G) eluted at ~ 
9.6 min. Electrospray ionization was achieved at a spray voltage of 3200 V and a capillary 
temperature of 270 °C. Collision induced dissociation was performed with Ar as a collision 
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gas (1.5 mTorr) at a collision energy of 23 V. Instrument parameters were optimized for 
maximum response during infusion of a standard solution of Cys-NOR-N7G. 
HPLC-ESI+-MS/MS analysis of Cys-NOR-N7G was performed in the selected 
reaction monitoring mode by following the neutral loss of guanine from protonated 
molecules of the analyte (m/z 342.1 [M + H]+ → 191.0 [M + H − Gua]+) and the 
corresponding mass transitions corresponding to 15N5- labeled internal standard (m/z 347.1 
[M + H]+ → 191.0 [M + H − 15N5 − Gua]+). Analyte concentrations were determined using 
the relative response ratios calculated from HPLC-ESI+-MS/MS peak areas in extracted 
ion chromatograms corresponding to Cys-NOR-N7G and its internal standard. 
 
Cys-NOR-N7G Quantitation in Wild Type and DNA Repair-Deficient Fibroblasts 
Human fibrosarcoma cells (HT1080), NER-deficient Xeroderma pigmentosum 
cells (XPA), FANCD2-deficient cells (PD20), and the corresponding FANCD2-corrected 
cells (PD20-corrected, 1x107) were treated with 250 µM NOR for 3 h at 37 °C. Following 
treatment, cell media was replaced, and the cells were allowed to recover at 37 °C for either 
4 h (n = 6) or 0, 4, 12, or 24 h (n = 3) to allow for repair. DNA was isolated using Qiagen 
Cell Lysis Solution extraction procedure and quantified by dG analysis as described above. 
DNA samples (100 µg) were subjected to neutral thermal hydrolysis (1 h at 70 °C) to 
release protein-guanine conjugates. Conjugated peptides were further digested to amino 
acids in the presence of trypsin (10 μg protein in 25 mM ammonium bicarbonate, overnight 
at 37 o C), followed by proteinase K (10 μg in 250 μL water, overnight at 37 °C). The 
digests were spiked with Cys-NOR-[15N5]-N7G internal standard (200 fmol), followed by 
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off-line HPLC purification as described above. Cys-NOR-N7G conjugates were quantified 
by isotope dilution HPLC-ESI+-MS/MS as described above.  
 
2.3. Results 
2.3.1. Cytotoxicity experiments in human cell culture 
To characterize the toxicity of PM in human fibrosarcoma cell cultures, HT1080 
cells (in triplicate) were treated with increasing amounts of PM, and their viability was 
determined by the Alamar Blue assay.441 The fraction of live cells following treatment with 
50, 100, 250, 500, 750, 1000, 1500, and 2000 μM PM was 87.0 ± 2.63, 73.0 ± 3.44, 59.5 ± 
3.70, 42.9 ± 3.03, 30.3 ± 3.60, 17.7 ± 1.66, 7.08 ± 0.34, and 8.5 ± 0.33 % (Figure 2-2A). 
We found that PM was significantly less toxic than mechlorethamine, a structurally related 
nitrogen mustard investigated in our earlier publication (IC50 = 317 ± 42.9 and 20.2 ± 4.59, 
respectively),287 but had similar toxicity to 1,2,3,4-diepoxybutane IC50 = 480.8 ± 41.9 
(Figure 2-2B).  
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Figure 2-2: Cytoxicity of human fibrosarcoma (HT1080) cells to DPC-inducing agents. 
(A) HT1080 cytotoxicity (in triplicate) to 0 – 2000 µM PM. (B) Comparison of HT1080 
cytotoxicity (in triplicate) to PM, 1,2,3,4-diepoxybutane, and mechlorethamine. 
A.  
 
 
 
 
B.  
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2.3.2. Concentration-dependent formation of DPCs in PM-treated human cells 
To monitor PM-mediated DPC formation, human fibrosarcoma cells (HT1080) 
were treated with increasing concentrations of PM (0, 50, 100, 250, and 500 µM) for 3 h. 
DNA was extracted under mild conditions that preserved covalent DNA-protein 
conjugates. The samples were subjected to thermal hydrolysis to release proteins in the 
form of protein-guanine conjugates, which were resolved by gel electrophoresis (Scheme 
2-2 and Figure 2-3A). Although small amounts of endogenous DPCs were present in 
untreated cells (Lane 3 in Figure 2-3A), the amounts of cross-linked proteins increased in 
a concentration dependent manner (Lanes 5, 7, 9, 11 in Figure 2-3A, Figure 2-3B). In our 
previous studies, a 20-fold greater concentration of 1,2,3,4-diepoxybutane (DEB, 2 mM) 
was required to produce similar numbers of DPCs in HT1080 cells,440 while comparable 
cross-linking efficiency was observed upon treatment with mechlorethamine.287 This 
suggests that PM and NOR are equally efficient at forming DPCs, while DEB is less 
efficient than the two nitrogen mustards.  
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Scheme 2-2: Experimental strategy for isolation of DNA-protein cross-links from phosphoramide mustard-treated cells and their 
characterization by mass spectrometry. 
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Figure 2-3: (A) Concentration-dependent formation of DPCs in HT1080 cells treated with 
0 – 500 µM PM for 3 h. Lane 1: molecular weight marker. Lanes 2, 4, 6, 8, 10 are blank. 
Lane 3: 50 μM PM. Lane 5: 100 μM PM. Lane 7: 250 μM PM. Lane 9: 500 μM PM. (B) 
Densitometry measurements of the band intensity form Figure 2A, normalized to the 
untreated control.  
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2.3.3. Identification of cross-linked proteins by mass spectrometry-based proteomics  
To identify the proteins participating in DPC formation following exposure to PM, 
HT1080 cells (in triplicate) were treated with 100 µM PM for 3 h. Control cells were 
incubated with PM-free cell culture media. DPC-containing DNA was extracted as 
described above, and equal amounts of DNA from each sample (30 µg) were subjected to 
neutral thermal hydrolysis to release protein-guanine conjugates (Scheme 2-2), which were 
detected by gel electrophoresis.  
SDS-PAGE analysis of protein-guanine conjugates isolated from PM-treated 
samples (Lanes 9-11 in Figure 2-4) revealed intense protein bands, while control samples 
contained considerably weaker bands corresponding to endogenous DPCs (Lanes 3 – 5 in 
Figure 2-4). The gel lanes from both experiments were divided into five sections covering 
the molecular weight range of 5 – 260 kDa (A – E in Figure 2-4) and cut out of the gel. 
Individual gel pieces of each region were subjected to in-gel tryptic digestion, and the 
resulting peptides were extracted from the gel, desalted, and subjected to HPLC-ESI+-
MS/MS analysis for protein identification.  
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Figure 2-4: DNA-protein cross-linking in human fibroblasts used for proteomics 
experiments. HT1080 cells (~5.0 x 106, in triplicate) were treated with 100 µM PM (lanes 
9 – 11) or buffer only (lanes 3 – 5) for 3 h. Following DPC extraction and thermal 
hydrolysis to release guanine-protein conjugates, the cross-linked proteins were resolved 
by 12% SDS-PAGE and visualized by staining with SimplyBlue SafeStain. Proteins within 
the molecular weight ranges of 30 – 5 kDa (A), 50 – 30 kDa (B), 80 – 50 kDa (C), 110 – 
80 kDa (D), and 260 – 110 kD (E) were excised from the gels, subjected to in-gel trypsin 
digestion, and analyzed by HPLC-ESI+-MS/MS.  
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MS/MS analysis of tryptic peptides from cross-linked proteins yielded 
characteristic b and y series ions, which were used to determine their amino acid sequences 
and to identify the corresponding proteins. Protein identification was based on the sequence 
of at least two unique peptides. Any proteins that were also detected in control samples or 
were not present in all three treated samples were omitted from the final list. Using these 
criteria, a total of 134 proteins were identified (Table 2-1).  
Proteins found to form covalent cross-links to chromosomal DNA following 
exposure to PM (Table 2-1) were categorized based on their cellular distribution, 
molecular function, and biological process using the GO database available from the 
European Bioinformatics Institute (http://www.ebi.ac.uk/GOA).443 A large portion of the 
cross-linked proteins are classified as nuclear (67 total, 50%), including histones, high 
mobility group proteins, protein MAK16 homolog, and U1 small nuclear ribonucleoprotein 
70 kDa (Figure 2-5, Table 2-1). This is not unexpected as nuclear proteins are most likely 
to form DPCs due to their proximity to nuclear DNA. The remaining proteins were 
classified as cytoplasmic (38 total, 28.4%), membrane bound/cytoskeleton (18 total, 
13.4%), endoplasmic reticulum (7 total, 5.2%), mitochondrial (5 total, 3.7%), golgi 
apparatus (2, 1.5%) and unknown (2 total, 1.5%) (Figure 2-5). It is important to note that 
many of the proteins may be present in multiple cellular compartments due to their 
participation in many diverse biological processes. For example, S100 A9 is classified as 
a cytoplasmic protein, but it has been shown to enter the nucleus and bind the promoter 
region of complement component 4 (C3), upregulating C3 expression.444  
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Table 2-1: Proteins forming covalent cross-links to chromosomal DNA following exposure to PM. 
Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
P53999 Activated RNA polymerase II 
transcriptional coactivator p15 
37 4 4 Transcriptional 
Regulation 
14395.9 
O15347 High mobility group protein B3 19 3 3  22980.7 
P39687 Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
21 5 7  28586.1 
Q99623 Prohibitin-2 10 2 2  33297.6 
P16989 DNA-binding protein A 8 2 2  40089.4 
Q14320 Protein FAM50A 8 2 2  40242.8 
Q5BKZ1 Zinc finger protein 326 11 4 4  65653.5 
P11142 Heat shock cognate 71 kDa protein 8 3 3  70899.8 
Q8WVC0 RNA polymerase-associated protein 
LEO1 
4 2 2  75405.3 
Q9Y3T9 Nucleolar complex protein 2 3 2 2  84907.1 
P43243 Matrin-3 13 10 11  94626.7 
P55884 Eukaryotic translation initiation factor 
3 subunit B 
22 15 18  92482.8 
Q8TDD1 ATP-dependent RNA helicase DDX54 2 2 2  98597.9 
Q9BXP5 Serrate RNA effector molecule 
homolog 
3 3 3  100669.7 
Q9Y5B9 FACT complex subunit SPT16 16 15 17  119917.4 
Q03701 CCAAT/enhancer binding protein zeta 2 2 2  120992.2 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
Q9BQG0 Myb-binding Protein 1A 2 2 2  148858.3 
P51532 Transcription activator BRG1 2 3 3  184649.6 
O60216 Double-strand-break repair protein 
rad21 homolog 
6 3 3 DNA Repair 71691.6 
P12956 X-ray repair cross-complementing 
protein 5 
22 10 12  69846.4 
P84103 Splicing factor, arginine/serine-rich 3 30 5 5 RNA 
Splicing/Process
ing 
19330.0 
Q07955 Splicing factor, arginine/serine-rich 1 12 3 3  27745.1 
Q32P51 Heterogeneous nuclear 
ribonucleoprotein A1-like 2 
15 4 5  34225.4 
P22626 Heterogeneous nuclear 
ribonucleoprotein A2/B1 
10 3 3  37430.3 
P08621 U1 small nuclear ribonucleoprotein 70 
kDa 
5 2 2  51558.4 
O00566 U3 small nucleolar ribonucleoprotein 
protein MPP10 
7 3 3  78866.8 
Q15029 116 kDa U5 small nuclear 
ribonucleoprotein component 
4 3 3  109438.1 
Q15393 Splicing factor 3B subunit 3 2 2 2  135579.4 
O75643 U5 small nuclear ribonucleoprotein 200 
kDa helicase 
2 4 4  244513.8 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
P51665 26S proteasome non-ATPase 
regulatory subunit 7 
18 3 3 Apoptosis 37025.6 
P04083 26S proteasome non-ATPase 
regulatory subunit 3 
19 9 9  60979.6 
Q9NY61 Protein AATF 22 7 8  63135.0 
P25205 DNA replication licensing factor 
MCM3 
6 4 4 DNA Replication 90982.6 
Q14566 DNA replication licensing factor 
MCM6 
3 2 2  92890.2 
P33778 Histone H2B type 1-B 20 3 14 Chromatin 
Organization 
13950.8 
Q92522 Histone H1x 10 2 2  22487.9 
Q9P0M6 Core histone macro-H2A.2 7 2 3  40060.1 
Q969G3 SWI/SNF-related matrix associated 
actin dependent regulator of chromatin 
subfamily E member 1 
13 4 5  46649.7 
Q14839 Chromodomain-helicase-DNA-binding 
protein 4 
4 6 6  217994.6 
Q12873 Chromodomain-helicase-DNA-binding 
protein 3 
1 2 2  226597.2 
P63173 60S ribosomal protein L38 29 2 4 Translation 8218.5 
P62979 40S ribosomal protein S27a 40 2 3  9418.4 
Q6NW1 Putative 60S ribosomal protein L13a-
like MGC87657 
29 3 3  12135.0 
P83881 60S ribosomal protein L36a 30 4 4  12441.1 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
Q5JNZ5 Putative 40S ribosomal protein S26-
like 1 
27 3 10  13002.2 
P60866 40S ribosomal protein S20 19 2 3  13373.0 
P62899 60S ribosomal protein L31 30 4 11  14463.2 
P35268 60S ribosomal protein L22 19 2 3  14787.3 
P62244 40S ribosomal protein S15a 31 4 4  14840.0 
P62829 60S ribosomal protein L23 32 3 4  14865.9 
P62847 40S ribosomal protein S24 29 4 9  15423.8 
P08708 40S ribosomal protein S17 16 2 3  15550.5 
P62266 40S ribosomal protein S23 15 2 3  15807.7 
P62263 40S ribosomal protein S14 34 4 4  16272.9 
P62249 40S ribosomal protein S16 28 4 6  16445.9 
P46776 60S ribosomal protein L27a 20 3 3  16561.4 
P62841 40S ribosomal protein S15 40 3 6  17040.8 
P62277 40S ribosomal protein S13 36 6 7  17223.3 
P30050 60S ribosomal protein L12 24 3 4  17819.1 
P62280 40S ribosomal protein S11 35 5 5  18431.3 
P46778 60S ribosomal protein L21 21 3 8  18565.0 
P46783 40S ribosomal protein S10 15 2 4  18898.3 
Q9NQ39 Putative 40S ribosomal protein S10-
like 
13 2 3  20120.6 
Q02543 60S ribosomal protein L18a 21 3 4  20762.6 
T1W3K1 60S ribosomal protein L17 41 6 11  21397.4 
P32969 60S ribosomal protein L9 18 3 4  21863.7 
P62081 40S ribosomal protein S7 47 6 10  22127.5 
P46781 40S ribosomal protein S9 45 12 21  22592.5 
P23396 40S ribosomal protein S3 27 5 5  26688.6 
P62753 40S ribosomal protein S6 18 4 5  28681.7 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
P18124 60S ribosomal protein L7 38 12 16  29227.7 
P15880 40S ribosomal protein S2 24 6 6  31325.2 
P05198 Eukaryotic translation initiation factor 
2 subunit 1 
10 2 2  36112.7 
P20042 Eukaryotic translation initiation factor 
2 subunit 2-like protein 
16 5 5  37788.3 
P60842 Eukaryotic initiation factor 4A-I 22 7 7  46155.3 
O15371 Eukaryotic translation initiation factor 
3 subunit D 
11 5 5  63973.8 
P55884 Eukaryotic translation initiation factor 
3 subunit B 
22 15 18  92482.8 
Q14152 Eukaryotic translation initiation factor 
3 subunit A 
12 15 18  166574.9 
Q04637 Eukaryotic translation initiation factor 
4 gamma 1 
9 13 14  175494.2 
P05109 Protein S100 A8 32 3 4 Inflammatory 
Response 
10835.0 
P06702 Protein S100 A9 45 4 6  13242.3 
P66905 Hemoglobin subunit alpha 22 2 3 Oxygen 
Transport 
15257.6 
Q13765 Nascent polypeptide-associated 
complex subunit alpha 
26 4 5 Protein 
Transport 
23383.3 
Q96FZ7 Charged multivesicular body protein 6 10 2 2  23485.3 
O76021 Ribosomal L1 domain-containing 
protein 1 
11 4 4  54974.7 
O00203 AP-3 complex subunit beta-1 5 4 4  121324.0 
Q9P2E9 Ribosome-binding protein 1 14 16 21  152470.6 
Q08378 Golgin subfamily A member 3 3 3 3  167356.0 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
Q00610 Clathrin heavy chain 1 11 15 15  191618.9 
Q13268 Dehydrogenase/reductase SDR family 
member 2, mitochondrial 
11 3 3 Cellular 
Homeostasis 
27438.4 
Q15006 Tetratricopeptide repeat protein 35 18 4 4  34834.8 
P00338 L-lactate dehydrogenase A chain 13 4 5  36689.2 
P11201 78 kDa glucose-regulated protein 17 8 8  72334.7 
P04083 Annexin A1 27 6 8  38715.9 
Q96A33 Coiled-coil domain-containing protein 
47 
9 3 3  55874.9 
P25705 ATP synthase subunit alpha, 
mitochondrial 
12 6 6  59752.1 
Q9NR30 Nucleolar RNA helicase 2 6 4 4  87346.0 
P36776 Lon protease homolog, mitochondrial 6 5 6  106491.3 
P63104 14-3-3 protein zeta/delta 17 3 4 Cellular 
Signaling 
27745.9 
P31946 14-3-3 protein beta/alpha 9 2 5  28083.1 
P62258 14-3-3 protein epsilon 12 3 3  29175.0 
Q9UBS4 DnaJ homolog subfamily B member 11 14 3 3  40514.6 
Q3TIV5 Zinc finger CCCH domain-containing 
protein 15 
10 3 3  48603.7 
Q13283 Ras GTPase-activating protein-binding 
protein 1 
9 3 4  52162.8 
Q1KMD3 Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
9 6 7  85105.2 
P05556 Integrin beta-1 6 4 4  88415.1 
O14786 Neuropilin-1 19 12 13  103136.6 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
P08865 40S ribosomal protein SA 19 3 3 Cell 
Structure/Archite
cture 
32854.1 
P60709 Actin, cytoplasmic 1 19 5 6  41737.8 
P68363 Tubulin alpha-1B chain 6 2 5  50151.7 
       
P55081 Microfibrillar-associated protein 1 17 5 6  51958.7 
P17661 Desmin 4 2 8  53536.6 
P41219 Peripherin 4 2 10  53652.0 
P08670 Vimentin 67 30 142  53652.7 
Q16352 Alpha-internexin 6 3 4  55392.3 
Q07065 Cytoskeleton-associated protein 4 48 23 27  66022.2 
Q16643 Drebrin 6 2 2  71428.6 
P23284 Peptidyl-prolyl cis-trans isomerase B 21 4 4 Protein Folding 23743.2 
Q9UKD2 mRNA turnover protein homolog 4 16 3 3 Ribosome 
Assembly 
27561.3 
Q99848 Probable rRNA-processing protein 
EBP2 
27 6 8  34852.9 
Q15050 Ribosome biogenesis regulatory protein 
homolog 
24 7 9  41194.4 
O00541 Pescadillo homolog 6 4 4  68004.9 
Q14692 Ribosome biogenesis protein BMS1 4 3 3  145812.2 
P54652 Heat shock-related 70 kDa protein 2 5 3 3 Cell Cycle 70023.0 
Q5TAP6 U3 small nucleolar RNA-associated 
protein 14 homolog A 
12 7 7  87979.4 
P46087 Putative ribosomal RNA 
methyltransferase NOP2 
9 5 5  89303.6 
Q8WTT2 Nucleolar complex protein 3 homolog 3 2 2  92552.2 
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Swiss-Prot 
ID Identified Protein 
% 
Coverage 
No. of Unique 
Peptides 
Total 
Spectra 
Primary 
Biological 
Function 
Protein 
MW (Da) 
A0LTM5 Cell division protein 11B 3 2 2  92709.0 
O75400 Pre-mRNA-processing factor 40 
homolog A 
5 5 5  108807.3 
Q14980 Nuclear mitotic apparatus protein 1 5 9 10  238259.7 
Q9BXY0 Protein MAK16 homolog 15 3 4 Unknown 35370.0 
Q14257 Reticulocalbin-2 32 9 12  36877.6 
Q9NZM5 Glioma tumor suppressor candidate 
region gene 2 protein 
14 6 6  54390.7 
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With respect to their molecular function, the majority of the cross-linked proteins 
are known to bind DNA and RNA (69 total, 37.7%). In addition, 10 of the proteins are 
known to participate in transcription factor binding, while 7 are involved in translation 
initiation factor binding (Figure 2-5). With regard to biological processes, many of the 
cross-linked proteins are known to be involved in transcriptional regulation (20 total, 
12.0%), mRNA/RNA processing (17 total, 10.2%), translation (40 total, 23.9%), DNA 
damage response (8 total, 4.8%), and chromatin organization (7, 3.8%) (Figure 2-5). 
Included in this group are the nucleolar complex protein 2 (inhibitor of histone 
deacetyltransferase and p53/TP53-regulated target promoters),445 Myb-binding protein 1A 
(binds sequence-specific DNA-binding proteins),446, 447 double-strand-break repair protein 
rad21homolog,448 and chromodomain-helicase-DNA-binding protein 4 (regulation of 
homologous recombination DNA repair).449  
Some of the proteins were identified as structural constituents of the ribosome (27 
total, 14.8%) (Figure 2-5). These include the 40S ribosomal protein S6, 60S ribosomal 
protein L7, 40S ribosomal protein S2, and 40S ribosomal S3 (Table 2-1). This is not a 
result of RNA contamination in our experiments, because HPLC analysis of enzymatic 
digests has confirmed that DNA isolated by our methodology was free of RNA. An 
alternative explanation is that many of known RNA binding proteins may also have an 
affinity for DNA. We also observed proteins involved in cell signaling (15 total, 8.9%) 
such as the heterogeneous nuclear ribonucleoprotein U-like protein 2, integrin β-1,450 and 
neurophilin 1,451 cell cycle/homeostasis (21 total, 11.5%) such as the Lon protease 
homolog452 and dehydrogenase/reductase SDR family member 2,453 and cell 
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structure/architecture (11 total, 6.6%) such as actin,454 tubulin alpha-1B chain, and 
microfibrillar associated protein 1 (Table 1). 
Many of the gene products identified in our study were counted into multiple GO 
categories due to their diverse cellular functions and their involvement in multiple 
biological processes. For example, the FACT complex subunit SPT16 is involved in 
regulating transcription from RNA polymerase II promoters,455-457 cellular response to 
DNA damage stimulus,458 and DNA replication.459 As a result, it is listed under three GO 
annotation categories: DNA repair, DNA replication, and transcriptional regulation. It is 
also possible that the GO annotation does not take into account every protein’s secondary 
cellular distributions and molecular functions. The identities of a subset of proteins 
detected by mass spectrometry-based proteomics were further confirmed by western blot 
analysis using commercially available antibodies (Figure 2-6).  
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Figure 2-5: GO annotations for the proteins involved in PM-induced DPC formation in 
human HT1080 cells according to cellular distribution, molecular function, and biological 
processes. The numbers of proteins falling into each category are included.  
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Figure 2-6: Western blot analysis of concentration-dependent DPC formation identifying 
Matrin-3 and GAPDH. 
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2.3.4. HPLC-ESI-MS/MS detection of Cys-NOR-N7G conjugates 
To quantify DPC formation in NOR-treated fibroblasts, HT1080 cells (in triplicate) 
were treated with 50, 100, 250, or 500 µM NOR, and DPC-containing chromosomal DNA 
was extracted as described above. Following thermal hydrolysis to release DNA and 
proteolytic digestion of proteins to amino acids, isotope dilution HPLC-ESI+-MS/MS was 
used to quantify N-[2-[cysteinyl]ethyl]-N-[2-(guan-7-yl)ethyl]methylamine (Cys-NOR-
N7G) conjugates, which correspond to cross-linking between the N7-position of guanine 
in DNA and cysteine thiols of proteins (Scheme 2-2 and Figure 2-7A). Cys-NOR-N7G 
adducts levels increased linearly with increasing concentrations of NOR, ranging between 
3 and 14 adducts per 108 nucleotides (Figure 2-7B). These results confirm that PM and 
NOR treatment induces DPC formation between the N7-position of guanine and the 
cysteine thiols of proteins, as was previously reported for other nitrogen mustard drugs.287, 
435  
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Figure 2-7: Representative HPLC-ESI+-MS/MS trace (A) and quantitative results for Cys-
NOR-N7G conjugates in HT1080 cells treated with 0-500 μM NOR for 3 h (B). Following 
treatment, genomic DNA containing DPCs was extracted, hydrolyzed to release DNA-
protein conjugates, and digested by proteinase K to amino acids. NOR-induced Cys-NOR-
N7G conjugates were analyzed by isotope dilution HPLC-ESI+-MS/MS using the 
corresponding 15N5-labeled internal standard.  
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2.3.5. Adduct formation in repair deficient cells 
To gain insight into potential mechanisms of repair of NOR-induced DPCs in 
human cells, we examined PM toxicity and DPC formation in repair proficient and repair 
deficient cells. HT1080 (wild type), XPA (NER deficient), XPD (NER deficient), PD20 
(FANCD2 deficient), XPD corrected cells (XPD proficient), and PD20 corrected cells 
(FANCD2 proficient) were employed in these experiments. Both NER-deficient 
Xeroderma pigmentosum cells (XPA and XPD) cells and Fanconi Anemia pathway-
deficient cells (PD20) exhibited an increased sensitivity towards PM than the 
corresponding wild type cells (IC50 = 146 ± 31.2 and 168 ± 35.7 respectively, Table 2-2). 
PD20-corrected cells had similar sensitivity as HT1080 cells (IC50 = 313 ± 64.9 vs 317 ± 
42.9, Table 2-2). These results suggest that both NER and FA repair pathways help protect 
cells against PM-mediated toxicity.  
To determine whether the observed differences in sensitivity to PM can be 
attributed to impaired removal of DPC lesions, HT0180, XPA, PD20, and PD-corrected 
cells were treated with NOR (250 μM) and allowed to recover in drug-free media for 4h to 
allow for repair of NOR-induced DPCs. HPLC-ESI+-MS/MS analyses have revealed that 
NER-deficient XPA and XPD cells had the highest numbers of Cys-NOR-N7G adducts 
(24.3 ± 3.5 adducts/108 nucleotides, Figure 2-8A) as compared to HT1080 (8.7 ± 1.5 
adducts/108 nucleotides), PD20 (5.2 ± 1.3 adducts/108 nucleotides) and PD20-corrected 
cells (5.6 ± 1.6 adducts/108 nucleotides) (Figure 2-8A). To measure NOR-induced DPC 
repair over time, HT1080, XPA, PD20, and PD-corrected cells were treated with NOR 
(250 μM) and allowed to recover in drug-free media for 0, 4, 12, or 24 h.  HPLC-ESI+-
MS/MS analysis revealed that XPA cells had the highest Cys-NOR-N7G adduct levels at 
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each time point measured (14.7 ± 6.2, 19.2 ± 5.1, 10.2 ± 6.1, and 7.2 ± 3.3 at 0, 4, 12, and 
24 h respectively, Figure 2-8B). After 24 hours of repair, Cys-NOR-N7G adduct levels in 
all four cell types decreased to below 10 adducts/108 nucleotides (Figure 2-8B). Taken 
together, the results shown in Table 2-2 and Figure 2-8 are consistent with an involvement 
of nucleotide excision repair in the removal of cyclophosphamide-mediated DPCs. Fanconi 
Anemia pathway deficient cells (PD20) were more sensitive to PM (Table 2-2), but 
contained similar Cys-NOR-N7G adducts levels as compared to corrected cells (Figure 2-
8). This could be rationalized by FA-mediated removal of other toxic DNA lesions induced 
by PM, such as DNA-DNA cross-links.42-44 
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Table 2-2: Cell cytotoxicity of HT1080 (wild type), XPA (NER-deficient), XPD (NER-
deficient), XPD corrected (NER-proficient), PD20 (FANCD2-deficient), PD20 corrected 
(PD20 + FANCD2) to PM. 
 
 
Cell Type IC50 
[μM 
HT1080 317 ± 43 
PD20 
Corrected 313 ± 65 
XPD Corrected 162 ± 34 
PD20 168 ± 34 
XPD 89 ± 17 
XPA 146 ± 31 
 
 
 
 
 
 
 
 
 
 
 
Cell Type IC50 [μM 
HT1080 317 ± 43 
PD20 Corrected 313 ± 65 
XPD Corrected 162 ± 34 
PD20 168 ± 34 
XPD 89 ± 17 
XPA 146 ± 31 
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Figure 2-8: Quantitation of Cys-NOR-N7G formation and repair in cells. HT1080, XPA, 
XPD, XPD-corrected, PD20, and PD20- corrected cells treated with 250 μM NOR for 3 h. 
Following treatment, NOR-containing media was removed, and the cells were allowed to 
recover in fresh media for 4 h (A) or over a time frame of 0 – 24 h (B). 
A.  
 
 
 
 
 
 
 
 
B.  
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2.4. Discussion 
DNA-protein cross-links are bulky DNA adducts that can form upon exposure to 
bis-electrophiles, reactive oxygen species, and transition metals.262, 263 DPC formation is 
thought to contribute to the biological activity of bis-electrophiles. For example, the 
cytotoxicity and mutagenicity of dibromoethane and diepoxybutane is enhanced in bacteria 
overexpressing O6-alkylguanine DNA transferase (AGT) protein due to the formation of 
covalent AGT-DNA conjugates.284 Furthermore, proteins functionalized with DNA-
reactive 2-hydroxy-3,4-epoxybutyl groups induced cell death and mutations in human 
cells.336  
Identification of the proteins involved in DPC formation in living cells and 
determining the mechanisms of DPC repair are important for our understanding of the 
etiology of cardiovascular disease, age-related neurodegeneration, and cancer. DPCs 
accumulate in the heart and brain tissues of mice with age270 and are generated as a result 
of ischemia-reperfusion injury (Chapter 3). DPC formation is likely to contribute to both 
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target and off-target toxicity of DNA bis-alkylating agents commonly used as antitumor 
drugs, and single nucleotide polymorphisms in DPC repair genes may contribute to inter-
individual differences in response to antitumor therapy.  
In the first part of this study, a mass spectrometry-based approach was used to 
characterize DNA-protein cross-linking following exposure of human cells to two 
biologically active metabolites of CPA (PM and NOR, Scheme 2-1). We found that PM 
and NOR induced covalent cross-links between DNA and over 130 cellular proteins, 
including those participating in chromatin remodeling, translation, DNA replication, DNA 
repair, RNA metabolism, transcriptional regulation, and apoptosis (Table 2-1). These 
proteins are involved in a variety of cellular functions including transcriptional regulation 
(e.g. prohibitin-2, protein FAM50A, and transcription activator BRG1), RNA 
splicing/processing (e.g. splicing factor, arginine/serine-rich 3, splicing factor 3B subunit 
3, and 116 kDa U5 small nuclear ribonucleoprotein component), chromatin organization 
(e.g. core histone macro-H2A.2, SWI/SNF-related matrix associated actin dependent 
regulator of chromatin subfamily E member 1, chromodomain-helicase-DNA-binding 
protein 4), protein transport (e.g. charged multivesicular body protein 6, AP-3 complex 
subunit beta-1, and clathrin heavy chain1), cellular signaling (14-3-3 protein zeta/delta, 
DnaJ homolog subfamily B member 11, and neuropilin-1), and cell structure/architecture 
(actin, cytoplasmic-1, desmin, and vimentin).460-462 When the list of proteins participating 
in cross-linking to DNA in the presence of PM was compared to an analogous lists proteins 
cross-linked to DNA in the presence of DEB,440 a total of 47 proteins (30.9%) were found 
in common (Figure 2-9A). When compared to a list of cisplatin cross-linked proteins, 106 
(41.4%) proteins were found in common (Figure 2-9B). These results suggest that nitrogen 
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mustards and platinum drugs may target the same group of proteins for cross-linking to 
DNA, while a distinct group of proteins is cross-linked by DEB. Further studies will 
establish whether these differences in specificity could contribute to different biological 
outcomes of DEB (known carcinogen)212, 463, 464 and cyclophosphamide (useful antitumor 
agent).326, 378, 439  
 
 
 
 
Figure 2-9: Venn diagrams showing the overlaps between the identified proteins that form 
DPCs in human cells following exposure to PM and DEB (A) and cisplatin (B). 
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HPLC-ESI+-MS/MS analysis have revealed that similarly to other nitrogen 
mustards, PM and NOR cross-link cysteine thiols of proteins to the N7 position of guanine 
in DNA. Cys-NOR-N7G conjugates were formed in a concentration-dependent manner in 
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NOR-treated cells (Figure 2-7). Although N7-guanine cross links are expected to have 
limited hydrolytic stability, they may persist long enough to affect cellular replication and 
transcription, potentially leading to toxicity and mutations.  
The biological outcomes of DNA-protein cross-linking are currently under active 
investigation. Nakano et al. have shown that covalent DPCs larger than 16.0 kDa blocked 
the progression of DNA helicases, thus preventing the unwinding of double stranded DNA 
ahead of the replication fork.264 In our experiments with recombinant human DNA 
polymerases, we found that proteins and large peptides (> 20 amino acids) conjugated to 
the C-5 position of dT blocked DNA synthesis in the presence of lesion bypass polymerases 
η and κ, while smaller DNA-peptide conjugates (< 10-mer) were bypassed by in an error-
prone manner, giving rise to deletions and point mutations.265, 266 Recent in vivo studies of 
model peptide cross-links in human embryonic kidney cells have provided preliminary 
evidence for the ability of these conjugates to cause both targeted and off-target mutations 
(Pande et al., manuscript in preparation). 
The processes by which covalent protein-DNA complexes are recognized as DNA 
damage and removed from genomic DNA are incompletely understood. Recently, Duxin 
et al used a plasmid containing a site-specific DPC to demonstrate that in Xenopus egg 
extracts, DPC repair is coupled to DNA replication.430 These authors proposed that the 
collision of the replisome/CMG helicase with a DPC located on the DNA leading strand 
triggers proteolytic degradation of the protein constituent of DPC.430 In the yeast, the 
metalloprotease Wss1 has been identified as the DPC-specific protease.421 The resulting 
DNA-peptide cross-links may serve as substrates for nucleotide excision repair (NER).309, 
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426, 427 Alternatively, Nakano et al proposed that large DPCs do not undergo proteolysis, 
but rather are directly repaired by the HR pathway.424, 425 
Our quantitative isotope dilution HPLC-ESI+-MS/MS results are consistent with a 
role for NER in removal of NOR-induced DPCs (Figure 2-8). Cys-NOR-N7G numbers 
were significantly higher in cells deficient in nucleotide excision repair as compared with 
repair proficient cells. In contrast, the presence of functional FA pathway (PD 20 vs PD20 
corrected) did not influence the numbers of Cys-NOR-N7G adducts observed in NOR-
treated human cells (Figure 2-8). These results are consistent with a model that in 
replicating human cells, NOR-induced DPCs are proteolytically digested to smaller DNA-
NOR-peptide conjugates, which are subject to repair by NER. Further investigations are 
needed to elucidate the relative contributions of NER and HR in protecting human cells 
form toxic effects of DPCs and to establish the role of DNA-specific proteases such as 
Dvc1/Spartan421, 429 in initiating DPC repair.  
 
2.5. Conclusions 
In conclusion, a mass spectrometry-based proteomics approach was employed to 
characterize PM- and NOR-mediated DNA-protein cross-linking in human cells. 
Following treatment of human fibrosarcoma cells (HT1080) with cytotoxic concentrations 
of PM, over 130 proteins were found to be covalently trapped to DNA, including those 
involved in transcriptional regulation, RNA splicing/processing, chromatin organization, 
and protein transport. HPLC-ESI+-MS/MS analysis of proteolytic digests of DPC-
containing DNA from NOR-treated cells revealed a concentration-dependent formation of 
N-[2-[cysteinyl]ethyl]-N-[2-(guan-7-yl)ethyl]amine (Cys-NOR-N7G) conjugates, 
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confirming that it cross-links cysteine thiols of proteins to the N7 position of guanines in 
DNA. A sensitive and accurate Cys-NOR-N7G HPLC-ESI-MS/MS assay was developed 
to investigate the formation and repair of PM-induced DPCs. Cys-NOR-N7G adduct 
numbers were higher in NER-deficient Xeroderma pigmentosum cells (XPA and XPD) as 
compared with repair proficient cells, suggesting that NER is crucial for the repair of NER.  
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3. Oxidative Cross-Linking of Proteins to 
DNA Following Ischemia-Reperfusion 
Injury 
3.1. Introduction 
Heart disease is the leading cause of mortality for both men and women in the 
United States, accounting for 1 out of every 4 deaths.364, 365 Coronary heart disease disrupts 
the flow of oxygenated blood to the heart, potentially leading to myocardial infarction 
(MI).364, 365 Current MI therapies are based on the revascularization of the injured area 
using thrombolytic or angioplasty techniques in an attempt to rapidly return oxygenated 
blood flow to the damaged myocardium. Reperfusion-induced return of oxygenated blood 
to the affected myocardium, however, can lead to reactivation of the electron transport 
chain, producing large amounts of reactive oxygen species (ROS) such as superoxide 
anions (O2•-), hydrogen peroxide (H2O2), and hydroxyl radicals (OH•).465, 466 Furthermore, 
neutrophils accumulating in the infarcted myocardium can mediate tissue damage by 
releasing matrix-degrading enzymes and peroxides for downstream signaling.370-372  
ROS generated during ischemia-reperfusion injury can cause oxidative damage to 
cellular biomolecules including lipids, proteins, and DNA.367, 369 Several types of ROS-
induced DNA damage can be formed including DNA strand breaks, nucleobase 
monoadducts, and covalent DNA-DNA and DNA-protein cross-links (DPCs).262, 263, 359, 360 
DPCs are super-bulky DNA lesions containing proteins irreversibly attached to DNA 
strands.262, 263, 467 ROS-induced DPCs include covalent cross-links between ε-amino group 
of lysine and spirodiiminodihydantoin in DNA,293 lysine and guanidinohydantoine in 
135 
 
DNA,294 tyrosine, and 8-oxoguanosine in DNA,293 lysine and guanine in DNA (Nε- lysine 
guanin-8-yl cross-links),293, 294, 361 and tyrosine and thymidine in DNA (dT-Tyr) (Scheme 
3-1).362, 363 If not repaired, DPCs can induce DNA fragmentation and cell death.262, 263, 467 
In the present study, we employed left anterior descending artery (LAD) 
ligation/reperfusion surgery 468 to examine the formation of radical-induced DPCs in 
cardiomyocytes after ischemia-reperfusion injury in a rat model. A sensitive isotope 
dilution nanoLC-ESI+-MS/MS assay developed in our laboratory was used to quantify the 
formation of hydroxyl radical-mediated DPCs, while mass spectrometry based quantitative 
proteomics was employed to examine the proteins participating in DPC formation and to 
detect changes in the global cardiomyocyte proteome following ischemia-reperfusion 
injury.
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Scheme 3-1: Structures of oxidant-induced DNA-protein cross-links. Chemical structures of previously identified oxidant-induced 
DNA-protein cross-links including; 2-amino-3-(2-amino-10-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4,11-dioxo-3,4-
dihydro-4a,9a-(epiminomethanoimino)benzofuro[2,3-d]pyrimidin-6-yl)propanoic acid ([4.3.3.0] dOG-Tyr), N6-(7-amino-1-(4-
hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,9-dioxo-1,3,6,8-tetraazaspiro[4.4]nona-3,7-dien-4-yl)lysine (5-Lys-Sp), N6-(5-
guanidino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-2,3-dihydro-1H-imidazol-4-yl)lysine (Gh-Lys), O-(1-(4-
hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-ureido-4,5-dihydro-1H-imidazole-4-carbonyl)serine (Oxa-Ser), N6-(7-amino-1-
(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4,9-dioxo-1,3,6,8-tetraazaspiro[4.4]nona-2,7-dien-2-yl)lysine (8-Lys-Sp), N6-(2-
amino-9-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-8-yl)lysine (8-Lys-dG), and 2-amino-3-(4-
hydroxy-3-((1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)methyl)phenyl)propanoic acid (dT-Tyr). 
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3.2. Materials and Methods 
Chemicals and Reagents. 
2'-Deoxythymidine, Boc-L-Tyr-OH, trifluoroacetic acid, Nuclease P1 from 
Penicillium citrinum, and DL-dithiothreitol were purchased from Sigma-Aldrich (St. 
Louis, MO). Pierce™ BCA Protein Assay kit, Pierce™ Quantitative Colorimetric Peptide 
Assay, Pierce Quantitative Colorimetric Peptide Assay, and TMT 6-plex reagents were 
purchased from Thermo Fischer Scientific (Waltham, MA). Glacial acetic acid, 
hydrochloric acid, and acetonitrile were obtained from Fisher Scientific (Buchs, 
Switzerland). Mass spectrometry grade Trypsin Gold was purchased from Promega 
(Madison, WI). Cell lysis solution, protein precipitation solution, and RNaseA were 
purchased from Qiagen (Hilden, Germany). Amicon 3K filters were purchased from 
Millapore (Darmstadt, Germany). Omega Nanosep 10K Omega filters were obtained from 
PALL Life Science (Port Washington, NY). The OxiSelect™ 8-iso-prostaglandin F2α 
ELISA kit was purchased from Cell Biolabs (San Diego, CA). Matrin-3 and 
glyceraldehyde-3-phosphate dehydrogenase primary antibody and goat anti-rabbit IgG-
HRP secondary antibody were purchased from Santa Cruz Biotechnology (Dallas, TX). 
Superoxide dismutase [Mn] mitochondrial and pyruvate dehydrogenase E1 beta subunit 
primary antibodies were purchased from Abcam (Cambridge, UK).  
 
Animal safety statement 
Age-matched male Sprague-Dawley rats were randomly divided into two 
experimental groups: left anterior descending artery (LAD) ligation surgery/reperfusion 
group and sham surgery control group. Animals were housed in standard rodent cages with 
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12-hour light-dark cycles and were given food and water ad libitum. All experimental 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) 
of the University of Minnesota. All studies were conducted in accordance with the United 
States Department of Health and Human Services National Institutes of Health Guide for 
the Care and Use of Laboratory Animals. 
 
Animal model of myocardial infarction/reperfusion 
A subset of animals within the weight range of 150–175 g underwent thoracic 
surgery. Anesthesia was induced with isoflurane gas (2–5% in 100% oxygen), and 
subsequently animals were intubated and ventilated. A thoracotomy was performed 
exposing the heart, and the left anterior descending (LAD) coronary artery was ligated to 
simulate myocardial infarction for one hour as previously described.468 Following 1 h, the 
ligation was removed to restore blood flow for an additional 30 minutes to simulate 
reperfusion. Immediately after 30 minutes, the animals were euthanized, and the hearts 
excised for cardiomyocyte isolation via Langendorff reperfusion method as previously 
described.469 Typical cell recovery ranged from 1.7 x 106 to 5.0 x 106 cardiomyocytes per 
heart, with approximately 80% cell viability. Prior to the thoracic surgery, blood was drawn 
from the tail vein of each animal to serve as the pre-surgery blood sample for both cardiac 
troponin-i (cTni) and 8-iso-prostaglandin F2α measurement assays described below. 
Immediately after the 30-min reperfusion, an additional blood draw occurred to serve as 
the post-surgery blood sample for both assays. 
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Troponin-I (cTni) ELISA assay 
cTni levels in plasma pre- and post-LAD ligation/reperfusion was measured using 
the i-STAT cardiac troponin I cartridge test (Abbott, Chicago, IL) using a VetScan i-STAT 
1 handheld analyzer (Abaxis, Union City, CA) following manufacturer's protocol as 
described previously.470, 471 
 
8-iso-Prostaglandin F2α (8-iso-PGF2α) ELISA assay 
8-iso-PGF2α levels in plasma pre- and post-LAD ligation/reperfusion were 
measured using the OxiSelect™ 8-iso-prostoglandin F2α ELISA kit following the 
manufacturer's protocol. In short, 50 μL plasma samples (in triplicate) were treated with 
2N NaOH at 45 °C for 2 hours to hydrolyze lipoprotein or phospholipids coupled to 8-iso-
PGF2α. The solutions were neutralized with 10 N HCl to pH 6.0 – 8.0. The goat anti-rabbit 
antibody-coated 96-well plate was incubated with 100 μL anti-8-iso-PGF2α antibody 
(1:1000 dilution) at 25 °C for 1 hour with gentle shaking. A serial dilution of 8-iso-PGF2α 
standards were prepared, and 55 μL of the standards or the prepared plasma samples were 
combined with 55 μL of a provided 8-iso-PGF2α-HRP conjugate. The anti-8-iso-PGF2α 
antibody-treated plate was incubated with the prepared standards or samples at 25 °C for 1 
h with gentle shaking, followed by incubation with 100 μL HRP substrate at room 
temperature for 30 min with gentle shaking. The HRP reaction was quenched by adding 
100 μL stop solution, and the plates were immediately analyzed on a BioTek Synergy H1 
microplate reader (absorbance at 450 nm).  
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5-Hydroxymethyl-2'-deoxyuracil (5'-hm-dU) 
2'-Deoxythymidine (100 mg, 0.3875 mmol) was suspended in 25 mL 0.1M 
phosphate buffer (pH 7.5). Sodium persulfate (21.5 mg, 0.3875 mmol) was added, and the 
solution was heated at 75 °C for 4 h. The reaction mixtures were separated by semi-
preparative HPLC using a Zorbex XDB C18 (250 mm x 10 mm, 5 µm) column eluted with 
a linear gradient of water (A) and acetonitrile (B) at 3 mL/min. Solvent composition was 
changed from 3% B to 5% B over 30 min, then increased to 50% over 5 min, held at 50% 
for 2 min, decreased to 3% over 2 minutes, and finally held at 3% for 4 min for re-
equilibration. Under these conditions, 5'-hm-dU eluted at 8.7 min. ESI+-MS/MS (5'-hm-
dU): m/z = 259.2 [M+H]+ → 143.1[M – dR + H]+.  
 
2-amino-3-(4-hydroxy-3-((1-((2R,4R,5R)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)methyl)phenyl)propanoic acid (dT-Tyr) 
5'-hm-dU (180 mg, 0.4128 mmol) was dissolved in 1 mL glacial acetic acid and 6 
M HCl. Boc-L-Tyr-OH (116 mg, 0.4541 mmol) was added and the solution was refluxed 
(110 °C) for 1 h. Following neutralization to pH 7.0 using 1 M NaOH, the precipitate was 
filtered and the supernatant separated by semi-preparative HPLC on a Zorbex XDB C18 
(250 mm x 10 mm, 5 µm) column eluted with a linear gradient of water (A) and acetonitrile 
(B). The solvent composition was held at 2% B for 5 min, increased to 30% B in 5 min, 
then held at 30% B for 2 min, then increased to 75% B in 1 min, held at 75% B for 1 min, 
decreased to 2% B in 15 min, and finally held at 2% B for 10 min for re-equilibration. 
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Under these conditions, dT-Boc-L-Tyr-OH eluted at 19.2 min. ESI+-MS/MS (dT-Boc-L-
Tyr-OH): m/z = 522.3 [M + H]+ → 406.4 [M – dR + H]+, 360.4 [M – dR – CO2H + H]+. 
Following HPLC purification, dT-Boc-L-Tyr-OH was dissolved in 50% TFA and 
incubated at room temperature for 1 hour. The solution was neutralized to pH 7.0, and the 
supernatant was separated by the same procedure described above. Under these conditions, 
dT-Tyr eluted at 10 min. ESI+-MS/MS (dT-Tyr): m/z = 422.1 [M + H]+ → 306.1 [M –dR 
+ H]+ and 260.1[M – dR – CO2H + H]+.  
 
DPC extraction from rat cardiomyocytes 
Isolated rat cardiomyocytes (~ 1.0 x 106) were re-suspended in 1 mL of cell lysis 
solution (Qiagen, Hilden, Germany) and pipetted until the cells were completely lysed. The 
resulting lysates were treated with 40 μg RNaseA overnight at room temperature. 
Following incubation, each sample was treated with 750 μL of protein precipitation 
solution (Qiagen, Hilden, Germany) and vortexed for one minute to yield a white turbid 
solution. Each sample was then centrifuged at 2500 rcf for 10 minutes to pellet the protein 
precipitate, which was subsequently used for global proteome analyses descried below. 
The supernatant containing DNA and DPCs was decanted, and an equal volume of cold 
100% EtOH was added to precipitate DNA/DPCs. Precipitated DNA/DPCs were washed 
with 70% EtOH twice and 100% EtOH, followed by re-suspending in water. DNA 
concentrations were determined by dG analysis as described in Section 2.2.  
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Enzymatic digestion of DPCs to tryptic peptides 
DNA/DPCs (10 µg) were dissolved in 100 μL of 50 mM ammonium acetate buffer, 
pH 5.5 containing 5 mM ZnCl2 and heated at 90 °C for 10 min to denature the DNA. 
Immediately after heating, the samples were chilled in an ice bath (0 °C) to prevent DNA 
re-annealing. Once chilled, 2 U of nuclease P1 was added to each sample and the solutions 
were incubated for 4 hours at 37 oC. After 4 hours, the pH was raised to 7.0 by adding 1 
μL 1 M ammonium bicarbonate, and 120 U phosphodiesterase 1 and 22 U alkaline 
phosphatase (Sigma, St. Louis, MO) were added to each sample. The solutions were 
incubated at 37 °C overnight to complete digestion of the DNA constituent of DPCs. After 
digestion, the solutions were transferred to Amicon 3K filters (Millapore, Darmstadt, 
Germany), and the free nucleosides were removed by centrifugation at 14,000 g for 10 min.
  
Filter-aided sample preparation (FASP) protocol for DPC protein trypsin digestion 
Protein-nucleoside conjugates were washed with 100 mM HEPES three times 
(14,000 g for 10 minutes) and re-suspended in 100 μL 100 mM HEPES buffer. A fresh 
solution of 100 mM DTT/0.1% SDS in 100 mM HEPES was prepared, and 10 μL aliquot 
was added to each sample, followed by heating at 55 °C for 1 hour. After heating, 5 μL of 
freshly prepared iodoacetamide solution (375 mM) was added, and the solution was 
incubated for 30 min at room temperature. Each sample was then centrifuged at 14,000 g 
for 10 minutes to remove excess reagents, followed by resuspension in 50 µL of 25 mM 
ammonium bicarbonate. Proteins were digested to tryptic peptides by incubation with 1 µg 
trypsin overnight at 37 °C.  
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FASP protocol for whole proteome trypsin digestion 
The pelleted proteins from each LAD ligation/reperfusion and sham surgery sample 
were reconstituted in 5 mL 15 mM Tris buffer, pH 7.5/0.1% SDS and the protein 
concentrations were measured using the Pierce™ BCA Protein Assay kit. Equivalent 
amounts (100 μg) from each sample were transferred to Amicon 3K filters and washed 
with 100 μL 100 mM HEPES three times (14,000 g for 10 minutes). The proteins were 
treated with DTT and iodoacetamide as described above, followed by incubation with 1 μg 
trypsin overnight at 37 °C. 
 
TMT labeling of tryptic peptides 
Tryptic peptides were recovered by centrifugation at 14,000 g for 10 min and 
concentrated in glass MS vials to dryness. Once dry, the samples were re-suspended in 100 
µL of water and peptide concentrations were determined by the Pierce Quantitative 
Colorimetric Peptide Assay (Thermo, Waltham, MA). For peptides from whole proteome 
samples, 10 μg of peptide were diluted to 35 µL of 100 mM HEPES, and the solution pH 
was adjusted to pH 8.0 using 100 mM NaOH. For peptides from DPC proteins, peptide 
amounts corresponding to 10 µg DNA were prepared as described above. To each peptide 
solution was added 5 µL of ACN and 10 µL of a TMT-6plex reagent (19.5 µg/µL, 40-fold 
excess), and the reaction mixtures were incubated at room temperature for 2 h. The 
reactions were quenched with 4 µL of 5% hydroxylamine for 15 minutes at room 
temperature.  
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The derivatized peptides were evaporated to dryness under reduced pressure and 
re-suspended in 60 µL 98/2/0.1 water/ACN/formic acid. The samples were combined and 
desalted by stage tip procedure as follows. Stage tips were manually packed with C18 SDX 
packing discs and washed with 60 µL 60/40/0.1 ACN/water/formic acid (500 rcf for 5 min) 
and 60 µL 98/2/0.1 water/ACN/formic acid (500 rcf for 5 minutes). The reconstituted 
samples were then loaded onto the tips (500 rcf for 5 minutes) and washed with 60 µL 
98/2/0.1 water/ACN/formic (5000 rcf for 5 minutes) twice. Labeled peptides were eluted 
with 120 µL 60/40/0.1 ACN/water/ formic acid and 60 µL 80/20/0.1 ACN/water/ formic 
acid, then concentrated under vacuum. 
 
nanoHPLC-NSI+-MS/MS analysis of tryptic peptides 
TMT-labeled peptides were reconstituted in 20 µL 0.1% formic acid and analyzed 
using an LTQ Orbitrap Fusion mass spectrometer (Thermo Scientific) interfaced to a 
Dionex Ultimate 3000 RS autosampler and an Dionex UltiMate 3000 RSLCnano system. 
The samples were loaded onto a pulled-tip fused silica column with a 100 µm inner 
diameter packed in-house with 45 cm of 5µm Luna-C18 resin (Phenomenex, Torrence, Ca) 
that served both as an analytical column and as a nanospray ionization emitter. HPLC flow 
was held at 300 nL/min. HPLC solvents were comprised of 0.1% formic acid in water 
(solvent A) and 0.1% formic acid in acetonitrile (solvent B). Solvent composition was held 
at 5% solvent B for 17 min, followed by an increase to 7% over 2 min, 25% over 100 min, 
60% over 20 min, and finally to 95% over 1 min. The solvent composition was held at 95% 
for 8 min, and returned to 5% over 1 minute and re-equilibration for 28 min. 
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The mass spectrometer was operated in a data dependent mode with dynamic 
exclusion enabled (repeat count: 1, exclusion duration: 15 sec). Every scan cycle, one full 
MS scan (m/z 320 to 2000) was collected at a resolution of 120,000 at an AGC target value 
of 2x105, followed by MS2 scans of as many dependent scans as possible within a cycle 
time of 3 seconds with HCD (normalized collision energy = 38%, isolation width = 0.7 
m/z, resolution = 30,000) at an AGC target value of 1x105. Ions with a charge state of +1 
were excluded from the analysis. 
 
Protein identification  
Peptide sequences were determined from their MS2 spectra using Proteome 
Discover 2.1 software (Thermo, Waltham, MA) and a SwissProt rat proteome database.472 
Precursor ion m/z mass tolerance was set at ± 10 ppm, fragment ion m/z tolerance at ± 0.06 
Da, and up to two missed cleavages were allowed. Static modifications included 
carbamidomethylation (+57.02146 Da) of cysteine and TMT 6-plex (+219.163 Da) groups 
on lysines, tyrosines and protein N-termini. Dynamic modifications included oxidation 
(+15.99492 Da, M) and deamidation (+0.98402 Da, N). Identified peptides were filtered 
using a 1% false discovery rate and at least 1 unique peptide fragment. Isotope distributions 
for all six TMT reporter regions, provided by the supplier, were included in the analysis.  
 
Relative protein quantitation  
For relative quantification of DPC proteins and free proteins in cardiomyocytes 
from LAD surgery and sham surgery groups, reporter ion intensities (m/z 126.1277, 
127.1247, 128.1344, 129.1314, 130.1411, 131.1381) were extracted using Proteome 
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Discoverer 2.1 software. All quantitative values were rejected if not all quantitative 
channels were present, and we did not replace missing quantitative values with the 
minimum intensity. The mass tolerance for reporter ion extraction was 0.01 Da, and the 
signal to noise ratio of the reporter ion was at least 10. 
 
Bioinformatic analysis of quantitative proteomics data 
Whole proteome and DPC protein abundance data were processed by the Ingenuity 
Pathway Analysis (IPA, Qiagen, Hilden, Germany) and Cluster 3.0. To develop protein 
interaction networks, protein TMT abundance data were processed using a core expression 
analysis measuring expression fold change. Whole proteome and DPC TMT abundance 
data was further processed using Ingenuity Pathway Analysis (IPA) comparison analysis 
to identify shared protein interaction networks (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/ products/ingenuity-pathway-analysis). Clustering 
analysis of the protein TMT abundance data was analyzed using a hierarchical clustering 
algorithm (uncentered correlation).473 
 
Quantitation of dT-Tyr conjugates 
DPC-containing DNA (10 μg) isolated from rat cardiomyocytes as described above 
was dissolved in 100 μL of 10 mM Tris, pH 7.5 containing 8 Units proteinase K (10 μL, 
New England Biolabs, Ipswich, MA) and 50 μg of pronase (Sigma, St. Louis, MO) at 37 
°C overnight to digest the protein constituents of DPCs to single amino acids. DNA was 
enzymatically digested to nucleosides as follows. The solutions were concentrated to 
dryness, and samples were re-suspended in 100 μL 10 mM Tris, pH 5.5 with 5 mM ZnCl2. 
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Each sample was supplemented with 2.5 U of NucP1 and incubated at 37 °C overnight. 
Next morning, the solution pH was raised to pH 7.0 by adding 1 μL 1 M ammonium 
bicarbonate, followed by adding 15 μL of 100 mM MgCl2, 35 U DNase1, and 160 U of 
PDE1 (total volume 150 μL) and incubated for 4 h at 37 °C. Each sample was then spiked 
with 22 U of alkaline phosphatase and incubated for an additional at 37 °C overnight. 
The digests were spiked with dT[15N1,13C9]-Tyr (internal standard for mass 
spectrometry, 200 fmol), followed by ultrafiltration through Nanosep 10K filters at 5000 g 
for 10 minutes. The filters were further washed with 100 μL 0.1% formic acid in water and 
100 μL 0.1% formic acid in ACN. The filtrates were concentrated to dryness, re-suspended 
in 100 μL 0.1% acetic acid, and enriched by offline HPLC purification as follows. An 
Agilent Technologies HPLC system (1100 model) was used incorporating a diode array 
detector, an autosampler, and a fraction collector. HPLC solvents were comprised of 0.1% 
acetic acid in water (solvent A) and 0.1% acetic acid in acetonitrile (solvent B). The 
samples were loaded on a Supelcosil LC-18 (4.6 × 250 mm, 5 μm) column (Thermo 
Scientific, Waltham, MA) and eluted at a flow rate of 1 mL/min. Solvent composition was 
held at 2% B over 5 min, increased to 30% over 7 min, further to 75% over 1 min, held at 
75% for 2 min, decreased to 2% over 1 min, and finally re-equilibrated at 2% B for 14 min. 
Fractions containing dT-Tyr and its isotopically labeled internal standard (12.9 – 13.9 min) 
were collected, dried under vacuum, and reconstituted in 0.1% formic acid (16 µL) for 
quantitative analysis. Due to interfering peaks, additional HPLC purification of the 
collected analyte and internal standard using the same method was required for some 
samples. To exclude the possibility of analyte carryover between runs, a blank sample (100 
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μL of 0.1% acetic acid in water) spiked with 200 fmol internal standard was analyzed after 
every third sample. 
Quantitative analysis of dT-Tyr was conducted using a Dionex UltiMate 3000 
RSLC nanoHPLC system (Thermo Scientific, Waltham, MA) interfaced to a TSQ 
Quantiva mass spectrometer (Thermo Scientific, Waltham, MA). The samples were loaded 
onto a pulled-tip fused silica column with a 100 µm inner diameter packed in-house with 
15 cm of Synergi 4 μm Hydro RP 80A resin (Phenomenex, Torrence, Ca) that served both 
as a resolving column and as a nanospray ionization emitter. HPLC solvents were 
comprised of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B). dT-Tyr was eluted with a gradient of 1% solvent B over 6 min at a flow rate 
of 1.0 μL/min, followed by an increase to 30% over 10 min at a flow rate of 0.3 μL/min, 
then held at 30% over 2 min, then increased to 75% over 2 min, decreased to 1% over 1 
min, then finally re-equilibrated at 1% for 11 min at 1 μL/min. Under these conditions, dT-
Tyr and its internal standard (dT-[15N1, 13C9]Tyr) eluted at ~ 13.8 min. Electrospray 
ionization was achieved at a spray voltage of 2800 V and a capillary temperature of 350 
°C. Collision induced dissociation was performed with Ar as a collision gas (1.0 mTorr) at 
a collision energy of 23 V. MS/MS parameters were optimized for maximum response 
during infusion of a standard solution of dT-[15N1, 13C9]Tyr. 
nanoLC-ESI+-MS/MS analysis of dT-Tyr was performed in the selected reaction 
monitoring mode by monitoring the neutral loss of dR and the loss of dR and CO2 from 
protonated molecules of the analyte (m/z 422.2 [M + H]+ → 306.1 [M + H − dR]+, m/z 
422.2 [M + H]+ →  260.1) and the corresponding mass transitions corresponding to 
15N1,13C9- labeled internal standard (m/z 432.1 [M + H]+ → 316.1 [M + H − dR]+, m/z 432.2 
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[M + H]+ → 269.1). Analyte concentrations were determined using the relative response 
ratios calculated from HPLC-ESI+-MS/MS peak areas in extracted ion chromatograms 
corresponding to dT-Tyr and its internal standard. 
 
nanoLC-ESI+-MS/MS method validation  
Calf thymus DNA (CT DNA, 50 μg, in triplicate) was spiked with increasing 
amounts of dT-Tyr analyte (2-500 fmol) and 200 fmol dT-[15N1,13C9]Tyr. Each sample was 
processed as described above. The linearity of each validation sample was determined by 
plotting the observed peak area ratio (analyte/internal standard) to the expected peak area 
ratio. The limit of detection was defined as the analyte signal at least 3 times the response 
as compared to the background. Accuracy and precision of the method was calculated for 
three samples (200 fmol, high point; 50 fmol, middle point; 10 fmol, low point). Accuracy 
was calculated by subtracting the average observed peak area ratio (analyte/internal 
standard) by the expected peak area ratio, followed by dividing the difference by the 
expected peak area ratio multiplied by 100. Accuracy was expressed as the % difference. 
Precision was calculated by dividing the standard deviation between samples by the mean 
observed peak area multiplied by 100, expressed as % coefficient of variation (%CV). 
 
Western Blot Analysis 
Cardiomyocyte proteins (50 μg) were resolved by NuPAGE Novex 12% Bis-Tris 
gels (Invitrogen, Carlsbad, CA) and transferred to Invitrolon PVDF filter paper membranes 
(0.45 μm pore size, Life Technologies, Carlsbad, CA). The membranes were blocked for 1 
h in Tris-buffered saline-Tween 20 (TBST) containing 5% (w/v) blotting grade blocker 
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(BioRad, Hercules, CA). Following blocking, the membranes were incubated with the 
primary antibodies against matrin-3, superoxide dismutase [Mn], mitochondrial (SOD2), 
pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDH-1Eβ), troponin-
T (cTni), and actin overnight at 4 °C. The membranes were rinsed with TBST and 
incubated with the corresponding alkaline phosphatase-conjugated antibody for 1 h at room 
temperature. The membranes were developed using the Clarity Western ECL substrate 
(BioRad) and visualized on an Odyssey 2800 Fc imager (Li-COR, Lincoln, NE) with Image 
Studio version 3.1 software (Li-COR). To confirm the identity of the protein constituents 
from cardiomyocyte DPCs, 5 μg of DNA from one LAD ligation/reperfusion and sham 
surgery samples were enzymatically digested to yield a nucleoside-protein conjugate. 
Nucleoside-protein conjugates were resolved and immunoblotted as described above. 
 
3.3. Results 
3.3.1. Ischemia-reperfusion injury increases plasma troponin I levels and induces 
ROS 
To confirm that the LAD ligation procedure successfully induced myocardial 
infarction, plasma levels of cardiac troponin I (cTnI) were measured using a sensitive 
ELISA test.474, 475 cTnI is a useful biomarker of MI commonly used in the clinic to diagnose 
MI and acute coronary syndrome.476, 477 cTnI levels in all plasma samples collected before 
the thoracotomy were below the limit of detection of the assay (Table 3-1). The animals 
that underwent a sham surgery (thoracotomy only) experienced a modest increase in 
plasma cTnI levels to 4.4-6.6 ng/mL respectively (Table 3-1). In contrast, plasma levels of 
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cTnI in animals that underwent LAD ligation/reperfusion procedure were above 50 ng/mL, 
confirming that they experienced an MI (Table 3-1).  
To determine whether the ischemia/reperfusion procedure led to an increase in 
ROS, plasma levels of 8-iso-PGF2α were measured pre- and post-procedure using the 
OxiSelect™ 8-iso-prostoglandin F2α ELISA assay.478-480 8-iso-PGF2α is an isoprostane 
produced by ROS-mediated peroxidation of arachidonic acid in membrane phospholipids 
and is commonly used as a biomarker of oxidative stress in vivo.478-480 It is important to 
note that prior to the surgeries, animals where anesthetization under 100% oxygen, 
potentially exposing them to hyperoxic conditions and an artificial increase in ROS levels. 
Therefore, the baseline levels of 8-iso-PGF2α could have been elevated prior to the 
surgery. We found that 8-iso-PGF2α levels slightly decreased post-thoracotomy in control 
group that underwent sham surgery (Controls 1 – 3) (Figure 3-1). In contrast, animals that 
underwent LAD ligation/reperfusion procedure (LAD 1 – 3) experienced a 273.8%, 
357.1%, and 178.3% increase in 8-iso-PGF2α levels post-surgery compared to the pre-
procedure levels, indicative of increased oxidant levels in this group (Figure 3-1).  
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Table 3-1: Plasma cTni measurements pre- and post-surgery to confirm myocardial 
infarction. The cTni levels after LAD ligation/reperfusion was above the limit of detection 
of the assay (50 ng/mL), while the average cTni levels after the sham surgery was 5.82 ± 
1.03 ng/mL. 
 
Experiment Pre-Surgery cTni 
(ng/mL) 
Post-Surgery cTni 
(ng/mL) 
LAD 1 ND >50 
LAD 2 ND >50 
LAD 3 ND >50 
Control 1 ND 6.57 
Control 2 ND 6.52 
Control 3 ND 4.37 
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Figure 3-1: Plasma 8-iso-PGF2α measurements. Plasma 8-iso-PGF2α levels were 
measured pre- and post-surgery using the OxiSelect™ 8-iso-prostoglandin F2α ELISA kit. 
A standard curve of 200,000 ng/mL, 50,000 ng/mL, 12,500 ng/mL, 3125 ng/mL, 
781ng/mL, 195 ng/mL, and 49 ng/mL was analyzed by a “log inhibitor vs response, 
variable slope with 4-parameters” equation to determine 8-iso-PGF2α concentration. The 
animals that underwent LAD ligation/reperfusion (LAD 1, 2, and 3) had a significant 
increase (p value < 0.05) in 8-iso-PGF2α post-surgery as compared to pre-surgery. No 
significant increase in 8-iso-PGF2α levels was detected in the animals that underwent the 
sham surgery (Control 1, 2, and 3). 
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3.3.2. Total DPC numbers are increased following ischemia-reperfusion injury 
To allow for absolute quantification of ROS-induced DPCs in rat cardiomyocytes, 
an isotope dilution tandem mass spectrometry assay was developed for dT-Tyr conjugates 
(Scheme 3-2). This type of ROS-induced cross-linking involves radical-mediated reactions 
between the 5'-methyl of thymidine in DNA and the 3-position of tyrosine residue in 
proteins (Scheme 3-2).362, 363, 481, 482 DPCs extracted from rat cardiomyocytes were 
enzymatically digested with nucleases and proteases to afford dT-Tyr and analyzed by 
isotope dilution HPLC-ESI+-MS/MS allowing for accurate and precise quantification of 
hydroxyl radical-induced DNA-protein conjugates. 
Authentic standards of dT-Tyr and dT-[15N1,13C9]Tyr were prepared in our 
laboratory using published methodologies.483 These standards were used to develop a 
sensitive and precise nanoLC-ESI+-MS/MS method for dT-Tyr using a triple quadrupole 
mass spectrometer. In our approach, DPC-containing DNA is spiked with known amounts 
of internal standard and enzymatically digested to free nucleosides. The analyte and its 
internal standard are enriched by offline HPLC, followed by quantitative analysis using 
HPLC-ESI+-MS/MS. Selected reaction monitoring transitions included the neutral loss of 
dR and the simultaneous loss of dR and CO2 from protonated molecules of the analyte (m/z 
422.2 [M + H]+ → 306.1 [M + H − dR]+, m/z 422.2 [M + H]+ → 260.1) and the 15N1,13C9-
isotopically labelled internal standard (m/z 432.1 [M + H]+ → 316.1 [M + H − dR]+, m/z 
432.2 [M + H]+ → 269.1) (Figure 3-2A). The new HPLC-ESI+-MS/MS method was 
validated by analyzing blank DNA samples spiked with known amounts of dT-Tyr analyte 
and internal standard. HPLC-ESI+-MS/MS limit of detection (LOD) was calculated as 250 
amol of dT-Tyr on column, while the limit of quantification was 2 fmol on column (Figure 
156 
 
3-3). The accuracy (% difference) of the method was calculated as 3.0%, 4.0%, and 20.0% 
for the high, middle, and low validation points. The precision of the method was calculated 
as 4.1, 4.2, and 0.0 % CV for the high, middle, and low validation points respectively. 
The new method was used to quantify radical-induced DPCs after LAD ligation/ 
reperfusion compared to sham surgery (3 per group). We found that dT-Tyr amounts were 
significantly increased in cardiomyocytes of rats that underwent LAD ligation/reperfusion 
as compared to the sham group (35.7 ± 2.2 vs 18.2 ± 1.5 dT-Tyr adducts per 108 
nucleotides, respectively, p-value < 0.01) (Figure 3-2B). These findings support our 
hypothesis that ischemia-reperfusion injury increases the levels of hydroxyl radical-
mediated DPCs in cardiomyocyte DNA. 
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Scheme 3-2: Proposed mechanism of hydroxyl radical-induced DPC formation between thymidine in DNA and tyrosine residue in 
proteins. Hydroxyl radicals abstract a hydrogen from the 5-methyl position of thymidine to yield a reactive thymidine radical (19), which 
undergoes a one-electron addition to the 3-position of a tyrosine to yield a stable methylene linkage. Subsequent hydrogen abstraction 
from the 3-position of tyrosine (20) re-aromatizes the phenol ring to yield the stable DNA-protein cross-link (21). 
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Figure 3-2: Representative nanoHPLC-ESI+-MS/MS trace of dT-Tyr observed in rat 
cardiomyocytes following LAD ligation/reperfusion surgery (A) and quantitative data for 
dT-Tyr adducts formed in rat cardiomyocytes after LAD ligation/reperfusion or sham 
surgery (B). 
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Figure 3-3: Validation of the developed dT-Tyr nanoLC-ESI+-MS/MS assay. Calf thymus 
DNA (50 μg, in triplicate) was spiked with dT-Tyr analyte (500, 200, 100, 50, 20, 10, or 2 
fmol) and 200 fmol dT-Tyr (15N1,13C9) IS. Each sample was processed for dT-Tyr 
enrichment as described in the Materials and Methods (Section 3.2). The linearity of each 
validation replicate was determined by plotting the observed peak area ratio 
(analyte/internal standard) to the expected peak area ratio. The limit of detection was 
defined as the analyte signal at least 3 times the response as compared to the background. 
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3.3.3. Quantitative proteomic analysis of the protein constituents of cardiomyocyte 
DPCs 
We next aimed to identify and quantify the proteins participating in DPC formation 
following LAD ligation/reperfusion surgery. Following DPC isolation from control and 
LAD ligation/reperfusion rat cardiomyocytes, protein constituents were analyzed by TMT 
quantitative proteomics technique.484 In brief, each of the six samples (3 LAD 
ligation/reperfusion, 3 sham surgery) was labeled with a unique isotope tag. The samples 
were combined and analyzed by nanoLC-ESI-MS/MS on an Orbitrap Fusion mass 
spectrometer. MS/MS sequencing of tryptic peptides was used to determine their amino 
acid sequences, and the proteins were identified using Proteome Discoverer 2.1 
software.485 Relative quantitation of the proteins was achieved using ion intensities of 
reporter ions (m/z 126.1277, 127.1247, 128.1344, 129.1314, 130.1411, 131.1381) 
originating from their tryptic peptides. The relative abundances of proteins in LAD 
ligation/reperfusion animals as compared to the sham group was determined by comparing 
the grouped reporter ion intensities of 126.1277, 128.1344, and 131.1381 (LAD 1-3) to the 
grouped reporter ion intensities of corresponding to control group (m/z 127.1247, 
129.1314, and 130.1411 (controls 1-3).  
The relative abundances of proteins covalently bound to DNA following LAD 
ligation/reperfusion were determined by comparing the grouped reporter ion intensities of 
128.1344, 129.1314 and 131.1381 (LAD 1-3) to the grouped reporter ion intensities of 
126.1277, 127.1247, and 130.1411 (control animals 1-3). Using these criteria, a total of 90 
proteins were identified in all six samples (Table 3-2). The majority of the identified DPC 
protein constituents (80, 88.9%) increased in abundance at least 1.2-fold after LAD 
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ligation/reperfusion as compared to sham surgery, with 21 (23.3%) of these proteins 
increasing in abundance at least 5-fold (Table 3-2). Proteins that showed the greatest 
change included myosins, heat shock proteins, Cu-Zn superoxide dismutases, thioredoxin, 
actin, and mitochondrial creatinine kinase. Of the remaining DPC proteins, 8 proteins 
(8.9%) did not change in abundance and one protein (1.1%, lysosome-associated 
membrane glycoprotein 1) decreased in abundance (Table 3-2).  
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Table 3-2: Identification and quantification of proteins irreversible trapped on DNA in cardiomyocytes of rats subjected to ischemia-
reperfusion or sham surgery.  
Accession Description of Protein % 
Coverage 
# Peptides # PSMs # Unique 
Peptides 
MW 
[kDa] 
Fold Change 
(LAD/Sham) 
P13437 3-ketoacyl-CoA thiolase, 
mitochondrial 
5.54 2 2 2 41.84 12.38 
P49432 Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial 
13.65 5 10 5 38.96 9.28 
Q64591 2,4-dienoyl-CoA reductase, 
mitochondrial 
8.06 3 4 3 36.11 8.95 
P29117 Peptidyl-prolyl cis-trans isomerase 
F, mitochondrial 
6.80 2 2 2 21.80 8.70 
P11980 Pyruvate kinase PKM 3.58 2 2 2 57.78 8.65 
Q9Z0V6 Thioredoxin-dependent peroxide 
reductase, mitochondrial 
21.40 5 7 5 28.28 7.77 
P42123 L-lactate dehydrogenase B chain 23.95 8 11 7 36.59 7.38 
P35434 ATP synthase subunit delta, 
mitochondrial 
13.69 2 11 2 17.58 6.98 
P13086 Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, 
mitochondrial 
9.54 3 4 3 36.13 6.66 
P04642 L-lactate dehydrogenase A chain 9.64 3 5 2 36.43 6.46 
P14604 Enoyl-CoA hydratase, 
mitochondrial 
32.41 9 22 9 31.50 6.42 
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P26284 Pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial 
5.90 3 3 3 43.20 6.20 
P07895 Superoxide dismutase [Mn], 
mitochondrial 
13.06 3 5 3 24.66 5.95 
Q8VHF5 Citrate synthase, mitochondrial 17.38 8 13 8 51.83 5.95 
P62898 Cytochrome c, somatic 43.81 5 8 5 11.60 5.94 
P02563 Myosin-6 48.19 118 457 39 223.37 5.90 
P02564 Myosin-7 42.38 96 355 17 222.95 5.87 
P15650 Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
39.07 17 60 17 47.84 5.60 
O35854 Branched-chain-amino-acid 
aminotransferase, mitochondrial 
4.58 2 2 2 44.25 5.49 
P18418 Calreticulin 4.81 2 2 2 47.97 5.47 
O88767 Protein deglycase DJ-1 8.47 2 2 2 19.96 5.11 
P51868 Calsequestrin-2 10.17 4 5 4 47.81 5.07 
P04636 Malate dehydrogenase, 
mitochondrial 
51.18 16 59 16 35.66 4.91 
P00507 Aspartate aminotransferase, 
mitochondrial 
39.07 22 54 22 47.28 4.72 
Q01205 Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase 
complex, mitochondrial 
7.27 4 4 4 48.89 4.69 
P19804 Nucleoside diphosphate kinase B 28.95 4 5 4 17.27 4.55 
P07483 Fatty acid-binding protein, heart 57.89 8 34 8 14.77 4.53 
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P31044 Phosphatidylethanolamine-binding 
protein 1 
25.13 3 8 3 20.79 4.45 
P04785 Protein disulfide-isomerase 8.64 4 4 4 56.92 4.40 
P26772 10 kDa heat shock protein, 
mitochondrial 
48.04 5 9 5 10.90 4.16 
P08461 Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
14.87 9 25 9 67.12 4.07 
P16409 Myosin light chain 3 73.50 15 51 12 22.14 3.99 
P70623 Fatty acid-binding protein, 
adipocyte 
21.21 3 3 3 14.70 3.98 
P00564 Creatine kinase M-type 35.43 14 32 12 43.02 3.88 
Q9JM53 Apoptosis-inducing factor 1, 
mitochondrial 
7.84 4 5 4 66.68 3.82 
Q4FZU2 Keratin, type II cytoskeletal 6A 4.35 3 6 2 59.21 3.77 
P48500 Triosephosphate isomerase 20.08 5 7 5 26.83 3.75 
P08503 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
6.41 3 4 3 46.53 3.71 
O88989 Malate dehydrogenase, cytoplasmic 29.34 11 19 11 36.46 3.70 
Q62812 Myosin-9 1.94 4 4 3 226.20 3.69 
P04692 Tropomyosin alpha-1 chain 88.73 51 326 32 32.66 3.59 
P13221 Aspartate aminotransferase, 
cytoplasmic 
26.15 9 12 9 46.40 3.58 
P09605 Creatine kinase S-type, 
mitochondrial 
33.41 16 124 15 47.36 3.46 
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P56741 Myosin-binding protein C, cardiac-
type 
17.43 20 45 20 140.67 3.46 
O35796 Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
11.83 2 2 2 30.98 3.45 
P58775 Tropomyosin beta chain 48.24 23 125 4 32.82 3.43 
P05065 Fructose-bisphosphate aldolase A 10.16 4 5 4 39.33 3.38 
P15999 ATP synthase subunit alpha, 
mitochondrial 
26.94 13 29 13 59.72 3.30 
P06761 78 kDa glucose-regulated protein 8.72 5 7 5 72.30 3.29 
P23965 Enoyl-CoA delta isomerase 1, 
mitochondrial 
14.53 4 5 4 32.23 3.26 
P11507 Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
5.27 5 16 5 114.69 3.24 
P56571 ES1 protein homolog, 
mitochondrial 
19.17 6 10 6 28.16 3.18 
Q68FU3 Electron transfer flavoprotein 
subunit beta 
12.94 3 5 3 27.67 3.18 
P08733 Myosin regulatory light chain 2, 
ventricular/cardiac muscle isoform 
59.64 10 40 10 18.87 3.15 
P02770 Serum albumin 3.45 2 7 2 68.69 3.10 
P48721 Stress-70 protein, mitochondrial 7.36 4 4 3 73.81 2.97 
Q62651 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial 
25.99 9 11 9 36.15 2.91 
P07632 Superoxide dismutase [Cu-Zn] 22.73 3 5 3 15.90 2.77 
P13803 Electron transfer flavoprotein 
subunit alpha, mitochondrial 
15.02 4 6 4 34.93 2.75 
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Q5XIF3 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4, mitochondrial 
31.43 5 9 5 19.73 2.71 
Q6P6R2 Dihydrolipoyl dehydrogenase, 
mitochondrial 
20.04 9 15 9 54.00 2.69 
P18886 Carnitine O-palmitoyltransferase 2, 
mitochondrial 
3.50 3 3 3 74.06 2.65 
D3ZHA0 Filamin-C 0.77 2 2 2 290.80 2.52 
P63018 Heat shock cognate 71 kDa protein 9.44 7 11 6 70.83 2.51 
Q9ER34 Aconitate hydratase, mitochondrial 19.87 15 33 15 85.38 2.38 
P16290 Phosphoglycerate mutase 2 17.00 5 5 5 28.74 2.36 
P28042 Single-stranded DNA-binding 
protein, mitochondrial 
11.26 2 2 2 17.44 2.21 
Q6IFW6 Keratin, type I cytoskeletal 10 9.70 5 10 4 56.47 2.17 
Q6IMF3 Keratin, type II cytoskeletal 1 6.24 4 6 3 64.79 2.08 
P11240 Cytochrome c oxidase subunit 5A, 
mitochondrial 
21.23 3 3 3 16.12 2.03 
Q6IFV3 Keratin, type I cytoskeletal 15 3.58 3 3 2 48.84 1.95 
Q9ESS6 Basal cell adhesion molecule 7.53 4 5 4 67.47 1.92 
P62738 Actin, aortic smooth muscle 47.21 16 65 6 41.98 1.78 
P01946 Hemoglobin subunit alpha-1/2 15.49 2 3 2 15.32 1.75 
P04762 Catalase 5.88 3 5 3 59.72 1.65 
P56574 Isocitrate dehydrogenase [NADP], 
mitochondrial 
5.75 2 3 2 50.94 1.59 
P10719 ATP synthase subunit beta, 
mitochondrial 
17.77 7 8 7 56.32 1.56 
167 
 
P32551 Cytochrome b-c1 complex subunit 
2, mitochondrial 
9.07 3 3 3 48.37 1.42 
Q920L2 Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial 
2.90 2 3 2 71.57 1.42 
Q6UPE1 Electron transfer flavoprotein-
ubiquinone oxidoreductase, 
mitochondrial 
3.73 2 2 2 68.16 1.41 
Q05962 ADP/ATP translocase 1 16.11 5 6 3 32.97 1.38 
Q64119 Myosin light polypeptide 6 21.85 4 8 1 16.96 1.14 
P50339 Chymase 9.72 2 2 2 27.55 1.11 
P51740 Intestinal-type alkaline phosphatase 
2 
7.08 4 14 2 59.76 1.09 
P15693 Intestinal-type alkaline phosphatase 
1 
8.33 4 21 2 58.37 1.07 
P26453 Basigin 7.99 3 5 3 42.41 1.02 
P02091 Hemoglobin subunit beta-1 27.21 3 4 3 15.97 1.00 
P21961 Mast cell carboxypeptidase A 
(Fragment) 
12.14 6 7 6 47.91 0.91 
Q01129 Decorin 7.34 3 4 3 39.78 0.91 
P14562 Lysosome-associated membrane 
glycoprotein 1 
4.91 2 3 2 43.94 0.83 
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The proteomics data for DNA-conjugated proteins was further analyzed using the 
Cluster 3.0 software and IPA. A subset of 25 identified DPC proteins, consisting of the 
most abundant proteins, underwent hierarchical clustering analysis. Significant differences 
in protein abundances were observed between the LAD ligation/reperfusion replicates as 
compared to the sham surgery group (Figure 3-4). Hierarchical clustering of the 25 
proteins revealed tight grouping between the LAD ligation/reperfusion replicates and the 
sham surgery replicates, but not between the two conditions (Figure 3-4). IPA core 
analysis of the DPC proteins developed 7 protein interaction networks; organismal injury 
and abnormality (score 59, 26 proteins), cardiovascular system development and function 
(score 33, 17 proteins), free radical scavenging (score 28, 15 proteins), developmental 
disorder/hereditary disorder (score 26, 14 proteins), energy production or lipid metabolism 
(score 24, 13 proteins), and cell morphology and cellular function and maintenance (score 
21, 12 proteins). Relative protein quantitation results for SOD2, PDH-1Eβ, and actin were 
further confirmed by western blot analysis using commercially available antibodies 
(Figure 3-5). Overall, our results indicate that ischemia/reperfusion injury drastically 
increases the concentrations of proteins covalently attached to DNA, potentially leading to 
cell death and tissue damage. 
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Figure 3-4: Heat map analysis of the TMT abundance data for 23 representative proteins 
identified from the DPC samples. Proteins analyzed include sarcomere proteins (8), ROS 
scavenging proteins (8), and the remaining most abundant proteins (7). 
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Figure 3-5: Western blot confirmation of proteins identified in the whole-proteome 
analysis and DPC analysis after LAD ligation/reperfusion compared to sham. For whole 
proteome analysis, 50 μg of protein from each sample was immunoblotted against 
GAPDH, PDH-1Eβ, troponin-T, and actninin primay antibody. For DPC analysis, 5 μg of 
DNA from a LAD ligation/reperfusion and sham surgery sample was enzymatically 
digested to yield protein-nucleoside conjugates that were immunoblotted against SOD2 
and PDH-1Eβ.  
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3.3.4. Quantitative proteomic analysis of cardiomyocyte proteome 
To determine whether the observed increases in DNA-protein cross-linking are 
linked to global changes in protein abundance in response to LAD ligation/reperfusion 
injury, the entire cardiomyocyte proteome from control and MI/reperfusion groups were 
analyzed using the same TMT quantitative proteomics technique described above 484. A 
total of 359 proteins were identified in all six samples (Table 3-3). Of these, the majority 
(N = 288, 80.2%) did not change in abundance after LAD ligation/reperfusion as compared 
to the sham surgery (Table 3-3). Of the remaining 71 proteins, 48 proteins were found to 
increase in abundance at least 1.2-fold after LAD ligation/reperfusion and 23 proteins 
decreased in abundance under the same conditions (Table 3-3).  
The majority of the proteins that increased in abundance following LAD ligation/ 
reperfusion (N =20, 41.7%) were mitochondrial proteins including malate dehydrogenase, 
enoyl-CoA hydratase, cytochrome C oxidase, and NADH dehydrogenase. This is not 
unexpected, as the sudden switch from hypoxic conditions to normoxic conditions when 
the blood flow to the affected area is restored increases the expression of proteins required 
for aerobic respiration 367. The remaining proteins were categorized as 
membrane/extracellular proteins (14, 29.2%), sarcomere proteins (5, 10.4%), cytoplasmic 
proteins (4, 8.3%), nuclear proteins (4, 8.3%), and endoplasmic reticulum proteins (1, 
2.1%). Among the proteins that decreased in abundance following LAD 
ligation/reperfusion, 39.1% (9) were nuclear, followed by cytoplasmic (6, 26.1%), 
mitochondrial (3, 13.0%), cell membrane (3, 13.0%), and endoplasmic reticulum (2, 8.7%). 
Relative protein quantitation results for GAPDH and PDH-1Eβ were further confirmed by 
western blot analysis using commercially available antibodies (Figure 3-5). 
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Table 3-3: Table of identified proteins from the cardiomyocyte proteome of rats subjected to ischemia-reperfusion or sham surgery. 
 
Accession Description Coverage # Peptides # PSMs # Unique 
Peptides 
MW [kDa] Fold Change 
(LAD/Sham) 
Q6IMF3 Keratin, type II cytoskeletal 1 5.12 3 5 3 64.79 2.90 
Q5M7U6 Actin-related protein 2 1.78 2 5 1 44.71 2.17 
P50753 Troponin T, cardiac muscle 20.40 8 11 8 35.71 1.68 
P04636 Malate dehydrogenase, mitochondrial 60.95 18 91 18 35.66 1.63 
P14604 Enoyl-CoA hydratase, mitochondrial 25.17 8 14 8 31.50 1.61 
P51638 Caveolin-3 11.92 3 4 1 17.39 1.58 
P12847 Myosin-3 12.78 33 227 1 223.72 1.53 
P02091 Hemoglobin subunit beta-1 77.55 11 92 3 15.97 1.53 
P23693 Troponin I, cardiac muscle 15.64 5 12 5 24.15 1.49 
Q6PCU8 NADH dehydrogenase [ubiquinone] 
flavoprotein 3, mitochondrial 
29.63 3 7 3 11.93 1.48 
P01946 Hemoglobin subunit alpha-1/2 64.08 9 45 9 15.32 1.43 
P68370 Tubulin alpha-1A chain 14.63 6 9 1 50.10 1.42 
Q6AYZ1 Tubulin alpha-1C chain 10.69 5 6 1 49.91 1.42 
Q68FR8 Tubulin alpha-3 chain 12.89 5 8 1 49.93 1.42 
P16290 Phosphoglycerate mutase 2 8.70 2 3 2 28.74 1.42 
Q91XR8 Phospholipid hydroperoxide 
glutathione peroxidase, nuclear 
5.93 2 2 2 29.32 1.38 
P36970 Phospholipid hydroperoxide 
glutathione peroxidase, mitochondrial 
7.61 2 2 2 22.21 1.38 
Q63041 Alpha-1-macroglobulin 0.93 2 2 2 167.02 1.35 
P05508 NADH-ubiquinone oxidoreductase 
chain 4 
8.28 4 7 4 51.77 1.34 
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P48675 Desmin 39.87 19 49 15 53.42 1.33 
P00406 Cytochrome c oxidase subunit 2 22.03 5 25 5 25.93 1.32 
P07895 Superoxide dismutase [Mn], 
mitochondrial 
6.31 2 4 2 24.66 1.32 
Q6P6R2 Dihydrolipoyl dehydrogenase, 
mitochondrial 
8.84 3 4 3 54.00 1.30 
P07335 Creatine kinase B-type 7.87 4 8 2 42.70 1.30 
P17209 Myosin light chain 4 17.10 3 8 2 21.27 1.30 
P84817 Mitochondrial fission 1 protein 17.11 3 6 3 16.98 1.30 
B2RZ37 Receptor expression-enhancing 
protein 5 
13.76 3 6 3 21.42 1.29 
O88813 Long-chain-fatty-acid--CoA ligase 5 4.10 3 11 3 76.36 1.26 
P80431 Cytochrome c oxidase subunit 7B, 
mitochondrial 
10.00 2 4 2 8.99 1.26 
P27274 CD59 glycoprotein 16.67 2 3 2 13.78 1.25 
P53534 Glycogen phosphorylase, brain form 
(Fragment) 
7.64 7 8 4 96.11 1.24 
P60711 Actin, cytoplasmic 1 43.73 21 363 5 41.71 1.24 
P18886 Carnitine O-palmitoyltransferase 2, 
mitochondrial 
24.62 18 36 18 74.06 1.24 
Q63619 Ubiquinone biosynthesis protein 
COQ7 homolog (Fragment) 
11.17 2 3 2 20.13 1.24 
P47819 Glial fibrillary acidic protein 3.49 2 2 1 49.93 1.23 
P12346 Serotransferrin 8.02 6 8 6 76.35 1.23 
Q9Z0V6 Thioredoxin-dependent peroxide 
reductase, mitochondrial 
21.40 5 11 5 28.28 1.23 
Q9JK11 Reticulon-4 1.89 2 3 2 126.31 1.23 
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P26284 Pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial 
22.82 10 26 10 43.20 1.23 
Q3KR86 MICOS complex subunit Mic60 
(Fragment) 
32.68 19 40 19 67.14 1.23 
P10888 Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial 
48.52 10 100 10 19.50 1.22 
P23928 Alpha-crystallin B chain 32.57 4 9 4 20.08 1.22 
Q9JLJ3 4-trimethylaminobutyraldehyde 
dehydrogenase 
3.64 2 2 2 53.62 1.21 
P41350 Caveolin-1 14.61 4 5 2 20.54 1.21 
P31000 Vimentin 12.23 7 13 2 53.70 1.21 
Q68FU7 Ubiquinone biosynthesis 
monooxygenase COQ6 
4.83 2 2 2 51.46 1.20 
P00507 Aspartate aminotransferase, 
mitochondrial 
41.16 18 47 18 47.28 1.20 
P38718 Mitochondrial pyruvate carrier 2 33.86 5 10 5 14.25 1.20 
P35704 Peroxiredoxin-2 18.69 4 5 4 21.77 1.19 
P29117 Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial 
6.80 2 3 2 21.80 1.19 
P07340 Sodium/potassium-transporting 
ATPase subunit beta-1 
27.63 8 28 8 35.18 1.19 
P00564 Creatine kinase M-type 28.87 12 31 10 43.02 1.19 
P15650 Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
35.12 15 68 15 47.84 1.19 
P16036 Phosphate carrier protein, 
mitochondrial 
29.78 12 57 12 39.42 1.18 
Q5XIT9 Methylcrotonoyl-CoA carboxylase 
beta chain, mitochondrial 
6.75 4 5 4 61.48 1.18 
P07943 Aldose reductase 9.81 3 3 3 35.77 1.18 
175 
 
P81155 Voltage-dependent anion-selective 
channel protein 2 
60.00 14 42 12 31.73 1.17 
Q07969 Platelet glycoprotein 4 17.80 9 18 9 52.70 1.17 
P21396 Amine oxidase [flavin-containing] 21.29 13 16 13 59.47 1.17 
P30427 Plectin 0.30 2 2 2 533.21 1.17 
Q62651 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial 
7.34 3 4 3 36.15 1.17 
P24368 Peptidyl-prolyl cis-trans isomerase B 25.00 5 6 5 23.79 1.17 
P62632 Elongation factor 1-alpha 2 13.17 7 11 3 50.42 1.17 
Q5XIF6 Tubulin alpha-4A chain 16.74 7 12 2 49.89 1.17 
Q80W89 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 11 
19.15 2 2 2 14.84 1.17 
P62329 Thymosin beta-4 29.55 2 3 2 5.05 1.16 
P63312 Thymosin beta-10 29.55 2 3 2 5.02 1.16 
D3ZTX0 Transmembrane emp24 domain-
containing protein 7 
7.52 2 2 2 25.46 1.16 
P06685 Sodium/potassium-transporting 
ATPase subunit alpha-1 
33.43 31 91 19 112.98 1.16 
P14046 Alpha-1-inhibitor 3 1.35 2 2 2 163.67 1.16 
Q03626 Murinoglobulin-1 1.34 2 2 2 165.22 1.16 
P21913 Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, 
mitochondrial 
53.19 17 51 17 31.81 1.16 
P05708 Hexokinase-1 17.21 17 31 14 102.34 1.15 
Q01129 Decorin 11.86 5 6 4 39.78 1.15 
Q920L2 Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial 
40.40 20 66 20 71.57 1.15 
O88989 Malate dehydrogenase, cytoplasmic 27.54 9 19 9 36.46 1.15 
176 
 
Q9R1Z0 Voltage-dependent anion-selective 
channel protein 3 
50.53 12 23 10 30.78 1.15 
P40241 CD9 antigen 7.52 2 2 2 25.20 1.15 
P97700 Mitochondrial 2-oxoglutarate/malate 
carrier protein 
31.85 10 42 10 34.22 1.15 
P19643 Amine oxidase [flavin-containing] B 2.88 2 3 2 58.42 1.15 
P70470 Acyl-protein thioesterase 1 11.30 3 3 3 24.69 1.15 
P18163 Long-chain-fatty-acid--CoA ligase 1 46.78 30 95 30 78.13 1.15 
P47853 Biglycan 5.69 3 4 2 41.68 1.15 
P62630 Elongation factor 1-alpha 1 9.09 5 8 1 50.08 1.15 
Q68FT1 Ubiquinone biosynthesis protein 
COQ9, mitochondrial 
25.00 6 12 6 35.12 1.14 
P26772 10 kDa heat shock protein, 
mitochondrial 
57.84 7 28 7 10.90 1.14 
Q63716 Peroxiredoxin-1 22.11 5 7 5 22.10 1.14 
Q68FU3 Electron transfer flavoprotein subunit 
beta 
52.55 13 33 13 27.67 1.14 
P48500 Triosephosphate isomerase 22.89 6 12 6 26.83 1.14 
O35854 Branched-chain-amino-acid 
aminotransferase, mitochondrial 
7.12 3 6 3 44.25 1.14 
P21588 5'-nucleotidase 2.08 2 2 2 63.93 1.14 
P07483 Fatty acid-binding protein, heart 57.89 8 24 8 14.77 1.14 
P08461 Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
20.57 11 23 11 67.12 1.14 
P08733 Myosin regulatory light chain 2, 
ventricular/cardiac muscle isoform 
87.35 14 93 14 18.87 1.14 
Q62812 Myosin-9 8.36 16 22 10 226.20 1.13 
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P80432 Cytochrome c oxidase subunit 7C, 
mitochondrial 
28.57 2 11 2 7.37 1.13 
Q99ML5 Prenylcysteine oxidase 5.16 2 2 2 56.25 1.13 
P10111 Peptidyl-prolyl cis-trans isomerase A 12.20 3 5 3 17.86 1.13 
Q01728 Sodium/calcium exchanger 1 1.75 2 2 2 108.12 1.13 
D3ZHA0 Filamin-C 1.32 4 6 4 290.80 1.13 
B0K020 CDGSH iron-sulfur domain-
containing protein 1 
34.26 3 20 3 12.09 1.13 
P11608 ATP synthase protein 8 46.27 3 14 3 7.64 1.12 
Q05962 ADP/ATP translocase 1 47.65 15 133 6 32.97 1.12 
P70623 Fatty acid-binding protein, adipocyte 21.97 3 6 3 14.70 1.12 
Q6PCT8 Succinate dehydrogenase 
[ubiquinone] cytochrome b small 
subunit, mitochondrial 
10.69 2 2 2 16.97 1.12 
Q2TA68 Dynamin-like 120 kDa protein, 
mitochondrial 
7.50 8 9 8 111.24 1.12 
P11951 Cytochrome c oxidase subunit 6C-2 46.05 4 17 4 8.45 1.11 
P11232 Thioredoxin 20.95 2 2 2 11.67 1.11 
P12075 Cytochrome c oxidase subunit 5B, 
mitochondrial 
36.43 7 83 7 13.91 1.11 
O88767 Protein deglycase DJ-1 23.81 5 7 5 19.96 1.11 
P13803 Electron transfer flavoprotein subunit 
alpha, mitochondrial 
41.74 12 31 12 34.93 1.11 
P62074 Mitochondrial import inner 
membrane translocase subunit Tim10 
14.44 2 3 2 10.33 1.11 
P97521 Mitochondrial carnitine/acylcarnitine 
carrier protein 
36.54 11 27 11 33.13 1.11 
P19234 NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
61.29 13 68 13 27.36 1.11 
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B5DEH2 Erlin-2 5.90 3 5 3 37.69 1.11 
A2VD12 Pre-B-cell leukemia transcription 
factor-interacting protein 1 
3.60 3 4 3 80.23 1.11 
P68136 Actin, alpha skeletal muscle 69.50 26 445 2 42.02 1.10 
P35435 ATP synthase subunit gamma, 
mitochondrial 
44.69 12 91 12 30.17 1.10 
P11884 Aldehyde dehydrogenase, 
mitochondrial 
30.06 14 29 14 56.45 1.10 
Q8VBU2 Protein NDRG2 4.31 2 4 2 40.75 1.10 
Q6UPE1 Electron transfer flavoprotein-
ubiquinone oxidoreductase, 
mitochondrial 
44.97 24 95 24 68.16 1.10 
P62076 Mitochondrial import inner 
membrane translocase subunit Tim13 
36.84 3 6 3 10.45 1.10 
Q5RKI0 WD repeat-containing protein 1 4.13 3 3 3 66.14 1.09 
Q5XIN6 LETM1 and EF-hand domain-
containing protein 1, mitochondrial 
4.33 3 3 3 83.01 1.09 
P29266 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial 
8.66 2 4 2 35.28 1.09 
Q64119 Myosin light polypeptide 6 30.46 5 45 2 16.96 1.09 
P11661 NADH-ubiquinone oxidoreductase 
chain 5 
6.07 3 8 3 68.92 1.09 
Q924S5 Lon protease homolog, mitochondrial 2.63 3 4 3 105.73 1.08 
Q63610 Tropomyosin alpha-3 chain 18.95 8 27 2 28.99 1.08 
Q6AXV4 Sorting and assembly machinery 
component 50 homolog 
22.39 10 18 10 51.93 1.08 
Q9QWN8 Spectrin beta chain, non-erythrocytic 
2 
0.63 2 2 2 270.90 1.08 
P35286 Ras-related protein Rab-13 8.87 2 5 1 22.89 1.08 
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Q9Z0V5 Peroxiredoxin-4 6.96 2 2 2 30.99 1.08 
Q03346 Mitochondrial-processing peptidase 
subunit beta 
3.48 2 4 1 54.23 1.08 
Q8VHF5 Citrate synthase, mitochondrial 31.55 14 73 14 51.83 1.07 
D3ZAF6 ATP synthase subunit f, 
mitochondrial 
30.68 3 19 3 10.45 1.07 
P45953 Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
40.92 27 76 27 70.71 1.07 
P02770 Serum albumin 6.74 5 37 5 68.69 1.07 
P35434 ATP synthase subunit delta, 
mitochondrial 
13.69 2 11 2 17.58 1.07 
O70351 3-hydroxyacyl-CoA dehydrogenase 
type-2 
35.63 7 17 7 27.23 1.07 
Q99376 Transferrin receptor protein 1 
(Fragment) 
5.47 4 4 4 70.11 1.07 
Q9ER34 Aconitate hydratase, mitochondrial 45.26 32 117 32 85.38 1.07 
Q5I0C3 Methylcrotonoyl-CoA carboxylase 
subunit alpha, mitochondrial 
3.22 2 3 2 79.28 1.07 
P20788 Cytochrome b-c1 complex subunit 
Rieske, mitochondrial 
48.18 11 64 11 29.43 1.07 
Q9QZ76 Myoglobin 56.49 7 43 7 17.15 1.06 
P51868 Calsequestrin-2 16.22 7 18 7 47.81 1.06 
P35280 Ras-related protein Rab-8A 14.01 3 8 1 23.65 1.06 
Q7TQ16 Cytochrome b-c1 complex subunit 8 18.29 2 5 2 9.84 1.06 
Q6NYB7 Ras-related protein Rab-1A 25.85 6 11 4 22.66 1.06 
P08010 Glutathione S-transferase Mu 2 8.26 2 2 2 25.69 1.06 
P61589 Transforming protein RhoA 9.33 2 2 2 21.77 1.06 
P11980 Pyruvate kinase PKM 24.11 13 18 13 57.78 1.06 
P45592 Cofilin-1 12.65 3 3 2 18.52 1.06 
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P62909 40S ribosomal protein S3 8.64 2 3 2 26.66 1.06 
Q9ESS6 Basal cell adhesion molecule 7.37 4 4 4 67.47 1.06 
P49432 Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial 
34.54 11 32 11 38.96 1.05 
P17764 Acetyl-CoA acetyltransferase, 
mitochondrial 
40.09 16 51 16 44.67 1.05 
Q64591 2,4-dienoyl-CoA reductase, 
mitochondrial 
8.66 3 7 3 36.11 1.05 
Q9WVA1 Mitochondrial import inner 
membrane translocase subunit Tim8 
A 
22.68 2 2 2 11.04 1.05 
P04642 L-lactate dehydrogenase A chain 36.14 13 25 11 36.43 1.05 
P56571 ES1 protein homolog, mitochondrial 32.71 8 11 8 28.16 1.05 
P11240 Cytochrome c oxidase subunit 5A, 
mitochondrial 
30.82 7 105 7 16.12 1.05 
P10536 Ras-related protein Rab-1B 22.39 5 10 3 22.15 1.05 
Q5HZA9 Transmembrane protein 126A 14.80 3 5 3 21.64 1.05 
Q06647 ATP synthase subunit O, 
mitochondrial 
60.09 12 71 12 23.38 1.05 
P35171 Cytochrome c oxidase subunit 7A2, 
mitochondrial 
27.71 2 13 2 9.35 1.05 
Q01205 Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial 
22.25 9 17 9 48.89 1.05 
Q6RJR6 Reticulon-3 2.87 3 4 3 101.45 1.05 
P10719 ATP synthase subunit beta, 
mitochondrial 
52.55 22 224 22 56.32 1.04 
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D4A3K5 Histone H1.1 7.48 2 3 2 21.99 1.04 
P41565 Isocitrate dehydrogenase [NAD] 
subunit gamma 1, mitochondrial 
7.12 4 7 3 42.82 1.04 
P15865 Histone H1.4 17.81 4 9 4 21.97 1.04 
P58775 Tropomyosin beta chain 23.24 11 33 5 32.82 1.04 
Q29RW1 Myosin-4 16.30 40 323 1 222.74 1.04 
P07632 Superoxide dismutase [Cu-Zn] 16.23 3 3 3 15.90 1.04 
P63039 60 kDa heat shock protein, 
mitochondrial 
34.03 17 40 17 60.92 1.04 
P85972 Vinculin 15.20 17 19 17 116.54 1.04 
P63269 Actin, gamma-enteric smooth muscle 65.96 24 448 2 41.85 1.03 
P25809 Creatine kinase U-type, mitochondrial 8.37 4 16 3 47.00 1.03 
Q4G069 Regulator of microtubule dynamics 
protein 1 
12.90 5 8 5 35.38 1.03 
P49134 Integrin beta-1 11.51 7 8 7 88.44 1.03 
P68035 Actin, alpha cardiac muscle 1 69.50 26 463 2 41.99 1.03 
P62738 Actin, aortic smooth muscle 69.50 26 463 2 41.98 1.03 
P21571 ATP synthase-coupling factor 6, 
mitochondrial 
50.93 6 19 6 12.49 1.03 
P07633 Propionyl-CoA carboxylase beta 
chain, mitochondrial 
11.28 5 7 5 58.59 1.03 
P08503 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
22.09 9 23 9 46.53 1.03 
P24473 Glutathione S-transferase kappa 1 11.50 3 3 3 25.48 1.02 
Q63258 Integrin alpha-7 6.08 7 8 7 124.12 1.02 
P06761 78 kDa glucose-regulated protein 35.32 22 37 19 72.30 1.02 
P42123 L-lactate dehydrogenase B chain 34.13 12 28 10 36.59 1.02 
P16409 Myosin light chain 3 81.50 16 211 12 22.14 1.02 
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P11517 Hemoglobin subunit beta-2 67.35 10 85 2 15.97 1.02 
Q641Y2 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial 
38.23 13 61 13 52.53 1.02 
P85834 Elongation factor Tu, mitochondrial 30.75 14 22 14 49.49 1.02 
P04692 Tropomyosin alpha-1 chain 69.72 30 88 24 32.66 1.02 
P29975 Aquaporin-1 5.95 2 3 2 28.84 1.02 
P14668 Annexin A5 12.85 5 6 4 35.72 1.01 
P23965 Enoyl-CoA delta isomerase 1, 
mitochondrial 
32.87 10 17 10 32.23 1.01 
P27952 40S ribosomal protein S2 7.85 3 3 3 31.21 1.01 
Q9WVK7 Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial 
18.79 9 20 9 34.43 1.01 
P15651 Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
33.98 11 22 11 44.74 1.01 
Q5U316 Ras-related protein Rab-35 10.95 2 6 0 23.01 1.01 
P35289 Ras-related protein Rab-15 10.38 2 6 0 24.27 1.01 
Q5XIH7 Prohibitin-2 52.17 18 35 18 33.29 1.01 
P35281 Ras-related protein Rab-10 18.00 4 8 2 22.84 1.01 
P67779 Prohibitin 49.26 12 29 12 29.80 1.01 
Q68FX0 Isocitrate dehydrogenase [NAD] 
subunit beta, mitochondrial 
7.79 4 8 3 42.33 1.01 
Q8VID1 Dehydrogenase/reductase SDR family 
member 4 
20.43 5 10 5 29.80 1.01 
P62982 Ubiquitin-40S ribosomal protein S27a 9.62 2 5 2 17.94 1.01 
P0CG51 Polyubiquitin-B 19.67 2 5 2 34.35 1.01 
P62986 Ubiquitin-60S ribosomal protein L40 11.72 2 5 2 14.72 1.01 
Q63429 Polyubiquitin-C 18.52 2 5 2 91.03 1.01 
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Q5BK63 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 9, 
mitochondrial 
35.54 12 30 12 42.53 1.01 
P54290 Voltage-dependent calcium channel 
subunit alpha-2/delta-1 
2.20 2 3 2 123.75 1.01 
P24329 Thiosulfate sulfurtransferase 5.39 2 3 2 33.39 1.00 
Q09073 ADP/ATP translocase 2 42.28 15 86 6 32.88 1.00 
Q66HF1 NADH-ubiquinone oxidoreductase 75 
kDa subunit, mitochondrial 
53.23 32 117 32 79.36 1.00 
P48284 Carbonic anhydrase 4 7.77 2 2 2 35.05 1.00 
P04797 Glyceraldehyde-3-phosphate 
dehydrogenase 
31.23 10 23 10 35.81 1.00 
P16086 Spectrin alpha chain, non-erythrocytic 
1 
0.57 2 2 2 284.46 1.00 
P62260 14-3-3 protein epsilon 15.29 4 5 3 29.16 1.00 
Q64536 [Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 2, 
mitochondrial 
3.69 2 2 2 46.08 1.00 
Q02253 Methylmalonate-semialdehyde 
dehydrogenase [acylating], 
mitochondrial 
28.22 14 30 14 57.77 1.00 
P09605 Creatine kinase S-type, mitochondrial 37.95 15 110 14 47.36 1.00 
P14669 Annexin A3 7.10 3 3 3 36.34 0.99 
Q6AY30 Saccharopine dehydrogenase-like 
oxidoreductase 
6.76 3 3 3 47.06 0.99 
Q68FT3 Pyridine nucleotide-disulfide 
oxidoreductase domain-containing 
protein 2 
7.57 5 6 5 62.84 0.99 
P13221 Aspartate aminotransferase, 
cytoplasmic 
7.99 4 5 4 46.40 0.99 
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Q60587 Trifunctional enzyme subunit beta, 
mitochondrial 
33.05 16 54 16 51.38 0.99 
Q9Z2L0 Voltage-dependent anion-selective 
channel protein 1 
69.96 18 71 17 30.74 0.99 
P29410 Adenylate kinase 2, mitochondrial 15.48 4 8 4 26.36 0.99 
Q5XIF3 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4, mitochondrial 
31.43 5 16 5 19.73 0.99 
P31399 ATP synthase subunit d, 
mitochondrial 
69.57 10 35 10 18.75 0.98 
P32551 Cytochrome b-c1 complex subunit 2, 
mitochondrial 
44.69 19 90 19 48.37 0.98 
A0JPQ4 Tripartite motif-containing protein 72 20.75 9 12 9 52.80 0.98 
Q4V8F9 Hydroxysteroid dehydrogenase-like 
protein 2 
11.83 7 13 7 58.31 0.98 
P05065 Fructose-bisphosphate aldolase A 37.09 13 29 13 39.33 0.98 
P70567 Tropomodulin-1 4.18 2 3 2 40.46 0.98 
P48037 Annexin A6 21.55 16 26 15 75.71 0.98 
P48721 Stress-70 protein, mitochondrial 40.50 26 45 25 73.81 0.98 
P15999 ATP synthase subunit alpha, 
mitochondrial 
61.48 36 220 36 59.72 0.97 
P06686 Sodium/potassium-transporting 
ATPase subunit alpha-2 
20.39 18 56 6 112.15 0.97 
P14408 Fumarate hydratase, mitochondrial 29.78 15 42 15 54.43 0.97 
Q66HD0 Endoplasmin 12.06 10 12 9 92.71 0.97 
Q5XI32 F-actin-capping protein subunit beta 18.01 6 7 6 30.61 0.97 
Q5XIJ4 Protein FAM210A 11.72 3 6 3 31.46 0.97 
P27881 Hexokinase-2 3.49 4 7 1 102.48 0.97 
Q9R063 Peroxiredoxin-5, mitochondrial 27.23 5 7 5 22.17 0.96 
Q9Z2S9 Flotillin-2 11.92 6 7 6 47.01 0.96 
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Q63862 Myosin-11 (Fragments) 7.39 9 31 1 152.40 0.96 
P56741 Myosin-binding protein C, cardiac-
type 
30.30 35 75 35 140.67 0.96 
Q5XIC0 Enoyl-CoA delta isomerase 2, 
mitochondrial 
15.60 5 8 5 42.99 0.96 
Q5M9I5 Cytochrome b-c1 complex subunit 6, 
mitochondrial 
60.67 5 17 5 10.42 0.95 
P38983 40S ribosomal protein SA 7.12 2 3 2 32.80 0.95 
P07323 Gamma-enolase 8.53 3 5 2 47.11 0.95 
P02564 Myosin-7 51.68 114 931 16 222.95 0.95 
P29457 Serpin H1 7.67 4 6 4 46.49 0.95 
P63018 Heat shock cognate 71 kDa protein 29.72 18 26 14 70.83 0.95 
P11598 Protein disulfide-isomerase A3 20.59 11 16 11 56.59 0.95 
P14659 Heat shock-related 70 kDa protein 2 13.27 8 10 4 69.60 0.95 
P15800 Laminin subunit beta-2 6.89 12 13 12 196.35 0.95 
P52504 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 6, mitochondrial 
18.97 2 5 2 12.78 0.95 
P62898 Cytochrome c, somatic 39.05 5 18 5 11.60 0.94 
Q07439 Heat shock 70 kDa protein 1A/1B 5.93 4 6 2 70.14 0.94 
P55063 Heat shock 70 kDa protein 1-like 8.42 5 7 2 70.51 0.94 
P13437 3-ketoacyl-CoA thiolase, 
mitochondrial 
54.66 16 39 16 41.84 0.94 
P30839 Fatty aldehyde dehydrogenase 3.31 2 2 2 54.05 0.94 
Q499N5 Acyl-CoA synthetase family member 
2, mitochondrial 
16.91 11 17 11 67.84 0.94 
P0C219 Sarcolemmal membrane-associated 
protein 
1.98 2 2 2 98.16 0.94 
P29418 ATP synthase subunit epsilon, 
mitochondrial 
45.10 3 9 3 5.76 0.94 
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P18418 Calreticulin 18.99 9 20 9 47.97 0.94 
P19511 ATP synthase F(0) complex subunit 
B1, mitochondrial 
42.58 13 51 13 28.85 0.94 
Q9EQP5 Prolargin 4.24 2 3 2 43.15 0.94 
B0LPN4 Ryanodine receptor 2 3.59 18 23 18 562.59 0.94 
P36201 Cysteine-rich protein 2 8.65 2 2 2 22.68 0.94 
P56574 Isocitrate dehydrogenase [NADP], 
mitochondrial 
44.25 20 79 20 50.94 0.94 
Q9Z1P2 Alpha-actinin-1 10.99 9 24 4 102.90 0.93 
Q64578 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 1 
15.29 15 77 15 109.34 0.93 
P07153 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
3.31 2 2 2 68.26 0.93 
Q64428 Trifunctional enzyme subunit alpha, 
mitochondrial 
47.31 31 114 31 82.61 0.93 
P02563 Myosin-6 61.40 146 1232 43 223.37 0.93 
P34058 Heat shock protein HSP 90-beta 12.29 9 13 5 83.23 0.93 
P10860 Glutamate dehydrogenase 1, 
mitochondrial 
15.95 9 15 9 61.38 0.92 
B2GV06 Succinyl-CoA:3-ketoacid coenzyme 
A transferase 1, mitochondrial 
21.92 9 20 9 56.17 0.92 
Q4V8H8 EH domain-containing protein 2 11.97 7 11 6 61.20 0.92 
Q561S0 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 10, 
mitochondrial 
26.48 9 37 9 40.47 0.92 
Q07936 Annexin A2 11.50 4 4 4 38.65 0.92 
P05197 Elongation factor 2 3.26 3 5 3 95.22 0.92 
P63219 Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-5 
23.53 2 2 2 7.31 0.92 
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P09811 Glycogen phosphorylase, liver form 3.06 3 3 1 97.42 0.92 
P38652 Phosphoglucomutase-1 6.41 3 3 3 61.37 0.91 
P18596 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 3 
7.26 7 34 7 116.21 0.91 
Q6P7S1 Acid ceramidase 4.82 2 2 2 44.42 0.91 
Q5XI78 2-oxoglutarate dehydrogenase, 
mitochondrial 
18.28 18 41 18 116.22 0.91 
P16617 Phosphoglycerate kinase 1 18.94 9 17 9 44.51 0.91 
P26453 Basigin 15.46 6 13 6 42.41 0.91 
Q6RUV5 Ras-related C3 botulinum toxin 
substrate 1 
18.23 4 5 4 21.44 0.91 
P24268 Cathepsin D 19.41 7 10 7 44.65 0.90 
Q9ESV6 Glyceraldehyde-3-phosphate 
dehydrogenase, testis-specific 
4.86 2 6 2 46.68 0.90 
P11507 Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
42.28 41 170 41 114.69 0.90 
Q9JM53 Apoptosis-inducing factor 1, 
mitochondrial 
11.44 7 11 7 66.68 0.90 
P12007 Isovaleryl-CoA dehydrogenase, 
mitochondrial 
19.81 9 14 9 46.41 0.90 
P14882 Propionyl-CoA carboxylase alpha 
chain, mitochondrial 
15.74 11 16 11 81.57 0.90 
Q63704 Carnitine O-palmitoyltransferase 1, 
muscle isoform 
16.06 12 24 12 88.16 0.90 
Q4QQV3 Protein FAM162A 15.48 2 3 2 17.82 0.90 
P04764 Alpha-enolase 26.27 10 22 7 47.10 0.90 
P13086 Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, mitochondrial 
17.63 6 9 6 36.13 0.90 
Q63081 Protein disulfide-isomerase A6 10.23 4 5 4 48.14 0.89 
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Q5U2X7 Mitochondrial import inner 
membrane translocase subunit Tim21 
16.73 4 5 4 27.86 0.89 
O88267 Acyl-coenzyme A thioesterase 1 6.68 4 7 4 45.98 0.89 
Q68FY0 Cytochrome b-c1 complex subunit 1, 
mitochondrial 
30.00 15 70 14 52.82 0.89 
Q3T1K5 F-actin-capping protein subunit alpha-
2 OS=Rattus norvegicus GN=Capza2 
PE=1 SV=1 
15.03 3 5 3 32.95 0.89 
P05712 Ras-related protein Rab-2A 14.15 2 2 2 23.52 0.89 
Q99NA5 Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial 
16.94 7 13 7 39.59 0.89 
O35763 Moesin 2.77 2 2 2 67.70 0.89 
P85125 Polymerase I and transcript release 
factor 
18.37 5 8 5 43.88 0.89 
Q03410 Synaptonemal complex protein 1 0.70 2 4 2 116.44 0.88 
P09495 Tropomyosin alpha-4 chain 16.94 7 16 1 28.49 0.88 
Q63355 Unconventional myosin-Ic 3.54 4 5 4 119.74 0.88 
P13832 Myosin regulatory light chain RLC-A 16.28 3 5 3 19.88 0.87 
Q5I0E7 Transmembrane emp24 domain-
containing protein 9 
11.06 4 5 4 27.01 0.87 
P09812 Glycogen phosphorylase, muscle 
form 
11.16 12 14 9 97.21 0.87 
P61983 14-3-3 protein gamma 6.88 2 3 1 28.29 0.87 
O55171 Acyl-coenzyme A thioesterase 2, 
mitochondrial 
11.04 6 10 6 49.67 0.87 
Q6IFU8 Keratin, type I cytoskeletal 17 6.24 3 5 1 48.09 0.86 
Q641Z6 EH domain-containing protein 1 4.68 3 5 2 60.57 0.86 
Q5SGE0 Leucine-rich PPR motif-containing 
protein, mitochondrial 
11.35 17 21 17 156.55 0.86 
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P97576 GrpE protein homolog 1, 
mitochondrial 
15.21 4 6 4 24.28 0.86 
P15429 Beta-enolase 20.74 9 16 6 46.98 0.86 
P29419 ATP synthase subunit e, 
mitochondrial 
71.83 5 17 5 8.25 0.85 
P29147 D-beta-hydroxybutyrate 
dehydrogenase, mitochondrial 
13.12 4 6 4 38.18 0.85 
P35565 Calnexin 7.78 5 8 5 67.21 0.85 
P63031 Mitochondrial pyruvate carrier 1 22.02 4 7 4 12.45 0.84 
Q63362 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 5 
14.66 3 8 3 13.40 0.84 
Q66H98 Serum deprivation-response protein 7.91 3 3 3 46.36 0.84 
Q62902 Protein ERGIC-53 2.71 2 2 2 57.92 0.83 
P62836 Ras-related protein Rap-1A 15.76 3 6 3 20.97 0.82 
Q62636 Ras-related protein Rap-1b 15.76 3 6 3 20.79 0.82 
Q9QXQ0 Alpha-actinin-4 7.46 7 9 2 104.85 0.82 
P11762 Galectin-1 40.74 6 9 6 14.85 0.82 
P82995 Heat shock protein HSP 90-alpha 6.41 5 6 2 84.76 0.81 
Q9QY17 Protein kinase C and casein kinase 
substrate in neurons 2 protein 
3.28 2 2 2 55.94 0.80 
Q6PDU7 ATP synthase subunit g, 
mitochondrial 
26.21 3 10 3 11.43 0.79 
Q704S8 Carnitine O-acetyltransferase 8.63 6 8 6 70.76 0.79 
P04785 Protein disulfide-isomerase 24.17 13 18 13 56.92 0.79 
P63102 14-3-3 protein zeta/delta 6.53 2 2 1 27.75 0.78 
P62804 Histone H4 57.28 6 50 6 11.36 0.75 
Q6VBQ5 Myeloid-associated differentiation 
marker 
9.43 2 3 2 35.13 0.71 
P0C0S7 Histone H2A.Z 20.31 3 34 1 13.55 0.71 
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P54708 Potassium-transporting ATPase alpha 
chain 2 
4.73 5 11 1 114.90 0.70 
Q7M0E3 Destrin 12.12 2 2 1 18.52 0.67 
Q00715 Histone H2B type 1 35.20 5 24 1 13.98 0.66 
P02262 Histone H2A type 1 32.31 4 37 2 14.07 0.63 
A9UMV8 Histone H2A.J 32.56 4 37 2 14.04 0.63 
P0C170 Histone H2A type 1-E 32.31 4 37 2 14.11 0.63 
P84245 Histone H3.3 22.06 4 11 4 15.32 0.62 
Q6LED0 Histone H3.1 29.41 6 13 6 15.39 0.62 
Q00729 Histone H2B type 1-A 33.07 5 18 1 14.22 0.56 
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The proteomics data were further processed using the Cluster 3.0 software and IPA. 
A subset of 50 proteins, consisting of 12 sarcomeric proteins, 10 ROS-scavenging proteins, 
10 apoptotic proteins, and 15 abundant proteins, underwent hierarchical clustering analysis 
(Figure 3-6). Differences in protein abundances were observed across all the LAD 
ligation/reperfusion and sham replicates, and hierarchical clustering revealed no obvious 
grouping among the replicates (Figure 3-6). Overall, the cluster analysis results illustrated 
the slight increase in whole proteome ROS-scavenging proteins protein abundance after 
LAD ligation/reperfusion as compared to sham surgery, and no observable difference in 
the remaining proteins investigated. IPA core analysis of the identified proteome proteins 
developed 17 protein interaction networks, with metabolic disease/disorder (score 52, 29 
proteins), free radical scavenging (score 49, 28 proteins), and energy production/nucleic 
acid metabolism (score 37, 23 proteins) the highest scored pathways.  
A comparison of the quantitative proteomics results for free cardiomyocyte proteins 
and proteins covalently trapped on DNA revealed a total of 78 proteins (86.7%) that were 
identified in both experiments. Of the 78 proteins shared between the two experiments, 14 
proteins increased in abundance after LAD ligation/reperfusion compared to sham surgery 
in both whole protein and DPC samples, while the rest were only increased for the cross-
linked proteins, but not the global proteome (Figure 3-7). Overall, these results indicate 
little correlation between global protein amounts and DPC formation, suggesting that 
oxidative cross-linking between proteins and DNA is induced by the influx of hydroxyl 
radicals during reperfusion of cardiac tissues.  
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Figure 3-6: Heat map analysis of the TMT abundance data for 47 representative proteins 
identified in the whole proteome. Proteins analyzed include sarcomere proteins (13), ROS 
scavenging proteins (11), apoptosis regulating proteins (7), and the remaining most 
abundant proteins (16). 
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Figure 3-7: Changes in protein abundances in DPCs (red) vs whole proteome (blue). The 
protein abundances (LAD ligation/sham) in the whole proteome and DPCs of 10 
representative proteins were compared. Protein names correspond to gene symbols: Mdh2, 
malate dehydrogenase, mitochondrial; Hba1, hemoglobin subunit-alpha ½; Pgam2, 
phosphoglycerate mutase 2; Sod2, superoxide dismutase [Mn], mitochondrial; Dld, 
dihydrolipoyl dehydrogenase, mitochondrial; Echs1, enoyl-CoA hydratase, mitochondrial; 
Prdx3, thioredoxin-dependent peroxide reductase, mitochondrial; Cpt2, carnitine O-
palmitoyltransferase 2, mitochondrial; Got2, aspartate aminotransferase, mitochondrial. 
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3.4. Discussion 
DNA-protein crosslinks are super-bulky DNA adducts capable of interfering with 
crucial biological functions such DNA replication and transcription.262 Recent studies in 
our laboratory have shown that DPC lesions completely block human DNA 
polymerases.265-267, 337 Similarly, Nakano et al reported that DPCs over 14.1 kDa in size 
located on the translocating strand completely block DNA unwinding by human helicases 
(mini chromosome maintenance Mcm467 subcomplex), while DPCs between 5 to 14.1 
kDa severely inhibit helicase progression.264 Recently, our laboratory found that bacterial 
RNA polymerases were blocked by protein lesions conjugated to the N7 position of 
guanine (Ji and Tretyakova, unpublished data).  
Covalent DPCs readily form in cells via a radical mechanism in the presence of 
reactive oxygen species. Izzotti et al previously reported age-related DPC accumulation in 
the brain, liver, and heart of 12 or 24-month-old mice.270 In mouse myocardium, DPCs 
accounted for 2.2 ± 0.3% of total DNA in 12-month old mice and 3.4 ± 0.5% of total DNA 
in 24-month old mice.270 Furthermore, there was a strong correlation between the levels of 
measured 8-oxoguanine and DPCs (r = 0.800, P<0.0001), indicating the DPC formation 
was related to ROS exposure.270 However, protein identities have remained unknown, and 
no absolute quantitation of DPCs was conducted.  
Every year, 735,000 people in the United States suffer myocardial infarction.364, 365 
Although reperfusion surgery can successfully restore the blood flow to affected 
myocardium, a sudden influx of oxygenated blood leads to a spike in ROS and reperfusion 
injury, which is associated with acute cardiomyocyte necrosis, and potentially chronic heart 
disease.366, 367, 486 An estimated 40-50% of the final MI damage has been attributed to 
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reperfusion injury.367 However, the exact mechanism of ROS-mediated myocardium 
damage has yet to be elucidated. We hypothesized that the influx of hydroxyl radicals 
caused by ischemia/reperfusion leads to the formation of toxic DNA-protein cross-links, 
which may contribute to reperfusion injury.  
In the present study, we employed a well-established animal model (LAD 
ligation/reperfusion) to investigate DPC formation in cardiomyocytes following ischemia-
reperfusion injury.487 Animals in treatment group that underwent LAD ligation/reperfusion 
exhibited greatly elevated plasma levels of cTnI (>50 ng/mL), confirming severe MI 
(Table 3-1). Furthermore, plasma levels of the oxidative stress biomarker 8-iso-PGF2α 
were increased 3-5-fold in animals that underwent the LAD surgery and reperfusion as 
compared to sham surgery (Figure 3-1), although pre-surgery 8-iso-PGF2α may have been 
elevated because anesthetization created a hyperoxic environment. Taken together, our 
results shown in Table 3-1 and Figure 3-1 confirm that animals in the LAD group 
experienced MI/reperfusion injury that led to an increase in oxidants production in the 
heart.  
Two general approaches were employed to investigate DPC formation in rat 
cardiomyocytes following ischemia-reperfusion injury. Absolute numbers of hydroxyl 
radical-mediated DPCs were established using the sensitive and accurate isotope dilution 
nanoLC-ESI+-MS/MS method developed in our laboratory (Figure 3-2). Protein identities 
were established using quantitative proteomics, which was coupled with analysis of the 
global proteome in order to detect any system-wide changes in protein levels. It was 
necessary to employ quantitative proteomics in this case because background levels of 
DPCs are found in the normal heart as a result of aerobic respiration.  
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In order to determine the absolute numbers of hydroxyl radical-induced DPC in 
cardiomyocytes following ischemia/reperfusion injury, DPC-containing DNA was 
digested with nucleases and proteinases to single monomer level, and the amounts of 
thymidine-tyrosine conjugates (dT-Tyr, Scheme 3-2) were determined by isotope dilution 
nanoLC-ESI+-MS/MS using 13C labeled internal standard synthesized in our laboratory 
(Figure 3-2A). dT-Tyr conjugate numbers were significantly increased in cardiomyocytes 
of rats that underwent ischemia-reperfusion injury as compared to sham controls (Figure 
3-2B). Altman et al previously measured the structurally similar 3- [( 1,3-dihydro-2,4-
dioxopyrimidin-5- yl jmethyl] -L-tyrosine (Thy-Tyr) adduct in SP2/0 murine cells treated 
with Fe(II) using a gas chromatography mass spectrometry assay.488 Treatment with 1 mM 
Fe(II) yielded 32 Thy-Tyr adducts per 105 nucleotides,488 nearly a 1000-fold increase over 
our highest observed dT-Tyr levels. They were also able to detect up to 15 Thy-Tyr adducts 
per 106 nucleotides in control cells,488 which are once again significantly higher than what 
weobserved in our sham surgery samples. Taken together, this indicates that both cell 
culture and treatment of cells with Fe(II) may expose cells to levels of hydroxyl radicals 
that are not physiologically relevant.489 
Proteins covalently attached to DNA were identified and quantified using 
quantitative proteomics. These analyses have revealed a highly significant increase in 
radical-induced DPC formation following LAD ligation/reperfusion surgery as compared 
to sham surgery (Table 3-2, Figure 3-4, and Figure 3-5). Quantitative proteomic analysis 
of DNA-conjugated proteins has identified a total of 90 proteins: of these, 80 proteins were 
increased in abundance at least 1.2-fold after LAD ligation/ reperfusion as compared to 
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sham surgery and 1 protein was decreased in abundance under the same conditions (Table 
3-2).  
A large fraction of the oxidatively cross-linked proteins (43.3%) were 
mitochondrial in nature, including cytochrome C oxidase, pyruvate dehydrogenase, and 
enoyl-CoA hydratase (Table 3-2). Since our DPC extraction methodology does not 
discriminate chromosomal DNA from mitochondrial DNA, it is possible that these proteins 
are covalently trapped on mitochondrial DNA. Mitochondria increase the production of 
superoxide anions, hydrogen peroxide, and hydroxyl radicals in response to 
ischemia/reperfusion.465, 466, 490, 491 For example, all four complexes of the electron transport 
chain can produce reactive superoxide anions, and ischemic damage to complex I and III 
is believed to enhance the production of superoxides released during reperfusion injury.402, 
466, 492 Furthermore, NAD-dependent mitochondrial pyruvate dehydrogenase (PDH), a 
protein identified in the DPC samples, can produce both O2- and H2O2 as enzymatic 
byproducts.493, 494 The mitochondrial NADH/NAD+ ratio is elevated post-ischemia, leading 
to an increased enzymatic activity NAD-dependent dehydrogenases such as PDH and an 
increase in O2- and H2O2 byproducts.493 Therefore, it is not surprising that mitochondrial 
proteins are exposed to increased oxidant levels and thus susceptible to becoming 
covalently trapped on mitochondrial DNA. 
Additionally, many of the identified DPC protein constituents are known to be 
present in both the mitochondria or cytoplasm and the nucleus. For example, pyruvate 
dehydrogenase E1 components, which increased in DPC abundance 9.2-fold after LAD 
ligation/reperfusion compared to sham surgery, are classified as mitochondrial proteins. 
However, mitochondrial stress stimulates the translocation of pyruvate dehydrogenases to 
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the nucleus to generate nuclear acetyl CoA, which is required for histone acetylation and 
the activation of transcription.495 
Ironically, ROS scavenging enzymes, thioredoxin-dependent peroxide reductase, 
superoxide dismutase [Mn], superoxide dismutase [Cu-Zn], and catalase have been found 
to participate in cross-linking to DNA following reperfusion injury (Table 3-2). Although 
these ROS scavenging enzymes are induced in response to oxidative stress, superoxide 
dismutases and catalase are known to release hydroxyl radicals as a byproduct of peroxide 
metabolism.466, 496, 497 Hydroxyl radicals are extremely reactive species capable of 
abstracting hydrogen (H•) from nearby DNA bases.31, 35, 498 The resulting radical 
intermediates can react with nearby dismutase or catalase enzyme, yielding a DPC with the 
ROS scavenging protein.  
The observed increase in DNA-protein cross-linking (Figure 3-3) cannot be 
attributed to changes in global protein levels following reperfusion injury. Only modest 
increases in protein biomarkers of cardiomyocyte injury after LAD ligation/reperfusion 
compared to sham surgery, while the majority of the proteome was unchanged (Table 3-3, 
Figure 3-5, and Figure 3-6). Increased levels of troponin-T have been established as a 
specific biomarker of myocardial damage and the breakdown of the contractile 
apparatus.499-501 Furthermore, previous studies have observed the degradation and release 
of other sarcomere proteins including troponin-I, myosin light chain 1, and tropomyosins 
after LAD ligation/reperfusion in rats.502 Our observation of increased levels of the 
sarcomere proteins troponin-T, troponin-I, myosin-3, myosin light chain 4, and actin after 
LAD ligation/reperfusion is also consistent with the breakdown of the contractile apparatus 
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after reperfusion injury, and may indicate damaged sarcomere proteins are translocated to 
the cytoplasm of cardiac cells as well as into the extracellular plasma.  
Our results for global proteome changes are consistent with previous studies that 
utilized quantitative proteomics techniques to measure changes in protein expression after 
LAD ligation or LAD ligation/reperfusion injury compared to sham surgery.501, 503 De Celle 
et al utilized two-dimensional gel electrophoresis quantification and mass spectrometry-
based proteomics to identify 8 proteins (troponin T, heat shock protein 20 and 27, 
heterogeneous nuclear ribonucleoprotein K, pyruvate dehydrogenase E1-β, annexin A3, 
adenylate kinase 1, and serum amyloid p-component precursor) that were upregulated after 
LAD ligation/reperfusion and two proteins (myosin heavy chain α and catechol-o-
methyltransferase) that were downregulated after LAD ligation/reperfusion.501 Our 
quantitative proteomics analysis also observed upregulation of troponin T, pyruvate 
dehydrogenase E1-β, and annexin-3 after LAD ligation/reperfusion. Furthermore, we 
observed upregulation of two other heat shock proteins (10 kDa heat shock protein and 60 
kDa heat shock protein mitochondrial) and adenylate kinase 2 (Figure 3-6, Table 3-3). 
In another study, Liu et al utilized a label-free spectral counting analysis to identify 
15 mitochondrial proteins that became upregulated after LAD ligation as compared to a 
sham surgery.503 Our current study identified all 15 mitochondrial proteins, with six 
proteins (amine oxidase, mitochondrial 2-oxogluterate/malate carrier protein, ATP 
synthase subunit gamma, aldehyde dehydrogenase, dihydrolipoyllysine residue 
acetyltransferase component of pyruvate dehydrogenase complex, and electron transfer 
flavoprotein subunit alpha) upregulated after LAD ligation/reperfusion.503 These changes 
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in mitochondrial protein expression are indicative of the ischemia-induced mitochondrial 
dysfunction and dysregulation of the electron transport chain. 
 
3.5. Conclusions 
To our knowledge, our study is the first to provide conclusive evidence for the 
increased DPC formation following ischemia/reperfusion injury. Our results suggest that 
oxidative DNA-protein cross-linking formation is a biological consequence of a 
myocardial infarction/ reperfusion. Furthermore, the quantitative nanoLC-ESI+-MS/MS 
assay for DNA-protein cross-links reported here has the potential to improve the 
development of antioxidant and preventative reperfusion injury therapies. Previous 
experimental and clinical investigations of antioxidant therapies have reported mixed or 
inconsistent results.504, 505 This partially may be caused by the lack of specificity and 
sensitivity of assays used to measure oxidant production.506-508 Hydroxyl radical-induced 
dT-Tyr conjugates could serve as a novel biomarker of oxidant-induced tissue damage, 
providing a more accurate measure of the efficacy of future therapies designed to reduce 
oxidant levels brought by reperfusion. 
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4. Spartan Metalloprotease and 
Proteasomal Degradation in Repair of 
ROS-induced Chromosomal DNA-
Protein Cross-Links in Cells and 
Tissues 
4.1. Introduction 
DNA-protein cross-links (DPCs) are super-bulky DNA lesions that form when 
proteins are irreversibly trapped on chromosomal DNA.262, 263 DPCs can be induced after 
exposure to various physical and chemical agents including ionizing radiation,274, 275 UV 
light,276-278 transition metal ions such as Ni and Cr,279-282 halogenated hydrocarbons,283, 284 
environmental carcinogens,285 and common anticancer drugs such as nitrogen mustards 
and platinum compounds.286-289 Endogenous DPCs can form when DNA-binding proteins 
such as topoisomerases,290, 291 polymerases,29, 30 and repair enzymes509, 510 become trapped 
on DNA intermediates.  Furthermore, endogenous DPCs are induced upon exposure to 
reactive oxygen species (ROS) produced during cellular respiration and inflammation,292-
294 and aldehyde byproducts of lipid peroxidation such as methylglyoxal295 and 
malondialdehyde.296 Due to their bulky nature, DPCs can interfere with DNA 
replication264-267 and gene expression.268 DPC formation is proposed to play a role in 
aging,269, 270 cancer,271, 272 cardiovascular disease,269, 270 and neurodegenerative 
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disorders.273 Despite the significant threat DPCs pose to cells, the mechanism(s) of DPC 
recognition and active DPC repair has yet to be fully elucidated. 
Several canonical DNA repair pathways including nucleotide excision repair 
(NER) coupled to proteolysis of the protein constituent263, 309, 426, 427 and homologous 
recombination/Fanconi anemia (HR) repair pathways424, 425, 511 have been implicated in 
DPC repair. Stingele et al.421  discovered a protease-dependent DPC repair mechanism in 
the yeast. These authors demonstrated the yeast metalloprotease Wss1 (weak suppressor of 
smt3) coordinates with tyrosyl-DNA-phosphodiesterase 1 or 2 (TPD1 and TPD2 
respectively) to enzymatically process topoisomerase 1 and 2 cleavage complexes 
(Top1ccs and Top2ccs respectively) and allow for replication to proceed past 
topoisomerase-DNA cross-links.421 It was further shown that Wss1 protects yeast cells 
from FA-induced toxicity.421, 428  
In eukaryotic systems, proteolytic digestion of a DPC was first observed by Duxin 
et al.430 They incubated a Dnmt1-containing plasmid and the corresponding plasmid 
control in Xenopus egg extract, followed by restriction enzyme digestion of the plasmids 
to yield a 165-nucleotide fragment containing the DPC.430 Gel electrophoresis of the 
digestion lysates revealed one band for the control and multiple bands for the DPC-
containing plasmid, indicating the protein constituent was proteolytically digested to 
smaller peptides.430 Mammalian cells express the metalloprotease DVC1/Spartan 
(Spartan), which is considered the mammalian homolog of the yeast Wss1.512 Spartan and 
Wss1 both share a similar domain organization and have a common evolutionary origin.428, 
512 Furthermore, Stingele et al have shown that isolated Spartan can proteolytically digest 
the DNA-binding proteins H1, H2A, H2B, H3, and Hmg1 in the presence of ssDNA, but 
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will only perform autocleavage in the presence of dsDNA or without DNA.431 Due to this 
homology and confirmed activity, Spartan has been investigated as the protease required 
for DPC processing in mammalian cells.430, 431, 433, 513  
Recently, Spartan-mediated digestion of a protein has been linked to the stalling of 
the replisome during DNA replication. For example, Morocz et al utilized a DNA fibre 
assay to demonstrate that Spartan is required for the immediate bypass of DPCs.433  When 
Spartan-depleted cells were treated with FA to induce DPC formation, the length of newly 
formed DNA tracks was significantly decreased compared to FA-treated wild-type cells, 
indicating a strong inhibition of bypass across the FA-induced damage in the absence of 
Spartan.433 When the DNA fibre assay was performed with cells expressing Spartan with 
a mutated protease domain (SprT), DNA replication was inhibited to the same degree as 
Spartan depletion.433 These results are consistent with the replication-coupled DPC repair 
model proposed by Stingele et al428, 431 and Vaz et al.512, 513 During replication, the 
replisome/CMG helicase cannot bypass a DPC site and becomes stalled.264, 421 This triggers 
Spartan-mediated proteolytic degradation of the protein constituent of DPC, and the 
resulting peptide-DNA adduct is immediately bypassed DNA polymerase ζ430, 433, 512 and 
ultimately repaired by nucleotide excision repair.309, 426, 427 
Although the DPC protease activity of Spartan has been established for the repair 
of Top1ccs and FA-induced DPCs, Spartan’s involvement in removing other types of 
DPCs, such as ROS-induced DPCs, has not been demonstrated. Furthermore, Maskey et al 
were unable to detect differences in sensitivity of Spartan-deficient cells to etoposide 
(topoisomerase II DPCs), MK-4827 (PARP-DNA conjugates), and 5-aza-2’-deoxycytidine 
(DNA-methyltransferase DPCs), indicating that protein connectivity and protein identity 
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may impact Spartan’s DPC-protease activity.514 Finally, the molecular mechanism of 
Spartan recruitment and recognition of a DPC has yet to be fully elucidated. 
Alternatively, proteolytic degradation of DPCs can be accomplished via 
proteasome-mediated degradation.309, 427, 515-517 In mammalian systems, Top1ccs and 
Top2ccs are first proteolytically digested by the 26S proteasome to a smaller DNA-peptide 
cross-link,515-518 which are then enzymatically cleaved from DNA by TPD1 and TPD2 
respectively.519-521 The first evidence of the 26S proteasome digesting non-topoisomerase 
DPCs was provided by Quievryn and Zecevic et al, who utilized the K+/SDS precipitation 
method to demonstrate pharmacological inhibition of the 26S proteasome decreased the 
repair of FA and Cr(IV)-induced DPCs respectively.309, 522 Furthermore, Baker et al 
utilized fluorescence-activated cell sorting (FACS) to demonstrate that inhibition of the 
26S proteasome decreased the repair of a Dmnt-containing plasmid by 50% in Chinese 
hamster ovary (CHO) cells.427 However, the relatively small decrease in repair observed 
by both Quievryn et al and Baker et al demonstrates that the 26S proteasome cannot 
independently digest the protein constituent of a DPC. Furthermore, no previous 
investigations have demonstrated that the 26S proteasome is involved in the repair of more 
ubiquitous DPCs, such as those induced by a radical-induced mechanism. 
In the present study, we employed a combination of cytotoxicity screening and 
mass spectrometry based DPC quantitation to investigate the role of Spartan and the 26S 
proteasome in the repair of DPCs induced via a free radical mechanism. The common 
reactive oxygen species hydroxyl radicals can abstract a hydrogen from the methyl group 
of a thymidine in DNA, which can undergo an one electron addition to the 3-position of 
tyrosine residue in proteins to form a cross-link.362, 363, 481, 482 We recently developed a 
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sensitive nanoLC-ESI+-MS/MS assay for the total digestion product 2-amino-3-(4-
hydroxy-3-((1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-
dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)phenyl)propanoic acid (dT-Tyr) to 
perform absolute quantitation of hydroxyl radical-induced DPC formation in 
cardiomyocytes (Chapter 3). Ionizing radiation (IR), a high energy radiation that induces 
the release of electrons from molecules, also generates hydroxyl radicals capable of 
inducing DPCs via the same mechanism.523, 524 We employed cell viability assays to 
investigate the effects of exposing Spartan-deficient and 26S proteasome-inhibited cells to 
DPC inducing agents. Furthermore, quantitative HPLC-ESI+-MS/MS methodologies were 
employed to elucidate the role of Spartan in the repair of radical-induced DPCs in the 
tissues of wild type and SPRTN hypomorphic (SPRTN H/H) mice.429  
 
4.2. Materials and methods 
Chemicals and Reagents 
2’-deoxythymidine, Boc-L-Tyr-OH, trifluoroacetic acid, and Nuclease P1 from 
Penicillium citrinum were purchased from Sigma-Aldrich (St. Louis, MO). Glacial acetic 
acid, hydrochloric acid, and acetonitrile were obtained from Fisher Scientific (Buchs, 
Switzerland). Cell Lysis Solution, Protein Precipitation Solution, and RNaseA were 
purchased from Qiagen (Hilden, Germany). Amicon 3K filters were purchased from 
Millapore (Darmstadt, Germany). Omega Nanosep 10K Omega filters were purchased 
from PALL Life Science (Port Washington, NY).  
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Animal safety statement 
 Spartan hypomorphic mice (SPRTNH/H) were obtained as described previously.429 
Animals were housed in standard rodent cages with 12-hour light-dark cycles and were 
given food and water ad libitum. Age-matched SPRTNH/H and wild type mice were 
euthanized by carbon dioxide inhalation and the liver, spleen, kidney, heart, thymus, and 
brain were excised for future study. All experimental procedures were approved by the 
Mayo Clinic Institutional Animal care and Use Committee (IACUC). In addition, all 
studies were conducted in accordance with the United States Department of Health and 
Human Services National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. 
 
Cytotoxicity of DPC-inducing agents in Spartan proficient and Spartan deficient cell 
lines (MEF5 and MEF7) 
Wild type MEF (MEF5, SPRTN +/+) and isogenic SPRTN-deficient (MEF7, SPRTN 
f/-) cells were obtained and used with permission from Dr. Yuichi Machida’s laboratory 
(Mayo Clinic, MN).429 The MEF7 cell lines were originally obtained from E13.5 embryos 
produced by crossing hemizygous (SPRTN +/-) and floxed (SPRTN f/+) mice and 
immortalized by serial passage.429 The inducible Cre-ERT2 element was incorporated by 
infection with retroviral vectors and selected with 3 μg/μL puromycin.  
MEF5 and MEF7 cells were plated in 100 μL Dulbecco’s Modified Eagle’s 
Medium containing 10% FBS at a density of 1 x 104 cells/well. Cells were permitted to 
adhere in an incubator humidified atmosphere of 5% carbon dioxide, 95% air, at 37 °C for 
24 hours. Cells were then treated with 0 – 100,000 μM hydrogen peroxide or 0 – 1000 μM 
207 
 
cisplatin, DEB, or PM in 100 μL serum-free medium for 3 h at 37 oC. Following treatment, 
cell media was replaced with 200 μL fresh FBS-containing media, and the cells were 
incubated an additional 48 h at 37 oC. Cell viability was determined using an Alamar Blue 
assay441 using a Synergy HI Microplate reader (BioTek, Winooski, VT). 
 
Cytotoxicity of hydrogen peroxide in MEF5 and MEF7 cells after pharmacological 
inhibition of proteasome 
MEF5 and MEF7 cells were plated in 100 μL Dulbecco’s Modified Eagle’s 
Medium containing 10% FBS at a density of 1 x 104 cells/well. Cells were permitted to 
adhere in an incubator humidified atmosphere of 5% carbon dioxide, 95% air, at 37 °C for 
24 hours. The media was replaced with 100 μL of 10 μM lactacystin or 1 μM MG-132 in 
DMEM media, and the cells were incubated for 1 hour. Concentrations of lactacystin and 
MG-132 were selected based on previously calculated IC50 values for 26S proteasome 
inhibition. Cells were then treated with 0 – 100,000 μM hydrogen peroxide in 100 μL 
serum-free medium for 3 h at 37 oC. Following treatment, cell media was replaced with 
200 μL fresh FBS-containing media, and the cells were incubated an additional 48 h at 37 
oC. Cell viability was determined using an Alamar Blue assay441 using a Synergy HI 
Microplate reader (BioTek, Winooski, VT). 
 
DPC formation in HeLa cells and mice subjected to ionizing radiation (IR) treatment 
HeLa cells (in triplicate) were plated in 10 mL Dulbecco’s Modified Eagle’s 
Medium containing 10% FBS at a density of 1 x 106 cells per 10cm dish. Cells were 
permitted to adhere in an incubator humidified atmosphere of 5% carbon dioxide, 95% air 
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until 50% confluency was reached, followed by treatment with 8 gy of ionizing radiation 
on a Precision X-Ray X-RAD 320 biological irradiator (North Branford, CT) for 174 
seconds. Cells were immediately irradiated with 8 gy for an additional 174 seconds for 16 
gy exposure. After irradiation, cells were collected and IR-induced DPCs were extracted 
as described below. As a control, HeLa cells (in triplicate) were cultured and left untreated 
before harvesting.  
To investigate IR-induced DPC formation in vivo, C57BL/6 wild type mice were 
irradiated in a 137Cs Mark I-68 irradiator (JL Shepherd & Associates, San Francisco, CA) 
at a rate of 137.44 cGy/min for 8.73 min to yield a 12 gy dose. After irradiation, the animals 
were euthanized and the livers and brains were immediately frozen at -20 oC. IR-induced 
DPCs were extracted from the tissues as described below. 
 
Cell extraction from wild type and SPRTNH/H mouse tissues (Scheme 1) 
Brain, heart, liver, thymus, spleen, and kidney tissues from 10-month old wild type 
and hypomorphic (SPRTNH/H) mice (100 – 800 mg, 3 per group) were diced using a razor 
blade and homogenized in 2 mL of sucrose buffer (20 mM phosphate buffer, pH 7.2, 250 
mM sucrose) using gentle pipetting. The resulting homogenate was incubated on ice for 10 
minutes, followed by centrifugation at 1500 RPM at 4 oC for 10 min. The pelleted cells 
were re-suspended in 2 mL cell lysis solution (Qiagen, Hilden, Germany) and DNA/DPCs 
were extracted as described below.  
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DPC extraction from cells extracted from mouse tissues and IR-treated HeLa cells 
(Scheme 4-1) 
IR-exposed HeLa cells (~ 1.0 x 107) or cells extracted from mouse tissue (~ 1.0 x 
107) were re-suspended in 2 mL of cell lysis solution (Qiagen, Hilden, Germany) and 
pipetted until the cells were completely lysed. For cells obtained from brain and liver tissue 
(~ 1.0 x 108), the cells were typically re-suspended in 3 mL of cell lysis solution and 
processed as described above. The resulting lysates were treated with 40 μg RNaseA (10 
μL, Qiagen) overnight at room temperature with gentle inversion. Following incubation, 
each sample was treated with 8 Units proteinase K (10 μL, Qiagen) and incubated overnight 
at room temperature with gentle inversion. Following incubation, each solution was treated 
with 750 μL of protein precipitation solution (Qiagen, Hilden, Germany) and vortexed for 
1 min to yield a white turbid solution. Each sample was then centrifuged at 1500 RPM for 
10 min to pellet the free proteins.  
The supernatant containing the DNA/DPCs was decanted, and an equal volume of 
cold 100% EtOH was added to precipitate DNA/DPCs. Precipitated DNA/DPCs were 
washed with 70% EtOH twice and 100% EtOH, followed by re-suspending in 10 mM Tris 
buffer, pH 7.5. Successful extraction of DNA was confirmed by UV spectrophotometry at 
λ = 260 nm, and DNA concentrations were determined by dG analysis described in Section 
3.2.  
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Scheme 4-1: Methodology for extracting ROS-induced or IR-induced DNA-protein cross-links. Tissues from either wild type 
(SPRTN+/+) or hypomorphic (SPRTNH/H) mice are homogenized to pellet cells. The recovered cells, or cells obtained from in-vitro 
experiments, are then lysed and DPCs are extracted following a previously published procedure. Isolated DPCs can then be 
enzymatically digested to a single nucleoside and amino acid (dT-Tyr), an adduct that can be quantified by our developed isotope 
dilution tandem mass spectrometry assay. 
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Quantitation of dT-Tyr obtained from wild type or SPRTNH/H tissues or IR-treated 
MEF cells 
DPC-containing DNA extracted from the MEF cells and animal tissues as described 
above was re-suspended in 100 μL 10 mM Tris, pH 7.5 and treated with proteases and 
nucleases to digest the protein and DNA constituents of DPCs as described in detail in 
Section 3.2. The total digestion product dT-Tyr were enriched by offline HPLC 
purification, and radical-induced DPC formation was quantified using the developed dT-
Tyr nanoLC-ESI+-MS/MS assay (Section 3.2).  
 
4.3. Results 
4.3.1. Sensitivity of Spartan deficient (MEF5) and Spartan proficient (MEF7) cells 
towards DPC inducing agents  
MEF5 and MEF7 cells were genetically engineered as described previously.429 
MEF7 only contain one floxed copy of the SPRTN gene, and expresses less than 50% of 
MEF5 wild type Spartan levels.429 Floxing of the SPRTN gene was confirmed by PCR 
amplification of the 527 base pair floxed allele, and decreased Spartan expression was 
confirmed by western blot quantitation as described previously.429 
To compare the sensitivity of Spartan deficient (MEF5) and Spartan proficient 
(MEF7) towards known DPC inducing agents, cells (in quadruplet) were treated with 
increasing amounts of hydrogen peroxide, 1,2,3,4-diepoxybutane, cisplatin, 
phosphoramide mustard, and DEB from 0 to 2000 μM (Figure 4-1A – D). These agents 
were selected because they had been previously shown to form covalent DPCs in cells.288, 
289, 399, 525 Final concentration ranges were determined based on previous cell viability 
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results with other mammalian cells288, 289, 399 and preliminary investigations. Cell viability 
and IC50 values were determined using the commercially available Alamar Blue assay.441  
Overall, cells expressing lower amounts of Spartan (MEF7) were more sensitive 
towards DPC forming agents than their Spartan proficient counterparts (Table 4-1). When 
treated with hydrogen peroxide, MEF7 cells were 1.5-fold more sensitive than MEF5 cells 
(IC50 = 561.8 ± 69 and 839.3 ± 28.4 respectively. Similarly, MEF7 cells were also 1.5-fold 
more sensitive to PM (IC50 = 630.0 ± 46) compared to MEF5 cells (IC50 = 963.9 ± 62.1) 
and 1.3-fold more sensitive to cisplatin (IC50 = 39.1 ± 5.6) compared to MEF5 cells (IC50 
= 50.4 ± 4.3).  Finally, MEF7 cells were 2.4-fold more sensitive to DEB (IC50 = 64.7 ± 
12.7) compared to MEF5 cells (IC50 = 155.4 ± 49.8). 
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Figure 4-1: Cytotoxicity of known DPC-inducing agents H2O2 (A), DEB (B), PM (C), and 
cisplatin (D) in Spartan deficient (MEF5) and Spartan proficient cells (MEF7). 
A.  
 
 
 
 
 
B.  
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Table 4-1: Calculated IC50 values of MEF5 and MEF7 cells treated with 0 – 1000 μM 
cisplatin, PM, or DEB, or 0 – 100,000 μM hydrogen peroxide (H2O2). 
Agent MEF5 IC50 (μM) MEF7 IC50 (μM) Difference 
H2O2 717.3 ± 59.9 504.0 ± 44 1.4 fold 
Cisplatin 50.4 ± 4.3 39.1 ± 5.6 1.3 fold 
Phosphoramide 
mustard 
963.9 ± 62.1 630.0 ± 46 1.5 fold 
DEB 155.4 ± 49.8 64.7 ± 12.7 2.4 fold 
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4.3.2. Effects of proteasome inhibitors on cell sensitivity towards DPC forming 
agents  
As discussed above, 26S proteasomal degradation has been previously reported to 
facilitate DPC repair by reducing the size of the lesion.309, 427, 522, 526 However, others have 
failed to observe any effect of proteasomal inhibitors on DPC repair kinetics.424 It is 
possible that the structural identity of DPC lesions affects their ability to be processed via 
proteasomal degradation. To determine the role of proteasome in repair of DPCs of varied 
structure, MEF5 and MEF7 cells were pretreated with proteasome inhibitor MG-132 (1 
μM) or lactacystin (10 μM). MG-132 is a tripeptide aldehyde (Z-Leu-Leu-Leu-al) that 
inhibits catalytic subunits of the 26-proteasome complex,527 and at higher concentrations 
(3 – 10 μM) retards the growth of mammalian cells by promoting cell cycle arrest.528 
Lactacystin is a selective and irreversible beta-lactone that inhibits the 20-S proteasome 
complex.529, 530 Following treatment of MEF cells with hydrogen peroxide, cell viability 
was measured as described above to determine if the inhibition of the proteasome further 
sensitized cells to ROS-induced DPCs.  
When MEF5 cells were pretreated with MG-132, there was no difference in cell 
cytotoxicity to hydrogen peroxide treatment only (IC50 = 717.3 ± 59.9 vs IC50 = 764.2 ± 
224.4 Figure 4-2A). MEF7 cells pretreated with MG-132 showed a slight decrease in cell 
cytotoxicity to hydrogen peroxide treatment only (IC50 = 504.0 ± 44 and 469.3 ± 48.1 
respectively, Figure 4-2B). Similarly, pretreatment with lactacystin modestly sensitized 
both cell types to hydrogen peroxide treatment. MEF5 IC50 values decreased from 717.3 ± 
59.9 to 552.2 ± 65.7 (Figure 4-3A), while MEF7 IC50 decreased from 504.0 ± 44 to 475.6 
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± 21.7 respectively (Figure 4-3B). Taken together, inhibition of the proteasome does not 
sensitize both cell lines to hydrogen peroxide-induced DNA damage. 
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Figure 4-2: Cytotoxicity of hydrogen peroxide in MEF5 (A) and MEF7 cells (B) with and 
without pretreatment with proteasome inhibitor lactacystin (10 μM). 
A.  
 
 
 
 
 
 
 
B.  
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Figure 4-3: Cytotoxicity of hydrogen peroxide in MEF5 (A) and MEF7 (B) cells after 
pretreatment with proteasome inhibitor MG-132 (1 μM). 
A.  
 
 
 
 
 
 
 
B.  
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4.3.3. DPC formation in cells and tissues treated with ionizing radiation (IR)  
To detect the formation of radical-induced DPCs in cells exposed to IR, HeLa cells 
were treated with 0, 8, and 16 gy of irradiation. Immediately following treatment, DPCs 
were extracted and enzymatically digested to release dT-Tyr adducts, which were 
quantified by isotope dilution HPLC-ESI-MS/MS using our previously validated 
methodology (Groehler et al, Free Radic. Biol. Med., 2018). A linear increase of dT-Tyr 
concentrations was observed in IR treated cells, with 3.36 ± 0.79 and 6.32 ± 0.17 adducts 
per 108 nucleotides observed in cells treated with 8 and 16 gy IR, respectively (Figure 4-
4). dT-Tyr levels in HeLa cells not exposed to IR were below the method’s limit of 
quantitation (2 fmol).  
We next investigated whether our nanoLC-ESI+-MS/MS assay could be utilized to 
detect IR-induced DPC formation in vivo. C57BL/6 wild type mice were treated with 12 
gy of IR, followed by extracting and processing IR-induced DPCs from the livers and 
brains as described above. We were able to detect dT-Tyr in both the brain (5.4 and 8.5 per 
108 nucleotides) and liver (5.4 and 6.63 dT-Tyr per 108 nucleotides, Figure 4-5), 
confirming our assay could detect IR-induced DPC formation in vivo.  
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Figure 4-4: Quantitative analysis of radical-induced DPC formation in MEF cells exposed 
to 0, 8, and 16 gy of ionizing radiation. 
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Figure 4-5: Quantitative analysis of radical-induced DPC formation in the brains and livers 
of mice exposed to 12 gy of ionizing radiation. 
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4.3.4. Quantitation of ROS-induced DPCs in the tissues of wild type and SPRTNH/H 
mice 
To investigate the contribution of Spartan to repair endogenous DPCs, dT-Tyr 
conjugates were quantified in DNA isolated from liver, brain, thymus, spleen, kidney, and 
heart tissues of 10-month old wild type and SPRTNH/H (hypomorphic) mice (Figure 4-
6A). Hypomorhic SPRTNH/H mice express only 10% of Spartan compared to wild type.429 
Previous studies have shown that Spartan-deficient mice experience rapid ageing, genome 
instability, kyphosis, and early development of cataracts.429 Furthermore, recent study has 
revealed that SPRTNH/H mice accumulate significantly higher levels of Topoisomerase-
DNA cross-links over time compared to wild type mice.514 nanoLC-ESI-MS/MS detected 
significant amounts of dT-Tyr analyte (1.39 ± 1.05 to 47.91 ± 6.64 dT-Tyr per 108 
nucleotides) in the liver, brain, heart, and kidneys of both strains of mice, while no 
detectable levels of dT-Tyr analyte were observed in the spleen and thymus (Figure 4-6B). 
Quantitative analysis of the liver, brain, heart, and kidney DNA revealed that 
hypomorhic SPRTNH/H mice had significantly higher levels of dT-Tyr analyte compared 
to the wild type mice (Figure 4-6B). The highest levels of dT-Tyr were observed in the 
liver, with 47.91 ± 6.64 and 26.84 ± 3.72 adducts per 108 nucleotides in SPRTNH/H and 
wild type mice respectively, and in the heart, with 46.02 ± 6.08 and 29.89 ± 3.68 adducts 
per 108 nucleotides in SPRTNH/H and wild type mice respectively (Figure 4-6B). Analysis 
of the brain revealed 38.48 ± 4.37 and 19.34 ± 11.37 dT-Tyr adducts per 108 nucleotides 
in SPRTNH/H and wild type mice, respectively (Figure 4-6B). The greatest difference in 
dT-Tyr adduct levels were found in the kidney, with 4.81 ± 1.12 and 1.39 ± 1.05 adducts 
per 108 nucleotides in SPRTNH/H and wild type mice, respectively (Figure 4-6B). Overall, 
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these results indicate that while Spartan contributes to DPC repair in mouse tissues, another 
proteolytic pathway must be also in place to allow for DPC removal in the absence of 
Spartan. 
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Figure 4-6: Representative trace of dT-Tyr adduct detected in the heart of SPRTN-
deficient mouse (A). Quantitation of dT-Tyr adducts in the brain, heart, liver, kidney, 
thymus, and spleen of 10-month-old wild type (SPRTN+/+, blue bars) and hypomorphic 
(SPRTNH/H, red bars) mice (B). 
A.  
B.  
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4.4. Discussion 
Ionizing radiation is a high energy radiation (alpha particles, beta particles, and x-
rays) that induces the release of electrons from molecules, which generates ions that can 
break covalent bonds.523, 524 IR exposure can directly damage DNA by creating ions that 
physically break the phosphodiester backbone, yielding lesions such as double strand 
breaks.523, 524 IR exposure can also damage DNA indirectly through the formation of 
hydroxyl radicals,523, 524 which can then oxidatively damage positions on DNA nucleosides 
and residues of proteins. Therefore, IR exposure could potentially lead to hydrogen 
abstraction from the methyl position of a thymidine nucleoside and subsequently form a 
cross-link with a neighboring tyrosine residue as observed with hydroxyl radicals.362, 363, 
481  
Interestingly, the same types of thymine-tyrosine DNA-protein cross-links can also 
form endogenously in unexposed cells and tissues. ROS-induced DPCs are formed after 
hydroxyl radicals abstract a hydrogen from the 5-methyl position of thymidine to yield a 
reactive thymidine radical, which undergoes a one-electron addition to the 3-position of a 
tyrosine to yield a stable methylene linkage (Scheme 3-2).481, 482 Subsequent hydrogen 
abstraction from the 3-position of tyrosine re-aromatizes the phenol ring to yield the stable 
DNA-protein cross-link (Scheme 3-2).481, 482  
We recently developed a sensitive nanoLC-ESI+-MS/MS assay for the total 
digestion product, 2-amino-3-(4-hydroxy-3-((1-((2R,4R,5R)-4-hydroxy-5-
(hydroxymethyl)tetrahydro-furan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)methyl)phenyl)propanoic acid (dT-Tyr), to perform absolute quantitation of hydroxyl 
radical-induced DPC formation in cardiomyocytes, (Groehler et al, Free Radic. Biol. Med., 
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2018). Using our developed dT-Tyr nanoLC-ESI+-MS/MS assay, we reported that radical-
induced DPC formation increased in the cardiomyocytes of rats that underwent LAD 
ligation/reperfusion as compared to sham surgery (35.7 ± 2.2 vs 18.2 ± 1.5 dT-Tyr adducts 
per 108 nucleotides respectively, Figure 3-2B). We concluded that ischemia-reperfusion 
injury increased the levels of hydroxyl radicals in affected myocardium, leading to an 
increase in radical-mediated DPCs in cardiomyocyte DNA as described in Section 3.3.2. 
In the present study, we investigated the respective roles of Spartan and the 26S 
proteasome in the repair of ROS and IR-induced DPCs. We first confirmed that our 
previously developed dT-Tyr MS/MS assay, which has successfully been used to quantify 
ROS-induced DPC formation in cardiomyocytes, could be used to quantify IR-induced 
DPC formation. After treating HeLa cells with 0, 8, and 16 gy of IR, we observed a linear 
increase (0 – 6.32 ± 0.17) in dT-Tyr per 108 nucleotides (Figure 4-4). Furthermore, we 
were able to quantify dT-Tyr in the livers and brains of mice treated with 12 gy of IR 
(Figure 4-5). Together, these experiments confirmed our assay could be used to quantify 
IR-induced DPC formation in both cells and tissues, and we could investigate DPC repair 
of both ROS and IR-induced DPCs. 
To investigate the role of Spartan in protecting cells against the cytotoxic effects of 
DPCs, cell cytotoxicity experiments were conducted with MEF5 (wild type) and MEF7 
(SPRTN f/-) cells. These experiments revealed that the Spartan-deficient cells were 
modestly more sensitive to the DPC-inducing agents hydrogen peroxide, cisplatin, 
phosphoramide mustard (PM), and 1,2,3,4-diepoxybutane (DEB) (Table 4-1). These 
results support a role for Spartan in removing toxic DPCs induced by cross-linking agents. 
However, it should be noted that all four of the agents investigated here are known to also 
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induce significant levels of nucleoside monoadducts,31, 34, 201, 210, 327, 383-385, 531-533 as well as 
DNA intrastrand cross-links215, 534-536 and interstrand cross-links, which can contribute to 
the observed toxicity.215-218, 327, 384, 537, 538  For example, Kim et al  discovered that the 
depletion of Spartan by siRNA leads to an increase in error prone bypass across the UV-
induced thymine dimers.539, 540 Therefore our toxicity experiments must be interpreted with 
caution. 
Inhibitors of the 26S proteasome (MG-132 or lactacystin) had minimal effects on 
toxicity of hydrogen peroxide in MEF5 and MEF7 cells (Figure 4-3 and 4-4). These results 
are consistent with previous results by Nakano et al,424, 467 who failed to observe 
ubiquitination of FA-induced DPCs, which is required for proteolytic digestion by the 26S 
proteasome. In contrast, Baker et al and Quievryn et al observed a reduced repair of a 
Dmnt1-containing plasmid427 and FA- and Cr(IV)-induced DPCs309, 522 in cells when the 
26S proteasome was pharmacologically inhibited. Furthermore, Maskey et al showed that 
a deficiency in Spartan also lead to an increase in Top1ccs, indicating that the 26S 
proteasome cannot independently digest topoisomerases ccs to allow the excision of this 
proteasome work together in the repair of this DPC.514 These discrepancies could be due 
to the different DPC structures examined.  
To directly test the role of Spartan in repair of endogenous ROS induced DPCs in 
vivo, we employed wild type (SPRTN+/+) and hypomorphic (SPRTNH/H) mice. nanoLC-
ESI-MS/MS analysis of dT-Tyr conjugates in DNA isolated from brain, liver, spleen, heart, 
thymus, and kidney tissues of the two strains of mice revealed a 1.5 to 2-fold increase in 
dT-Tyr adduct in the liver, brain, kidney, and heart of hypomorphic (SPRTNH/H) mice 
compared to wild type (SPRTN+/+) mice (Figure 4-6). Previous investigations by Vaz et al 
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observed a 3-fold increase in endogenous DPCs in Spartan-depleted HeLa cells (CRISPR-
Cas9-created SPRTN partial knockouts) compared to wild type cells using silver staining 
technique.513 When endogenous DPC levels in the same HeLa cells were quantified by the 
SDS/K+ precipitation assay, a similar 1.5-fold increase was observed in Spartan-depleted 
cells compared to the wild type.513 Taken together with our dT-Tyr results, these results 
suggest that Spartan is directly involved in repair of radical-induced DPCs, although 
additional proteases may be involved in DPC repair. 
Previous investigations have detected ROS-mediated DPCs in unexposed animals.  
For example, Izzotti et al observed an age-related increase in ROS-induced DPC formation 
and the ROS biomarker 8-oxoguanine in the liver, brain, and heart of mice.270 Similarly, 
Leutner et al observed an age-related increase in the lipid peroxidation biomarker 
malondialdehyde coupled with an increase in activity of CuZn-superoxide dismustase and 
glutathione reductase in the brain,541 providing additional evidence that hydroxyl radical 
concentration increases in brain tissues over time. Finally, the filtration of blood by kidneys 
exposes glomeruli cells to particulate and soluble stimuli, such as phorbal 12-myristate 13-
acetate (PMA)542 and arachidonic acid,543 which induces phagocytotic cells to release 
peroxides and hydroxyl radicals.544 However, to our knowledge, our study in the first to 
accurately quantify DPC formation in unexposed mice.  
Our failure to detect dT-Tyr in DNA isolated from mouse spleen and thymus tissues 
(Figure 4-6) suggests that the specialized lymphatic immunoproteasomes (i-proteasomes) 
may be involved in repair of radical-induced DPCs. I-proteasomes are defined by tissue-
specific inducible catalytic subunits of the low-molecular-weight protein 2 (LMP2), LMP7, 
and multicatalytic endopeptidase complex subunit-1 (MECL-1).545 The primary function 
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of i-proteasomes is to digest proteins to peptides with a hydrophobic C terminus, which 
can be processed to recognize major histocompatibility (MHC) class 1 molecules.545-547 
Displaying these processed peptides on the membranes of CD8 T-cells allows for the 
detection of bacterial and viral pathogens.545-547 Recently, additional functions of i-
proteasomes, including regulating cellular homeostasis,545, 548 tumor development,549 acute 
retinal injury,550-552 and insulin-dependent diabetes mellitus/diabetes insipidus,553 have 
been elucidated in both humans and mice. Most interestingly, Ding et al observed an 
increase in oxidatively damaged proteins in the tissues of i-proteasome knockout (LMP2 
KO) mice.554 Similarly, Ferrington et al observed that retinal pigment epithelial cells from 
LMP7/MECL-1 double knockout mice were significantly more sensitive to oxidative stress 
in culture.550 Taken together, i-proteasomes expressed in lymphatic tissues can be 
transported to other tissues to protect them from oxidative damage and digest any 
oxidatively damaged proteins, potentially including the radical-induced DPCs investigated 
in this manuscript. We are currently investigating whether i-proteasomes are directly 
involved in the repair of ROS-induced DPCs by quantifying dT-Tyr adducts in the tissues 
of LMP2 and LMP2/LMP7 KO mice.  
One proposed model of DPC repair in mammalian systems couples the recruitment 
of proteases to a DPC with stalled DNA replication.428, 431, 512 In this model, the 
replisome/CMG helicase becomes stalled after encountering a DPC,264, 265, 421 which leads 
to the recruitment of Spartan (or any protease) to the lesion.427, 430, 431, 514 Once recruited, 
Spartan will bind to ssDNA regions created by the bulky nature of DPCs, bringing Spartan 
into proximity of its substrate and allowing for proteolytic digestion of the protein 
constituent (Scheme 4-2).431 The resulting DNA-peptide lesion can then be immediately 
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bypassed by TLS polymerases,430, 431 and eventually repaired by NER (Scheme 4-2).309, 426, 
427, 555 Recently, Chesner et al utilized strand-specific primer extension-quantitative 
polymerase chain reaction (SSPE-qPCR) to show that the repair of a plasmid containing 
human oxoguanine glycosylase 1 (OGG1) occurred within 2 hours post-transfection in wild 
type (V79) and NER-deficient (VH1) CHO cells, well before DNA replication would 
become a factor.555 Combined with our results suggesting that multiple proteases are 
required for the digestion of the protein constituent, it is unlikely the stalling of the 
replisome is the only molecular signal to stimulate DPC repair.  
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Scheme 4-2: Proposed Spartan-induced protein digestion mechanism for DPC removal. After the DPC is recognized, the metalloprotease 
Spartan is recruited to the area and binds a ssDNA region induced by the bulkiness of the lesion. The resulting DNA-peptide cross-link 
can then be immediately bypassed by TLS polymerases if DNA replication is occurring, of the smaller adduct can be excised via NER. 
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5. EB-FAPy-dG Adducts of 1,3-
Butadiene: Synthesis, Structural 
Identification, and Detection in 
Human Cells 
5.1. Introduction 
1,3-butadiene (BD) is a recognized human and animal carcinogen present in 
cigarette  smoke,556 automobile exhaust,177 and wood burning fumes.557 BD is also an 
important industrial chemical broadly used in polymer and rubber production, with 519,400 
workers exposed to BD in the United States (Bureau of labor statistics).184 BD is 
metabolically activated by cytochrome P450 monooxygenases to three inherently reactive 
epoxides: 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB), and 1,2-dihydroxy-3,4-
epoxybutane (EBD) (Scheme 1-6).192 These electrophilic species can enter the cell nuclei 
and react with nucleophilic bases of DNA to form covalent nucleobase adducts.558  BD-
DNA adducts are thought to be responsible for its carcinogenicity, as they can lead to DNA 
polymerase errors during replication.196, 197, 559-562 A number of BD-DNA adducts have 
been identified, including N-7-(2-hydroxy-3-buten-1-yl)-guanine (EB-Gua I),200, 563 N-7-
(1-hydroxy-3-buten-2-yl) guanine (EB-Gua II),200, 563 N7-(2,3,4-trihydroxybut-1-yl)-
guanine (N7-THBG),206, 207 N1-(2,3,4-trihydroxybut-1-yl)-adenine (N1-THB-Ade),564 1,4-
bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD)565,566 and 1,N6-(1-hydroxymethyl-2-
hydroxypropan-1,3-diyl)-2′-deoxyadenosine (1,N6-HMHP-dA) (Figure 1-6).209, 567 
Among these, N7-guanine adducts (EB-Gua and N7-THBG) are by far the most abundant 
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and have been detected in BD-treated laboratory animals,202, 206, 565 occupationally exposed 
workers,207 and current smokers.207 
Despite their predominant formation, N7-guanine adducts of BD may not be the 
most biologically relevant because they retain the ability to pair with cytosine,252, 568 and 
are hydrolytically labile because of the intrinsic destabilization of the glycosydic bond 
when the N7 position of guanine is alkylated.33 Spontaneous depurination of N7-THBG 
and EB-Gua releases free base adducts form the DNA backbone and leads to the formation 
of abasic sites (Scheme 1-8). Alternatively, the C8 position of EB-Gua can be attacked by 
hydroxyl anions (17, Scheme 1-8), leading to imidazole ring opening and the formation of 
N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-(2-
hydroxybut-3-en-1-yl)formamidopyrimidine (EB-Fapy-dG) adducts (18, Scheme 1-8).233  
This imidazole ring scission dramatically changes the molecular shape and the 
hydrogen bonding characteristics of the parent nucleobase, modifying its base pairing 
preferences and leading to mispairing during DNA replication.227, 228  Alternatively, FAPy 
adducts may be recognized by DNA repair enzymes and excised from the DNA 
backbone.254, 256, 569-572 Unsubstituted (FAPy-dG) and alkyl-FAPy adducts (N5-alkyl-FAPy-
dG) are known substrates for the base excision repair (BER) enzymes 8-oxoguanine 
glycosylase (OGG1),570, 571 endonuclease III-like protein (NTHL1),570, 572 and 
endonuclease 8-like protein I – III (NEIL1, NEIL2, and NEIL3 respectively).570, 572 
Recently, NEIL1 has been shown to excise the bulky aflatoxin B1-FAPy-dG adduct,573 
making it the primary candidate to recognize and excise any N5-alkyl-FAPy-dG formed 
after exposure to the epoxide metabolites of BD.  
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The most studied example of the N5-alkyl-FAPy-dG adducts are those formed upon 
exposure to aflatoxin B1 (AFB1), a potent liver carcinogen produced by the common soil 
fungus Aspergillus flavus.574, 575 Dietary exposure to AFB1 is recognized as a major risk 
factor for hepatocellular carcinoma in developing countries.241, 576, 577 Metabolic activation 
of AFB1 yields electrophilic AFB1-exo-8,9-epoxide,578 which  alkylates DNA to form 
trans-8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N7-dG), and the 
corresponding ring open AFB1-β-FAPy adducts (Scheme 1B).579 AFB1-β-FAPy-dG 
adducts have been shown to induce high levels of G→T transversion mutations in 
Escherichia coli, nearly 6 times more frequent than G→T transversions caused by the 
cationic AFB1-N7-dG adduct.235 AFB1-FAPy-dG ability to induce G → T transversion 
mutations is consistent with the observed G→ T mutations in codon 249 of the p53 tumor 
suppressor gene observed in AFB1-treated human hepatocytes cultures.249, 250 In addition, 
AFB1-induced G → T mutations in the ras oncogene contribute to liver tumor 
progression.247  
In addition to AFB1-β-FAPy, other N5-alkyl-FAPy-dG reported in vivo include Me-
FAPy-dG and Me-FAPy-dA induced by methylating agents and FAPy adducts of 
antitumor nitrogen mustards.227, 233, 253, 580 When Me-FAPy lesions incorporated into 
M13mp18 vector were introduced in E. Coli bacteria, they blocked DNA replication and 
increased mutational frequency following SOS induction.227, 253 Gruppi et al treated human 
mammary tumor (MDA-MB-321) cells with bis-(2-chloroethyl)ethylamine (NM) and 
structurally characterized two novel NM-FAPy lesions, NM-FAPy-dG adduct and FAPy-
dG-NM-dG cross-link, which were measured at 180 and 6 adducts per 106 nucleotides 
respectively. Overall, previous studies indicate that N5-alkyl-FAPy-dG adducts can form 
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in mammalian cells, however, their prevalence and biological significance is not fully 
understood.    
We hypothesized that BD-induced EB-Gua I and EB-Gua II can form the 
corresponding EB-Fapy-dG adducts in the presence of hydroxyl anions (Figure 5-1). In 
the present study, authentic standards of 3,4-epoxy-1-butene (EB)-derived guanine Fapy 
adducts (EB-Fapy) were prepared for the first time, structurally characterized by NMR and 
mass spectrometry, and used to develop an isotope dilution mass spectrometry based 
methods for their quantitation in EB-treated DNA and human cell culture. pH and 
concentration dependence for adduct formation was investigated to determine whether EB-
FAPy-dG could form under physiological conditions, potentially contributing to 
genotoxicity and mutagenic effects of BD. 
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Figure 5-1: Chemical complexity of EB-Fapy-dG adduct, showing all possible isomers, 
rotamers, and atropisomers. 
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5.2. Materials and methods 
Note: 3,4-epoxy-1-butene (EB) is a known carcinogen and must be handled with adequate 
safety precautions.  
 
Chemicals and Reagents: 
LC-MS grade water, methanol and acetonitrile were purchased from Fisher 
Scientific (Pittsburgh, PA). 3,4-epoxy-1-butene (EB), N,N-dimethylformamide dimethyl 
acetal, dimethoxytrityl chloride, trifluoroethanol, dichloroacetic acid, and calf thymus 
DNA were obtained from Sigma-Aldrich (Millwaukee, WI/St. Louis, MO). 2’-
deoxyguanosine was obtained from Carbosynth (San Diego, Ca). Hypersep Hypercarb SPE 
cartridges (100 mg/3 mL) were obtained from Thermo Scientific (Waltham, MA). Omega 
Nanosep 10K filters were obtained from PALL Life Science (Port Washington, NY). All 
other chemicals and solvents were obtained from Sigma-Aldrich (Millwaukee, WI; St. 
Louis, MO) unless specified otherwise. Isotopically labeled 15N3-dG was provided by Dr. 
Rajat Subhra Das and Professor Ashis Basu (University of Connecticut). 
 
Cell culture of wild type mouse embryonic fibroblast (MEF) cells and isogenic 
knockouts of Endonuclease 8-like 1 (NEIL1)  
Wild type MEF (NEIL1+/+) and isogenic NEIL1-/- MEF cells were a gift from Dr. 
Robert Turesky’s laboratory (University of Minnesota), used with permission from Dr. R. 
Stephen Lloyd (Oregon Health and Science University).581 Both cell lines were seeded at 
a density of 1 x 106 cells in DMEM supplemented with 10% FBS. Cells were cultured in 
an incubator humidified atmosphere of 5% carbon dioxide, 95% air at 37 oC. 
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Synthesis of N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-
5-N-(2-hydroxybut-3-en-1-yl)formamidopyrimidine (EB-FAPy-dG, Scheme 5-1) 
(E)-N'-(9-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-
dihydro-1H-purin-2-yl)-N,N-dimethylformimidamide (2’-dG-N2-N,N-
dimethylformimidamide) (22)  
2’-Deoxyguanosine (1 g, 3.70 mmol) was dissolved in dry methanol (9.5 mL) under 
argon, followed by the dropwise addition of N,N-dimethylformamide dimethyl acetal (2 
mL, 14.8 mmol) over 5 minutes. The resulting suspension was stirred at room temperature 
for 60 h. The precipitate was collected by vacuum filtration, and the solid was washed with 
cold methanol to yield a white solid (980 mg, 81.7% yield). ESI+-MS/MS (22): 323.0 [M 
+ H]+ → 207.1 [M – dR + H]+. 1H-NMR (500 MHz, DMSO-d6): 11.32 (s, N1-H, 1H), 8.56 
(s, C8-H, 1H), 8.04 (s, N=CH-N(Me)2, 1H), 6.25 (t, J = 7 Hz, C’1-H, 1H), 5.30 (d, J = 3 
Hz, C’3-OH, 1H), 4.94 (t, J = 5 Hz, C’5-OH, 1H), 4.42 – 4.34 (m, C’3-H, 1H), 3.89 – 3.79 
(m, C’4-H, 1H), 3.59 – 3.51 (m, C’5-H, 2H), 3.16 (s, N-(CH3)2, 3H), 3.04 (s, N-(CH3)2, 
3H), 2.64 – 2.64 (qt, J = 7 Hz, C’2-H, 1H), 2.28 – 2.19 (ddd, J = 14, 6, 3 Hz, C’2-H, 1H). 
13C-NMR (400 MHz, DMSO-d6): 158.46, 158.06, 157.74, 150.10, 137.12, 120.16, 88.20, 
83.24, 71.39, 62.29, 41.12, 35.12. 
 
(E)-N'-(9-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)-N,N-
dimethylformimidamide (23) 
Compound 22 (958 mg, 2.97 mmol) was dissolved in 20 mL anhydrous pyridine, 
and 300 mg of 4,4-dimethoxytrityl chloride (DMTCl) was added. Three aliquots of 300 mg 
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DMTCl was added to the solution every 15 minutes (1.2 g total, 2.97 mmol), and the 
solution was allowed to stir at room temperature for 4 h. The solution was concentrated in 
vacuo to yield a brownish red oil, which was purified by silica column chromatography 
using methanol in dichloromethane to yield pure 23 as a white solid (1.6 g, 86%). ESI+-
MS/MS (23): 625.0 [M + H]+ → 207.1 [M – dR + H]+ and 303.1 [DMT+].  1H-NMR (500 
MHz, CDCl3): 8.93 (s, N1-H, 1H), 8.59 (s, C8-H, 1H), 7.72 (s, N=CH-N(Me)2, 1H), 7.42 
(d, J = 8 Hz, DMT-H, 2H), 7.36 – 7.26 (m, DMT-H, 8H), 6.82 (d, J = 8, DMT-H, 4H), 
6.40 (t, J = 6 Hz, C’1-H, 1H), 4.68 – 4.58 (m, C’4-H,1H), 4.18 – 4.11 (m, C’3-H, 1H), 3.80 
(s, DMT-OCH3, 6H), 3.47 – 3.42 (m, C’5-H, 1H), 3.34 – 3.29 (m, C’5-H, 1H), 3.14 (s, N-
(CH3)2, 3H), 3.08 (s, N-(CH3)2, 3H), 2.76 (s, C’3-OH, 1H), 2.62 – 2.54 (q, J = 5 Hz, C’2-
H, 1H), 2.58 – 2.49 (m, C’2-H, 1H).  
 
N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-(2-
hydroxybut-3-en-1-yl)formamidopyrimidine (25) 
Protected dG (23) (1 g, 1.6 mmol) was dissolved in 8.17 mL trifluoroethanol, and 
1.93 mL of 3,4-epoxybutene (24 mmol, 10 equiv.) was added dropwise over 15 min. The 
solution was allowed to stir for 24 h at room temperature and concentrated in vacuo to yield 
a white gum. Intermediate 24 was isolated by silica column purification (eluent methanol 
in dichloromethane with 1% triethylamine) to yield an off-white solid (150 mg, 13.5% 
yield). ESI+-MS/MS (24): 695 [M + H]+ → 277.2 [M – dR + H]+, 303.1 [DMT+], and 207.1 
[M – dR – EB + H]+.  
Compound 24 (150 mg, 0.216 mmol) was dissolved in 100 μL trifluoroethanol and 
100 μL 1 M NaOH, and the solution was stirred for 16 h at room temperature. The solution 
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pH was neutralized to pH 7.0 using 5% HCl, and the solution was concentrated under 
vacuum to yield an off-white solid. The resulting solid was chilled in an ice bath (0 oC) for 
15 min and dissolved in 250 μL of 1% dichloroacetic acid in dichloromethane. The solution 
was stirred for 10 min and immediately neutralized to pH 7.0 using triethylamine. The 
solution was concentrated in vacuo to yield a reddish yellow solid.  
The resulting crude product was re-suspended in 1 mL of water and purified by 
semi preparative RP-HPLC using Zorbax XDB C18 column (250 mm × 10 mm, 5 µ, 
Agilent Technologies, Palo Alto, CA) with a gradient of water and acetonitrile at a flow 
rate of 1 mL/min. Solvent composition was changed from 0 to 3% B over the course of 5 
min, 3 to 5% B over the course of 5 min, 5 to 10% B over the course of 10 min, 10 to 75% 
over the course of 5 min, 75 to 0% over the course of 3 min, and held at 0% B over 7 min. 
Broad peaks eluting at 9.5, 10.7, and 11.8 min corresponded to the EB-FAPy base (25a, 
Scheme 5-1), and broad peaks eluting at 13.7, 14.1, and 14.8 min corresponded to the 
desired EB-FAPy nucleoside (25b, Scheme 5-1). The collected fractions were 
concentrated in vacuo and characterized by ESI+-MS/MS, 1H-NMR, and HSQC. 15N3-EB-
Fapy adducts were prepared analogously starting with 15 mg of 15N3–dG to be used as 
internal standards for mass spectrometry. 
 
N-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-N-(2-hydroxybut-3-en-1-yl)-
formamido-pyrimidine (25a): ESI+-MS/MS (27a): 240.1 [M + H]+ → 222.2 [M – H2O + 
H]+ and 194.1 [M – H2O – CO + H]+. 1H-NMR (600 MHz, DMSO-d6): 10.34 (s, N1-H, 
1H), 8.10 (s, HC=O, 0.5 H), 7.79 (s, HC=O, 0.5 H), 6.47 (s, N2H2, 2H), 6.34 (s, C4-NH2, 
2H), 6.13 (s, OH, 1H), 5.85 – 5.75 (m, CH=CH2, 1H), 5.30 – 5.18 (dd, J = 17, 6 Hz, 
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CH=CH2, 1H), 5.15 – 5.00 (dd, J = 12, 5 Hz, CH=CH2, 1H), 4.79 – 4.69 (q, J = 7 Hz, CH-
OH, 1H), 3.55 – 3.47 (m, CH2, 2H). 
 
N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-(2-
hydroxybut-3-en-1-yl)formamidopyrimidine (25b) ESI+-MS/MS: 356.1 [M + H]+ → 240.1 
[M – dR + H]+, 222.2 [M – dR – H2O + H]+ and 194.1 [M – dR – H2O – CO + H]+. 1H-
NMR (600 MHz, DMSO-d6): 10.34 (s, N1-H, 1H), 7.90 (s, HC=O, 0.25 H), 7.83 (s, HC=O, 
0.25 H), 7.77 (s, HC=O, 0.5 H), 6.45 (s, N2H2, 2H), 6.35 (s, C4-NH, 1H), 6.0 (s, C’5-OH, 
0.5 H) 5.85 – 5.75 (m, CH=CH2, 1H), 5.80 (s, C’5-OH, 0.5 H), 5.75 (s, C’3-OH, 0.5 H), 
5.64 (s, C’3-OH, 0.5 H), 5.30 – 5.18 (m, J = 17, 6 Hz, CH=CH2, 1H), 5.15 – 5.00 (m, J = 
12, 5 Hz, CH=CH2, 1H), 4.77 – 4.70 (q, J = 8 Hz, CH-OH, 1H), 4.28 – 4.22 (m, C’1-H, 
1H), 4.08 – 3.98 (m, C’3-H, 1H), 3.73 – 3.64 (m, CH2, 2H), 3.50 (m, C’4-H, 1H) 3.20 (dd, 
J = 13, 10 Hz, C’5-H, 1H), 3.12 – 3.04 (dd, J = 18, 3 Hz, C’5-H, 1H), 2.92 – 2.86 (dd, J = 
13, 3 Hz, C’2-H, 1H), 2.87 – 2.81 (dd, J = 13, 9 Hz, C’2-H, 1H) 
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Scheme 5-1: Reaction scheme for EB-Fapy nucleoside adduct formation starting from 2’-
deoxyguanosine. 
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Figure 5-2: UV-visible spectra of EB-Fapy base peaks in solutions of 0.1N HCl (pH: 1.0), 
water (pH: 7.0) and 0.1N NaOH (pH: 12.0). λ max, neutral pH : 266 nm, λ max, acidic pH(1.0) :  264 
nm, λ max, basic pH(13.0) : 274 nm. 
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UV-Vis characterization of EB-FAPy nucleoside and molar concentration 
measurement (Figure 5-2): 
UV measurements were performed for synthesized EB-Fapy base peaks in 
solutions of 0.1N HCl (pH: 1.0), water (pH: 7.0) and 0.1N NaOH (pH: 12.0) for the 
determination of absorption maxima. Molar concentrations of EB-Fapy standard solutions 
were determined by UV spectrophotometry using the molar extinction coefficient (ε) of 
12589.2 M-1 cm-1 at 266 nm at neutral pH.582  
 
Treatment of Calf-Thymus DNA with 3,4-epoxy-1-butene (EB) to determine dose-
dependent increase in EB-FAPy-dG 
Calf thymus DNA (1 mg/mL in 10 mM Tris-HCl buffer, pH 7.5) was treated with 
10 μM, 50 μM, 100 μM, 250 μM, 500 μM, 1 mM, 5 mM, and 10 mM EB at 37 °C for 24 
h. Any unreacted EB was extracted with diethyl ether (3× at 2 mL), and alkylated DNA 
was precipitated with cold ethanol. The recovered DNA was washed with 70% EtOH and 
100% EtOH. DNA was reconstituted in 200 μL 1 N NaOH (pH 12) and kept for 1 h at 
room temperature to induce EB-Fapy adduct formation. The solution was neutralized with 
0.1M HCl, followed by ethanol precipitation of DNA as described above. The DNA was 
then reconstituted in 200 µL 10 mM tris, pH 7.5 in milli-Q water and DNA was confirmed 
by nanodrop UV spectrophotometer measurement (Thermo Scientific, Waltham, MA).  
DNA concentration was determined by dG analysis described in Section 3.2. 
 
 
 
245 
 
Enzymatic hydrolysis of DNA and sample preparation for nanoLC-ESI+-MS/MS 
DNA (100 µg) was enzymatically digested in the presence of nuclease P1 (5 U) in 
50 μL 10 mM tris-HCl/5 mM ZnCl2 (pH 5.5) for 18 h. The pH of the solution was raised 
to 7.0 by the addition of 1 μL of 1 M ammonium bicarbonate, followed by incubation with 
120 mU phosphodiesterase I, 105 mU phosphodiesterase II, 35 U DNase, and 22 U alkaline 
phosphatase, in the presence of 15 mM MgCl2 at 37 °C for 18 hours to yield 2’-
deoxynucleosides.  
The enzymatic digests were spiked with 15N3-EB-FAPy-dG internal standard (1 
pmol) and purified by solid-phase extraction on Hypercarb Hypersep SPE cartridges (100 
mg/3 mL). SPE cartridges were conditioned using 3 mL of methanol, followed by 3 mL of 
water. DNA samples (200 µL) were loaded under neutral pH, washed with 3 mL of water 
and 10 % methanol, and then eluted with 70 % methanol in water. SPE fractions were dried 
under vacuum and reconstituted in 16 µL of 5 mM ammonium formate, pH 4.5 for nanoLC-
ESI+-MS/MS analysis as described below. 
 
EB-FAPy-dG and EB-Gua II formation in EB-treated CT DNA  
To investigate pH dependence for EB-Fapy-dG and EB-Gua II adduct formation, 
calf thymus DNA (1 mg/mL in 10 mM Tris-HCl buffer, pH 7.5) was treated with 5 mM 
EB at 37 °C for 24 h (in duplicate). Following extraction of unreacted EB with diethyl ether 
(3 x 2 mL), DNA was precipitated with ice cold ethanol. The recovered DNA was washed 
with 70% ethanol and re-suspended in 10 mM Tris buffer (200 μL) adjusted to pH 7.5, 9.0, 
10.0, 11.0, or 12.0. DNA was incubated 1 h, precipitated with cold ethanol, and 
reconstituted in 10 mM Tris buffer, pH 7.5 (200 µL). Samples were incubated at 70 oC for 
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1 hour to release any remaining EB-Gua as a free base. The DNA backbone was 
precipitated using 100% EtOH and washed as described above, while the supernatant was 
concentrated under vacuum. Each sample was reconstituted in 200 μL of water, spiked 
with 15N5-EB-Gua II internal standard (200 fmol),563 and subjected to SPE enrichment 
using hypercarb SPE cartridges (100 mg, Thermo). 
To quantify EB-Fapy-dG adducts, the precipitated, partially depurinated DNA was 
reconstituted in 10 mM Tris, pH 7.5 buffer (200 μL). DNA aliquots (100 μg) were taken 
and subjected to enzymatic digestion and solid phase extraction on Hypersep Hypercarb 
cartridges as described above. EB-Gua II and EB-Fapy-dG adduct numbers were expressed 
per 106 normal nucleotides, and the data were plotted together as a function of pH.  
 
Cytotoxicity of EB in mouse embryonic fibroblasts (MEF) NEIL1+/+ and NEIL-/- cells 
Wild type and NEIL-/- MEF cells581 were plated in 100 μL of Dulbecco’s Modified 
Eagle’s Medium containing 10% FBS at a density of 1 x 104 cells/well. Cells were 
permitted to adhere in an incubator humidified atmosphere of 5% carbon dioxide, 95% air, 
at 37 °C for 24 h. Cells were treated with 0 – 20 mM EB in 100 μL of serum-free medium 
for 3 h at 37 oC. Following treatment, cell media was replaced with 200 μL fresh FBS-
containing media, and the cells were maintained for an additional 48 h at 37 oC. Cell 
viability was determined using an Alamar Blue assay441 using a Synergy HI Microplate 
reader (BioTek, Winooski, VT). 
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EB-Fapy-dG and EB-Gua II adduct formation in EB-treated MEF cells 
Wild type and NEIL-/- MEF cells were grown in Dulbecco’s modified Eagle’s 
media (DMEM) supplemented with 10% fetal bovine serum. Cells were cultured in a 
humidified atmosphere of 5% carbon dioxide, 95% air, at 37 °C in 15 cm dishes, with at 
least 70% confluency. Adhered HT1080 cells (1 x 107) were treated with 500 μM EB (in 
triplicate) for 24 hours at 37 °C. Following treatment, EB containing media was discarded, 
and the cells were washed twice with ice-cold phosphate-buffered saline (PBS) to remove 
EB. Cells were harvested by trypsin treatment, and DNA was extracted as reported 
previously using Qiagen Cell Lysis solution.207 DNA concentrations were determined by 
dG analysis as described in Section 3.2. Extracted DNA (50 μg) was subjected to 
enzymatic digestion and enrichment for EB-FAPy-dG and EB-Gua II analysis as described 
above. 
 
EB-Fapy-dG adduct nanoLC-ESI+-MS/MS analysis 
Quantitative analyses of EB-FAPy-dG were conducted by nanoLC-ESI+-MS/MS 
using a TSQ Quantiva mass spectrometer (Thermo Scientific, Waltham, MA) interfaced 
with a Dionex UltiMate 3000 RSLC nanoHPLC system (Thermo Scientific, Waltham, 
MA). Samples were loaded onto a pulled-tip fused silica column with a 100 µm inner 
diameter packed in-house with 15 cm of 5µm Synergy Hydro RP resin (Phenomenex, 
Torrence, Ca) that served both as a resolving column and as a nanospray ionization emitter. 
HPLC solvents were comprised of 5 mM ammonium formate, pH 4.5 (solvent A) and 90/10 
acetonitrile/solvent A (solvent B). Solvent composition was kept at 2% solvent B over 6 
min, followed by an increase to 20% over 10 min, further to 80% over 2 min, held at 80% 
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B over 2 min, then decreased to 2% over 2 min, and finally re-equilibrated at 2% B for 11 
min. The flow rate was 1.0 μL/min for the first 6 min of the run, then reduced to 0.3 μL/min, 
until the final equilibration for 11 min at 1 μL/min. Under these conditions, EB-FAPy and 
its internal standard (15N3–EB-FAPy) eluted at ~ 13.8 min. Electrospray ionization was 
achieved at a spray voltage of 2600 V and a capillary temperature of 350 °C. Collision 
induced dissociation was performed with Ar as a collision gas (1.0 mTorr) at a collision 
energy of 10 V. MS/MS parameters were optimized for maximum response during infusion 
of a standard solution of EB-FAPy. 
NanoLC-ESI+-MS/MS analysis of EB-FAPy was performed in the selected 
reaction monitoring mode by following the neutral loss of dR and both dR and water from 
protonated molecules of the analyte (m/z 356.1 [M + H]+ → 240.1 [M + H − dR]+ and m/z 
356.1 [M + H]+ → 222.1 [M + H – dR – H2O]+) (Figure 5-3A). The corresponding mass 
transitions corresponding to 15N3-labeled internal standard were m/z 359.1 [M + H]+ → 
243.1 [M + H − dR]+ and  m/z 359.1 [M + H]+ → 225.1 [M + H – dR – H2O]+) (Figure 5-
3B). Analyte concentrations were determined using the relative response ratios calculated 
from HPLC-ESI+-MS/MS peak areas in extracted ion chromatograms corresponding to 
EB-FAPy and its internal standard. 
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Figure 5-3A: Observed fragmentation patterns of EB-FAPy-dG by infusion, including the neutral loss of sugar and the loss of sugar 
and water; 356.1 [M + H]+ → 338.21 [M – H2O +H]+, 240.1 [M – dR + H]+, 222.1 [M – dR – H2O + H]+, and 194.1 [M – dR – H2O – 
CO +H]+. 
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Figure 5-3B: Observed fragmentation patterns of EB-FAPy-dG by infusion, including the neutral loss of sugar and the loss of sugar and 
water; 359.1 [M + H]+ → 341.21 [M – H2O +H]+, 243.1 [M – dR + H]+, 225.1 [M – dR – H2O + H]+, and 197.1 [M – dR – H2O – CO 
+H]+. 
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EB-Gua II adduct nanoLC-ESI+-MS/MS analysis 
NanoLC-ESI+-MS/MS was conducted using a TSQ Quantiva mass spectrometer 
(Thermo Scientific, Waltham, MA) interfaced with a Dionex UltiMate 3000 RSLC 
nanoHPLC system (Thermo Scientific, Waltham, MA). Samples were loaded onto a 
pulled-tip fused silica column with a 100 µm inner diameter packed in-house with 15 cm 
of 5µm Synergy Hydro RP resin (Phenomenex, Torrence, Ca) that served both as a 
resolving column and as a nanospray ionization emitter. HPLC solvents included (A) 
0.01% acetic acid in LC-MS grade water and (B) 0.02% acetic acid in LC-MS grade 
acetonitrile. Solvent composition was kept at 2% solvent B over 8 min, followed by an 
increase to 30% over 9 min, further to 80% over 1 min, held at 80% B over 10 min, then 
decreased to 2% over 1 min, and finally re-equilibrated at 2% B for 8 min. The flow rate 
was 0.7 μL/min for the first 7.5 min of the run, then reduced to 0.3 μL/min, until the final 
equilibration for 11 min at 0.7 μL/min. Sample injection volume was 4 µL. Under these 
conditions, both analyte its internal standard eluted around 16.3 min. 
Electrospray ionization was achieved at a spray voltage 3100 V and capillary 
temperature of 350 °C. Collision induced dissociation was performed with Ar as a collision 
gas (1.5 mTorr). MS tuning was performed upon infusion of EB-Gua II internal standard 
to obtain maximum sensitivity. HPLC-ESI+-MS/MS analysis was performed in the selected 
reaction monitoring (SRM) mode using 15N5 labeled internal standard (15N5-EB-Gua II). 
SRM transitions included neutral loss of 1-hydroxy-3-buten-2-yl from protonated EB-Gua 
II analyte m/z 222.1 (M + H)+  m/z 152.1 (M – C4H8O + H)+ with a collision energy (CE) 
of 15 V and a neutral loss of 1-hydroxy-3-buten-2-yl and ammonia from protonated EB-
Gua II (m/z 222.1 (M + H)+  m/z 135.0 (M – C4H8O – NH3 + H)+) with a CE of 29 V. 
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Similarly, SRM transitions for 15N5-EB-Gua II included m/z 227.1 (15N5-M + H)+ →m/z 
157.0 (15N5-M – C4H8O + H)+, CE = 17 V and m/z 227.1 (15N5-M + H)+ → m/z 139.0 (15N5-
M – C4H8O – 15NH3 + H)+, CE = 32 V. Quantitative analyses was performed on the ratio 
of the area under the peak using SRM transitions m/z 222.1 (M + H)+ → m/z 152.1 (M –  
C4H8O + H)+ for the analyte and m/z 227.1 (15N5-M + H)+ → m/z 157.0 (15N5-M –  C4H8O 
+ H)+ for the internal standard.  
 
NanoLC-ESI+-MS/MS method validation  
Calf thymus DNA (CT DNA, 100 μg, in triplicate) was spiked with increasing 
amounts of EB-FAPy-dG analyte (40-2000 fmol) and 15N3-EB-FAPy-dG internal standard 
(1 pmol). Each sample was processed as described above. The linearity of our nanoLC-
ESI+-MS/MS methodology was determined by plotting the observed analyte/internal 
standard peak area ratio versus the expected peak area ratio. The limit of detection was 
defined as the analyte signal at least 3 times the height as compared to the background. 
Accuracy and precision of the method was calculated for three samples (1000 fmol, high 
point; 400 fmol, middle point; 100 fmol, low point). Accuracy was calculated by 
subtracting the average observed peak area ratio (analyte/internal standard) from the 
expected peak area ratio, followed by dividing the difference by the expected peak area 
ratio multiplied by 100. Accuracy was expressed as the % difference. Precision was 
calculated by dividing the standard deviation between samples by the mean observed peak 
area multiplied by 100, expressed as 100 - % coefficient of variation (100 - %CV). 
Validation results are presented below in the results. 
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5.3. Results 
5.3.1. Synthesis and structural characterization of EB-FAPy-dG adduct 
In our initial efforts to synthesize authentic standards of EB-Fapy-dG adducts, 2’-
deoxyguanosine (dG) was reacted with excess S,R-EB at pH 7.2, followed by base 
treatment with 1N NaOH to induce imidazole ring opening reaction. Although ESI+-
MS/MS analyses have revealed the presence of small amounts of EB-Fapy-dG (M = 356.1), 
they could not be purified due to the low adduct yields and the complexity of the reaction 
mixtures (results not shown). 
To improve EB-Fapy-dG yields, doubly protected dG (23 in Scheme 5-1) was 
employed as a starting material. This approach was previously employed by Rizzo et al in 
the synthesis of Me-FAPy-dG phosphoramidite.231  Following reaction with EB to generate 
N7-alkylated dG 24, the reaction mixtures were incubated in the presence of 1N NaOH to 
induce imidazole ring opening. Following neutralization and deprotection steps, reaction 
mixtures were separated by semi-preparative reverse phase HPLC. All major HPLC peaks 
were collected and subjected to HPLC-ESI+-MS/MS analysis. We found that the peaks 
eluting at 9.5, 10.7, and 11.8 min contained EB-FAPy as a free base (M = 240.1), while the 
HPLC fractions collected at 13.7, 14.1, and 14.8 min contained EB-FAPy nucleoside (M = 
356.1).   
HPLC purified EB-FAPy base and EB-FAPy-dG were first structurally 
characterized by MS infusion. The EB-FAPy base was characterized by the loss of water 
and the loss of water and carbon monoxide from the protonated parent molecules (m/z 
240.1 [M + H]+ → 222.1 [M – H2O + H]+ and 194.1 [M – H2O - CO + H]+. EB-FAPy-dG 
was characterized by a loss of sugar, a loss of sugar and water, and a loss of sugar, water, 
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and carbon monoxide from the protonated parent molecules (m/z 356.1 [M + H]+ → 240.1 
[M + H − dR]+, 222.1 [M + H – dR – H2O]+, and 194.1 [M – dR – H2O – CO + H]+ (Figure 
5-3A). 
EB-FAPy base and EB-FAPy nucleoside (Compound 25a and 25b in Scheme 5-1) 
were further structurally characterized by 1H-NMR and 1H-13C HSQC using a 600 MHz 
NMR. 1H-NMR confirmed the presence of the 2-hydroxybut-3-en-1-yl group as revealed 
by the observation of geminal alkene protons at 5.22 and 5.08 ppm, internal alkene at 5.82 
ppm, a quartet at 4.26 ppm (2-position of substituent), and a multiplet at 3.51 ppm (Figure 
5-4A). Further analysis of the EB-FAPy base by 1H-13C HSQC spectroscopy revealed 1H 
signals at 5.80, 5.22, and 5.08 ppm, which correlated to 13C signals at 117.6 and 134.5, 
confirming the presence of a terminal alkene (Figure 5-4B). Furthermore, the 1H-quartet 
at 4.74 ppm and a multiplet at 3.51 ppm correlated with carbon atoms observed at 63.2 and 
60.9 ppm, respectively, as expected for the 2-hydroxybut-3-en-1-yl substituent (Figure 5-
4B). 
The presence of formamido group was confirmed by the presence of 1H signals at 
7.78 and 8.10 ppm, which correlated to 13C signals at 164.2 and 166.2 ppm in the HSQC 
analysis (Figure 5-4B). Our observation of two major formamide peaks is consistent with 
the EB-FAPy molecule existing as a mixture of atropisomers caused by sterically hindered 
rotation about the C5-N5-bond (Figure 5-4A).224, 230, 231 Additional splitting of the 
formamide peaks can be attributed to the presence of another pair of rotamers caused by 
the slow rotation around the N5-CO bond respectively (Figure 5-4B). N1H, exocyclic 
amines at C2 and C4, and the alcohol OH were observed at 10.34, 6.47, 6.34, and 6.13 ppm 
respectively (Figure 5-4A).  
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1H-NMR and 1H-13C HSQC analysis of EB-FAPy nucleoside confirmed its 
structure as N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-
(2-hydroxybut-3-en-1-yl)formamidopyrimidine (Figure 5-5A). Additional peaks 
corresponding to 2’-deoxyribose were observed at 4.25, 4.03, 3.50, 3.20, 3.08, 2.89, and 
2.84 ppm. Compared to the NMR spectrum of the free EB-FAPy base, EB-FAPy 
nucleoside exhibited a small downfield shift of the protons corresponding to 2-hydroxybut-
3-en-1-yl substituent observed at 4.74 ppm and 3.68 ppm (Figure 5-5A). Furthermore, 1H 
signals corresponding to the formamide group were observed at 7.90, 7.83, and 7.77 ppm. 
However, HSQC spectra revealed no significant changes in 13C chemical shifts 
corresponding to the 2-hydroxybut-3-en-1-yl substituent (Figure 5-5B). As was the case 
for NMR spectra of EB-FAPy base (Figure 5-4A), multiple signals corresponding to the 
formamide protons were observed due to the presence of multiple atropisomers and 
rotamers of the adduct (Figure 5-5B).224, 230, 231   
Collectively, our mass spectrometry and NMR results are consistent with the 
structure of N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-
(2-hydroxybut-3-en-1-yl)formamidopyrimidine (EB-Fapy-dG, 4 in Scheme 2). 
Isotopically labeled analog, 15N3- EB-FAPy-dG, was synthesized analogously using 15N3-
dG as a starting material.    
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Figure 5-4: H-NMR (A) and HSQC (B) analysis of EB-FAPy base (25A) 
A. 
 
 
 
 
 
 
 
 
 
 
 
B. 
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Figure 5-5: H-NMR (A) and HSQC (B) analysis of EB-FAPy nucleoside (25B) 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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5.3.2.  nanoLC-ESI+-MS/MS method development and validation 
Authentic standards of EB-FAPy-dG and its 15N3- labeled isotopomer (15N3- EB-
FAPy-dG) were used to develop an isotope dilution nanoLC-ESI+-MS/MS method for 
accurate quantitation of the adduct in EB-treated DNA and in human cells exposed to EB. 
In our approach, DNA (50 μg) was fortified with known amounts of 15N3- EB-FAPy-dG 
internal standard, followed by enzymatic hydrolysis to release EB-FAPy-dG nucleoside.  
EB-FAPy-dG and its internal standard are enriched by solid phase extraction on 
Carbograph SPE cartridges. BD induced EB-Fapy adducts are very polar molecules and do 
not retain well on SPE columns. We found that among SPE cartridges tested (Isolute ENV+ 
(50 mg/1 mL, Biotage, Charlotte, NC), Sep-pack C18 (50 mg/1 mL, Waters Corp., 
Millford, MA), Strata X polymeric C18 (30 mg/ 1mL, Phenomenex, Torrance, CA)) 
graphitised carbon based packing (Carbograph, Grace or Hypersep Hypercarb, 
ThermoFisher Scientific) was the only one that allowed for good retention of EB-FAPy-
dG, leading to good SPE recovery (90.3%) and the removal of impurities that interfere with 
nanoLC-ESI+-MS/MS. 
SPE fractions containing EB-FAPy-dG were concentrated under vacuum and re-
constituted for isotope dilution nanoLC-ESI+-MS/MS analysis. We chose nanoLC because 
it allows for the best sensitivity in mass-spectrometry based approaches for DNA adduct 
detection.202 Because of its highly polar nature (calculated lopP = – 1.498), EB-FAPy-dG 
does not retain well on standard C18 packing materials. Furthermore, it exhibits a complex 
HPLC peak shape due to the presence of multiple rotamers/ atropisomers in its tructure. A 
number of HPLC solid phases (Synergi Max-RP (Phenomenex, Torrance, CA), Hypersil 
Gold aq (Thermo Scientific, Waltham, MA), Zorbax SB-C18 (Agilent technologies, Santa 
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Clara, CA) and solvent systems (0.05% acetic acid, 0.1 % formic acid, 15 mM ammonium 
acetate (pH 6.8) with methanol or acetonitrile) were tested. The best HPLC retention and 
peak shape were achieved with Synergi Hydro RP packing material (Phenomenex, 
Waltham, MA) (Figure 5-6). When using a gradient of acetonitrile in 5 mM ammonium 
formate, pH 4.5, EB-FAPy-dG eluted as a complex peak at 12.5-14 min (Figure 5-6). Our 
attempts to focus all EB-FAPy-dG rotamers into a single peak were unsuccessful as they 
compromised analyte retention and reduced the sensitivity. 
As noted above, MS/MS spectrum of EB-Fapy-dG (m/z 356.1, Figure 5-2A) 
revealed two major fragments corresponding to the neutral loss of deoxyribose sugar (m/z 
240.1) and both deoxyribose sugar and a molecule of water (m/z 222.1). 15N3-EB-Fapy-dG 
exhibited analogous signals at m/z 243.1 and 225, respectively (Figure 5-2B). Therefore, 
our quantitative nanoLC-ESI+-MS/MS methodology is based on selected reaction 
monitoring of mass transitions m/z 356.1 → 240.1 (analyte) and m/z 359.1 → 243.1 
(internal standard). Secondary (qualifier) SRM transitions (m/z 356.1 → 222.1 (analyte) 
and m/z 359.1 → 225.1 (internal standard) were used to confirm signal identities (Figure 
5-2B). Mass spectrometer parameters were optimized for maximum sensitivity upon 
infusion of synthesized standards.  
The newly developed nanoLC-ESI+-MS/MS method was validated by analyzing 
CT DNA samples spiked with known amounts of the analyte (40 – 2000 fmol) and 1000 
fmol internal standard. The nanoLC-ESI+-MS/MS limit of detection (LOD) was 10 fmol 
EB-FAPy-dG on column, while the limit of quantification was 25 fmol EB-FAPy-dG on 
column (Figure 5-7). The accuracy (% difference) of the method was calculated as 97.7%, 
91.7%, and 97.8% for the high, middle, and low validation points. The accuracy (% CV) 
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of the method was calculated as 0.3, 3.9, and 3.1 % CV for the high, middle, and low 
validation points. 
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Figure 5-6: NanoLC-ESI+-MS/MS analysis chromatogram of EB-FAPy-dG standard (200 
fmol on column) and 15N3-internal standard (200 fmol on column) in water showing two 
different MS/MS transitions of the protonated parent ion. 
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Figure 5-7: Validation of the developed EB-FAPy-dG nanoLC-ESI+-MS/MS assay. Calf 
thymus DNA (50 μg, in triplicate) was spiked with EB-FAPy-dG analyte (2000, 1000, 400, 
200, 100, and 40 fmol) and 1000 fmol 15N3-EB-FAPy-dG IS. Each sample was processed 
for EB-FAPy SPE enrichment as described in the Materials and Methods. The linearity of 
each validation replicate was determined by plotting the observed peak area ratio 
(analyte/internal standard) to the expected peak area ratio. The limit of detection was 
defined as the analyte signal at least 3 times the response as compared to the background. 
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5.3.3. EB-FAPy-dG adduct detection and quantitation in CT DNA  
To determine whether EB-Fapy-dG adducts can be formed in DNA, calf thymus 
DNA was treated with increasing concentrations of EB. Aliquots of treated DNA were 
taken and either analyzed directly or pre-treated with NaOH to induce FAPy adduct 
formation. The new isotope dilution nanoLC-ESI+-MS/MS methodology described above 
was employed to allow for accurate quantification. Samples pre-treated with NaOH 
exhibited concentration dependent formation of EB-Fapy-dG (Figure 5-8), with adduct 
numbers ranging from 1.8 to 234.5 EB-FAPy-dG adducts per 105 nucleotides, depending 
on EB concentrations. EB-FAPy-dG adduct numbers increased linearly between 10 μM to 
5 mM EB, followed by plateauing at 10 mM (Figure 5-8). In contrast, samples not pre-
treated with base contained much lower adduct numbers (e.g. 2.09 ± 0.07 EB-FAPy-dG 
per 106 nucleotides for sample treated with 5 mM EB) (Figure 5-9). 
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Figure 5-8: Concentration dependent formation of EB-Fapy-dG adducts in CT DNA 
treated with increasing concentrations of EB, followed by treatment with base (1N NaOH, 
1 h). 
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Figure 5-9: Representative trace of EB-FAPy-dG detected in CTDNA treated with 5 mM 
EB but not treated with 1 M NaOH. 
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To establish pH requirements for EB-FAPy formation following treatment with EB, 
and to determine what fraction of N7-EB-dG adducts converts to EB-FAPy, we have also 
quantified EB-Gua II as a free base using the previously reported methodology.200, 206, 563 
After treating CT DNA with 5 mM EB, the DNA was incubated at increasing pH (pH 7.5, 
8.0, 9.0, 10.0, 11.0, 12.0) to induce EB-FAPy formation, followed by heating at 37 oC for 
three days to release EB-Gua II as a free base. EB-Fapy adducts were detected in every 
CT-DNA sample, with levels measured at 20.9 ± 9.7, 26.1 ± 6.3, 27.4 ± 10.5, 322.7 ± 43.7, 
and 1397.1 ± 306.4 adducts per 106 nucleotides at pH 7.5, 9.0, 10.0, 11.0, and 12.0 (Figure 
5-10). EB-Gua II adducts revealed an inverse relationship to EB-FAPy-dG formation. EB-
Gua II levels in the same samples were measured at 1190.2 ± 89.3, 879.4 ± 207.6, 813.8 ± 
240.4, 512.3 ± 53.3, and 420.6 ± 223.5 adducts per 106 nucleotides at pH 7.5, 9.0, 10.0, 
11.0, and 12.0 respectively (Figure 5-10).   
 
 
 
 
 
 
 
 
 
 
 
267 
 
Figure 5-10: pH dependent EB-FAPy-dG and EB-Gua II adduct formation in CT DNA 
treated with 5mM EB, incubated at 37 oC for 3 days to allow EB-FAPy-dG formation, and 
then heated at 70 oC for 1 h to release remaining alkylated dG. 
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5.3.4. NEIL1+/+ and NEIL1-/- MEF EB cytotoxicity and EB-FAPy-dG formation in 
MEF cells 
As mentioned above, NEIL1 enzyme has been shown to repair of alkyl-FAPy-dG 
adducts such as those induced by Aflatoxin B1 (AFB1-FAPy-dG) and methylating agents 
(Me-FAPy-dG).573, 583 To elucidate the role NEIL1 plays in the repair of EB-FAPy-dG, we 
first performed cell cytotoxicity experiment to determine the toxicity of EB in wild type 
and NEIL1-/- MEF cells. Both cell types (in quadruplet) were treated with increasing 
amounts of EB from 0 to 20,000 μM for 3 hours, followed by incubating an additional 48 
hours and measuring cell viability using the Alamar Blue assay.441 NEIL1+/+ cells were 
found to be 1.5-fold less sensitive to EB (IC50 = 1456 ± 126 µM) than NEIL1-/- cells (IC50 
= 1006 ± 108 µM) (Figure 5-11).  
We next investigated EB-Fapy-dG and EB-Gua II adduct formation in both 
NEIL1+/+ and NEIL1-/- MEF cells treated with 500 μM of EB for 24 hours. After enzymatic 
digestion and adduct enrichment, both EB-FAPy-dG and EB-Gua II were quantified by 
LC-MS/MS analysis (Figure 5-12). NEIL1-/- cells had nearly 2-fold greater numbers of 
EB-FAPy-dG adducts (6.68 ± 0.51 EB-FAPy-dG per 106 nucleotides) compared to 
NEIL1+/+ cells (3.40 ± 0.032 EB-FAPy-dG per 106 nucleotides, Figure 5-12). Similarly, 
NEIL1-/- cells had nearly 3-fold greater EB-Gua II adducts (14.01 ± 1.52 EB-Gua II per 106 
nucleotides) compared to NEIL1+/+ cells (5.35 ± 0.22 EB-Gua II per 106 nucleotides, 
Figure 5-12).  
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Figure 5-11: Cell cytotoxicity to EB treatment in NEIL1+/+ and NEIL1-/- MEF cells. 
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Figure 5-12: Quantitation of EB-FAPy-dG and EB-Gua adducts in NEIL1+/+ and  
NEIL1-/- MEF cells treated with 500 μM EB. NEIL1-/- cells had nearly 2-fold greater 
numbers of EB-FAPy-dG adducts (4.45 ± 0.51 compared to 2.27 ± 0.032 EB-FAPy-dG per 
106 nucleotides, p-value < 0.01) and nearly 3-fold greater EB-Gua II adducts (14.01 ± 1.52 
compared to 5.35 ± 0.22 EB-Gua II per 106 nucleotides, p-value < 0.01).  
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5.4. Discussion  
1,3-butadiene (BD) is a known carcinogen present in cigarette smoke,556 
automobile exhaust,177 urban air, and still utilized in industrial processes.184 Previous 
studies have confirmed the reactive epoxide metabolites of BD, such as EB, DEB, and 
EDB, are all capable of alkylating nucleophilic positions of DNA.202, 558 The formation of 
covalent BD-DNA adducts are thought to be responsible for BD-induced carcinogenicity, 
as these adducts can lead to mutations during DNA replication.196, 197, 559-562 However, 
cationic N7-purinic adducts are not believed to be mutagenic because the N7-position of 
purines does not participate in Watson-Crick base pairing.252, 568 Furthermore, N7-adducts 
are susceptible to depurination, leaving apurinic sites which are an ubiquitous endogenous 
lesion that can be efficiently recognized and repaired.584-586 However, N7-adducts can 
undergo base-catalyzed imidazole ring opening to yield the hydrolytically stable ans 
strongly genotoxic N5-alkyl-Fapy-dG adducts. To our knowledge, no BD-derived FAPy 
adducts have been reported previously. Furthermore, it is unknown whether these adducts 
contribute to the observed mutagenic and genotoxic effects of BD. 
Authentic N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-
oxo-5-N-(2-hydroxybut-3-en-1-yl)formamidopyrimidine (EB-Fapy-dG) standard was 
prepared by a synthetic strategy analogous to published methods for other alkyl-FAPy 
adducts,231, 232 EB-FAPy free base and EB-FAPy-dG were characterized by UV-vis, ESI+-
MS/MS, 1H-NMR, and 1H-13C HSQC. NMR analysis of purified EB-FAPy revealed this 
adduct spontaneously undergoes isomerization in solution (Figure 5-1). Previous studies 
with AFB1-FAPy-dG and Me-FAPy-dG have shown the C5-N5 bond is capable of 
restricted rotation to form atropisomers, while the formyl N-CO bond is capable of rotation 
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as well to yield stable rotamers.224, 230, 231 Additional isomers include β- and α-anomers and 
regioisomers formed after ring-opening of the deoxyribose sugar and reclosure of the 
deoxyribose sugar involving the 5’-hydoxyl group to yield the pyranose nucleoside (Figure 
5-1).224, 587 Acid cleavage of the 5’-hydroxyl trityl-protecting group has been shown to 
rapidly catalyze anomerization and pyranose/furanose conversion in AFB1-FAPy-dG and 
Me-FAPy-dG containing DNA.230, 231 However, we did not observe additional peaks 
corresponding to the pyranose sugar, suggesting that our method’s trityl-deprotection  step 
(single exposure, 10 min at 0 oC) was not sufficient to stimulate acid-catalyzed deoxyribose 
ring opening required for nucleoside anomerization.  
Our investigation to find the optimal pH for imidazole ring opening of EB-N7-dG 
revealed that EB-FAPy-dG form at physiological pH, but the optimal pH for adduct 
formation is pH 12.0 (Figure 5-10). EB-FAPy-dG adduct levels in CT DNA treated with 
5 mM EB at pH 7.5 – 10.0 were below 30 adducts per 106 nucleotides, but significantly 
increased to 322.7 ± 43.7, and 1397.1 ± 306.4 adducts per 106 nucleotides at pH 11.0 and 
12.0 respectively. After EB alkylates the N7-position of dG, a positive charge is formed 
leading to the instability of the N-glycosidic bond and hydrolysis of the modified base from 
the DNA backbone. EB-Fapy-dG adduct formation competes with this spontaneous 
hydrolysis reaction, with imidazole ring opening greatly accelerated in presence of free 
base (OH-).  
We found that incubation at 37 oC for 72 h does not successfully release EB-N7-
dG adducts from DNA backbone, allowing EB-FAPy-dG adducts to form. When we 
quantified EB-Gua II released from the DNA backbone after this heating step, we detected 
less EB-Gua II compared to EB-FAPy-dG at every pH analyzed (Figure 5-13A). 
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Furthermore, we were unable to detect EB-FAPy base adduct formation when EB-treated 
DNA was not further incubated after treatment at pH 7.5 and 9.0 for only 1 hour (Figure 
5-13B). Previous in-vitro studies have shown that N5-alkyl-FAPy-dG adducts are 
hydrolytically stable at physiological pH, but significantly less stable under slightly acidic 
conditions. Christov et al observed complete depurination of methyl-FAPy-dG from a 13-
mer oligodeoxynucleotide after 48 h at pH 6.5, while the same lesion was stable at 
physiological pH.231  Therefore, it is conceivable that any formed EB-FAPy-dG would 
remain on DNA during our experiment, reaching detectable levels after three days of 
incubation.   
Failure to repair alkyl-FAPy-dG adducts is known to lead to significant biological 
consequences such as mutagenicity and genotoxicity. Methyl-FAPy-dG adducts have been 
identified as an inhibitor to DNA replication.227, 236, 237, 588 Ide et al investigated the bypass 
of a site-specific methyl-FAPy-dG adduct in an oligonucleotide by the Klenow fragment 
of E. Coli DNA polymerase 1 (KF), and observed the FAPy lesion inhibited the extension 
step of lesion bypass.237 Similarily, Rizzo et al investigated the bypass of methyl-FAPy-
dG by eukaryotic DNA polymeraeses α, β, and hPol δ/ PCNA, and observed the lesion 
blocked all three high fidelity polymerases at either the insertion or extension site.234 Rizzo 
et al also investigated the human translesion synthesis polymerases hPol η, κ, and 
hRev1/Pol ζ ability to bypass the lesion.234 All three TLS polymerases primarily inserted 
the correct base (2’-deoxycytidine), but hPol η and κ incorrectly inserted thymidine, 2’-
deoxyguanosine, and 2’-deoxyadenosine opposite the lesion and produced single 
nucleotide deletion products.234 Recently, Minko et al showed that the α-anomer of 
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nitrogen mustard-FAPy-dG adducts caused targeted G → T transversion mutations in 
primate COS7 cellsgeted mutations at a frequency.238  
Tudek et al observed that M13mp18 phage DNA containing methyl-FAPy-dG did 
not lead to an increase in GC mutations in E. Coli following SOS induction.227 Conversely, 
methyl-FAPy-dA lesions in the same vector lead to an increase in A → G transition 
mutations two-fold greater than GC mutation.227, 253 These results suggested that methyl-
FAPy-dA lesions mispairs with 2’-deoxycytidine in SOS-induced E. Coli while methyl-
FAPy-dG adducts were primarily a lethal lesion.227 Considering the structural similarity 
between EB-FAPy-dG and methyl-FAPy-dG, it is conceivable that the formation and 
accumulation of EB-FAPy-dG lesions could be lethal or lead to replication-induced 
mutations that will contribute to the observed mutagenicity and toxicity after BD exposure. 
Our cytotoxicity experiments showed NEIL1-/- MEF cells were 1.5-fold more 
sensitive to EB than NEIL1+/+ MEF cells, and therefore EB-FAPy-dG could potentially be 
a substrate for NEIL1 enzyme. NEIL1 is a BER bifunctional DNA glycosylase enzyme 
with the known substrates of thymine glycol, FAPy-G, FAPy-A, 8-oxoguanine, 5-
hydroxyuracil, dihydroxyuracil, spiroaminohydantioins, guanidinohydantoins, and AFB1-
FAPy-dG.259, 260, 573 To investigate whether EB-FAPy-dG was a substrate for NEIL1, we 
treated wild type (NEIL1+/+) and NEIL1-/- isogenic control MEF cells with 500 μM for 24 
h and quantified EB-FAPy-dG and EB-Gua II adducts. NEIL1-/- cells had 2-fold greater 
EB-FAPy-dG formation (6.7 ± 0.5 and 3.4 ± 0.03 EB-FAPy-dG per 106 nucleotides) and 
3-fold greater EB-Gua II levels (14.0 ± 1.5 and 5.3 ± 0.2 EB-Gua II per 106 nucleotides) 
compared to wild type cells (Figure 5-11). The increase in both EB-FAPy-dG and EB-Gua 
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II adduct in NEIL1-/- cells suggests that the NEIL1 enzyme can excise a portion of the 
formed EB-FAPy-dG within 24 hours.  
The modest difference in EB-FAPy-dG levels between NEIL1+/+ and NEIL1-/- cells 
suggests EB-FAPy-dG can be excised by additional BER enzyme(s). Structurally 
analogous alkyl-FAPy-dG adducts have been identified as substrates for other BER 
enzymes. For example, methyl-FAPy-dG has been identified as a substrate for both 
formamidopyrimidine DNA glycosylase (FPG) and E. Coli endonuclease IV.254, 569 We 
observed the selective release of EB-FAPy base from the backbone of EB-treated CT DNA 
by FPG, which was equally efficient as neutral thermal hydrolysis by 70 oC for 40 min 
(unpublished data). However, ethyl-FAPy-dG adducts were found to be excised 7-times 
slower by endonuclease IV than methyl-FAPy-dG, making it unlikely the much larger EB-
FAPy-dG is a substrate.256 Furthermore, endonuclease IV has been identified as selective 
for the α-anomer of methyl-FAPy-dG, suggesting it plays a specialized role in FAPy repair 
in general.569 Therefore, additional experiments are needed to identify all the enzymes and 
repair pathway(s) involved in the removal of EB-FAPy-dG. 
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Figure 5-13: Analysis of EB-Gua II and EB-FAPy-dG formation during different steps of 
sample processing. (A) In vitro pH-dependent EB-Gua II formation in CT DNA that was 
treated with 5mM EB, then incubated at 37 oC for 3 days to release alkylated dG. (B) pH-
dependent formation of EB-FAPy base without incubation at 37 oC for 3 days. No EB-
FAPy base was detected at pH 7.5 and 9.0. 
A.  
B.  
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5.5. Conclusions 
In conclusion, we studied the formation of ring open FAPy adducts in DNA treated 
with carcinogenic metabolite of 1,3-butadiene, 3,4-epoxy-1-butene. An accurate 
quantitative nanoLC/ESI+-MS/MS isotope dilution methodology was developed for the 
detection and quantitation of EB-FAPy-dG in vitro and in vivo. The applicability of this 
method was demonstrated by quantitation of EB-Fapy adducts in EB treated CT DNA 
followed by base treatment. We showed that EB-Fapy adducts preferentially form at pH 
11.0 and above, but adduct formation does occur at physiologically relevant pH. Finally, 
we observed a modest increase in EB-FAPy-dG formation in NEIL1-/- MEF cells compared 
to wild type MEF cells treated with 500 μM EB, suggesting that EB-FAPy-dG is a substrate 
of the BER enzyme NEIL1. We conclude that the EB-Fapy-dG is an adduct that can form 
under physiological conditions, and can therefore contribute to the observed genotoxicity 
and mutagenicity of BD.   
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6. Summary and Conclusions 
DNA is constantly under the threat of chemical modification by various 
endogenous and exogenous agents, leading to structural modification of nucleobases to 
form DNA adducts.3, 78 The formation of DNA adducts threatens the faithful replication of 
genetic material, as they can be replicated in an error-prone manner or inhibit DNA 
replication, ultimately leading to mutations or apoptosis, respectively.1, 2 To restore DNA 
to its native state, DNA adducts can be recognized and removed by DNA repair enzymes, 
preventing mutagenesis (Figure 1-1).5, 6 Elucidating the structure and repair mechanisms 
of each DNA adduct, as well as their effects on DNA replication , is critical in order to 
fully understand their biological consequences.  
DNA-protein cross-links (DPCs) are ubiquitous, super-bulky DNA lesions that 
form when proteins become irreversibly trapped on chromosomal DNA.262, 263 DPCs can 
be induced after exposure to various physical and chemical agents including ionizing 
radiation,274, 275 UV light,276-278 transition metal ions,279-282 halogenated hydrocarbons,283, 
284 environmental carcinogens,285 and common anticancer drugs (Figure 1-11).286-289 
Additionally, endogenous DPCs can also form as part of epigenetic regulation589 or as a 
result of DNA binding proteins (e.g. topoisomerases290, 291 and DNA polymerases)29, 30 
becoming trapped on DNA intermediates. DPCs can be induced by reactive oxygen species 
(ROS) produced during cellular respiration and inflammation,292-294 and by aldehyde 
byproducts of lipid peroxidation such as methylglyoxal295 and malondialdehyde.296 
Previous in vitro investigations have shown that DPCs interfere with key biological 
processes including DNA replication264-267 and transcription.268 Due to these properties, the 
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formation and accumulation of DPCs have been proposed to play a role in aging,269, 270 
cancer,271, 272 heart disease,269, 270 and neurodegenerative disorders.273  
Despite recent interest in the formation and biological consequences of DPCs, there 
are still many unanswered questions. The identity of the protein constituents susceptible to 
DPC formation and the cross-linking mechanisms have not been fully investigated for 
many DPC-inducing agents. Furthermore, the extent of DPC formation after exposure to 
DPC-inducing agents has not been accurately quantified. Finally, the mechanism(s) of 
active DPC repair remains controversial and is still not fully understood (Section 1-7). 
Towards these goals, in the first part of this Thesis, we investigated the identity of the 
protein constituents, the atomic connectivity, and the repair mechanism(s) of DPCs induced 
by bis-electrophiles and ROS.  
In Chapter 2 of this thesis, we istudied the formation and repair of DPCs induced 
by the active metabolites of cyclophosphamide, phosphoramide mustard (PM) and 
nornitrogen mustard (NOR, Chapter 2). Cyclophosphamide (CP) is a nitrogen mustard 
drug used as first-line chemotherapy treatment for cancers including lymphoma,373, 374 
leukemia,375 and myeloma.376, 377 CP is bioactivated by the cytochrome P450 
monooxygenases CYP2B5 and CYP3A4 to yield 4-hydroxy cyclophosphamide (4-OH-
CPA), which spontaneously breaks down to DNA-reactive metabolites PM and NOR, 
which are both capable of inducing DPCs (Figure 1-11, Scheme 1-6).381, 382  
We first utilized mass spectrometry-based proteomics technique to characterize the 
proteins susceptible to PM-induced DPC formation in cells (Section 2.2.4). Human 
fibrosarcoma cells (HT1080) were treated with 100 μM PM, and the proteins covalently 
trapped to chromosomal DNA were isolated using a modified phenol/chloroform 
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extraction methodology developed by our group. After mass spectrometry based 
proteomics analysis, a total of 134 proteins were found to form DPCs in the presence of 
PM (Table 2-1). Gene ontology analysis revealed that these proteins are involved in a 
diverse set of biological processes, including transcriptional regulation, DNA repair, 
chromosomal organization, apoptosis, and apoptosis (Figure 2-4). When our list of PM-
induced DPCs was compared to analogous lists of proteins crosslinked to DNA by DEB 
and cisplatin, a total of 47 proteins (30.9%) and 106 proteins (41.4%) proteins were found 
in common respectively (Figure 2-9). This comparison suggests that nitrogen mustards 
and platinum drugs may target similar proteins for cross-linking to DNA, while DEB 
targets a distinct group of protein targets. 
HPLC-ESI+-MS/MS analysis of complete proteolytic digests of PM-induced DPCs 
revealed N-[2-[cysteinyl]ethyl]-N-[2-(guan-7-yl)ethyl]amine (Cys-NOR-N7G) 
conjugates, confirming that PM-induced cross-linking occurred between the cysteine thiols 
of proteins and the N7-position of guanines in DNA. Authentic standards and internal 
standards (15N5-labeled guanine) of Cys-NOR-N7G were synthesized and used to develop 
a sensitive isotope dilution tandem mass spectrometry assay to perform absolute 
quantitation of PM-induced DPC formation (Section 2.2.1 and Section 2.2.5). When 
HT1080 cells were treated with an increasing amount of PM (0 – 1000 μM), a dose-
dependent increase in Cys-NOR-N7G was observed, confirming the assay could be utilized 
for quantifying PM-induced DPC formation (Figure 2-7). 
To begin elucidating the repair mechanism of PM-induced DPCs, we conducted 
cytotoxicity experiments using human cell lines deficient in a single DNA repair pathway 
and their corresponding isogenic controls (Section 2.2.2). Both human NER-deficient 
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(XPA and XPD cells) and HR-deficient (FANCD2 cells) were twice as sensitive to PM 
compared to wild type controls, suggesting these pathways may be involved in the repair 
of PM-induced DPCs (Table 2-2). To determine whether the observed sensitivity 
differences were caused by impaired removal of PM-induced DPCs, the cell lines were 
treated with 250 μM NOR, then allowed to recover for 4 hours to allow DPC repair. 
Quantitation of Cys-NOR-N7G revealed that the NER-deficient cell lines had significantly 
greater DPC levels (24.3 ± 3.5 and 18.7 ± 4.3 adducts/108 nucleotides for XPA and XPD 
cell lines respectively) as compared to XPD corrected isogenic controls (10 ± 2.3 
adducts/108 nucleotides), HT1080 (8.7 ± 1.5 adducts/108 nucleotides), PD20 (5.2 ± 1.3 
adducts/108 nucleotides), and PD20-corrected cells (5.6 ± 1.6 adducts/108 nucleotides) 
(Figure 2-8A). Furthermore, we measured changes in NOR-induced DPC repair over time 
by treating HT1080, XPA, PD20, and PD-corrected cells with NOR (250 μM), followed 
by allowing the cells to recover in drug-free media for 0, 4, 12, or 24 h. HPLC-ESI+-
MS/MS analysis revealed that XPA cells had the highest Cys-NOR-N7G adduct levels at 
each time point measured (14.7 ± 6.2, 19.2 ± 5.1, 10.2 ± 6.1, and 7.2 ± 3.3 at 0, 4, 12, and 
24 h, respectively (Figure 2-8B). Taken together, these results are consistent with 
nucleotide excision repair being required for active repair of cyclophosphamide-mediated 
DPCs.  
Reactive oxygen species (ROS) are radical and non-radical oxygen species formed 
by a partial reduction of oxygen. Examples of ROS include superoxide anions (O2-), 
hydrogen peroxide (H2O2), and hydroxyl radicals (•OH). ROS can be produced 
endogenously in cells during aerobic cellular respiration,338-340 immune response,341, 342 and 
inflammation,35 and are used as intracellular messengers in cellular signaling pathways.349-
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355 However, ROS can also oxidatively damage cellular biomolecules including DNA and 
proteins, leading to the direct covalent attachment of proteins to DNA to form DPCs. Some 
oxidative DNA lesions can undergo secondary reactions with nucleophilic sites of proteins, 
leading to the formation of hydrolytically stable DPCs.263, 356 Alternatively, DPCs can form 
directly via one electron addition reactions after the oxidation of DNA bases. For example, 
one electron oxidation of guanine can form radicals that react with lysine side chain of 
proteins to yield Nε-(guanin-8-yl)-lysine cross-links.361 Similarly, hydrogen abstraction 
from the C5-methyl group of thymidine yields 5-(uracilyl)methyl radical, which can 
undergo a radical addition reaction to the C-3 position of a neighboring tyrosine molecule 
to form thymidine-tyrosine cross-links.362, 363 
One biological event that stimulates a significant influx of ROS in the heart is 
myocardial infarction/reperfusion (MI, heart attack). MI occurs when the blood flow is 
decreased or stopped in a cardiac artery, restricting the delivery of oxygenated blood to the 
affected myocardium. Current MI therapies are based on reperfusion, or the re-opening, of 
the blocked artery, returning blood flow to the damaged myocardium. However, the sudden 
influx of oxygenated blood is associated with a rapid influx of ROS to the already damaged 
myocardium.366-368 During the MI, the lack of oxygen switches cardiomyocytes and cardiac 
fibroblast cells to anaerobic respiration mode.367, 369 Reperfusion-induced oxygen return 
triggers the sudden reactivation of the electron transport chain, producing a spike in ROS 
that can permeate from the mitochondrial matrix.367, 369 Furthermore, neutrophils 
accumulating at the damaged myocardium mediate tissue damage by releasing matrix-
degrading enzymes that release ROS.370-372 Despite the evidence that MI/reperfusion 
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significantly increase ROS levels in myocardium, at the time of this investigation there was 
no evidence that this leads to an increase in ROS-induced DPC formation. 
In Chapter 3 of this thesis, we investigated ROS-induced DPC formation caused by 
MI/reperfusion using the model of left anterior descending artery ligation/reperfusion 
surgery in rat.468, 487 To serve as controls, additional rats were subjected to a sham surgery. 
Immediately after reperfusion, cardiomyocytes and cardiac fibroblasts were separated by 
Langendorff reperfusion,590 allowing us to focus on DPC formation in cardiomyocytes, the 
functional unit of the heart. Rats that underwent LAD ligation/reperfusion exhibited 
elevated plasma levels of cTnI (>50 ng/mL), confirming severe MI (Table 3-1). 
Furthermore, plasma levels of oxidative stress biomarker 8-iso-PGF2α were increased 3-
5-fold in animals that underwent the LAD surgery as compared to sham surgery (Figure 
3-1), confirming that the reperfusion step led to an influx of ROS. Taken together, these 
results confirmed that our LAD ligation/reperfusion animals experienced an 
MI/reperfusion injury and could be further investigated. 
Previous research has demonstrated that the total digestion of ROS-induced DPCs 
yields thymine-tyrosine conjugates, 2-amino-3-(4-hydroxy-3-((1-((2R,4R,5R)-4-hydroxy-
5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl)methyl)phenyl)propanoic acid (dT-Tyr). We synthesized authentic dT-Tyr and 
[15N1,13C9]- dT-Tyr that were used to develop a sensitive and accurate isotope dilution 
nanoLC-ESI+-MS/MS assay to perform absolute quantitation of ROS-induced DPCs. We 
found that dT-Tyr amounts were significantly increased in cardiomyocytes of rats that 
underwent LAD ligation/reperfusion as compared to the sham group (35.7 ± 2.2 vs 18.2 ± 
1.5 dT-Tyr adducts per 108 nucleotides respectively, Figure 3-2B), supporting our 
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hypothesis that ischemia-reperfusion injury increases the levels of ROS-mediated DPCs in 
cardiomyocyte DNA. 
To simultaneously identify the proteins susceptible to DPC formation and quantify 
the changes in ROS-induced DPC formation, tryptic peptides were labeled with Themo 
Mass Tags (TMT) and performed quantitative proteomics. A total of 90 proteins 
participating in ROS-induced DPC formation were characterized, including ROS 
scavengers, contractile proteins, and regulators of apoptosis (Table 3-2). The majority of 
these proteins (N = 80, 88.9%) were increased in abundance at least 1.2-fold after LAD 
ligation/reperfusion as compared to sham surgery, with 21 (23.3%) of these proteins 
increasing in abundance at least 5-fold (Table 3-2). Quantitative proteomics analysis of the 
global proteome changes was significantly less pronounced, confirming that the increase 
in DPC formation after LAD ligation/reperfusion were not due to an overall increase in 
protein expression but rather an increase in DNA-bound proteins due to ROS production.  
Although significant progress has been made recently toward elucidating the 
cellular mechanisms of DPC repair, many questions remain unanswered. Specifically, 
Spartan metalloprotease was proposed to play a key role in replication-coupled repair of 
DPCs.428, 431, 512 Spartan is a mammalian homolog to the yeast Wss1, as Spartan shares both 
similar domain organization and a common evolutionary origin.428 Furthermore, purified 
Spartan protein has been shown to proteolytically digest the DNA-bound proteins histone 
H1, H2A, H2B, H3, and Hmg1 in the presence of ssDNA.431 However, at the time this 
investigation started, there was no direct evidence confirming that Spartan in involved in 
repair of chromosomal DPCs in vivo. 
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In Chapter 4 of this thesis, we utilized our nanoLC-ESI+-MS/MS assay for dT-Tyr 
to quantify ROS-induced DPC formation in tissues of 10-month-old wild type (SPRTN +/+) 
and hypomorphic (SPRTN H/H) mice. A significant (1.5 – 2-fold) increase in ROS-induced 
DPCs was observed in the brain, liver, heart, and kidney tissues of Spartan deficient mice 
(SPRTN H/H) as compared to their wild type controls. To our knowledge, this is the first 
direct evidence that Spartan is involved in repair of ROS-induced DPCs in normal tissues. 
Interestingly, we were unable to detect dT-Tyr in the spleen or thymus tissues, suggesting 
that in these tissues, there is an additional mechanism for DPC processing, e.g. 
immunoproteasome,545 this hypothesis required additional experimnets to be tested. 
In the second section of this Thesis (Chapter 5), we elucidated the structures of 
novel DNA adducts induced by human carcinogen 1,3-butadiene (BD). BD is a colorless, 
volatile gas commonly present in automobile emissions, urban and industrial air, and 
cigarette smoke.172, 177-179 BD is also an important raw material used in the production of 
synthetic rubber and plastics, especially tires used in the automobile industry.178, 179 
Epidemiological studies have found that exposure to BD is linked to an increased risk of 
leukemia, lymphatic and hematopoietic cancers, cardiovascular disease, and respiratory 
disorders.183-190  
BD is metabolically activated by cytochrome P450 monooxygenases to three 
inherently reactive epoxides: 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB), and 
1,2-dihydroxy-3,4-epoxybutane (EBD).192 These electrophilic species can react with 
nucleophilic bases of DNA to form covalent nucleobase adducts,558 which are thought to 
be responsible for BD-induced mutagenesis and carcinogenicity.196, 197, 559-562 Previously 
identified and structurally characterized BD-DNA monoadducts include N-7-(2-hydroxy-
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3-buten-1-yl)-guanine (EB-Gua I),200, 563 N-7-(1-hydroxy-3-buten-2-yl) guanine (EB-Gua 
II),200, 563 N7-(2,3,4-trihydroxybut-1-yl)-guanine (N7-THBG),206, 207 N1-(2,3,4-
trihydroxybut-1-yl)-adenine (N1-THB-Ade),564 1,4-bis-(guan-7-yl)-2,3-butanediol (bis-
N7G-BD)565,566 and 1,N6-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2′-
deoxyadenosine (1,N6-HMHP-dA).209, 567  
Alkylation of the N7-position of guanine by EB initially generates the positively 
charged DNA adduct N7-EB-dG.77, 252 This adduct is hydrolytically labile because of the 
intrinsic destabilization of the glycosidic bond, and is therefore subject to spontaneous 
depurination to release EB-Gua from the DNA backbone.33Alternatively, the C8 position 
of N7-EB-dG can be attacked by a hydroxyl anion, leading to imidazole ring opening and 
the formation of N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-
5-N-(2-hydroxybut-3-en-1-yl)formamidopyrimidine (EB-Fapy-dG) adducts (Figure 1-
9).233 However, at the time of this investigation, no BD-induced FAPy-dG adducts had 
been identified or structurally characterized. Furthermore, it was unknown whether these 
adducts contribute to the observed mutagenic and genotoxic effects of BD. 
In Chapter 5 of this thesis, we synthesized authentic standards and internal 
standards of N6-(2-Deoxy-D-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-
N-(2-hydroxybut-3-en-1-yl)formamidopyrimidine (EB-Fapy-dG), and structurally 
characterized these standards by UV-vis, ESI+-MS/MS, 1H-NMR, and 1H-13C HSQC 
(Figures 5-2A, 5-2B, 5-3A, and 5-3B). Our NMR analysis revealed that EB-FAPy-dG 
could exist as multiple isomers in solution, including atropisomers caused by restricted 
rotation around the C5-N5 bond and distinct rotamers caused by rotation around the formyl 
N-CO bond. However, our NMR analysis revealed that EB-FAPy-dG does not 
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spontaneously interconvert between β- and α-anomers as observed with other FAPy-dG 
adducts.224, 587 
The synthetic EB-FAPy-dG and its 15N-labeled analogue were used to develop a 
nanoLC-ESI+-MS/MS assay in order to detect EB-FAPy-dG formation in EB-treated DNA 
and living cells. Using this novel assay, we observed a linear increase in EB-FAPy-dG 
adducts in CT DNA treated with increasing concentrations of EB under basic conditions 
(Figure 5-5). Furthermore, we were able to detect in vitro EB-FAPy-dG formation at pH 
7.5 (Figure 5-6), proving that EB-FAPy-dG could form under physiologically relevant 
conditions. However, the highest EB-FAPy-dG adduct levels were detected at pH 12.0 
(Figure 5-6). 
Recently, the human base excision repair (BER) enzyme endonuclease 8-like 
protein 1 (NEIL1) was identified as the enzyme that excises the bulky aflatoxin B1-FAPy-
dG adduct.573 Given that NEIL1 has also been implicated as the BER enzyme that removes 
Me-FAPy-dG in mammalian cells,572 we hypothesized that EB-FAPy-dG could be a 
substrate for NEIL1 mediated repair. When NEIL1-/- and isogenic corrected (NEIL1+/+) 
MEF cells were treated with 500 μM EB for 24 hours, we detected increased formation of 
EB-FAPy-dG in the NEIL1-deficient cells (4.45 ± 0.51 EB-FAPy-dG per 106 nucleotides) 
as compared to repair proficient wild type fibroblasts (2.27 ± 0.032 ± 0.03 EB-FAPy-dG 
per 106 nucleotides, Figure 5-8). 
In summary, the studies presented herein employed a combination of organic 
synthesis and mass spectrometry based analytical methodologies to investigate the 
formation and repair of DNA lesions in vitro and in vivo. Mass spectrometry-based 
proteomics techniques were utilized to identify the proteins susceptible to PM- and ROS-
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induced DPC formation (Chapters 2 and 3). The atomic connectivity of these lesions was 
then confirmed by analyzing the complete digestion products of PM- and ROS-induced 
DPCs (Cys-NOR-N7G and dT-Tyr respectively) by HPLC-ESI+-MS/MS (Chapters 2 and 
3). Authentic standards and internal standards of Cys-NOR-N7G and dT-Tyr were 
synthesized and to develop sensitive and accurate isotope dilution tandem mass 
spectrometry assays to perform absolute quantitation of PM- and ROS-induced DPCs 
(Chapters 2 – 4). Specifically, these assays were used to confirm MI/reperfusion leads to 
an increase in ROS-induced DPCs (Chapter 3) and to begin elucidating the repair 
mechanisms of PM- and ROS-induced DPCs. Overall, our initial repair experiments 
suggest that NER (Chapter 2) and the metalloprotease Spartan (Chapter 4) are crucial for 
DPC repair in vivo. Finally, we successfully synthesized and structurally characterized a 
novel BD-induced DNA adduct EB-FAPy-dG (Chapter 5) and developed a sensitive 
isotope dilution tandem mass spectrometry assay for its detection in cells and treated DNA 
(Chapter 5). To our knowledge, this is the first report of a BD-induced FAPy adduct, and 
future studies will examine whether BD-induced FAPy adducts contribute to mutagenicity 
and carcinogenicity of BD.  
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7.  Future Directions 
7.1. Investigating the cardioprotection potential of the natural products 
Ruscogenin and Ophiopogonin D via preventing ROS-induced 
DPC formation after reperfusion injury  
As described in Chapters 3 and 4, we have developed a sensitive stable isotope 
dilution nanoLC-MS/MS assay for the absolute quantification of endogenous ROS-
induced and IR-induced DNA-protein cross-linking in cells and tissues. ROS- and IR-
induced DPCs are formed by hydroxyl-radical hydrogen abstraction from the 5-methyl 
position of a thymidine base to yield a reactive thymidine radical, which undergoes a one-
electron addition to the 3-position of a tyrosine to yield a stable methylene linkage (Scheme 
3-2). Subsequent hydrogen abstraction from the 3-position of tyrosine re-aromatizes the 
phenol ring to yield a stable DNA-protein cross-link (Scheme 3.2). The protein and DNA 
constituents of IR- or ROS-induced DPCs can be enzymatically digested to 2-amino-3-(4-
hydroxy-3-((1-((2R,4R,5R)-4-hydroxy-5-(hydroxy-methyl)tetrahydrofuran-2-yl)-2,4-
dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl) phenyl)propanoic acid (dT-Tyr, Scheme 
3-1), which can serve as a biomarker of ROS-induced DPC formation.   
Using our nanoLC-ESI+-MS/MS dT-Tyr assay, we observed an increase in ROS-
induced DPC formation in cardiomyocytes following LAD ligation/reperfusion (Figure 3-
2). The assay was sensitive enough to detect changes in ROS-induced DPC formation 
caused by reperfusion injury. Therefore, the same methodology could be used to 
investigate the efficacy of novel antioxidant therapies to prevent reperfusion-induced ROS 
accumulation and subsequent DPC formation.  
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Extracts of the plant Ophiopogon japonicus have been used for centuries in 
traditional Chinese herbal medicine to treat cardiovascular disease. Studies have shown 
that O. japonicus extract may provide cardiovascular protection through anti-
arrhythmia,591 ROS scavenging,592, 593 inhibiting platelet aggregation,594 and improving 
microcirculation.594 One active component of O. japonicus, the steroidal glycoside 
Ophiopogonin D (Figure 7-1), has been shown to partially protect endothelial cells from 
H2O2-induced oxidative stress595 and to prevent doxorubicin-induced cardiac toxicity.596 
Our collaborator Professor Boyang Yu (Chinese Pharmaceutical University) is currently 
investigating an additional steroidal glycoside, Ruscogenin (Figure 7-1), which has anti-
inflammatory and anti-arrhythemia properties.594, 597 However, neither Ophiopogonin D 
nor Ruscogenin have been previously investigated as an antioxidant therapy to mitigate 
reperfusion injury.  
We propose to investigate Ophiopogonin D and Ruscogenin’s potential as a 
preventative antioxidant therapy following ischemia/reperfusion injury. A set of age-
matched Sprague Dawley rats (N = 5) will be administered either Ophiopogonin D or 
Ruscogenin (5, 10, or 20 mg/kg) via intraperitoneal injection every other day for seven 
consecutive days.596 The other set of rats (N = 5) will remain untreated. Following the 
pretreatment period, all rats will undergo an LAD ligation/reperfusion procedure, followed 
by the isolation of cardiomyocytes by Langendorff reperfusion and extraction of ROS-
induced DPCs as described in Section 3.2. ROS-induced DPCs will then be enzymatically 
digested, and dT-Tyr will be quantified as a biomarker of ROS-induced DPC formation 
(Section 3.2). If pretreatment with the two natural products successfully reduces ROS 
formation, we would expect to see a decrease in dT-Tyr levels after pretreatment compared 
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to LAD ligation/reperfusion only at every concentration investigated. If pretreatment with 
the steroidal glycosides does not prevent ROS accumulation, we would expect to observe 
similar dT-Tyr levels as observed in Section 3.3.2 regardless of the condition.  
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Figure 7-1: Structures of the cardioprotective Ruscogenin and Ophiopogonin D, active 
metabolites found in O. japanicus extract. 
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If either Ophiopogonin D or Ruscogenin successfully prevents ROS-induced DPC 
formation, a series of structural analogs can be analyzed to perform a structure-activity 
relationship (SAR) study. For example, a series of novel Ophiogponones, a structurally 
similar active metabolite found in O. japonicus extract that shares a 3-benzyl chromone 
skeleton,598 can be synthesized from commercially available chromone via regioselective 
zincation (Scheme 7-1).599, 600 Similarly, a series of Furostane derivatives, another active 
metabolite in O. japonicus extract that shares a steroidal backbone,598 can be synthesized 
by opening the spiroketal moiety of commercially avaialable Diosgenin.601 The efficacy of 
each novel compound can be first tested by pretreating cardiomyocytes in culture with the 
novel glycoside, followed by treating cells with hydrogen peroxide and measuring changes 
in ROS-induced DPC formation by dT-Tyr quantitation. As a control, dT-Tyr levels will 
be quantified in cells pretreated with Ophiopogonin D or Ruscogenin and treated with 
hydrogen peroxide. Only analogs that decrease DPC formation better than the controls will 
be further investigated in the animal model experiments described above. 
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Scheme 7-1: Synthetic strategy for synthesizing series of Ophiopogonin D and Ruscogenin 
analogs. 
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7.2. Quantitative proteomic analysis and comparison between 
chromosomal DPCs and mitochondrial DPCs induced by 
reperfusion injury 
As described in Section 3.3.4, we utilized quantitative proteomics to 
simultaneously identify and relatively quantify ROS-induced DPC formation after 
reperfusion injury in a rat model of myocardial infarction/reperfusion (LAD 
ligation/reperfusion). A total of 90 proteins were found to participate in ROS-induced DPC 
formation, with increased crosslinking following the simulated heart attack. Similar 
analysis of global proteome abundance revealed very modest changes in protein expression 
after LAD ligation/reperfusion compared to sham surgery, confirming that the increases in 
DPC formation after LAD ligation/reperfusion was caused by an increase in ROS-mediated 
cross-linking and not total protein abundance (Table 3-3). However, our DPC extraction 
methodology completely lyses both the nuclei and the mitochondrial membranes of 
cardiomyocytes, and therefore cannot discriminate mitochondrial DPCs (mtDPCs) from 
chromosomal DPCs (cDPCs). Considering that DPCs are known to interfere with DNA 
replication264, 266, 267 and transcription,268 and the formation and accumulation of DPCs are 
thought to contribute to the etiology of cardiovascular disease after myocardial 
infarction,170, 171, 270 it is important to distinguish between mitochondrial and chromosomal 
DPCs.  
To identify proteins only covalently cross-linked to either chromosomal DNA or 
mitochondrial DNA, we can modify our DPC extraction methodology to separate nuclei 
and mitochondria from other organelles. In short, cardiomyocytes can be lysed using a 
weak hypotonic cell lysis solution that breaks the cell membrane but maintains the integrity 
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of nuclei and mitochondria.288, 440 Organelles can then be separated by ultracentrifugation 
(> 20,000 RPM) through sucrose gradients following established protocols.602, 603 With the 
nuclei and mitochondria isolated from each other, cDPCs and mtDPCs can be separately 
extracted using Qiagen cell lysis solution and the protocol described in Section 3.2. Tryptic 
digestion and TMT labeling of the cDPCs and mtDPCs would allow for simultaneous 
identification of the proteins susceptible to ROS-induced DPC formation in both 
organelles, and allow for relative quantitation to identify the proteins most susceptible to 
DPC formation (Section 3.2). Relative increases in ROS-induced DPC formation in both 
organelles can also be confirmed by absolute quantitation of dT-Tyr using our nanoLC-
ESI+-MS/MS methodology described above.  
We hypothesize that many of the mitochondrial proteins found in Table 3-2 will be 
identified as constituents of cDPCs. As described in Section 3.4, several proteins such as 
pyruvate dehydrogenase are known to be recruited to the nucleus during reperfusion injury 
generate nuclear acetyl CoA, which is required for histone acetylation and the activation 
of transcription. In contrast, other proteins such as Enoyl-CoA hydratase, 2,4-dienoyl-CoA 
reductase, and ATP synthase have no known function in the nucleus. To confirm the 
translocation of these mitochondrial proteins under the conditions of oxidative stress, 
future fluorescence microscopy experiments can be conducted. Specifically, primary 
cardiomyocytes can be treated with hydrogen peroxide (10 mM) and cells will be fixed at 
various times post treatment for primary antibody incubation. Incubation with a FITC-
labeled secondary antibody would then allow visualization of the protein by standard 
fluorescence microscopy technique.604 Co-staining with 4',6-diamidino-2-phenylindole 
(DAPI) and Rhodamine 123 would confirm the location of the nucleus and mitochondria, 
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respectively, and confirm the translocation of the proteins of interest from the mitochondria 
to the nucleus. We anticipate that mitochondrial proteins identified as constituents of 
cDPCs will be localized to mitochondria under the conditions of oxidative stress. 
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7.3. Elucidate the role of Spartan metalloprotease in the repair of ROS-
induced DPCs in cardiomyocytes 
As discussed in Section 1.7 and Chapter 4, Spartan metalloprotease is currently 
being investigated as the enzyme that digests the protein constituent of a DPC to smaller 
lesions to allow for their repair. Our collaborator Prof. Yuichi Machida (Mayo Clinic) has 
detected Spartan protein in the liver, brain, lung, and kidney of mice by western blot 
analysis,514 but did not investigate Spartan expression in the myocardium. In Section 4.3.4, 
we observed an increase in dT-Tyr in the myocardium of SPRTNH/H mice compared to 
wild type mice (46.02 ± 6.08 and 29.89 ± 3.68 adducts per 108 nucleotides respectively, 
see Figure 3-2B), suggesting that Spartan may play a role in the repair of ROS-induced 
DPCs in cardiomyocytes and cardiac fibroblasts.  
To test Spartan’s presence in myocardium, we will first isolate cardiomyocytes and 
cardiac fibroblasts from the hearts of wild type mice as described in Section 3.2, followed 
by standard western blot analysis of the proteome using mouse monoclonal anti-Spartan 
antibody (IgG2a, clone 11A).539 Based on our nanoLC-ESI+-MS/MS data dT-Tyr conjugates 
presented in in Chapter 4 (Figure 4-6B), we anticipate to detect Spartan protein in mouse 
cardiomyocytes and/or cardiac fibroblasts. Additionally, mRNA can be isolated from both 
cell types using a commercially available kit (Oligotex mRNA mini kit, Qiagen, Hilden 
Germany), and SPRTN mRNA levels can then be quantified using Real-Time Quantitative 
Polymerase Chain Reaction (RT-qPCR) to confirm Spartan expression.605 Spartan 
expression levels have been previously measured using the forward and reverse primers 
5΄-GGA CCT TGT AGA GAC TCT TTT G-3΄ and 5΄-CCT CAT CAT GGA AAG TGT 
GG-3΄ respectively.514 Given the limited sensitivity of the currently available Spartan 
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antibody,429, 514, 539 it is possible that we will be unable to detect Spartan by western blot 
but will observe SPRTN gene expression.  
In the current model of DPC repair, Spartan mediated DPC repair is linked to DNA 
replication because it was shown to be recruited to stalled replication forks (Chapter 
1.7).430, 431, 513 Since cardiomyocytes cannot replicate, a different repair mechanism must 
be in play in cardiac tissues. Our future studies will investigate possible recruitment of 
Spartan to DPC lesions in non-replicating cells. Furthermore, depletion of Spartan by 
siRNA methodology could be performed to investigate Spartan’s role in maintaining the 
genomic stability of myocardium.429 
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7.4. Determine the contribution of the proteasome in the digestion of 
the protein constituent of DPCs in DPC repair 
Using our sensitive dT-Tyr nanoLC-MS/MS assay, we observed a slight increase 
(1.5 – 2 fold) in dT-Tyr conjugates in the brain, liver, heart, and kidneys of SPRTN-
deficient hypomorphic mice compared to wild-type mice (Figure 4-6B in Chapter 4). 
Furthermore, we were unable to detect dT-Tyr adduct in the thymus and spleen tissues. 
Our data suggests that the metalloprotease Spartan is not the only protease involved in the 
digestion of the protein constituents of DPCs to allow for repair. Although Nakano et al 
was unable to detect ubiquitinated FA-induced DPCs by western blot,424, 425 studies in other 
laboratories suggested that the proteasome may play a role in DPC repair when Spartan is 
compromised.309, 426, 427 Specifically, In contrast, Baker et al and Quievryn et al observed 
a reduced repair of a Dmnt1-containing plasmid427 and FA- and Cr(IV)-induced DPCs309, 
522 in cells when the 26S proteasome was pharmacologically inhibited. Using our nanoLC-
MS/MS assay, we will test whether the pharmacological inhibition of the proteasome in 
cultured cells will lead to an increase in dT-Tyr adduct levels.  
Furthermore, in collaboration with Dr. Deborah Ferrington (UMN, Dept. of 
Opthamology and Visual Neuroscience), we are also investigating whether mouse 
knockouts of the 20S proteasome subunit beta-1i, low molecular mass protein-7, or 
multicatalytic endopeptidase complex subunits (LMP2, LMP7, and MECL genes 
respectively), which are catalytic subunits of the immunoproteasome, will lead to an 
increase in dT-Tyr in mouse tissues. Taken together, an increase in dT-Tyr adduct in cells 
and tissues with reduced proteasome activity will provide direct evidence that the 
proteasome plays a role in the repair of endogenous ROS-induced DPCs.  
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To investigate the role of the proteasome in DPC repair, we will pretreat MEF5 and 
MEF7 cells with lactacystin, a potent small molecule inhibitor of the 20S subunit of the 
proteasome (Section 4.3.2). The cells will then be irradiated as described in Section 4.2 
and incubated an additional 48 hours to allow the repair of any IR-induced damage. 
Following 48 hours, IR-induced DPCs will be extracted, and dT-Tyr will be quantified by 
nanoLC-MS/MS as described in Chapter 3 and 4. Control cells will be irradiated to but 
not treated with inhibitor. We expect to observe a modest increase in dT-Tyr levels in 
irradiated MEF7 cells compared to MEF5 cells, providing additional evidence that Spartan 
plays a role in global DPC repair. When the cells are pretreated with lactacystin, we expect 
to see a large increase in dT-Tyr levels in the irradiated MEF7 cells, but only a modest 
increase in dT-Tyr MEF5 cells compared to the irradiated controls. This is because MEF7 
cells possess only one floxed copy of the SPRTN gene, leading to a decrease in Spartan 
levels. Therefore, MEF7 cells pretreated with lactacystin will be deficient in two proteases 
capable of digesting the protein constituent, therefore leading to the largest accumulation 
of IR-induced DPCs.  
As described in Section 5.3.3, we were unable to observe dT-Tyr analyte in mouse 
spleen and thymus tissues, indicating that the immunoproteasome present in lymphatic 
tissues may participate in DPC repair. To confirm the contribution of the 
immunoproteasome, we will quantify dT-Tyr levels in the spleen and thymus of wild type 
and LMP2-/-, LMP7-/-, and MECL-/- mice. We expect to observe an increase in dT-Tyr 
levels in both the spleen and thymus of mice deficient in either subunit, indicating that the 
immunoproteasome contributes to the repair of DPCs. Failure to observe any increase in 
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dT-Tyr adduct levels in the knockout mice would indicate that another protease(s) must 
contribute to the digestion of DPCs. 
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7.5. Identify additional biomarkers of ROS-induced DPC formation 
Our studies described in Chapter 3 and 4 employed thymidine-tyrosine conjugates 
(dT-Tyr, Scheme 3-1) as biomarkers of ROS-induced DPC formation. However, exposure 
to hydroxyl radicals and other reactive oxygen species induces many other DNA lesions, 
including electrophilic species capable of DPC formation.31, 34 As described in Section 1.2 
and Chapter 4, cross-links between lysine and spiroiminodihydantoin (5-Lys-Sp and 8-
Lys-Sp),293 lysine and guanidinohydantoin,294 and serine and oxanines (Ser-Oxa)606 have 
been structurally characterized in vitro (Scheme 3-1 respectively). To our knowledge, these 
types of DPCs have not been detected in living cells or tissues. In our future studies, we 
can develop sensitive isotope dilution tandem mass spectrometry assays for these 
additional DPC lesions. Given that spirodihydantoins have been shown to be stable at 
physiological pH, and lysine is one of the most abundant residues in proteins, 5-Lys-Sp 
and 8-Lys-SP (Scheme 3-1) is anticipated to one of the more abundant ROS-induced DPC 
cross-links.  
Authentic standards of both 5-Lys-Sp and 8-Lys-Sp can be simultaneously 
synthesized by reacting a mixture of 2’-deoxyguanosine/N-acetyllysine with Na2IrCl6 and 
300 watt IR, while singlet oxygen oxidation of 2’-deoxyguanosine with Rose Bengal or 
methylene blue in the presence of N-acetyllysine and 300 watt IR exclusively produces 5-
Lys-Sp.293 The published high flow LC-MS method for 5-Lys-Sp293  can serve as our 
starting point for the development of a more sensitive nanoLC-ESI+-MS/MS. Both 5-Lys-
Sp and 8-Lys-Sp can be detected simultaneously. Furthermore, the methodologies for 
enzymatic digestion of lesion-containing DNA and enrichment of both lesions has been 
previously developed using a synthetic DNA oligonucleotide containing the lesion. Due to 
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the increased sensitivity of nanoLC-ESI+-MS/MS, we anticipate that it can be used to study 
the formation of these adducts in cells treated with hydrogen peroxide and in animal tissues.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
305 
 
7.6. Derivatization of EB-FAPy-dG to improve sensitivity of nanoLC-
ESI+-MS/MS assay 
As described in Chapter 5, we have developed a sensitive and specific nanoLC-
ESI+-MS/MS assay to detect butadiene-induced EB-FAPy-dG adducts in vitro. Using this 
assay, we detected EB-FAPy-dG formation in EB-treated CTDNA at physiological pH 
(Section 5.3.3) and in EB-treated mammalian cells (Section 5.3.4). However, the LOQ of 
EB-FAPy-dG is 25 fmol on column (Figure 5-6), showing that this methodology is 
insufficient for in vivo experiments. Furthermore, we were only able to detect EB-FAPy-
dG in cells treated with relatively high concentrations of EB (> 100 μM), which is 
significantly higher than exposure levels expected in animal experiments.  
In order to detect EB-FAPy-dG formation in cells treated with physiologically 
relevant levels of EB, or in animals or individuals exposed to BD, we need to improve the 
LOQ of the assay to sub-fmol levels. We attributed the low sensitivity of our HPLC-ESI-
MS/MS method for EB-FAPy-dG to poor ionization of the molecule under ESI conditions. 
Changing to different HPLC solvents and columns did not improve the sensitivity (Section 
3.5). Previous analysis of poorly ionizable analytes such as steroids, glycosides, ribosides, 
and nucleosides have utilized chemical derivatizations to improve both chromatography 
and sensitivity.607-610 However, we failed to successfully derivatize the formamide group 
of EB-FAPy-dG, and successful protection of the 2’-exocyclic amine with N,N-
dimethylformamide dimethyl acetal significantly decreased sensitivity (unpublished 
results).   
Considering the 2’-exocyclic amine could be protected on both dG and EB-FAPy-
dG, an acetal or aldehyde with a permanent positive charge could be used to derivatize EB-
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FAPy-dG. Unfortunately, there are no commercially available to reagents attempt these 
reactions. However, several esters including 4-ethoxycarbonyl-1-methyl-pyridinium 
iodide, 1-ethyl-4-(methoxycarbonyl)pyridinium iodide, and 4-ethoxycarbonyl-1-
isopropyl-pyridinium iodide, which can be reduced to aldehydes, are available from Sigma 
Aldrich (St. Louis, MO) (Scheme 7-2). Specifically, these esters could be reduced with 
DIBAL at low temperatures (-70 oC) to afford aldehydes as described previously (28 in 
Scheme 7-2).611-613 The synthesized products need to be fully structurally characterized by 
1H-NMR and C-NMR, specifically by observing the presence of the protecting group and 
the aldehyde peak at 9 – 10 ppm and 160 – 170 ppm respectively.  
The synthesized aldehydes can then be reacted with EB-FAPy-dG following the 
same conditions used for N,N-dimethylformamide dimethyl acetal protection described in 
Section 5.3.1 (26 in Scheme 7-2). Successful derivatization of EB-FAPy-dG can be 
confirmed by ESI MS, 1H-NMR, and 13C-NMR. The derivatives (26 in Scheme 7-2) would 
then be purified by HPLC (Section 5.2), and the pure product used to develop a new 
nanoLC-ESI+-MS/MS assay. Since the derivatized EB-FAPy-dG should be less polar than 
the unprotected nucleoside, more common column packing material such as XDB C18 or 
SB-300 C18 material could be investigated. If the derivatized EB-FAPy-dG is not stable 
enough to purify by column or HPLC, the N,N-dimethylformimidamide protecting group 
can be reduced to N,N-dimethylmethanediamine by sodium borohydride or sodium 
cyanoborohydride (27 in Scheme 7-2).   
To confirm that the novel aldehyde(s) (26 in Scheme 7-2) can derivatize EB-FAPy-
dG formed in vitro or in vivo, EB-FAPy-dG (Section 5.3.2) can be reacted with 20x excess 
reagent and analyzed by the developed assay. Successful detection of the derivatized EB-
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FAPy-dG would confirm that the DNA digestion and enrichment procedure successfully 
removes any interfering contaminates. SPE recovery after derivatization, synthesis and 
purification of an isotopically-labeled internal standard, and validation of the assay could 
then be performed to complete assay development before attempting to quantify EB-FAPy-
dG formation in animal or humans exposed to BD.    
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Scheme 7-2: Synthetic strategy to derivatize the exocyclic amine of EB-FAPy-dG to 
improve adduct sensitivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
309 
 
7.7. Site-specific incorporation of EB-FAPy-dG in DNA for structural 
and thermodynamics studies 
Previous studies with site-specific incorporated AFB1-FAPy-dG, NM-FAPy-dG, 
and Me-FAPy-dG lesions in duplex DNA have revealed characteristic physical properties. 
For example, all three lesions in duplex DNA showed a biphasic thermal melting profile,231, 
232, 245 with the β-anomer of the FAPy-dG lesion significantly stabilizing duplex DNA.232 
Furthermore, synthetic oligos containing a NM-FAPy-dG lesion exist in an anomeric ratio 
of 1:1 (α : β), but will slowly equilibrate to approximately 80% β-anomer.232 Finally, the 
equilibrium of the E and Z formamide isomers of FAPy-dG is controlled by the neighboring 
nucleotide and subsequent major groove hydrogen bonding interactions.614 However, we 
are unable to synthesize DNA oligomers containing an EB-FAPy-dG lesion using EB-
FAPy-dG nucleoside prepared in our work (Scheme 5-1) due to the presence of multiple 
secondary alcohols. Therefore, to investigate the biophysical properties of EB-FAPy-dG 
similar to every other FAPy-dG lesion, we will have to modify our synthetic strategy.    
To synthesize the EB-FAPy-dG phosphoramidite, we need to modify our scheme 
to alkylate protected dG (3, Figure 5.2) with an alcohol protected EB analog. Two potential 
EB analogs we could synthesize include 1-(tosyloxy)but-3-en-2-yl acetate and 1-
bromobut-3-en-2-yl acetate synthesized from 4-vinyl-1,3-dioxolan-2-one or 1-bromobut-
3-en-2-ol starting material respectively (29 and 30 in Scheme 7-3 respectively). Successful 
alkylation and base catalyzed imidazole-ring opening to 31 can be confirmed by mass spec 
infusion, 1H-NMR, and 13C-NMR. After obtaining the alcohol-protected EB-FAPy-dG 
nucleoside, the phosphoramidite can be synthesized following previously developed two-
step synthetic schemes (32 in Scheme 7-3).615 Finally, the EB-FAPy-dG adduct can be site-
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specifically incorporated into DNA using solid phase synthesis. We will prepare synthetic 
oligomer (5′-d(CGGACXAGAAG)-3′), where X = EB-FAPy-dG phosphoramidite, which 
was developed for previous NMR chemical perturbation analysis (Scheme 7-3).616 
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Scheme 7-3: Synthetic strategy to site-specifically incorporate an EB-FAPy-dG adduct 
into an 11-mer DNA oligo for structural studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
312 
 
After successfully incorporating the EB-FAPy-dG lesion into a synthetic 
oligonucleotide, we can perform DNA thermal stability studies to calculate the change in 
melting temperature (ΔTm) caused by the lesion. Specifically, a solution of unsubstituted 
DNA oligos 5′-d(CGGACGAGAAG)-3′ and 5′-d(CTTCTTGTCCG)-3’ will be heated 
from 5 to 90 oC at a rate of 1.0 oC/min while monitoring the UV absorbance at 260 nm. 
The Tm value of the 12-mer duplex can be determined by taking the first derivative of the 
UV absorbance vs temperature curve. When the EB-FAPy-dG-containing oligo 5′-
d(CGGACXAGAAG)-3′ is investigated, we expected to observe two Tm values 
corresponding to the α and β anomer similar to AFB1-FAPy-dG and Me-FAPy-dG 
lesions.231, 245 Furthermore, we also expect one of the Tm values will be only slightly 
stabilizing compared to the control (α-anomer, ΔTm = 1 – 5 oC), while the other Tm value 
will be significantly stabilizing compared to the control (β-anomer, ΔTm = 10 – 15 oC) as 
observed with the Me-FAPy-dG lesion.  
The synthesized 5′-d(CGGACXAGAAG)-3′ oligo can also be analyzed by high 
field NMR (600 – 800 mHz) 1H-NMR, NOESY and DQF-COSY experiments to provide 
structural information to support the thermal melting temperatures. Both NOESY and 
COSY data can be used to assign the base, amino, and imino protons, allowing chemical 
shift perturbations to be detected. These chemical shifts will allow us to determine the 
positioning and hydrogen bond interactions of the 2-hydroxybut-3-en-1-yl constituent, the 
ratio of furanose to pyranose anomerization, and how the EB-FAPy adduct effects base 
stacking. Furthermore, sequence effects can be determined by changing the nucleotide 
immediately downstream the EB-FAPy-dG adduct and analyzing the oligo by HMQC. 
Specifically, the ratio of the formyl proton can be used to calculate the E and Z isomer ratio 
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of the formamide group, providing additional information about the orientation of the 
adduct. 
The availability of the 12-mer oligo 5′-d(CGGACXAGAAG)-3′ would also allow 
us to confirm the anomerization rate of EB-FAPy-dG in-vitro. As described previously, the 
lesion-containing strand can be labeled with 32P and annealed with the complementary 
strand, followed by adding the FPG enzyme (180 nmol) and obtaining aliquots 1, 12, 24, 
48, 72, and 96 hours post annealing.232 FPG incision of the EB-FAPy-dG α-anomer can be 
heated at 90 oC to hydrolyze the DNA, followed by analysis with SDS-PAGE. We would 
expect to observe nearly 50% of the duplex incised after a short period of heating, with the 
nearly all the EB-FAPy-dG lesion anomerized to the β-anomer. Failure to observe loss of 
the α-anomer would indicate that EB-FAPy-dG is more stable than NM-FAPy-dG, and 
further NMR analysis would be required to understand the hydrogen bonds that stabilize 
the lesion. 
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7.8.  Polymerase bypass of EB-FAPy-dG adduct 
As described in Section 1.3.2, Me-FAPy-dG lesions block high fidelity eukaryotic 
DNA polymerases at the insertion or the extension step, and TLS polymerases bypass the 
lesion in an error-prone manner.234 Furthermore, AFB1-FAPy-dG lesions lead to G → T 
transversion mutations in human hepatocytes.249, 250 Successful synthesis of a lesion-
containing 18-mer oligonuclotide (5′-TCATXGAATCCTTCCCCC-3’, where X = EB-
FAPy-dG) would allow us to investigate “standing start” and “running start” primer 
extension studies and measure steady state kinetics of nucleotide insertion across the lesion 
as described previously.559  
Briefly, for “standing start” experiments an annealed mixture of 32P-labeled 13mer 
(5′-GGGGGAAGGATTC-3′) and lesion-containing 18-mer template will be incubated 
with a human DNA polymerase (hPol β, hPol η, hPol ι, hPol ζ and hPol κ). ADD A 
SCHEME The primer extension reaction will be initiated by adding a dNTP mix, with 
aliquots obtained and quenched every 10 min for 1 h. The primer extension products at 
every time point can be resolved by gel electrophoresis and observed by phosphorimaging. 
For running start reactions, the 13-mer primer can be replaced by a shorter 9-mer primer 
(5’-GGGGGAAGG-3’) and the experiment above repeated. Additionally, cooperativity of 
TLS polymerases in bypassing EB-FAPy will be investigated by incubating multiple 
enzymes with the annealed DNA and repeating the experiments described above. Based on 
previous reports for Me-FAPy-dG,234 we anticipate hPol β to be fully blocked by the lesion, 
while the TLS polymerases will be able to bypass the lesion. 
In order to investigate the fidelity of nucleotide insertion across the EB-FAPy-dG 
adduct, the “standing start” experiment can be repeated by increasing the concentration of 
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an individual dNTPs over a specific time period. Steady-state kinetic parameters (kcat and 
Km), catalytic specificity constants (kcat/Km), and the misinsertion frequency of nucleotide 
insertion can be calculated from the experiments above as described in detail previously.617 
We expect to observe several TLS polymerases inefficiently insert all four nucleotides 
across the lesion, showing that EB-FAPy-dG is mutagenic.  
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7.9. Elucidating the repair enzymes involved in excising EB-FAPy-dG 
As observed in Section 5.3.4, we observed a slight difference in EB-FAPy-dG 
formation in MEF NEIL1-/- cells as compared to the wild type NEIL1+/+ cells, indicating 
that the BER enzyme NEIL1 may contribute to the repair of EB-FAPy-dG. To fully 
elucidate the enzymes that recognize EB-FAPy-dG as a substrate, we will incubate the 32P-
labeled 12mer lesion-containing oligo with a commercially available BER enzyme (OGG1, 
NTHL1, NEIL1, NEIL2, and NEIL3). Aliquots will be obtained 1, 2, 4, 8, and 24 hours 
and analyzed as described in Section 6.8. Observation of a smaller 5-mer DNA fragments 
will provide evidence of repair. Based on already confirmed substrate selectivity (Table 
1.2), we expect one of the NEIL enzymes will efficiently excise EB-FAPy-dG.  If no BER 
enzyme is able to excise EB-FAPy-dG in-vitro, we can investigate NER repair of the 
adduct following a different assay.618 
Alternatively, an EB-FAPy-dG lesion can be site-specifically incorporated into a 
biotin-labeled DNA oligo and incubated in a cellular lysate. Subsequent enrichment using 
biotin-labeled beads would isolate the oligo and any proteins bound to the strand. The 
enriched proteins can then be removed from the DNA under denaturing conditions, and the 
proteins identified by mass spectrometry-based proteomics technique described in Section 
2.2. As a control, unmodified DNA can be incubated in the same lysate and the proteins 
analyzed as described above. Identification of any DNA repair enzymes could provide 
insight to the mechanism of EB-FAPy-dG repair, and lead to a directed in-vitro 
investigation described above.  
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